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Abstract

Abstract
Alzheimer’s disease (AD), the most common form of senile dementia, currently affects
over 35 million people worldwide. While there is no cure or effective treatment, early
intervention programs hold considerable promise. Following particular dietary patterns
represents one potential intervention strategy accessible to all.

Results from previous studies investigating the association of diet, cognition and
biomarkers of AD are inconsistent: Positive results have been reported (1-7), whilst
others have shown no associations. Prior to this thesis, no study has assessed the
relationship of four dietary patterns to cognition, blood-based and neuroimaging
biomarkers of AD in a large highly-characterised ageing cohort. Participants drawn
from the Australian Imaging, Biomarkers, and Lifestyle study of ageing, provided a
fasting blood sample, underwent comprehensive neuropsychological assessment and
neuroimaging at baseline, 18 and 36 month follow-up assessments, and completed a
Cancer Council of Victoria food frequency questionnaire (used to construct dietary
patterns) at baseline.

Chapter 3 explored the relationship between dietary pattern adherence and cognition.
AD participants demonstrated reduced adherence to the ‘healthy’ Mediterranean (MeDi)
and prudent diets, and higher adherence to the ‘unhealthy’ western diet and the
inflammatory dietary index compared to cognitively healthy controls (HC).
Longitudinal analysis conducted on individuals classified as HC at baseline proposes
the importance of adhering to a ‘healthy’ dietary pattern such as the MeDi, with respect
to reducing risk for cognitive decline: Executive function and visuospatial functioning
appeared most susceptible to the influence of diet.

Chapter 4 investigated the potential mechanisms underlying the observed effects of
dietary patterns on cognition. A lack of significant associations between the MeDi and
western diet patterns and biomarker indexes of metabolic syndrome and cardiovascular
disease risk, suggests that modulation of these factors may not underlie the effects of
diet on cognition reported in Chapter 3.

Consistent with published literature, we found our western dietary pattern to be
positively associated with levels of blood-based biomarkers of inflammation and the
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reverse to be true of our MeDi and prudent diet patterns. Our inflammatory dietary
index was also strongly positively correlated with levels of numerous inflammatory
biomarkers. The strong associations observed suggest that interplay between diet and
elevated chronic inflammation may contribute to the effects of diet on cognition
described in this thesis.

Chapter 5 assessed the ‘reliability’ (similarity of 12 month dietary intake recalled on
different occasions) and ‘validity’ (intake agreement between FFQ and a four-day
weighed food record) of the online CSIROFFQ following addition of questions
regarding foods of interest in AD research. Our results suggest that the modified
CSIROFFQ is ‘reliable’ and a ‘relatively valid’ tool which provides acceptable
assessment of long-term dietary intake in Australian older adults, particularly in the
context of AD research.

To our knowledge, this is the first study extensively comparing MeDi, inflammatory
dietary index, western and prudent diet patterns to cognition and biomarkers of AD in
an elderly, well-characterised cohort. Our results combined with published data, suggest
diet has a role to play in AD prevention; however, it is clear that the complex link
requires further characterisation.
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1.1. Alzheimer’s disease
Alzheimer’s disease (AD) is the most common form of senile dementia, and it currently
affects over 35 million people worldwide. Due to an increase in life expectancy and
therefore an increase in ageing populations, this figure is predicted to increase to more
than 115 million by 2050 (8).
In 1906, Alois Alzheimer was the first to report details of the symptoms together with
the neuropathology of the dementing illness, which now bears his name. One of his
patients, Auguste Deter, became ill in her 50’s, her mental status deteriorated through a
complex series of behavioural changes and cognitive decline, leaving her aggressive,
delusional and unable to remember recent events. After her death, Alois Alzheimer
performed an autopsy on her brain using recently developed staining methods, and
discovered neuritic plaques as well as peculiar changes in the neurofibrils, now
recognised as neurofibrillary tangles (9).
Neuritic plaques are extracellular deposits consisting mostly of aggregates of a 4 kDa
peptide known as amyloid-beta (Aβ), whereas neurofibrillary tangles (NFT) are found
intracellularly in neurons, and are composed of fibrils of abnormally phosphorylated tau
protein. These two pathological findings, together with cerebral atrophy and widespread
synaptic and neuronal loss are the pathological hallmarks of AD. Plaques and tangles
are found in high frequency in the cortex and hippocampus, which is consistent with the
behavioural changes seen in AD (10, 11). AD is a progressive neurodegenerative
disease which develops over several decades, and initial symptoms include decline in
cognitive function in domains including memory, executive function, language and
visuospatial functioning, which is sufficient to interfere with everyday performance.
Frequently there are also behavioural disturbances including depression, psychosis,
anxiety, agitation, sleep disturbance, disinhibition and apathy (12). Recent postdiagnosis estimates of survival in AD range from three to nine years. The estimation of
survival times using cohorts is problematic however, because of diversity in baseline
disease severity: the inclusion of cases with advanced disease can lead to an
underestimation of survival, while not including patients who die rapidly after diagnosis
overestimates survival (13). There is no cure for the disease, and currently available
treatments only reduce symptoms temporarily. It should be emphasised however, that
the disease is believed to develop in the brain for two to three decades before symptoms
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appear, providing a long time-frame for implementing any potentially preventative
therapy or measures.
1.2. Forms of Alzheimer’s disease
AD is broadly divided into early-onset AD (EOAD) and late-onset AD (LOAD). EOAD
accounts for about 3% of all AD sufferers, it is often identified due to a family history
of EOAD, and starts to affect people when they are less than 60 years of age. It is a fastprogressing, aggressive form of AD. Over 80% of those with EOAD have an autosomal
dominant mutation in one of three genes; the amyloid precursor protein gene (APP;
located on chromosome 21), the Presenilin-1 gene (PSEN1; located on chromosome 14)
or the Presenilin-2 gene (PSEN2; located on chromosome 1); such cases are referred to
as early-onset familial AD (14). The exact causes of non-familial cases of EOAD are
not completely understood. LOAD accounts for the majority of AD cases, it is generally
considered sporadic, and seen in patients above the age of 60 years; the causes are not
known, but risk factors have been identified, the main ones being age and carriage of an
Apolipoprotein E (APOE) ε4 allele (15).
1.3. Pathological hallmarks of Alzheimer’s disease
1.3.1. Neurofibrillary tangles
Neurofibrillary tangles (NFT) are intraneuronal bundles of paired helical filaments
(Figure 1.1; 16), composed of a microtubule-associated phosphoprotein known as tau.
Tau normally enhances the polymerization of tubulin into microtubules and stabilizes
these organelles in neurons. Tau becomes excessively phosphorylated, due to a
combination of enhanced activity of certain kinases and decreased activity of certain
phosphatases. Modification of this normally soluble neuronal protein into an insoluble
filamentous

polymer

appears

to

involve

a

dysregulation

of

cytoplasmic

phosphorylation/dephosphorylation cascades (17).
Defective proteosomal degradation of hyper-phosphorylated tau may contribute to the
build-up of NFT. Tau interacts with the carboxyl terminus of the Hsc70-interacting
protein (CHIP), an E3 ubiquitin ligase required for degradation of soluble
phosphorylated tau. In AD, the mechanism of stabilisation and accumulation of hyperphosphorylated tau may involve inhibition of tau interaction with CHIP. In addition to
phosphorylation, tau is also acetylated; acetylation has been shown to impair the
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proteosomal degradation and enhance the accumulation of tau (12). Recent advances in
in vivo imaging of cerebral tau deposits utilising positron emission tomography (PET)
will likely provide insight into the progression of tau pathology in AD (18, 19).
1.3.2. Neuritic plaques
Neuritic plaques are comprised of extracellular deposits of Aβ peptides, principally in a
filamentous form (Figure 1.1). The Aβ peptides are cleavage products of the much
larger membrane-spanning precursor protein already mentioned above – the amyloid
precursor protein (APP). Aβ peptides vary in length, with the Aβ1-40 and Aβ1-42 peptides
of greatest interest in AD research. In the cerebrospinal fluid (CSF) of healthy controls,
half of the Aβ ends at amino acid 40, 16% ends at amino acid 38, and 10% ends at
amino acid 42 (20). APP is found ubiquitously in the body, yet the disease pathology is
confined to the brain. The Aβ1-40 species is normally more abundantly produced by cells
than its aggregation-prone counterpart, Aβ1-42 (Aβ1-40 accounts for approximately 90%
of all Aβ normally released from cells, and Aβ1-42 approximately 10%), however much
of the fibrillar Aβ found in the amyloid plaques is the 42 amino acid species (Aβ1-42);
this slightly longer, more hydrophobic form of Aβ is particularly prone to aggregation
(21). Aβ1-42 oligomers produced in the early steps of aggregation are believed to be the
toxic principle behind the synaptic damage that occurs in AD, plaques and much larger
aggregates are believed to be relatively inert (22).
Diffuse plaques are also present in the brain, which are comprised of Aβ1-42. One
hypothesis suggests that these diffuse plaques represent precursor lesions of neuritic
plaques (21). Healthy aged individuals free of dementia often demonstrate solely diffuse
plaques, in the same brain regions that AD patients show mixtures of diffuse and
neuritic plaques; thus it is thought that the ratio of diffuse to neuritic plaques depends on
the severity of disease. This theory is supported by transgenic mouse models of AD
which show that diffuse deposits develop before fibrillar, thioflavin T-positive and
congo red-positive neuritic plaques (21).
In vivo imaging utilising PET and radiolabelled amyloid ligands has enabled the time
course of amyloid deposition in the brain to be studied: results suggest that deposition
of amyloid in the brain commences 15 – 20 years before clinical diagnosis of AD (23).
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Cerebral amyloid angiopathy (CAA), another major hallmark of AD, is characterised by
Aβ accumulation in the cortical and leptomeningeal vessel walls (24). CAA is also
known as congophilic amyloid angiopathy, as the amyloid aggregations can be stained
by the Congo red dye. CAA is commonly associated with mutations in the APP gene
within the Aβ sequence region of APP, at amino acid residue 693 (25).
A

B

Figure 1.1. Classic pathological hallmarks of Alzheimer’s disease. (A) Neuritic
plaques, shown by concentrated areas of brain staining and indicated by arrows; (B)
neuritic plaque and neurofibrillary tangles, indicated with arrows. Adapted from
Vandenberghe and Tournov (26).
1.4. Amyloid beta and amyloid precursor protein
The Aβ protein is derived from the type I transmembrane protein APP by the
amyloidogenic processing pathway involving two proteases. The APP gene (located on
chromosome 21q21.2) is mutated in a significant fraction of familial AD cases and such
mutations are associated with increased production of APP and alterations in the type of
Aβ produced. Normal physiological function of APP is poorly understood, however
punitive functions are proposed to include regulation of neuritic outgrowth, cell
adhesion, synaptogenesis and cell survival (27-29).
APP can undergo amyloidogenic (produces Aβ) or non-amyloidogenic processing,
depending on the proteases involved (see Figure 1.2). Amyloidogenic processing to
produce Aβ from its precursor APP involves a two-step cleavage process. Firstly, the β-
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site APP cleaving enzyme 1 (BACE1) cleaves APP in the luminal domain proximal to
the transmembrane segment and thereby releases the N-terminal soluble portion of APP.
Then the intramembrane γ-secretase enzyme mediates the subsequent cleavage at the Cterminus of Aβ, producing Aβ1-40 or Aβ1-42. As discussed in the previous section, the
Aβ1-40 form accounts for approximately 90% of all Aβ normally released from cells, and
the Aβ1-42 form accounts for approximately 10% of secreted Aβ, but is the predominant
form found in amyloid plaques (30). Non-amyloidogenic processing involves αsecretase in place of BACE1. The α-secretase cleaves APP within the Aβ domain, so no
Aβ is produced (see Figure 1.2).
Many factors have been shown to influence whether APP is processed via the
amyloidogenic or the non-amyloidogenic pathway. These factors include cell membrane
lipid composition, as APP cleavage enzymes (particularly γ-secretase which is found in
membrane lipid rafts) is influenced by membrane lipid composition. Furthermore, it has
been suggested that increasing α-secretase cleavage will reduce the production of Aβ,
and α-secretase-mediated APP cleavage can be activated via several G protein-coupled
receptors and receptor tyrosine kinases. For example, protein kinase C, mitogenactivated

protein

kinases,

phosphatidylinositol

3-kinase,

Cyclic

adenosine

monophosphate and calcium are activators of receptor-induced α-secretase cleavage
(31).
Amyloidogenic versus non-amyloidogenic processing of APP is also influenced by
other factors such as levels of cleavage enzymes in different cells, and levels of sex
hormones. For example, amyloidogenic processing is predominant in neurons due to the
high abundance of BACE1 in these cells (32), whilst oestrogen and testosterone have
been shown to promote APP processing through the non-amyloidogenic pathway at the
expense of the amyloidogenic pathway, resulting in the preclusion of Aβ generation
(33).
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Figure 1.2: Amyloidogenic and non-amyloidogenic APP processing pathways. Adapted
from Verdile et al. (30).
Abbreviations: AICD, APP intracellular domain; APP, amyloid precursor protein; Aβ, amyloid beta; BACE1, β-site APP cleaving
enzyme 1; C83, non-amyloidogenic C-terminal fragment of 83 amino acid residues; C99, amyloidogenic C-terminal fragment of 99
amino acid residues; sAPP, soluble N-terminal fragment APP.
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1.5. Amyloid cascade hypothesis
Amyloid plaques are large and highly insoluble, and as mentioned previously, they are
believed to be relatively inert. There is mounting evidence that the much smaller
oligomers of Aβ, particularly Aβ1-42, are highly neurotoxic; these have been shown to
induce free radical production, penetrate and damage cell membranes, and increase
oxidative stress. In some other studies however, it has been found that the slightly larger
aggregates - the Aβ-derived diffusible ligands (ADDLs - a neurotoxic subset of soluble
Aβ1-42 oligomers) are physiologically responsible for the memory malfunction and
neurodegeneration seen in AD (22).
Nevertheless, there is abundant evidence that the overproduction, or the reduced
clearance of Aβ1-42 from the brain (normally by uptake and degradation in brain cells or
by transfer to the periphery), together with oxidative stress, leads to inflammatory and
further oxidative changes including mitochondrial dysfunction, eventually resulting in
neuronal loss and associated cognitive decline. Some of the key evidence has arisen
from studies on the effects of the EOAD-related mutations in cell culture models and in
vivo in transgenic mice. These studies have indicated clearly that excessive levels of Aβ,
or an increased proportion of Aβ being the longer Aβ1-42 species, are implicated in
causing EOAD.
The amyloid cascade hypothesis proposes a central role for Aβ overproduction or
reduced clearance, followed by oligomerisation (and possibly fibrillogenesis) in
triggering a cascade of cellular and molecular events, which in turn leads to the
development of synaptic failure, synapse loss, neuronal death and eventually AD. This
cascade is illustrated in Figure 1.3 (34, 35).
The hypothesis suggests that the dysregulation of APP processing occurs early in the
disease process, resulting in the overproduction of Aβ1-42. Small toxic oligomers of this
Aβ are formed, causing membrane damage, oxidative stress and synaptic dysfunction.
These small oligomers of Aβ can coalesce into fibrils and diffuse plaques, which can act
as seeds for further deposition of Aβ. As plaques mature, the Aβ peptides reorganise
into β-pleated sheets and form neuritic plaques. The formation of the neuritic plaques
results in microglial and astrocyte activation, further oxidative injury, tau aggregation
and phosphorylation, culminating in further synaptic dysfunction and neuronal loss,
which eventually reaches a critical level and manifests as dementia (9).
9
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Familial AD –

Sporadic AD –

Missense Mutations in APP, PSEN1 or
PSEN2 genes, or unknown genes.

Deficiency of Aβ clearance mechanisms.
Increased Aβ accumulation.

Increased Aβ production and
accumulation.

Aβ1-42 accumulation and oligomerisation.

Deposition of aggregated Aβ1-42 as diffuse plaques.

Aggregation of Aβ1-40 onto diffuse plaques, forming
neuritic plaques.

Subtle effects of Aβ oligomers on synapses inflammatory response.
Microglial and astrocyte activation.

Progressive synaptic and neuritic injury.

Altered neuronal ionic homeostasis; oxidative
stress.
Altered kinase/phosphatase
activities.

Hyper-phosphorylation of
tau - formation of
neurofibrillary tangles.

Widespread neuronal/neuritic dysfunction and cell
death with transmitter deficits.
AD.

Figure 1.3: The amyloid cascade hypothesis. Adapted from Herrup (9).
Abbreviations: APP, amyloid precursor protein; Aβ, amyloid beta; Aβ1-40, Aβ species ending in amino acid 40; Aβ1-42, Aβ ending in
amino acid 42; PSEN1, Presenilin-1; PSEN2, Presenilin-2.
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1.6. Diagnostic strategies
1.6.1. Diagnostic criteria
Currently, a definitive diagnosis of AD requires an autopsy, to demonstrate the presence
and characteristic pattern of distribution in the brain of the neuropathological lesions
originally described by Alois Alzheimer: plaques and NFT.
Clinically, AD is most commonly diagnosed using one of the following three diagnostic
criteria: International Classification of Disease, 10th Revision (ICD-10; 36); the
Diagnostic and Statistical Manual of Mental Disorders 5th Edition (37); and the National
Institute of Neurological and Communicative Disorders and Stroke-Alzheimer’s
Disease and Related Disorders Association (NINCDS-ADRDA; 38). Clinical diagnosis
requires the exclusion of other disorders that also contribute to deficits in memory and
cognition, such as dementia with Lewy bodies (DLB) and fronto-temporal dementia
(38). The criteria for the clinical diagnosis of AD have recently been updated to
incorporate advances in our understanding of AD, advances in our ability to detect the
pathophysiological process of AD, and the application of biomarkers for diagnostic
purposes (see sections 1.6.4 and 1.6.5; 39).
1.6.2. Mild cognitive impairment
Mild cognitive impairment (MCI) is characterised by cognitive dysfunction at a level
that is not of sufficient severity for a diagnosis of AD, and which does not significantly
restrict activities of daily living (DSM-5; 40). MCI often, but not always, precedes AD.
Studies have been contradictory concerning the percentage of MCIs that convert to AD,
and the time frame in which this conversion occurs (40, 41). MCIs with higher cerebral
brain amyloid load are significantly more likely to convert to AD than those with less
amyloid load, with faster converters having higher amyloid levels at baseline than
slower converters (42, 43).
There are several types of MCI: amnestic MCIs have an impaired memory, nonamnestic MCIs do not have impaired memory but have impairment in other domains,
for example executive function, language or visuospatial functioning. These two groups
are then divided into single or multiple domain; amnestic single domain (aMCI-s) refers
to impairment in just memory, and multiple domain (aMCI-m) refers to impairment in
memory and at least one other cognitive domain. Single domain non-amnestic (naMCIs) refers to impairment in one non-memory domain, and multiple non-amnestic (naMCI11
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m) refers to impairment in more than one non-memory domain. MCI can also indicate
the development of other conditions such as vascular dementia (VaD), DLB and frontotemporal dementia (44).
1.6.3. Neuropsychological assessment
Neuropsychological assessment aids in the diagnosis of AD by objectively establishing
cognitive impairment from standardised tests. Neuropsychological testing may be
conducted to determine more specifically the type and level of cognitive impairment
being experienced, as well as determine which abilities are preserved. Therefore,
neuropsychologists administer tests that have been developed through rigorous research
in order to study people's short- and long-term memory, attention, concentration,
reasoning, and ability to solve problems and learn new information. Test results are then
compared to expected results of other individuals of the same age and education level,
to determine whether a specific individual is impaired (45).
Cognitive impairment is diagnosed when two of the following are observed •

Impaired ability to acquire and remember new information - symptoms include:

repetitive questions or conversations, misplacing personal belongings (in unexpected
places, such as a watch being placed in a fridge), forgetting events or appointments,
getting lost on a familiar route.
•

Impaired reasoning and handling of complex tasks, poor judgment - symptoms

include: poor understanding of safety risks, inability to manage finances, poor decisionmaking ability, and inability to plan complex or sequential activities.
•

Impaired visuospatial abilities - symptoms include: inability to recognize faces

or common objects or to find objects in direct view despite good acuity, inability to
operate simple implements, or orient clothing to the body.
•

Impaired language functions (speaking, reading, and writing) - symptoms

include: difficulty thinking of common words while speaking, hesitations, and speech,
spelling, and writing errors.
•

Changes in personality or behaviour - symptoms include: uncharacteristic mood

fluctuations such as agitation, impaired motivation, initiative, apathy, loss of drive,
social withdrawal, decreased interest in previously liked activities, loss of empathy,
compulsive or obsessive behaviours, and socially unacceptable behaviours (46).
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The clinical dementia rating (CDR) was developed for the evaluation of staging severity
of AD. The CDR is a five-point scale in which CDR 0 implies no cognitive impairment,
and then the remaining four points are various stages of AD (CDR 0.5 = very mild,
CDR 1 = mild, CDR 2 = moderate and CDR 3 = severe). There are six domains used to
construct the overall CDR – memory, orientation, judgement and problem solving,
community affairs, home and hobbies, and personal care. In rating each of the domains,
the assessment is on the patient’s cognitive ability to function in these areas. The CDR
is generated from a semi-structured interview with the patient and a knowledgeable
collateral source (47).
1.6.4. Pittsburgh compound-B positron emission tomography
Extensive cognitive assessment of a person suspected of cognitive impairment clearly
occurs only once symptoms are already present, and such assessment can only lead to a
diagnosis of probable AD at best. The disease pathology, including Aβ aggregation,
amyloid plaque deposition and NFT formation, is understood to develop for many years
before a threshold level of damage is reached and symptoms appear. There is currently
no cure or effective treatment for AD, despite at least three decades of extensive
research into AD-specific potential treatments. As a result, current emphasis in
treatment research is on preventative or disease-slowing therapy. For such treatments to
be most effective, diagnosis at the earliest possible stage of the disease is necessary,
thus the development of diagnostic methods that can detect the disease at early preclinical stages is of paramount importance. To this end, new Aβ-specific positron
emission tomography (PET) radiotracers have been developed recently, which allow
quantitative analysis of Aβ burden in vivo.
A PET scan is a sensitive molecular neuroimaging technique that uses radiolabelled
tracers to evaluate biological processes in vivo, PET may permit detection of disease
processes at asymptomatic stages when there is no evidence of anatomic changes using
magnetic resonance imaging (MRI; 16). PET is capable of assessing brain function as
well as structure and has proven even more powerful as a diagnostic tool compared with
structural imaging techniques such as MRI.
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For the purposes of detecting cerebral Aβ burden in AD, the radiolabelled tracer or
ligand must be a small molecule capable of crossing the blood-brain barrier (BBB), and
capable of binding to Aβ in a specific and selective fashion (16). Several radioligands
have been trialled for this purpose, and to date, the best radioligand that has been
developed is Pittsburgh compound-B (PiB; Figure 1.4). This ligand has high affinity
and high specificity for amyloid fibrils and binds to amyloid plaques (48). PiB is a
carbon-11-labelled derivative of the thioflavin-T amyloid dye (49). The molecular
probes are firstly produced with positron emitting isotopes, and the imaging procedure
begins with injection of the radioactive tracer into the patient. After a short time-span to
allow for the probes to bind to amyloid, their distribution in the brain is determined
using PET scanning.

Figure: 1.4: Derivation of Pittsburgh compound-B from the fluorescent histochemical
dye thioflavin T (50).
In a study of PiB PET by Klunk et al. (51) both imaging and time-activity curves
showed that the retention of PiB provided a quantifiable discrimination between most
mild AD patients and cognitively healthy controls (HC). In HC participants there was
very little retention of PiB in cortical regions. On the other hand, frontal and
temporoparietal cortical areas in AD patients, known to contain amyloid deposits,
showed preferential retention of PiB. In contrast, the absolute level of PiB retention
was approximately the same in the cerebellum and white matter of AD and HC subjects
- brain areas known to lack substantial deposition of fibrillary amyloid. The absolute
amount of PiB retained in the frontal cortex of AD patients was greater than 90% higher
than that retained in the frontal cortex of HC subjects. This pattern of PiB retention is
generally consistent with the pattern of amyloid plaque deposition described in post
mortem studies of AD brain tissue (51).
One potential and highly desired application of PiB PET imaging is to identify the
neuropathological manifestations associated with AD in clinically ‘normal’ individuals
prior to the development of cognitive changes. These individuals would be considered
14
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to have preclinical AD, and thus would be candidates for disease-delaying therapy. In
one study, Rowe et al. (48) showed cortical PiB binding in 22% of the HC participants.
This percentage is similar to the expected proportion of the general population that will
develop AD by the age of 85 years. However, Rowe et al. (48) also showed that Aβ
burden, as measured by PiB PET, does not correlate well with disease severity; yet there
is increased Aβ in all AD subjects regardless of severity, supporting the concept that Aβ
deposition occurs before the onset of cognitive symptoms. Therefore, PiB PET not only
shows great promise for accurate early diagnosis of AD, but may also be able to detect
preclinical AD. Other studies supporting this concept have shown extensive uptake of
PiB in neocortical areas, in asymptomatic elderly subjects with documented recent
decline in cognitive tests (16).

Furthermore, studies of EOAD have found that

autosomal dominant AD mutation carrier individuals have elevated PiB levels in nearly
every cortical region 15 years before the estimated age of onset – supporting the
potential of PiB PET in preclinical diagnosis (52). However, as in the study by Rowe et
al. (48), other studies have also found that there is wide individual variation in the brain
amyloid load in MCI, and in the course of amyloid accumulation in relation to the
clinical diagnosis of AD (53).
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Figure 1.5: Binding potential of Pittsburgh compound-B (PiB). From Mathis et al. (50).
Sample brain images depicting the binding potential of PiB (top row) measured in a 70
year old healthy control and a 75 year old person with Alzheimer’s disease (AD). Also
shown are the corresponding anatomical magnetic resonance images (MRIs: bottom
row). Greater retention of PiB is evident in frontal, temporoparietal, and posterior
cingulate cortices of the AD individual, relative to the control. Logan BP indicates
Logan binding potential (50).
In a cohort of 206 individuals from the Australian Imaging, Biomarkers and Lifestyle
(AIBL) study of ageing, 98% of participants with AD, 69% of MCIs and 31% of HCs
showed high PiB retention. After a mean follow-up of 20 months, small but significant
increases in PiB standard uptake value ratios (SUVRs) were observed in those with
high PiB retention at baseline. Increases were associated with the number of APOE ε4
alleles (known AD risk factor – see section 1.7.1 below) carried by these individuals.
Progression to AD occurred in 67% of MCIs with high PiB, versus 5% of those MCIs
with low PiB, but 20% of the low PiB MCI subjects progressed to other dementias. Of
the high PiB HCs, 16% developed MCI or AD by the 20 month follow-up and 25% by
three years. Other studies have also found that Aβ deposition increases slowly from
cognitively normal to moderate severity AD, that this deposition precedes cognitive
impairment, and is associated with the APOE genotype (43).
Chételat et al. found a specific relationship between episodic memory deficits and
neocortical temporal PiB, independent from hippocampal atrophy, in the predementia
stage of the disease, suggesting a relationship between regional Aβ deposition and
episodic memory deficits in the presymptomatic stage of AD (54). Interestingly, Pike
et al. found increased Aβ was related to worse episodic memory and visuospatial
performance in males but not females in a sample of 177 healthy older adults (55).
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PiB has a short half-life of only 20 minutes; this reduces its practical application due to
the need for onsite synthesis capabilities (cyclotron) which are only possible in
specialised research centres. This makes PiB PET very difficult to adapt to general
diagnostic usage. Other amyloid ligands utilising Fluorine-18 (18F), including
florbetaben, florbetapir and flutemetamol, are currently being tested. Although their
pharmacodynamic properties are generally less favourable than those of PiB, they are
nevertheless sensitive in the detection of brain amyloid in vivo, and their longer half-life
(110 minutes) would increase imaging capabilities (56).
Despite the aforementioned limitations, the benefits of neuroimaging include
improvements in early AD diagnosis with a presymptomatic biomarker, improved
understanding of the natural history of amyloid deposition and insights into the
pathophysiology of AD as well as the capability to measure effects of newly developed
anti-amyloid therapies (50). The development of a more widely accessible
neuroimaging technology will also be invaluable: when a treatment becomes available
for AD, the ability to identify patients early in the disease process or presymptomatically using amyloid imaging will become essential for early and optimal
initiation of therapy.
1.6.5. Magnetic resonance imaging
Data obtained from MRI scans can be merged with PET images, providing combined
structural/functional information (57). Structural MRI provides visualisation of the
macroscopic tissue atrophy that results from the cellular changes underlying AD. Recent
advances in image analysis algorithms have led to the development of structural MRIbased software tools that can automatically divide the brain into anatomic regions and
quantify the tissue atrophy in these regions for a single individual (58).
AD is significantly associated with cortical grey matter loss and ventricular
enlargement. From MRIs, the severity of volume loss of the entorhinal, perirhinal and
temporal cortices in patients with AD, has been shown to correlate with disease
severity; these areas have also been shown to be reduced in both MCI and AD
individuals compared to HCs (16). In a study of 112 cognitively HC, 226 MCI and 96
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AD patients, each of whom had undergone at least three MRI scans, it was found that
MCI and AD groups showed hippocampal volume loss over six months and accelerated
loss over one year, when compared to HCs. Increased rates of hippocampal loss were
also associated with the presence of APOE ε4 alleles (59).
Chételat et al. (60) published findings on the relationship between atrophy (measured by
MRI) and Aβ deposition (measured by PiB PET). They found a strong relationship
between Aβ deposition and atrophy very early in the disease process (in those with
subjective cognitive impairment) but not in patients with MCI or AD, suggesting that
anti-amyloid therapy should be administered early in the disease process to minimise
neuronal loss.
1.7. Alzheimer’s disease risk factors
1.7.1. Apolipoprotein E1
The human Apolipoprotein E (APOE) gene is located on the long arm of chromosome
19 (19q13.2). There are three APOE alleles, denoted as APOE ε2, APOE ε3 and APOE
ε4. The distribution of the three alleles in the general Caucasian population is
approximately 8%, 78% and 14% for APOE ε2, APOE ε3 and APOE ε4 respectively
(61). The apoE protein exists as three major isoforms, denoted apoE2, apoE3 and
apoE4, with single amino acid substitutions of cysteine/arginine at residues 112 and 158
accounting for their differences (62).
It has been shown that APOE ε2 alleles may be associated with a delayed age of onset
of AD, even in carriers of APP mutations. These findings have led to the proposal that
the APOE ε2 allele may offer a level of protection against the development of AD (63).
Conversely, the APOE ε4 allele is over-represented in sporadic and familial AD cases; it
is considered the most common genetic risk factor for AD, and is present in over 50%
of LOAD cases (63). Several studies have shown that the risk of AD increases as a
function of the APOE ε4 allele dosage. This implies that APOE alleles in the order of
ε4/ε4 > ε4/ε3 > ε4/ε2 or ε3/ε3 > ε3/ε2 > ε2/ε2 positively influence an individual’s risk
of developing AD (64, 65). However, carrying an APOE ε4 allele does not imply one is
guaranteed to develop AD, and similarly, nor does it imply that individuals without
APOE ε4 alleles are not at risk, they may nonetheless develop AD, though their risk is
lower than average (66).
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ApoE is one of several different classes of apolipoproteins, including apoD and apoJ,
which transport lipids in plasma and CSF. ApoE is one of the most important
cholesterol transport proteins, with peripheral apoE mainly synthesised in the liver,
whilst other major sources include tissue macrophages. It is the major lipoprotein within
the CNS, where it is synthesised and secreted from astrocytes and microglia (67).
Carriage of the APOE ε4 allele is linked to enhanced amounts of diffuse Aβ1-42 plaques
in the brain, and to an earlier age of onset of the disease. The mechanism by which the
apoE4 protein leads to these differences has been researched extensively, yet is still not
well understood (68). ApoE appears to be necessary for amyloid deposition, as apoE
knockout mice crossed with AD-model mice deposit considerably less amyloid (69, 70)
and when compared to apoE3, apoE4 promotes greater deposition of Aβ peptides. These
studies show that apoE assists Aβ deposition, and that apoE4 may increase AD risk by
increasing levels of amyloid deposition. However, apoE also appears to be involved in
the binding and clearance of brain Aβ, with apoE3 and apoE2 being more effective than
apoE4. ApoE3 interactions with Aβ oligomers and apoE receptors also reduce the
neurotoxicity of Aβ oligomers, and to a greater extent than apoE4, again possibly via
better clearance (71). In other studies, apoE4 has been found to be less protective
against oxidative stress, to affect signalling pathways, and to result in greater
cholinergic dysfunction in AD (72).
1.7.2. Age
The greatest known risk factor for AD is advancing age (Figure 1.6). Most individuals
with the disease are aged 65 years or older and the likelihood of developing AD doubles
approximately every five years after the age of 65. After the age of 85, the likelihood of
developing AD reaches nearly 50 percent (73, 74). Due to increased longevity, as a
result

of

improved

healthcare,

the

prevalence

of

AD

is

increasing.
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Figure 1.6: Prevalence of Alzheimer’s disease currently in America, and a projection of
the number by 2050. Graph courtesy of University of Oklahoma, 2012.
1.7.3. Cardiovascular disease
There is a large body of evidence which suggests that many cardiovascular disease
(CVD) risk factors directly influence AD risk (75, 76).
1.7.3.1. Obesity
Mid-life obesity, which is associated with altered cholesterol and lipid metabolism, has
been associated in a number of longitudinal studies with later life dementia risk (77-81).
Some studies have concluded the opposite, for example Fitzpatrick et al. (82) reported
an inverse association with mid-life (50 years) obesity and dementia risk; however, this
association became non-significant in late-life (65 years and older) in their study. Other
studies have indicated that this association is reversed in adults over 70 years of age,
with lower body fat a predictor of cognitive decline (83).
Obesity and its association with AD have been linked to abnormal metabolism of the
obesity-related protein leptin. For example, weight loss often precedes the onset of AD,
and there is a correlation between reduced levels of circulating leptin and the risk of
20
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AD; lower levels of circulating leptin have been observed in AD patients versus HCs
(84). A large prospective study involving 2871 elderly people followed over a period of
four years showed that lower leptin levels were associated with greater cognitive decline
(85).
Leptin is a peptide hormone secreted by adipose tissue; it exhibits a wide range of
central and peripheral actions, including providing signals to specific regions of the
hypothalamus to control energy homeostasis, thereby leading to fat storage or
mobilisation which also controls insulin sensitivity (86). Another activity of leptin is the
control of AMP-dependent kinase (AMPK); AMPK maintains lipid levels and also
regulates glycogen synthase kinase-3 which modulates tau phosphorylation (87).
Furthermore, leptin has been shown to suppress Aβ generation in vitro by attenuating
BACE1 processing of APP in neuronal cells, possibly through mechanisms involving
altered lipid composition of membrane lipid rafts. The chronic administration of leptin
to AD-model transgenic mice reduced the brain Aβ load and tau phosphorylation in
neuronal cells that normally develops in these mice, suggesting leptin has potential as a
therapeutic factor (88). Leptin appears to be regulated in humans and animals by shortterm alterations in energy intake, as leptin declines with fasting and increases with acute
overfeeding (89). It has been shown that leptin levels significantly correlate with levels
of certain dietary variables, particularly dietary fat levels and inversely with dietary
carbohydrate levels, but show no correlation with protein levels in the diet or total
energy intake (90).
1.7.3.2. Cholesterol
AD patients have been shown to have a lipoprotein profile commonly found in
atherosclerosis patients; as they frequently demonstrate increased levels of total plasma
cholesterol and low density lipoprotein (LDL) as well as reduced levels of high density
lipoproteins (HDL), when compared to age-matched controls (91). Disturbances in
cholesterol homeostasis are a hallmark of neurodegenerative diseases. Statins have been
used to lower cholesterol levels in coronary artery disease, and some studies suggest
they may protect against AD (91-93), although not all studies agree, partly due to the
different statins available, and due to patient age differences at the time of treatment.
Statins work by inhibiting 3-hydroxy-3-methylglutaryl reductase (HMG reductase),
which is the rate-limiting enzyme in cholesterol synthesis (67). Interestingly, levels of
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total cholesterol and LDL in serum correlate with Aβ load in the brains of patients with
AD, and epidemiological evidence suggests individuals with elevated cholesterol levels
during mid-life have a higher risk of developing AD later in life (67).
The brain is the most cholesterol-rich organ in the body; it contains approximately 25%
of total body cholesterol but is only 2% of total body weight. In the human brain,
cholesterol is a major component of myelin and of neuronal and glial membranes.
Nearly all brain cholesterol is synthesised in situ; virtually no cholesterol crosses the
BBB. The brain can’t degrade cholesterol, any excess is converted to 24Shydroxycholesterol (24S-OHC), which can readily cross the BBB. This allows the exit
of approximately 6 – 7 mg of cholesterol from the brain each day, with the liver then
being responsible for the removal of the 24S-OHC (67). CSF 24S-OHC has been found
to be higher in AD individuals, suggesting that cholesterol metabolism in CSF is
disturbed in AD; cholesterol efflux also appears to be elevated and related to the
increased risk for AD. It has been suggested that the increased levels of 24S-OHC
possibly reflect neuronal cell death, with release of cell membrane cholesterol. Other
factors that affect cholesterol equilibrium include disturbances and degeneration of the
BBB which occur as part of the neuropathology occurring in AD brains (91).
Furthermore, CVD-related reduced blood flow to the brain may also cause damage to
the BBB, which adds to the already present changes in cholesterol and lipid metabolism.
There are three major categories of brain lipids: glycerophospholipids, sphingolipids
and cholesterol. Sphingolipids and cholesterol self-aggregate into specific membrane
domains known as lipid rafts, and these are involved in cellular trafficking and
signalling functions.

They are also preferential sites for host interactions with

pathogens and toxins (94). Cholesterol can bind directly to APP, stimulating insertion
into phospholipid monolayers, cholesterol also binds to Aβ protofibrils. However,
whether cholesterol accelerates or decreases Aβ polymerisation is still uncertain. The
generation of Aβ peptides through APP proteolysis occurs within lipid rafts and this
proteolysis is sensitive to inhibitors of cholesterol biosynthesis (94). High cholesterol
intake has been linked with AD-like pathology in animal models such as rabbits, in
which diet-induced hypercholesterolemia is associated with increased Aβ levels and Aβ
plaque load in the brain (75).
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Increased LDL and decreased HDL (a form of dyslipidemia) are independent risk
factors for coronary heart disease (CHD) and carotid artery atherosclerosis, which in
turn leads to cognitive impairment through cerebral hypoperfusion or embolism (95).
HDL-cholesterol (HDL-C) is believed to influence small-vessel disease by playing a
protective role in the removal of excess cholesterol from the brain by interaction with
apoE and heparin sulphate proteoglycans in the subendothelial space of cerebral
microvessels (96).
A study by Ward et al. (97) found that grey matter volume within the right middle
temporal gyrus was significantly associated with certain neuropsychological test results,
suggesting that adults with decreased levels of HDL-C may be experiencing cognitive
changes and grey matter reductions in regions associated with neurodegenerative
disease, and therefore may be at greater risk of future cognitive decline. HDL-C has
shown anti-inflammatory (98) and antioxidant effects (99), which may also help explain
its protective effect against AD. Lifestyle interventions proven to increase HDL-C
levels, for example healthy diet, exercise and weight control have also been shown to
provide neuroprotective effects (97).
Another mechanism through which HDL may be able to confer a degree of protection
against AD is through its ability to bind to Aβ, thereby maintaining its solubility in CSF
(in HDL-like particles) and plasma, and preventing the deposition of Aβ in the brain.
ApoE plays a major role in the regulation of lipid and lipoprotein (including HDL)
homeostasis, and facilitates the transport of cholesterol to the liver where it is degraded.
Interestingly, the apoE2 and apoE4 isoforms have been shown to influence HDL-C
levels in opposite directions; apoE4 adversely affects the HDL-Aβ interaction (100).
1.7.3.3. Atherosclerosis
Atherosclerosis, a major degenerative disease of arteries, involves a series of
inflammatory and oxidative modifications within the arterial wall. A study by Dolan et
al. (101) examining data from 200 autopsies, found that atherosclerosis and dementia
are related, however this only applied to intracranial atherosclerosis and not cardiac or
aortic atherosclerosis. A study by Itoh et al. (102) found no association between AD
pathology and aortic, cardiac or intracranial atherosclerosis, whilst Beeri et al. (103)
found a relationship between neuritic plaques and coronary atherosclerosis, mostly in
APOE ε4 allele carriers, using 99 brain autopsies of which 36 were APOE ε4 allele
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carriers. The significance of these studies is limited because of relatively small sample
sizes; there is a need for further larger studies to address inconsistent results. In a study
of 4971 subjects, those with overt or clinically silent vascular disease performed worse
on cognitive tests than those subjects without vascular pathology. Indicators of
atherosclerosis of the carotid arteries and presence of atherosclerosis of the large vessels
of the legs were associated with AD (104). The authors also reported that the prevalence
of AD increased with the degree of atherosclerosis, and subjects with at least one APOE
ε4 allele and severe atherosclerosis had nearly 20-fold increased risk for AD (104).
1.7.3.4. Hypertension
Hypertension affects 25% of the adult population and 50% of people over 70 years
(105), it is diagnosed when systolic blood pressure exceeds 140 mm Hg, and/or diastolic
pressure exceeds 90 mm Hg. Hypertension impairs the process by which brain activity
and blood flow are coordinated (106). Hypertension is one of the most important risk
factors for AD, stroke and CVD.

It has been shown that hypertension precedes

dementia onset by approximately 30 years, however this relationship is complex and
does not follow a linear progression. Mid-life hypertension is particularly associated
with an increased risk of developing AD, whereas elevated blood pressure late in life
does not appear to have the same associated risk (107). MRI investigations have
demonstrated that individuals with high blood pressure often have large areas of white
matter hyperintensities, ventricular enlargement and silent infarcts, all of which can lead
to cognitive dysfunction and dementia (108). In a longitudinal study, it was concluded
that both high systolic and high diastolic blood pressure were associated with AD onset
10 to 15 years later. Individuals with hypertension also exhibit higher than average
amounts of senile plaques and neurofibrillary tangles. However, the findings in the
literature are contradictory, with both high and low blood pressure being associated with
cognitive impairment, and some studies have reported no association. A possible
explanation is that high blood pressure does indeed increase risk of AD over a long
period, but in the years preceding onset, blood pressure starts to decline and declines
further with progression of the disease (104). Clearly more prospective studies with a
longer follow-up are required. Anti-hypertensive treatments have been associated with
lower incidence of clinically diagnosed AD and better cognitive function, however there
are several different antihypertensive medications, and not all of these have been found
to have an effect on AD. Also, several investigators failed to find treatments effective in
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reducing late-life AD. This could be due to differing methodology between studies,
including differences in estimates of prevalence and incorrect diagnosis of dementia
types, in particular vascular dementia (109). Larger studies utilising a greater age range
of participants may circumvent these limitations.
1.7.4. Metabolic syndrome - Diabetes
High caloric intake and diets high in sugar and refined flour are major health concerns
in the Western diet. Unhealthy lifestyle choices have led to a growing incidence of
obesity and altered insulin receptor signalling due to hyperglycaemic conditions (88),
this can often lead to type-2 diabetes. It has been reported in several studies that type-2
diabetes (characterised by resistance to the effects of insulin) is associated with a twoto three-fold increased relative risk for AD (110-114). Abnormalities in insulin
metabolism in diabetic conditions are thought to impact the onset of AD partly via their
influence on the synthesis and degradation of amyloidogenic Aβ peptides. For example,
insulin itself may significantly promote Aβ accumulation by accelerating APP/Aβ
trafficking from the trans-Golgi network, a major cellular site for Aβ generation, to the
plasma membrane. Elevated levels of circulating insulin in diabetic conditions may also
provoke amyloid accumulation by directly competing with Aβ for the insulin-degrading
enzyme (IDE), thereby limiting Aβ degradation by IDE (115).
Recent evidence suggests a role for insulin in normal memory function, supporting the
hypothesis that insulin by itself affects many mechanisms relating to neuronal activity
and cognitive function (88). Type-2 diabetes and AD both have significant
inflammatory components, and there is evidence that inflammation based mechanisms
in type-2 diabetes might help induce the neuroinflammation and microglial activation
that occurs in AD (116). However, not all studies support the hypothesis that diabetes
increases risk of AD (117-119). Arvanitakis et al. (120) reported that diabetes is
associated with a lower level of semantic memory but not with other cognitive domains.
There are factors within such studies which could provide an explanation as to why
some found a significant association and others did not. The reporting of diabetes
almost certainly underestimates the true prevalence of the condition; true prevalence is
believed to be twice that of self-reported disease. Another possible explanation is the
potential mis-classification of AD which would cause an underestimation of the
relationship between AD and diabetes: the studies use a variety of criteria to diagnose
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AD which may lead to misclassification of vascular dementia or stroke-associated
dementia as AD. This again highlights the need for better diagnostic methods.
1.8. Lifestyle risk factors
There is currently no cure in sight for AD, and for this reason much attention has shifted
to identifying factors or treatments which may delay the onset or slow disease
progression. Earlier in this chapter we reported neuropathological changes (specifically
cerebral Aβ deposition) that precede onset of symptoms by 15 – 20 years, thereby
presenting a ‘window of opportunity’ to modify disease course. There is significant
benefit to ascertaining which lifestyle factors may protect against or contribute to the
development of AD. The identification of such factors might permit early intervention
to modify disease course, to delay or defer the onset of AD (11). Physical activity,
smoking, and diet represent examples of lifestyle risk factors. Modification of these
lifestyle factors is accessible to all, and economically advantageous over medical
interventions with reduced incidence of adverse side effects.
1.8.1. Physical activity
1.8.1.1. Effects of physical activity
It is common knowledge that regular physical activity (PA) should be part of a healthy
lifestyle in all age groups. Benefits include reduced mortality, prevention of CVD,
positive effects on lipid profiles, successful weight management; the prevention and
management of type 2 diabetes, hypertension, stroke and certain cancers; also a reduced
risk of falls and bone fractures, and potentially an enhancement of cognitive function
(121).
In general, exercise has been shown to have positive effects on many aspects of
cognition such as reasoning, working memory, executive functioning, vigilance
monitoring and fluid intelligence test performance (122). PA is a complex behaviour
characterised by intensity, duration and frequency. Discrepancies between studies on
PA could be caused by differences in assessment methods and measurement, for
example, some studies use only self-reported PA questionnaires, whereas others use
accelerometers to measure daily PA. Accelerometers provide an objective measure of
habitual activity which is not dependent on self-reporting (123). Results from 217
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participants of the AIBL study have shown that intensity, rather than volume, of PA is
associated with cognitive functioning. Compared with individuals in the lowest tertile of
PA intensity, those in the highest tertile scored 9%, 9%, 6% and 21% higher on the digit
span, digit symbol coding, Rey Complex Figure Test copy and 30 minute delay recall,
respectively (124). A study by Scarmeas et al. (125) suggested that increased PA is
associated with a reduced risk for developing AD, and the higher the intensity,
frequency and duration of the PA, the more the decrease in risk, with a dose-dependent
response observed. In Scarmeas’ study, high PA corresponded to approximately 1.3
hours of vigorous PA per week, or 2.4 hours of moderate PA per week, or 4 hours of
light PA per week; even this relatively ‘small’ amount of PA was associated with a
reduction in risk for developing AD.
1.8.1.2. Possible mechanisms of action of physical activity
There are many possible mechanisms that may explain the protective effect of PA in
relation to AD risk, one of these mechanisms is angiogenesis; exercise promotes
vascular antioxidant pathways, capillary growth and improves cerebral perfusion (126).
Chronic exercise could maintain cerebrovascular integrity by enhancing oxygen
transportation to the brain and this enhanced blood flow may positively influence
cognitive performance (127). PA also enhances synaptic connections between brain
cells and influences neuronal plasticity (128). Prolonged PA has also been shown to
maintain neurogenesis and to slow age-associated cognitive decline (129). Exercise has
been shown to induce hippocampus hypertrophy - exercise-induced production of
growth factors such as the brain-derived neurotrophic factor (BDNF) has been shown to
enhance neurogenesis and to play a key role in positive cognitive effects. There is
evidence that insulin-like growth factor (IGF-1) may mediate the exercise-induced
changes in BDNF, neurogenesis, and cognitive performance. IGF-1 is also postulated to
regulate brain Aβ levels by increased clearance via the choroid plexus (130). Studies of
transgenic mouse models of AD have also shown that exercise causes a host of
beneficial changes, including repression of neuronal cell death, and the lowering of
blood cholesterol, insulin, glucose and corticosterone levels (131). Data from the AIBL
study has shown that higher levels of PA are associated with higher HDL levels, lower
insulin and triglyceride levels, as well as a reduced plasma Aβ1-42/1-40 ratio. After
stratification by APOE ε4 allele carriage, it was evident that only APOE ε4 non-carriers
received the benefit of reduced plasma Aβ1-42/1-40 ratio from PA. This analysis was
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completed in 546 cognitively normal participants. Additionally, a PiB-PET sub-study
on 116 of these participants determined that brain Aβ levels were lower in higher
exercising APOE ε4 allele carriers (with 116 included in the additional PiB PET sub
study; 132). Studies have shown that moderate levels of PA carried out for less than one
year may increase the HDL-C levels of young adult women despite only moderate
increases in fitness (133). Cross-sectional population-based investigations have
indicated that exercise levels attainable by older men and women are also associated
with significantly greater HDL-C levels (134). This suggests that frequency of exercise
and not high intensity of exercise may be more important in increasing HDL-C levels
(135).

Insulin sensitivity has been shown to improve with aerobic exercise, suggesting a
potential benefit of improved glucose metabolism on cognitive processes (136). In
animal models, exercise-induced cognitive benefits have been linked to improved
energy metabolism and insulin signalling in the brain (137). Rat studies of induced
diabetes for example, have shown that aerobic exercise can decrease tau
phosphorylation and APP expression, and increase levels of some proteins related to the
insulin/IGF-1 pathway in the hippocampus (138). The exercise also improved
performance of the rats in the Morris water maze test, compared to sedentary controls.
1.8.2. Smoking
Smoking is an established risk factor for many diseases, but its association with AD is
controversial. A recent study by Rusanen et al. (139) showed that smoking in mid-life
increases the risk of dementia among APOE ε4 allele carriers but not among APOE ε4
allele non-carriers, the participants were first studied in 1977 and were reassessed in
1998. Mouse models have been used to show that smoking increases the severity of
amyloidogenesis, neuroinflammation and tau phosphorylation (140). Controversially, a
study by Van Duijin and Hofman (141) concluded that there is an inverse association
between smoking and AD. The risk of AD decreased with increasing daily number of
cigarettes smoked before onset of disease. Recently, MRI studies have shown cigarette
smoking in a young-to-middle aged group is associated with smaller brain volumes
(142-147), and greater pack years (calculated by multiplying the number of packs
of cigarettes smoked per day by the number of years the person has smoked) is
associated with smaller anterior frontal, temporal and cerebellar grey matter volumes
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(143, 144) as well as thinner orbitofrontal cortex (145). In 2010, Cataldo et al. (148)
carried out a review of case control and cohort studies to examine the relationship
between smoking and AD: they reported on 43 individual studies after controlling for
study design and quality, and found a quarter (11 of the 43) of these studies had tobacco
industry affiliated authors, somewhat unsurprisingly three of these 11 studies found a
non-significant relative risk of AD associated with smoking and the remaining eight
suggested smoking actually protects against AD. Of the non-tobacco industry affiliated
studies, 18 had no significance with respect to AD risk and 14 found a significantly
increased risk of AD with smoking.
Nicotine has been shown to modulate the neurotoxic effects of Aβ and exert potent
neuroprotective effects (149, 150). The presence of nicotine causes an up-regulation and
activation of nicotinic acetylcholine receptors, which in turn protect against Aβ
cytotoxicity (150). Cholinergic deficits, characterised by reduced levels of acetylcholine
nicotinic receptors are found in AD, and it has been shown that AD patients with an
APOE ε4 allele have fewer nicotinic receptor binding sites and a depletion of choline
(105, 151). Nicotine may provide cascading effects via stimulation of the release of a
variety of neurotransmitters involved in cognitive function, including acetylcholine,
dopamine, norepinephrine, serotonin and glutamate (152). A study by White et al. (152)
has shown that wearing nicotine patches for four weeks produced a statistically
significant improvement in attention but no improvement in memory or overall clinical
status, in eight AD patients. Another four week nicotine patch study did not find any
differential improvement in short-term memory with nicotine compared to placebo
(153). It is possible that a high peak achieved by injection of nicotine is necessary to
produce memory improvement in AD patients, as shown by Newhouse et al. (154) and
Levin and Torry (155). It is of course important to note that nicotine is merely one
component of cigarettes, the effects of nicotine vary considerably from those of
smoking, which is already accepted to increase the risk of a variety of medical
conditions, including several already linked to AD, such as cardiovascular disease and
hypertension. Additional studies are needed to resolve whether smoking is a protective
or detrimental risk factor for AD.
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1.8.3. Diet
Diet plays a major role in the risk and development of neurodegenerative diseases such
as AD (156-158) and chronic diseases of the periphery like CVD and diabetes (159161).
1.8.3.1. Mechanisms of action of diet
There are multiple potential mechanisms underlying the effects of dietary components
on AD risk including: modulating oxidative stress, high density lipoprotein, low density
lipoprotein and homocysteine levels to name but a few.
1.8.3.1.1. Oxidative stress
AD brains exhibit considerable evidence of reactive-oxygen species (ROS) and reactive
nitrogen species-mediated injury. These species, formed during normal metabolic
processes, are generally unstable and highly reactive, for this reason their levels are kept
low by efficient antioxidant systems. In some circumstances their production can exceed
the antioxidant ability to destroy them, and oxidative stress/damage occurs. The brain is
particularly vulnerable to oxidative stress due to its high metabolic activity and the
presence of relatively few antioxidant enzymes; antioxidant nutrients are a natural
defence mechanism against these processes (162). Evidence suggests that oxidative
stress contributes to the pathogenesis of AD, therefore increasing the intake of
antioxidants could counteract the detrimental effects of oxidative stress and thereby
potentially reduce AD risk. Many foods have antioxidant properties including turmeric,
green tea, fruit and vegetables and supplements like Ginkgo biloba extracts.
Curcumin, a constituent of the Indian spice turmeric, is a strong antioxidant with antitumour and anti-inflammatory properties. The prevalence of AD in populations that are
between the ages of 70 and 79 years is reported to be 4.4 fold less in India (where
curcumin consumption is high) than in the United States of America (88). While this
would imply that the incidence of AD in India is much lower, these figures may be
heavily impacted by underreporting, reduced longevity and other health aspects such as
obesity in the USA. Despite this, animal work certainly suggests that curcumin may
play a role in combating AD. In mouse models of AD, curcumin has previously been
shown to decrease levels of oxidised proteins and induce a 43-50% decrease in soluble
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Aβ, insoluble Aβ and amyloid plaque formation. Furthermore, curcumin was shown to
inhibit both the formation and growth of Aβ fibrils from Aβ in a dose-dependent
manner (163). However, a pilot study in AD patients failed to show evidence of a
benefit of curcumin therapy (164). There are several reasons as to why this study might
have failed; the AD patients may have been late stage and therefore exhibiting
irreversible pathology. Also, the uptake of curcumin in the gut can be poor which may
account for the lack of clinically significant results. To date no clinical study has
measured curcumin levels in the blood to investigate bioavailability. Consumption of
curcumin together with black pepper increases uptake, the component within the black
pepper that facilitates this uptake is piperine. Piperine also exhibits antioxidant activity
with significant chemo-preventative and immunomodulary effects (164). However,
treating an older population with a combination of piperine and curcumin is not
recommended as piperine is known to irritate the bowel, which could be a serious
complication. Studies are being conducted with the aim of improving the bioavailability
of curcumin for future research (165).
Studies in India and Singapore have shown an association between green tea
consumption and decreased risk of AD; the most active ingredient of green tea is
epigallocatechin gallate (EGCG), and consumption of at least five cups per day is
required for effects to be observed (166). EGCG is a polyphenol which exhibits potent
antioxidant and anti-inflammatory properties, and it has been shown to confer
neuroprotection in AD mouse models. The accumulation of iron at sites where neurons
degenerate is thought to play a major role in the oxidative stress-induced process of
neurodegeneration. EGCG possesses iron-chelating properties, thereby conferring
additional potential protective mechanisms (88). EGCG is also known to activate αsecretase which cleaves APP via the non-amyloidogenic pathway (Figure 1.2) to prevent
Aβ formation (166).
A high intake of vitamin C and vitamin E from food may be associated with a lower
incidence of AD. Studies on supplement use are, however, prone to bias; a select
proportion of the population take supplements and these people may also either possess
more health problems or demonstrate additional beneficial lifestyle behaviours. There
are also differences in absorption and biological activity between antioxidants from
foods and antioxidants from supplements. Several studies have examined the
relationship between AD and intake of vitamin C and E from supplements: a case
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control study (167) and a prospective study (168) showed no association, whilst
another prospective study showed association with vitamin C but not with vitamin E
(169). A randomised controlled trial performed on AD patients, showed that those who
took vitamin E supplements had a slower progression of the disease than those who
ingested a placebo; it is conceivable therefore that high intake of antioxidants may slow
the progress of AD by reducing neuronal loss due to oxidative damage (170).
Supplement intake is however of shorter duration than food intake which generally
reflects long-term ingestion. If duration of antioxidant intake is more important than
dose, constant life-time intake from food would be more likely to be related to AD risk
than short-term high intake from supplements (162).
The standardised extract from the leaves of the Ginkgo biloba tree, labelled EGb761
(Ginkgo biloba) is one of the most popular herbal supplements. The proposed action of
Ginkgo biloba relates to its free-radical scavenging action, which is supported by
numerous in vitro and in vivo studies (171), including one in which pre-treating
cerebellar granule cells with Ginkgo biloba effectively attenuated oxidative damage
(172). Abnormalities in mitochondrial function are suggested to be associated with the
pathological changes seen in AD, and Ginkgo biloba has been proposed to have direct
protective effects on mitochondria (173): this may also contribute to its antioxidant
effects, as the mitochondrial respiratory chain is both the major target and the major
source of ROS. Ginkgo biloba may also stabilise the cellular redox state by upregulation of the protein level and activity of antioxidants (174). Reports suggest that
despite the preclinical promise that Ginkgo biloba may be effective in the treatment and
prevention of AD, this has not completely translated to clinical research benefits. Most
reviews to date have shown inconsistent results and failed to draw conclusions as to
whether Ginkgo biloba has clinically-relevant benefits in AD patients. One study with
176 participants could not demonstrate any evidence of effectiveness of 120 mg of
Ginkgo biloba in mild to moderate dementia (175). Furthermore, the Ginkgo Evaluation
of Memory Study found no favourable effects of 240 mg Ginkgo biloba on the
prevention of dementia onset in older people without AD or with MCI (176). In a
review by Weinmann et al. (177) however, it was concluded that Ginkgo biloba
ingestion produced favourable effects compared to placebo in relation to improvements
in cognition for patients with AD, vascular or mixed dementia. Their analysis showed
that a dosage of 240 mg might be necessary to yield results. Participant numbers ranged
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from 18 participants to 513, the average number of participants over the nine studies
was 249. All studies involved ingestion of either 120 mg or 240 mg Ginkgo biloba or
placebo, with the duration of the studies ranging from 12 to 52 weeks.
1.8.3.1.2. Fats and cholesterol
HDL particles carry cholesterol to the liver where it is processed and excreted from the
body, whereas LDL particles adhere to the walls of arteries causing plaque build-up,
which decreases blood flow and increases risk of a cardiac event. Therefore HDL
cholesterol (HDL-C) has been termed ‘good cholesterol’ and LDL cholesterol (LDL-C)
‘bad cholesterol’. Moderate alcohol intake has been associated with protection against
CVD in observational studies, an effect that appears to be mediated in large part by
alcohol-induced increases in HDL-C concentrations. The increase in HDL-C
concentrations with moderate alcohol intake results from increased transport rate of the
major HDL apolipoproteins apoA-I and -II (178).
In some European studies, a moderate dietary intake of alcohol is associated with a
decreased risk of dementia; however, the specific alcoholic beverages that mediate this
benefit are unknown, and evidence to the contrary also exists. A study by Luchsinger et
al. (179) concluded that individuals older than 65 years of age had a lower risk of AD if
they demonstrated a light to moderate intake of wine, there was no association with beer
or liquor, and this was restricted to individuals without the APOE ε4 allele. One
possible explanation for this could be that the presence of the APOE ε4 allele increases
the risk of AD in such a way that it overwhelms the potential protective mechanism of
wine. While it is not known why APOE ε4 allele carriers do not benefit from moderate
alcohol consumption, it is known that the APOE ε4 allele is associated with poor
clearance of Aβ and that alcohol increases HDL which is thought to play a role in Aβ
clearance. It is feasible therefore that the influence of moderate alcohol intake is not
sufficient for APOE ε4 allele carriers to increase HDL levels and thus increase clearance
of Aβ. We cannot exclude the possibility that it is not the effect of alcohol on HDL,
rather that other social and lifestyle related factors that ‘go together’ with certain
drinking habits are responsible for the reported favourable associations between alcohol
drinking and cognition. It is worthy of note however that there are also limitations to
previous studies on alcohol and risk of AD, including misclassification of alcohol
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consumption and assumption that alcohol intake was stable over time, when it is
probable that there is significant intra-person variation in alcohol intake.
If alcohol does provide a true protective effect, it is possible that the risk of dementia is
decreased at the expense of increasing other co-morbidities, including factors associated
with the high caloric intake of alcohol. Many of these alcohol-related studies have not
taken into account nutritional status of participants, for example whether they have
other risk factors like obesity or fatty liver, as under these conditions it is easily
appreciable that alcohol would not show a positive effect. Furthermore, the proposed
beneficial effect of alcohol on AD may be due to its association with decreased risk of
coronary disease, a risk factor for AD (179).
High intakes of total fat, saturated fat and cholesterol are associated with increased risk
of AD and CVD. High intakes of polyunsaturated fatty acids (PUFA) are associated
with a decreased risk for AD. There are two types of PUFA associated with AD, omega3 PUFA and omega-6 PUFA. One example of an omega-3 PUFA dietary source is fish,
and consumption of fish has been shown to be inversely related to AD, even at
relatively low levels. The omega-3 PUFA in fish have anti-inflammatory properties,
they can decrease the production of cytokines in humans; these are immune signalling
molecules believed to be involved in the pathogenesis of AD. PUFA also have a role in
brain development and the functioning of nerve membranes, and so may be of
importance in the regeneration of nerve cells. Brain autopsies have shown decreased
PUFA content in the hippocampus and frontal grey matter of AD brains, compared to
normal aged brains (180).
Docosahexaenoic acid (DHA) is an omega-3 PUFA, and fish is a direct dietary source
of DHA. DHA can also be synthesised endogenously through a process of desaturation
and elongation of precursor omega-3 PUFA, alpha-linolenic acid (ALA) and
eicosapentaenoic acid (EPA). DHA is an important lipid in neuronal membranes, where
it has a structural and functional role. DHA modulates properties of the hydrophobic
core of the membrane bilayer, including conferring a high degree of flexibility, and
directly interacting with membrane proteins, thereby impacting on speed of signal
transduction, neurotransmission, and the formation of lipid rafts (181). Animals fed
diets enriched with omega-3 PUFA have better regulation of neuronal membrane
excitability, increased levels of neurotransmitters, higher density of neurotransmitter
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membrane receptors, increased hippocampal nerve growth, greater fluidity of synaptic
membranes, higher levels of antioxidant enzymes, decreased levels of lipid peroxides,
reduced ischemic damage to neurons, increased cerebral blood flow and superior
learning acquisition and memory performance, compared to animals fed control diets
(182). Other findings reported by Morris et al. (183) showed that people who consumed
one fish meal a week had a 60% decreased risk of developing AD than those that rarely
or never ate fish. Of the omega-3 PUFA only DHA was protective against development
of AD. Intake of ALA was protective but only among people with the APOE ε4 allele.
No protective effect was associated with EPA consumption; however, intake was only
at low levels, so an effect at higher intake levels cannot be ruled out.

High intakes of monounsaturated fatty acids (MUFA) are also associated with lowering
LDL cholesterol and decreasing risk of AD (184), primary sources of MUFA include
olive oil and canola oil. It has been recommended that people at risk of obesity,
metabolic syndrome and diabetes should avoid refined sugars and white flour, and
should eat whole unrefined foods, with natural fats, especially fish, nuts, olives and
olive oil, in order to reduce their risk of AD in later life (88). Studies of olive oil have
shown that the MUFA are not the only beneficial components of the oil though, as
(virgin) olive oil contains biophenols and squalenes (oleocanthal, tyrosol, hydrotyrosol,
and oleuropein) which provide exceptional antioxidant activity; for example, biophenols
suppress the synthesis of LDL (185).
1.8.3.1.3. Homocysteine level

Elevated plasma homocysteine levels have been associated with increased risk of
carotid atherosclerosis and stroke (186). Both carotid atherosclerosis and stroke have in
turn been shown to increase the risk of AD (187). It can subsequently be hypothesised
that high homocysteine levels are a risk factor for AD. Numerous studies have
investigated this association, and reported a strong link between high homocysteine
levels and increased risk of AD (188-195). Furthermore, high levels of homocysteine at
AD diagnosis have been associated with rapid disease progression, increased cognitive
decline and atrophy of the medial temporal lobe (188, 196-199). Folate, vitamin B12 and
B6 are co-factors in the methylation of homocysteine (200), which is an intermediate
compound of the metabolic cycle of methionine (201). When the essential amino acid
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methionine provides a methyl group to other cell compounds, homocysteine is formed.
The cycle is completed by remethylation of homocysteine to produce methionine, a step
that requires both folate and vitamin B12. Another pathway for removal of homocysteine
is catabolism and entry into the Krebs cycle, which requires vitamin B6. Blockage of
either pathway increases homocysteine concentrations (202). Blood levels of folate,
vitamin B12 and vitamin B6 have been inversely related to homocysteine levels (203207), and therefore anyone with a nutritional deficiency that leads to low blood
concentrations of folate, vitamin B12 or vitamin B6 is at increased risk of raised plasma
levels of homocysteine (208). Several clinical trials have shown that plasma
homocysteine level can be decreased with increased intakes of fruit and vegetables, as
these are high in folate (209-211). Fung et al. (212) reported that their western diet
pattern was positively associated with homocysteine concentration, and their prudent
diet pattern (explained further in section 1.8.3.2.2) was inversely associated with
homocysteine level, and Gao et al. (213) found those with high adherence to a refined
cereals pattern were at greatest risk for high homocysteine level and low vitamin B
status compared to those with a high adherence to a fruit and milk pattern in a Chinese
population. Fruits and vegetables have a pivotal role in the Mediterranean diet (MeDi,
see section 1.8.3.2.1), and homocysteine levels have been shown to be lower in those in
the highest MeDi adherence tertile which may in part explain the reported associations
between high MeDi adherence and lower AD risk (2-4, 214).
Folate occurs in a variety of foods, especially dark green leafy vegetables, citrus fruits,
legumes, egg yolks and liver and kidney. Some bread, cereals and pasta are fortified
with folic acid; the supplementation form of naturally occurring folate. There is greater
folate concentration in vegetables than fruit, which may explain the findings of an
inverse association between vegetable intake and cognitive decline but no association
with fruit intake (215). The human body needs folate to synthesise DNA, repair DNA,
and methylate DNA. Low levels of folate can lead to homocysteine accumulation which
increases AD risk. By keeping homocysteine levels low, folate can protect cerebral
vessels and can prevent accumulation of DNA damage in neurons caused by oxidative
stress and facilitated by homocysteine.
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1.8.3.2. Dietary patterns
Diet is one of the few modifiable preventive health risk factors that affects all people
and is under the control of the individual. It is clear that diet can influence the levels of
undesirable substances in the body, as detailed in the sections above on LDL and
homocysteine. There is also increasing evidence to suggest that components in the
foods we consume interact with each other to impart disease protection and a higher
level of health; this is referred to as food synergy (216, 217). The evidence for health
benefits appear stronger when foods are inserted into synergistic dietary patterns rather
than considered as individual foods or food constituents (218). As an alternative
approach, dietary pattern analysis has emerged (219). Identified dietary patterns are
specific to the populations analysed and may not usually be generalised to all
populations. Future research needs to be conducted within different racial and ethnic
groups with varying dietary practises (220).
1.8.3.2.1. Mediterranean diet
The Mediterranean diet (MeDi) is not a specific diet but a combination of eating habits
traditionally followed by people in the countries bordering the Mediterranean Sea (201).
The MeDi is characterised by a high intake of vegetables, legumes, fruits, cereals, fish
and unsaturated fatty acids (mostly in the form of olive oil), low intake of saturated fatty
acids, meat and poultry, low-to-moderate intake of dairy products (mostly cheese and
yoghurt), and a regular but moderate amount of alcohol (mostly wine and generally with
meals). The MeDi includes many dietary components reported to be beneficial in
reducing neuronal degenerative disease risk (2-4, 221-225), and therefore has received
much attention.
1.8.3.2.1.1. Mediterranean diet, cognition and Alzheimer’s disease risk
Scarmeas et al. have published several papers on MeDi and AD in an American
population (2-4). In these studies they have found that higher adherence to the MeDi is
associated with lower risk for AD and slower cognitive decline. In 2009, they reported
that higher adherence to the MeDi was associated with lower risk of developing MCI
and MCI conversion to AD (222). Compared to subjects in the lowest MeDi adherence
tertile, subjects in the middle MeDi adherence tertile had 17% less risk of developing
MCI, while those in the highest MeDi adherence tertile had 28% less risk
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of developing MCI. There were 482 subjects with MCI, 106 of whom developed AD
during 4.3 years of follow-up. Those in the middle tertile had a 45% less risk of
developing AD and those in the highest tertile had a 48% less risk of developing AD.
The associations between MeDi and risk for development of MCI and of MCI
conversion to AD did not attenuate, even when simultaneously adjusted for more
commonly considered potential confounders such as age, gender, ethnicity, education,
APOE genotype, caloric intake and body mass index (BMI). In a French study of 1410
individuals aged 65 and over, without dementia at baseline and with a follow-up
assessment within five years, it was observed that each additional unit of the MeDi
score was associated with fewer Mini-Mental State Examination (MMSE) errors at
follow-up (1).
By contrast, the Personality and Total Health (PATH) through life study observed that
greater adherence to MeDi was not protective against cognitive decline. The apparent
lack of protection could be explained by the heterogeneous nature of the study
population. Furthermore, only 66 participants from the original 1528 demonstrated any
cognitive decline in the four year follow-up; a limitation with respect to sufficient
statistical power to detect the MeDi effects. The primary outcomes of the study were
MCI, a clinical dementia rating of 0.5, or any mild cognitive disorder at follow-up
(226).
MeDi adherence is also proposed to affect subsequent AD course. In another study by
Scarmeas et al. (4) it was shown that higher adherence to the MeDi was associated with
lower mortality in AD (Figure 1.7). The authors noted a gradual reduction in mortality
risk for higher MeDi adherence tertiles, which suggests a possible dose-response effect.
Translating results into mean survival times, as compared with subjects in the lower
MeDi adherence tertile, those in the middle MeDi adherence tertile lived 1.33 years
longer, whereas those in the highest MeDi adherence tertile lived 3.91 years longer.
Scarmeas et al. detected no differences in MeDi adherence between APOE ε4 carriers
and non-carriers, and no modification of the MeDi-mortality association when adjusted
for APOE genotype.
A prospective study by Gu et al. (227) concluded that a favourable association between
higher adherence to MeDi and lower risk of AD did not seem to be mediated by high
sensitivity C-reactive protein (CRP; index of systemic inflammation), fasting insulin or
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adiponectin (indices of metabolic profile). While biomarker levels were only measured
at baseline, it has been shown that circulating levels of these biomarkers are relatively
stable over three years (228, 229). Other aspects of the inflammatory and metabolic
pathways were not captured by the biomarkers measured by Gu et al. and may however,
be relevant to the observed MeDi-AD association, for example α1-antichymotrypsin and
interleukin 6.

Figure 1.7: Survival curves based on Cox analyses comparing Alzheimer disease
mortality in participants belonging to each Mediterranean diet (MeDi) tertile (p for
trend = 0.004). Low tertile (score 0 to 3) corresponds to lower adherence to MeDi,
middle tertile (score 4 to 5) to middle adherence, and high tertile (score 6 to 9) to
higher adherence to MeDi. The figure is derived from a model that is adjusted for
period of recruitment, age, gender, ethnicity, education, APOE genotype, caloric intake,
smoking,
and
body
mass
index.
From
Scarmeas
et
al.
(4).
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Figure 1.8: The probability of staying Alzheimer’s disease free associated with physical
activity (PA) and Mediterranean diet (MeDi) adherence. Adapted from Scarmeas et al.
(125).
Figure 1.8 illustrates the synergistic relationship between diet and PA on AD risk in an
American population. People undertaking more PA with higher adherence to the MeDi
have a higher probability of staying AD-free for longer, than those who undertake no
PA and have a low adherence to the MeDi.
1.8.3.2.1.2. Mediterranean diet and Alzheimer’s disease risk factors
The MeDi has been associated with lower risk for dyslipidaemia (214, 230),
hypertension (214, 230-232), abnormal glucose metabolism (230, 231), and CVD (223,
230, 233, 234) which are all risk factors for AD.
Scarmeas et al. (235) demonstrated an association between MeDi and cerebrovascular
disease, specifically infarcts measured by MRI; subjects within the highest MeDi
adherence tertile had approximately 40% reduction in the likelihood of a brain infarct
(Odds Ratio (OR): 0.64; 95% confidence interval (CI): 0.42 - 0.97; p for trend = 0.04).
This cohort of 707 elderly individuals was multi-ethnic, including Caucasians,
Hispanics, and African American participants, which increases the translational nature
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of these results. Hispanics adhered more, and African Americans less to the MeDi,
while ethnicity was not related to infarcts.
Gardener et al. (236) has shown that MeDi score is inversely associated with risk of the
composite outcome of ischemic stroke, myocardial infarction, or vascular death after
nine years of follow-up in American males and females, with a mean age of 69 years.
Dietary intake was collected at baseline and substantive changes in diet could have
preceded the pathological changes that were observed. The number of ischemic strokes
and myocardial infarctions was relatively small and therefore may not have provided
sufficient power to detect a significant relationship for these outcomes individually. In
a secondary CVD prevention trial, Vercambre et al. (237) reported that supplements of
vitamins E and C, and beta-carotene did not reduce CVD recurrence or influence
cognitive decline. In addition in 2504 of these women, who were ≥ 65 years of age and
had a follow-up of 5.4 years, adherence to the MeDi was not associated with
cardiovascular profile at baseline or with mean annual rate of cognitive change.
Prevention of cognitive decline may be more challenging in those with existing vascular
disease or risk factors. It is important to note however, that dietary intake was only
measured at baseline; this may not reflect long-term dietary patterns, which may be
more etiologically relevant.
A significant inverse association between MeDi and both systolic and diastolic blood
pressure was observed in a cross-sectional study from a Greek population of 20,343
men and women who had never had a diagnosis of hypertension. It was found that
vegetables and fruit were the principal factors that explained the overall effect of the
MeDi on blood pressure (232). However the components of fruit and vegetables that
confered this benefit are currently unknown.
In a Greek cohort, Trichopoulou et al. (223) found that a higher adherence to the MeDi
was associated with a reduction in total mortality, with a two-point increment in the
MeDi score corresponding to a 25% reduction. Reduction in mortality was evident with
respect to deaths resulting from CVD and cancer, but was more pronounced with
respect to the former. However, this study has limitations as it had a short follow-up
period of 44 months and dietary data was collected only at baseline, therefore, changes
in diet over the follow-up period may have indeed influenced these results.
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A population of 1507 men and 832 women from two different studies in 11 European
countries have shown that higher adherence to the MeDi is associated with a reduced
risk for all-cause mortality (Hazard Ratio (HR): 0.77; 95% CI: 0.68 – 0.88), CHD (HR:
0.61; 95% CI: 0.43 – 0.88), CVD (HR: 0.71; 95% CI: 0.58 – 0.88) and cancer (HR:
0.90; 95% CI: 0.70 – 1.17). This study had a follow-up period of 10 years, and in this
time, 935 participants died (371 from CVD, 233 from cancer, 122 from CHD and 23
from other causes, and 186 had an unknown cause of death). A MeDi score of four or
above was associated with a lower risk of all-cause and cause specific mortality; the
strongest observation was observed for CHD (234).
A large study in the USA has found that MeDi adherence is significantly associated
with reduced all-cause, CVD and cancer mortality. During ten years of follow-up,
27,799 deaths were recorded, from an initial cohort of 380,296 men and women. In
men, the multivariate hazard ratios of mortality from all-cause, cancer, and CVD for the
highest versus the lowest level of adherence was 0.77 (95% CI: 0.74 – 0.80), 0.79 (95%
CI: 0.73 – 0.87) and 0.76 (95% CI: 0.68 – 0.88), respectively. In women, higher
adherence was associated with a 22%, 14% and 21% decreased risk of all-cause (p <
0.001), cancer (p < 0.01) and CVD (p < 0.01) mortality, respectively. The beneficial
effect was more pronounced among smokers with high adherence to the MeDi (238).
Furthermore, Benetou et al. (239) reported a two-point increase in MeDi score was
associated with a 12% reduction in cancer incidence (HR: 0.88; 95% CI: 0.80 – 0.95).
This was in a Greek cohort of 10,582 men and 15,041 women, of which 421 men and
430 women reported incident cancer cases over a median follow-up of 7.9 years.
Mendez et al. (240) have investigated MeDi and obesity. In people already overweight
when the study started, 7.9% of women and 6.9% of men became obese over the mean
3.3 year follow-up, and a high MeDi was associated with significantly lower likelihood
of becoming obese (women; OR: 0.69; 95% CI: 0.54 – 0.89. men; OR: 0.68; 95% CI:
0.53 – 0.89). However, in normal weight individuals who became overweight, MeDi
was not associated with a lower risk for this progression. Although weight was
measured at baseline by study co-ordinators, it was self-reported at follow-up;
measurement error may have attenuated the results. Mendez et al. used an extensive
computerised diet-history instrument with over 600 items to capture intake over the
previous year. The number of items included is greatly increased compared to other
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studies (5, 235, 238, 241, 242), and participant fatigue when completing a questionnaire
of this length may have impaired response accuracy.
A higher baseline adherence to the MeDi has been associated with lower cumulative
incidence of metabolic syndrome compared to those with the lowest adherence (p =
0.003). These findings were reported in 2,563 participants of the Seguimiento
Universidad de Navarra (SUN) Spanish cohort after approximately six years of followup. Participants were excluded at baseline if they had a BMI > 30 kg/m2, or reported
risk factors (diabetes, hypertension, hypercholesterolemia, or hypertriglyceridemia), or
met the criteria for metabolic syndrome. A limitation of this study is the amount of selfreported information, including waist circumference, blood pressure, high density
lipoproteins, triglycerides, and plasma glucose. However, it is worthy to note that more
than 45% of the cohort were health professionals, and therefore this self-reported
information may be subject to increased bias as a result of health knowledge (242).
In a cohort of 13,380 Spanish graduates, who were followed for approximately four
years, those that adhered closely to the MeDi had a lower risk of diabetes. A two-point
increase in the MeDi score was associated with a 35% relative reduction in the risk of
diabetes (incidence rate ratio 0.65; 95% CI: 0.44 – 0.95). A limitation of this study
however, is the number of cases of diabetes identified at follow-up; 33 from an initial
cohort of 13,380, which compromises statistical power. Among participants with the
highest MeDi adherence, there was a high prevalence of risk factors for diabetes,
including older age, higher BMI, family history of diabetes, personal history of
hypertension, and a high proportion of ex-smokers. One would therefore have predicted
a higher incidence of diabetes amongst this group; the reduced risk of diabetes suggests
high MeDi adherence offers substantial potential for diabetes prevention. As reported
earlier in this review, the MeDi has a role in CVD prevention, and given that there are
many common risk factors for CVD and diabetes, it is expected that the MeDi is also
protective against diabetes (241).
When examining factors that influence AD risk, it is important to look at all risk factors
that could be associated. For example, whilst there is high adherence to the MeDi in
Greece, the rate of AD in Greece is not significantly lower than in other countries where
there is a lower MeDi adherence, and this could be due for example to the higher
proportion of people that smoke in Greece.
43

Chapter 1 Introduction literature review

1.8.3.2.2. Other dietary patterns, cognition and Alzheimer’s disease
‘Healthy’ and ‘unhealthy’ dietary patterns are produced by ‘a posteriori’ methods.
There are limited studies relating these types of dietary patterns to AD risk in the
elderly. This could be due to the identified patterns depending on the study cohort,
thereby limiting comparison between studies (243).

In a cross-sectional analysis,

Samieri et al. (6) identified five dietary patterns by cluster analysis, the ‘healthy’ diet
pattern was characterised by higher consumption of fish, fruit and vegetables, and
followers had a significantly lower mean number of errors on the MMSE (test of global
cognition). In another cross-sectional analysis, Akbaraly et al. (7) investigated dietary
patterns produced by principal components analysis including a whole foods pattern
(rich in fruit, vegetables, dried legume and fish) and a processed foods pattern (rich in
processed meat, chocolates, sweet desserts, fried food, refined cereals and high fat dairy
products). The authors found that after adjustment for demographic, behavioural and
health measures, higher consumption of the whole food pattern was associated with
lower odds of cognitive deficit, and higher consumption of the processed food pattern
was associated with higher odds of cognitive deficit. However, after adjustment for
education, these associations were significantly attenuated. Using reduced rank
regression, Gu et al. (219) identified a dietary pattern for which higher consumption
was strongly associated with lower AD risk. This pattern was characterised by higher
intakes of nuts, fish, tomatoes, poultry, cruciferous vegetables, fruits, salad dressing,
and dark and green leafy vegetables, and a lower intake of high fat dairy products, red
meat, organ meat and butter. Current findings reported in the literature are consistent in
their conclusion of a ‘healthy’ or prudent pattern in opposition to a western, ‘unhealthy’
or processed dietary pattern (6, 7, 219, 244, 245). The western diet is a dietary habit
chosen by many people in developed countries, and increasingly in developing
countries. Negative health consequences associated with the western diet are worsened
by the lack of portion control coupled with the trademark western sedentary lifestyle.
The amount of ‘fast food’ and ‘take-out’ restaurants within the Western part of the
world is vast. Furthermore, western supermarkets tend to stock far more packaged and
processed items than anywhere else in the world (246).
A substantial body of evidence suggests a role for inflammation in AD, the relationship
between diet, inflammation and AD, however, remains relatively unexplored. Cavicchia
et al. (247) have created an inflammatory dietary index which aims to provide a tool
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that can categorise individuals’ diets on a continuum from maximally anti-inflammatory
to maximally pro-inflammatory. The index is relatively novel and has not yet been
extensively analysed. Preliminary analysis showed movement toward an antiinflammatory diet was associated with a decrease in the inflammatory marker serum
high-sensitivity CRP (hs-CRP). Analyses using hs-CRP as a dichotomous variable
showed that an anti-inflammatory diet was associated with a decrease in the odds of an
elevated hs-CRP (p = 0.049). The results are consistent with the ability of the
inflammatory index to predict hs-CRP, and they provide additional evidence that diet
plays a role in the regulation of inflammation, even after careful control of a wide
variety of potential confounders (247).

1.9. Summary
Due to the paucity of information regarding dietary pattern adherence, cognitive
decline, risk of AD and AD-related pathology, the results of this thesis will increase
current knowledge and potentially significantly impact the AD field. This subject matter
has not previously been investigated in such a well-characterised ageing cohort as that
of the Australian Imaging, Biomarkers and Lifestyle study of ageing (AIBL). The AIBL
study enables access to a wide range of data, including blood and brain imaging
biomarkers, a comprehensive neuropsychological assessment as well as lifestyle data. It
is hoped that the results of this study will provide guidance regarding aspects of diet that
may contribute to reducing risk or delaying the onset of AD.
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2.1. Introduction
This chapter describes the ethics, research design, participants, and measures of dietary
intake, cognitive performance, blood biomarkers, neuroimaging biomarkers, and other
materials and protocols that have been used for the work described in this thesis.
2.2. Ethics
The Australian Imaging, Biomarkers and Lifestyle study of ageing (AIBL) is approved
by research ethics committees from the major participating institutions; Austin Health,
St Vincent’s Health, Hollywood Private Hospital and Edith Cowan University.
Recognition of the ethics approval from Hollywood Private Hospital was granted by
Edith Cowan University to enable me to undertake my PhD research as a student of the
university. All participants were provided with an information and consent document
that described all procedures, as well as the potential risks and benefits associated with
participation. After being provided with documentation describing all procedures, and
their risks and benefits, signed informed consent was obtained from each participant
before commencement of data collection (for consent and information document see
Appendix 1).
2.3. Study population
The AIBL volunteer database (n = 1112) was created by a partnership between leading
Australian researchers in Alzheimer’s disease and the Australian Commonwealth
Scientific Industrial and Research Organisation (CSIRO) in 2005 (11). The aims of this
collaboration were to establish a well-characterised cohort of older Australian adults
aged 60 years and over, and to collect comprehensive information on cognitive function,
amyloid brain load, blood biomarker levels and lifestyle behaviours every 18 months.
The AIBL cohort is composed of three main groups:
•

cognitively healthy controls (HC)

•

individuals with mild cognitive impairment (MCI)

•

individuals with early-stage Alzheimer’s disease (AD).

A number of high impact studies investigating cognitive function in the aged, lifestyle,
neuroimaging and blood biomarkers of AD have been published utilising data from the
AIBL study (for exhaustive AIBL publication list visit www.aibl.csiro.au). Figure 2.1
shows the tracking of the AIBL cohort from baseline to 36 month follow-up.
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Baseline
(1,112)
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18 Month followup
(968)
Non-Return:
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NMC 3
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(133)
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19

Figure 2.1: Detailed tracking of the whole AIBL cohort between baseline and 36 month follow-up.
Abbreviations: AD, Alzheimer’s disease; AIBL, Australian Imaging, biomarkers and Lifestyle study; MCI, mild cognitive impairment; NMC, healthy control non-memory complainer; SMC, healthy control subjective memory complainer.
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2.4. Recruitment, eligibility screening and exclusion criteria
The recruitment of volunteers was conducted through media advertisements (i.e.
television and radio commercials and newspaper advertisements) in Melbourne and
Perth, Australia, to which more than 4000 individuals responded. Volunteers underwent
eligibility screening by telephone, at which time basic demographics (contact details,
sex, and age) were obtained. In addition, information regarding medical history was
obtained, with specific information collected regarding eligibility. Furthermore,
information related to alcohol intake was collected. All AIBL volunteers were aged 60
years and above at baseline, and excluded if they had a history of non-AD dementia,
schizophrenia, bipolar disorder, significant current depression, Parkinson’s disease,
cancer (other than basal cell skin carcinoma) within the last two years, symptomatic
stroke, insulin-dependent diabetes, uncontrolled diabetes mellitus or current regular
alcohol use exceeding two standard drinks per day for women or four per day for men.
2.5. Classification of participants
All available information (medical history, memory complaints, information from
family, and neuropsychological test data) was utilised to classify individuals as AD,
MCI or cognitively healthy. During clinical review panels, a consensus diagnosis was
assigned for each participant, which included consideration of diagnostic criteria, DSMIV diagnosis (248) and ICD-10 diagnosis (249). Where appropriate, ICD-10 dementia
severity rating (249), NINCDS-ADRDA AD diagnosis (probable or possible) and MCI
classifications were applied. The clinical review panel comprised old age psychiatrists,
a neurologist, a geriatrician and neuropsychologists. MCI diagnoses were made
according to the protocol based upon the criteria of Winblad et al. (250) which are
informed by the criteria of Petersen et al. (251). Consistent with Winblad criteria, all
participants classified with MCI had either personally, or through an informant, reported
memory difficulties (250).
2.6. Study visit
All participants that met the inclusion criteria had a study visit arranged. Study visits
were conducted at three locations in Melbourne and one location in Perth. On the
morning of the participants’ visit, measurements of pulse, blood pressure, height, weight
and abdominal circumference were obtained. Following these measurements, an 80 mL
fasting blood sample was drawn from the antecubital vein using standard venipuncture
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technique. Immediately after blood collection, participants were provided with a light
breakfast after which they were required to fill out a medical history questionnaire
before undergoing a series of cognitive and mood assessments. All procedures were
repeated at 18 month intervals. At baseline and the 36 month follow-up, participants
completed the Cancer Council of Victoria food frequency questionnaire (CCVFFQ). At
the 36 month follow-up, Perth participants were also given instructions on how to
complete the online Australian Commonwealth Scientific Industrial and Research
Organisation food frequency questionnaire (CSIROFFQ). At the 72 month follow-up, a
subgroup of Perth participants completed a modified CSIROFFQ (further described in
section 2.9.3.).
2.7. Measures, materials and instruments
The assessment of each participant required the use of various measures. The measures
and methods used for this thesis are discussed in the following categories; 1) Cohort
characteristics, 2) Dietary intake assessment, 3) Neuropsychological assessment, 4)
Blood biomarker analysis, and 5) Neuroimaging biomarker analysis.
2.8. Cohort characteristics
2.8.1. Demographics, medical history and medication use
All participating individuals completed a detailed questionnaire regarding demographic
information, medical history, medication use, as well as specific questions about
tobacco and alcohol consumption. Demographic information included: marital status,
occupation (past/present), country of birth, living arrangements, handedness, primary
language spoken, years of education, primary source of income, participation in
community organisations and pet ownership. Current or past history of the following
conditions or diseases was collected; hypertension, angina, heart attack, stroke, diabetes,
visual defects, visual colour deficiency, cancer, history of falls, thyroid/parathyroid
disease, gastric complaints, arthritis, kidney disease, liver disease, joint replacement,
epilepsy, serious head injury, neurological disorders, depression, anxiety and psychiatric
disorders. The name, dose and frequency of all medications being taken at time of
assessment were also recorded on this form.
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2.8.2. Blood pressure and body mass index
Blood pressure was measured in the sitting position, before the commencement of
neuropsychological assessment. Both systolic and diastolic blood pressures were
measured using the Welch Allyn DS-65 Tycos Trigger® blood pressure monitor with the
Welch Allyn blood pressure cuff. Height (cm) was measured using a wall mounted
height rod, and weight (kg) using standard scales. Body mass index (BMI) was
calculated as weight (kilograms) divided by height (metres) squared (weight/height2).
2.8.3. Physical activity assessment using the International Physical Activity
Questionnaire
Self-reported habitual physical activity levels were measured using the International
Physical Activity Questionnaire (IPAQ; 252). The IPAQ is a subjective measure that
asks participants to recall the physical activity they completed in the previous seven
days. The questionnaire is separated into five different sections and consists of work
activity, transportation activity, housework, leisure time activity and time spent sitting.
Further, the intensity (i.e. light, moderate, or hard) of the physical activity was
quantified. Each question was allocated a metabolic equivalent score (MET); walking
was allocated 3.3 METs, moderate activities such as swimming and moderate garden
work were allocated 4 METs, whilst vigorous activities were given the metabolic
equivalent scores that ranged from 5.5 – 8 METs, depending on the type of activity
undertaken (252). The MET scores were then multiplied by the number of minutes per
week spent participating in that activity to produce a mean seven day activity score
(MET·min/wk-1). This approach was completed as per the IPAQ user manual
(http://www.ipaq.ki.se) and previous literature (252, 253). The IPAQ has been validated
in various studies which concluded that the IPAQ has acceptable properties for the
measurement of physical activity (252, 254). Individuals who did not properly complete
the IPAQ, or showed signs of over-estimation or over-reporting (more than two
standard deviations above the mean), were excluded from the analyses. The
MET·min/wk-1 IPAQ score was used to stratify the cohort into tertiles for further
analyses.
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2.9. Dietary intake assessment
2.9.1. Cancer Council of Victoria food frequency questionnaire
At baseline and the 36 month follow-up, participants completed the CCVFFQ. Food
frequency questionnaires (FFQ) have been developed as a means of assessing intakes of
foods and nutrients in large scale epidemiological studies and often record intake over
the previous 12 months. The CCVFFQ is a modification of an FFQ that was developed
in the late 1980s to measure diet in the Melbourne Collaborative Cohort Study, and has
been designed specifically for Australian adults. The CCVFFQ is a 74-item selfadministered FFQ which can be scanned to facilitate analysis of dietary intake. This
FFQ has been validated relative to seven-day weighed food records in pre-menopausal
women. Participants were asked to indicate how often they eat each of the 74 food items
using 10 frequency response options ranging from ‘Never’ to ‘3 or more times per day’.
The FFQ also contains three photographs of scaled portions for four foods (used to
calculate a portion size calibrator), questions on the overall frequency of consumption
of fruits and vegetables (used to calibrate the overestimation of these foods in the food
list) and questions on the consumption of foods such as bread that do not easily fit into
the frequency format. The 74 food items are grouped into four categories: 1) cereal
foods; sweets and snacks: 2) dairy products, meats and fish: 3) fruit: and 4) vegetables,
as well as a separate set of questions covering intake of alcoholic beverages. The
responses were analysed at the Cancer Council in Carlton, Victoria, to calculate usual
daily nutrient intake and grams consumed, using software based on the Nutrient Tables
for use in Australia 1995 (NUTTAB95). The output of this analysis consists of the
grams of 68 nutrients consumed per day and grams of 101 foods and beverages
consumed per day for each participant.
2.9.2. Commonwealth Scientific Industrial and Research Organisation food
frequency questionnaire
At the 36 month follow-up, participants in the Perth cohort completed the online
CSIROFFQ to add an extra layer of data to that obtained from the CCVFFQ. The
CSIROFFQ quantifies intake of over 200 foods and beverages. The online CSIROFFQ
was administered at the participant’s residence, over the phone or at our research
institution. The online delivery of the questionnaire ensures completion of all questions
as participants cannot proceed without finishing each section; questions on paper
questionnaires by contrast, can easily be missed. Participants were able to complete the
54

Chapter 2 Materials and methods

questionnaire in multiple sessions in order to prevent non-completion of questionnaires
due to fatigue. Questionnaires were analysed as each FFQ was completed, thus allowing
manual coding to be minimal, and costs to be reduced. A paper version of this online
CSIROFFQ has previously been validated (255-258); the paper version uses an earlier
version of NUTTAB (NUTTAB 1995) compared to the online version (NUTTAB
2006).
Table 2.1 shows an example of the results each participant received immediately after
completion of the online questionnaire. The output analysis provided quantitation of
grams of 456 foods and beverages consumed per day for each participant. Participant
responses were analysed by the CSIRO using food composition derived from the
Australian Food and Nutrient Database 2007 (AUSNUT 2007) and the British Food
Composition Tables. AUSNUT 2007 contains analytical data published in Nutrient
Tables for use in Australia 2006 (NUTTAB 2006) and data from the Food Standards
Australia New Zealand 2006 (FSANZ 2006) analytical program, as well as nutrient data
borrowed from overseas food composition tables, food label information, imputed data
from similar foods and data calculated using a recipe approach.
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Table 2.1: Example of CSIROFFQ results.
Average daily intake of each nutrient

Nutrient

Average Daily Intake

Nutrient

Average Daily Intake

Water

2959.80 g

Alcohol

19.50 g

Energy (total)

5782.03 kJ

Fat (total)

37.23 g

Energy (excluding dietary
fibre)

5460.31 kJ

Saturated fatty acids

11.19 g

Protein

79.50 g

Monounsaturated fatty acids

14.95 g

Carbohydrate (total)

126.91 g

Polyunsaturated fatty acids

7.35 g

Sugars (total)

66.98 g

Linoleic acid

5.44 g

Starch

57.34 g

Alpha linolenic acid

1.59 g

Dietary Fibre

39.96 g

Long chain omega 3 fatty
acids

239.27 mg

Vitamin A (as retinol
equivalents)

749.26 μg

Cholesterol

171.04 mg

Miscellaneous analysis results
Question

Response

Salt added when boiling foods?

No

Salt added to food at the table?

No

Reduced salt canned vegetables usually consumed?

No

Energy intake from macronutrients
Macronutrient

Energy Intake from Macronutrient

Percentage of Total Energy Intake

Protein

1272.07 kJ

22.00 %

Carbohydrate (total)

2157.44 kJ

37.31 %

Alcohol

565.58 kJ

9.78 %

Fat (total)

1377.57 kJ

23.83 %

Abbreviations: CSIROFFQ, Commonwealth Scientific Industrial and Research Organisation food frequency questionnaire; g, grams;
kJ, kilojoule; mg, milligrams; μg, micrograms.
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2.9.3. Modified Commonwealth Scientific Industrial and Research
Organisation food frequency questionnaire
The existing literature suggests that dietary questionnaires need to be specific to the
population being analysed, and also disease specific (259). Certain foods assist with
prevention of different diseases. We have modified the initial online CSIROFFQ
administered at 36 month follow-up to include foods of interest in the field of
Alzheimer’s disease research. These new questions were selected based on current
literature describing major dietary contributors thought to decrease AD risk. Questions
we have added or expanded on include capturing information in relation to the
following:
•

chocolate type

•

increased number of oils – e.g. grape seed, coconut oil added

•

wine type

•

green and white tea

•

pomegranates and pomegranate juice

•

types of grapes

•

types of berries

•

kidney, liver, heart

•

type of meat used in stew/casserole/curry/goulash

•

type of rice

•

type of nuts and seeds

•

supplements consumed

•

herbs and spices consumed
2.9.4. Food frequency questionnaire completion

The HCs in the AIBL cohort completed each FFQ themselves. The MCI participants
had cognitive dysfunction which did not significantly restrict the performance of
activities of daily living; therefore they were also able to complete the FFQ without
assistance. The majority of AD participants in the AIBL study who completed the FFQ
were early stage, mild AD; most were living at home with carers, normally a spouse or
family member. The AD participants either completed the FFQs with assistance from
their carer; alternatively, the carer validated the completed questionnaires afterwards. In
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each case, the carer lived with the AD participant, so either prepared the meals for them,
or was aware of meals they consumed.
The nature of the CSIROFFQ prohibits incomplete questionnaires; they cannot be
submitted online until all questions are answered. By contrast, the CCVFFQs were
manually checked following completion and the participant contacted to provide further
information if any questions were left unanswered.
Participants were excluded from analyses if their energy intake was less than 500 kCal
for women and 800 kCal for men, or greater than 3500 kCal for women and 4000 kCal
for men in either of the dietary questionnaires, as proposed by Willett (260).
2.9.5. Validation study
At the 72 month follow-up assessment, 49 HCs from the Perth cohort were included in a
validation study of the modified CSIROFFQ. The validation study required a second
specific consent form (Appendix 2). The aim of this study was to validate the modified
CSIROFFQ relative to four-day weighed food records in a subset of HC participants.
Participants completed an initial modified CSIROFFQ once before completing a
consecutive four-day weighed food record (which was started within the next three
days). They then completed the questionnaire once again after the four-day weighed
food record (within four days of completion) to assess reproducibility. If participants
had access to the internet at home they completed the online questionnaire themselves
(n = 47). Participants with no internet access at home completed the FFQ over the
phone (n = 2) with a researcher entering the answers into the online form.
Before commencing the validation study, participants attended an orientation session.
During the orientation session, verbal and written instructions regarding the completion
of the four-day weighed food records (Sunday through to Wednesday) were given in
detail to the participants by an accredited practising dietician from Edith Cowan
University. Digital scales (model 1348, Propert) weighing to the nearest gram, and
measuring cups and spoons were provided to each participant, as was a sample of a
completed food record. Each participant was requested to record the weight of all food
and beverages consumed during the four-day period (either at home or away from
home) and to record brand names, methods of food preparation and ingredients of
recipes in a specifically designed diary (Appendix 3). In addition, participants were
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asked to record the amount of any leftover food at the end of a meal or snack either at
home or away from home and to report any dietary supplements consumed. All food
records were reviewed face-to-face with the participant upon completion of the four-day
period and any unclear or missing information was clarified/completed. Four-day
weighed food records were analysed using FoodWorks 7 Professional version 7.0
(Xyris Software (Australia) Pty Ltd, Highgate Hill, QLD) and the AUSNUT 2007
database of Australian Foods, to yield grams per day of foods and beverages consumed.
The grams per day of foods and beverages consumed as documented by the weighed
food records was compared to the intake reported by completion of the modified
CSIROFFQ.
2.9.6. Mediterranean diet score construction
We followed the most commonly described method to construct the Mediterranean diet
(MeDi) score (223). An individual was assigned a value of 1 for each; beneficial
component (fruits, vegetables, legumes, cereals, and fish) if his/her caloric-adjusted
consumption was at or above the gender-specific median; for each detrimental
component (meat and dairy products) where caloric-adjusted consumption was below
the gender-specific median; and for a ratio of monounsaturated fats to saturated fats at
or above the median. Individuals were also assigned a value of 1 for mild to moderate
alcohol consumption (> 5 to < 25 grams per day (g/d) for females and > 10 to < 50 g/d
for males). The MeDi score was generated for each participant by adding the scores for
each category. Thus, the MeDi score could range from 0 to 9, with a higher score
indicating a greater MeDi adherence (227). Table 2.2 shows the components of the
MeDi.
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Table 2.2: Components of the Mediterranean diet
Mediterranean diet

High intake of vegetables
High intake of legumes
High intake of fruits
High intake of cereals
High intake of fish
High intake of unsaturated fatty acids
Low intake of saturated fatty acids
Low intake of meat
Low intake of poultry
Low-to-moderate intake of dairy products
Regular but moderate intake of alcohol

2.9.7. Inflammatory dietary index score construction
A group from the University of South Carolina, led by Professor James Hebert,
developed an inflammatory dietary index (247, 261), with the aim of providing a tool
that could categorise individuals’ diets on a continuum from maximally antiinflammatory to maximally pro-inflammatory. We provided Professor Hebert’s team
with baseline CCVFFQ data, from which they constructed an inflammatory dietary
index score for each AIBL study participant. The inflammatory dietary index
incorporates levels of the following dietary constituents: energy, carbohydrates, protein,
total fat, fibre, cholesterol, saturated fat, monounsaturated fat, polyunsaturated fat,
niacin, thiamine, riboflavin, iron, magnesium, zinc, vitamin A, C and E, folate, betacarotene, garlic and onion. As consumption of anti-inflammatory foods decreases, the
inflammatory dietary index increases. Professor Hebert’s team were blinded to all other
AIBL data i.e. clinical classification, neuropsychological assessment data, blood and
brain biomarker data etc. and all analysis excepting inflammatory dietary index
construction was undertaken by AIBL study researchers in Australia. Table 2.3 shows
the components of the inflammatory dietary index.
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Table 2.3: Components of the inflammatory dietary index
Inflammatory dietary index
Niacin
Thiamine
Riboflavin
Iron
Magnesium
Zinc
Vitamin A
Vitamin C
Vitamin E
Folate
Beta-carotene
Garlic
Onion
2.9.8. Western and prudent diet score construction - factor analysis
We first classified 101 food and drink items from the CCVFFQ into 33 predefined food
groups (Table 2.4) to minimize within person variations in intakes of individual foods.
Where possible, foods were separated into full and reduced fat groups. Individual food
items were preserved if they constituted a distinct item on their own. Factor analysis
(principle components) was conducted to derive dietary patterns based on the 33 food
groups (262). Food groups were entered into the analysis as absolute weight in grams
per day. The factors were rotated by a varimax procedure resulting in non-correlated
factors, to facilitate interpretability of the factors. In determining the number of factors
to retain, we considered; components with an eigenvalue > 1.25, the Scree tests (263),
and the interpretability of the factors. Percentage of variance explained by each factor
was not used as this largely relies on the total number of variables included in the
analysis. We extracted two patterns from the factor analysis; Table 2.5 shows factor
loadings for these two patterns. The larger the loading of a food group to the pattern, the
greater the contribution of that food group to that pattern. The first major pattern was
loaded heavily with red and processed meats, chips, refined grains, potatoes, sweets and
condiments. The second major pattern was loaded heavily with vegetables, fruits and
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nuts. We labelled the first pattern as the ‘western’ pattern and the second pattern as the
‘prudent’ pattern. Labelling of patterns was completed on the basis of our interpretation
of the data and did not represent ‘a priori’ patterns of intake. The factor score for each
pattern was constructed by summing observed intakes of the component food items
weighted by factor loadings. These loadings were used to create a western diet score
and a prudent diet score for the CCVFFQ data collected at baseline.
Table 2.4: Food groupings used in the dietary pattern analysis
Food group
Processed meats
Red meats
Fish
Poultry
Meat pies
Hamburgers
Eggs
Butter
Margarine

Items from FFQ in food group
Bacon, ham, salami, sausage
Beef, veal, lamb, pork
Fish, fried fish, tinned fish
Chicken
Meat pies
Hamburgers
Eggs
Butter, butter and margarine blends
Polyunsaturated margarine, monounsaturated margarine, margarine

Low-fat dairy

Skim milk, reduced-fat milk, yoghurt, low-fat cheese
Hard cheese, soft cheese, ricotta or cottage cheese, firm cheese, cream
cheese, full-cream milk, ice-cream, flavoured milk drink
Muesli, porridge, wholemeal bread, multi-grain bread, rye bread
High-fibre white bread, white bread, rice, pasta
All Bran, Bran flakes, Weet Bix, Cornflakes
Pizza
Crisps, crackers
Chips
Chocolate, cake, sweet biscuits, sugar
Jam, Vegemite
Nuts, peanut butter
Potatoes
Garlic
Celery, mushrooms, capsicum, beetroot, onion
Green beans, peas, other beans, tofu, bean sprouts, soya milk, baked
beans
Spinach, lettuce
Carrots, pumpkin, zucchini, cucumber
Tomatoes, tomato sauce
Broccoli, cauliflower, cabbage
Fruit juice
Avocado, oranges, strawberries, apricots, peaches, mango, apples, pears,
bananas, melon, pineapple, tinned fruit
Light beer, heavy beer
Red wine, white wine, fortified wines
Spirits

High-fat dairy
Whole grains
Refined grains
Other breakfast cereals
Pizza
Snacks
Chips
Sweets
Condiments
Nuts
Potatoes
Garlic
Other vegetables
Legumes
Green leafy vegetables
Dark-yellow vegetables
Tomatoes
Cruciferous vegetables
Fruit juice
Fruit
Beer
Wine
Spirits

Abbreviations: FFQ, food frequency questionnaire.
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Table 2.5: Factor loadings for the two factors (diet patterns) identified from factor
analysis.
Western diet pattern

Prudent diet pattern

Factor 1

Factor loadings

Factor 2

Factor loadings

Red meats

0.50

Dark yellow vegetables

0.72

Processed meats

0.49

Other vegetables

0.61

Chips

0.49

Green leafy vegetables

0.47

Refined grains

0.48

Fruit

0.41

Poultry

0.43

Cruciferous vegetables

0.39

Condiments

0.42

Nuts

0.30

Potatoes

0.40

Whole grains

0.29

Sweets

0.38

Tomatoes

0.29

Other breakfast
cereals

0.35

Fish

0.29

Meat pies

0.32

Low fat dairy

0.26

Margarine

0.31

Potatoes

0.25

High fat dairy

0.30

High fat dairy

-0.25

Dark yellow
vegetables

0.30

Poultry

0.22

Fruit juice

0.30

Garlic

0.21

Snacks

0.29

Snacks

0.20

Beer

0.29

Hamburger

0.24

Pizza

0.23

Low fat dairy

-0.21

2.10. Neuropsychological assessment
A comprehensive battery of neuropsychological tests was administered to all
participants by a trained staff member (11). The tests were chosen by senior
neuropsychologists and psychiatrists of the AIBL study, and were selected based on
international acknowledgement of these psychometric measures and their use in
previous literature. Table 2.6 depicts the order, duration and delay for cognitive
assessments and Table 2.7 shows the cognitive tests and the domains they each
examine, whilst subsequent sections describe each of the tests administered.
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Table 2.6: Order, duration, and delay for cognitive assessments

Task

Trial

Time to next part of
task

Duration
(approximately)

Mini-Mental State
Examination

10 minutes

Digit span

8 minutes

Logical memory I

Immediate story recall

25 – 35 minutes

3 minutes *

California Verbal
Learning Test-II

Retention and
immediate recall

20 minutes

12 minutes *

Rey Complex Figure
Test

Copy

3 minutes

2 - 10 minutes *

Controlled Oral Word
Association Task

3 minutes

Fruit and furniture
total and switching

2 minutes

Rey Complex Figure
Test

3 minute delayed recall

Boston naming test

27 minutes

2 – 10 minutes *
5 minutes *

Logical memory II

Delayed recall

2 minutes *

California Verbal
Learning Test-II

Delayed recall and
recognition

7 minutes *

Digit symbol coding
Rey Complex Figure
Test

2 minutes
30 minute delayed
recall and recognition

5 – 14 minutes *

Clock

2 minutes

The Stroop test

4 minutes
Total ~ 75 minutes

*Time of task variable based on participant’s completion speed.
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Table 2.7: Cognitive tests and the cognitive domains they examine
Cognitive Test

Cognitive domain

Mini-Mental State Examination

Global cognition, dementia screening tool

Logical memory I and II

Verbal learning and memory

California Verbal Learning Test-II

Verbal learning and memory

Rey Complex Figure Test

Visuospatial functioning and memory

Clock

Visuospatial functioning

Controlled Oral Word Association Task

Language, attention and fluent productivity

Digit span

Attention, processing speed and working memory

Digit symbol coding

Processing speed and attention

The Stroop test

Attention and cognitive flexibility

Boston naming test

Visual naming

Fruit and furniture total and switching

Language, attention, fluent productivity and
executive function

2.10.1. Mini-Mental State Examination
The purpose of the Mini-Mental State Examination (MMSE; 264) is to screen for
cognitive impairment or dementia, particularly in the elderly population. The items
included in the MMSE measure orientation (to both time and place), attention and
calculation, language, as well as immediate and delayed recall. A score is given for each
correct answer, with a maximum possible score of 30 points.
2.10.2. Digit span
Digit span is a measure of attention and concentration, and is incorporated in the
Wechsler Memory Scale (WMS) and the Wechsler Adult Intelligence Scale (WAIS-III;
265). The digit span task comprises two separate trials; digits forward and digits
backward. Firstly, in the digits forwards task, a random number sequence consisting of
three numbers is read aloud to the participant, who is then asked to repeat the numbers
back to the examiner in the same order in which they were read. This is followed by
another sequence of the same length. Following correct performance on the previous
shorter sequences, sequences with one extra number are read aloud and the process
continues until the participant makes an error on both of the two sequences of the same
length, or alternatively until they reach the end of the task. In the digits backwards task,
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the process is the same as digits forwards except the participant has to repeat the
numbers to the examiner backwards. The sum of correct digits forward and digits
backward make up the total digit span score.
2.10.3. Logical memory
The logical memory test is from the WMS Revised (266), and assesses the ability of
individuals to recall a short story. In this task, the examiner reads a short story to the
participant and then prompts them to recall as much information from the story as
possible (logical memory I). Twenty five to thirty five minutes following the first
administration of the story, participants are again asked to recall as much information
from the story as they can (logical memory II). The test is scored based on the number
of correct items recalled.
2.10.4. California Verbal Learning Test
California Verbal Learning Test Version 2 (CVLT-II; 267) is a multiple trial learning
and recall task which assesses verbal learning and memory. In this task, the examiner
begins by reading a 16-item word list, list A (four words belong to each of four
semantic categories), and instructs the participant to then say as many items from the
list as they can recall, in any order. During the participant recall, the examiner writes
down the responses verbatim. This list A trial is then repeated a further four times, with
the number of correct items over all five trials summed together, to create the CVLT-II
Retention score. Following the administration of trial 5 of list A, an interference list (list
B), containing different items to the previous list, is then read to the participant, who is
prompted to recall as many words as they can from this interference list. Following their
recall of list B, participants are asked to name as many words as they can recall from list
A forming the CVLT-II Immediate recall score. After a 20 minute delay, participants are
again asked to recall items from list A, with the number of correct items recalled
forming the CVLT-II Delayed recall score. A new list of items is then read to the
participant who is required to answer ‘yes’ if that item was included in list A, and ‘no’
if it was not. In this new list there are items from list A, list B and intrusions. The
number from list A correctly identified is the CVLT-II recognition score and items
falsely thought to be in list A make up the CVLT-II false positive score. Using both of
these scores, the CVLT-II recognition discrimination score is constructed.
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2.10.5. Rey Complex Figure Test
The Rey Complex Figure Test (RCFT; 268) is used as a measure of visuospatial
functioning and memory. Participants are presented with a complex figure, and
instructed to accurately copy it (RCFT copy). Three minutes following the copy,
participants are asked to re-draw the figure from memory to produce the RCFT 3 minute
delay score. Thirty minutes following the initial copy, participants are asked to again redraw the figure from memory to produce the RCFT 30 minute delay score. All three
drawings are scored via standardised procedures to produce the test scores.
2.10.6. Controlled Oral Word Association Task
The Controlled Oral Word Association Task (COWAT) is a verbal fluency task (269),
measuring fluent productivity in the verbal domain. It is part of the Delis-Kaplan
Executive Function System (D-KEFS; 269), which provides a standardised assessment
of higher-level cognitive functions in children, adolescents and adults between the ages
of 8 and 89. In the letter fluency task, participants are asked to name words that begin
with a specified letter (F, A, S), in a time limit of one minute. Participants are also given
the following rules to follow; 1) the word must not be a proper noun, 2) you cannot add
an ending onto a word (suffix) you have already said, e.g. saying ‘run’ and then
‘running’, ‘runner’, ‘runs’, and 3) words cannot be repeated. The number of eligible
words said for each letter are summed, and form the COWAT score.
2.10.7. Category fluency (Animals/Boys’ names) and fruit and furniture
total and switching
This is part of the Delis-Kaplan Executive Function System (D-KEFS; 269) in the same
verbal fluency section as COWAT. The verbal fluency test contains two category
fluency trials and a single switching condition. The category fluency trials are
administered first and require participants to verbally generate as many category
exemplars (animals and then boys’ names) as possible; participants are given 1 minute
for each category. Responses are recorded on paper by the examiner and the score is the
total number of correct responses (number of animals and number of boys’ names
summed together to form one score). Items are counted as correct if they meet the
constraints of the condition and are not repetitions. The second part of the test, the
switching task, measures the ability to generate words fluently while simultaneously
shifting between over learned concepts (category switching). The participant is given 1
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minute to alternately name a piece of fruit, and then an item of furniture. To make the
fruit and furniture total score, participants are given a score for every piece of fruit or
furniture they name, regardless of the order; repeated words are not given a point. To
make the fruit and furniture switching score, participants are given a point for every
correct switch between a fruit and a piece of furniture, even if they have repeated either
of the items previously.
2.10.8. Digit symbol coding
Digit symbol coding, a task that measures attention, working memory and speed, is
from the WAIS-III (265). The administration of the digit symbol coding task requires
participants to copy symbols that have been paired with numbers from a legend/key.
The number of correct symbols copied in a 120 second time limit is recorded.
2.10.9. Clock
The clock drawing test is used to screen for dementia as well as for visuospatial,
constructional and executive difficulties (270). The participant is provided with an
unlined sheet of paper and a pencil and asked to draw the face of a clock with all the
numbers on it. The participant is told to make the drawing big. After completion of the
clock face, they are instructed to set the time to 10 past 11. The clock is scored out of 10
points with criteria for each point. As an example a score of 1 would be given for an
irrelevant, uninterpretable figure or no attempt, a score of 5 would be given for
perseverative or otherwise inappropriate arrangement of numbers (e.g. numbers
indicated by dots) and hands may be represented but do not clearly point at a number. A
score of 10 would be given for a normal drawing, numbers and hands in approximately
correct positions, hour hand distinctly different from minute hand and at 11 o’clock.
2.10.10. The Stroop test
The Stroop test is a timed measure of attention and cognitive flexibility. Various
versions of the Stroop test are available; in this study the Victorian version was used
(271). There are three parts to the task; the first part requires participants to name the
colour of dots. They are given a card with four lines of six dots of four colours (red,
green, yellow and blue). Participants have to read across the rows as quickly as possible
reading out the colour of each dot as they go. The time to complete the task and number
of errors made is recorded. For the second task, a new card with four rows each with six
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words written in four different colours is used. As quickly as possible participants have
to read out the colour the word is written in, again time to complete task and number of
errors is recorded. The third task, the colours task, is the most difficult of the three
Victorian Stroop tasks, and assesses the examinees’ ability to suppress usual responses
for a less favourable, yet correct, response. In this task, a card is presented with words
printed in any of the four colours, however the words are the four aforementioned
colours (e.g. the word ‘green’ printed in the colour red). Participants are asked to name
the colour of the ink of the printed words, not read the actual word. This task requires
the participant to inhibit the automatic response of reading the word, for the more
difficult, naming of the colour. Time to complete task and number of errors is recorded
in seconds.
2.10.11 Boston naming test
The purpose of the Boston naming test is to assess confrontation visual naming ability
using black and white drawings of common objects. The original version was published
in 1987 and included 85 ink drawings, which was later shortened to 60 items. The
version used in the AIBL study is 30 items, including half of these 60 items. Drawings
are two-dimensional line drawings of objects ranging in difficulty, beginning with
common objects with high word frequency for example “tree” and “pencil” and ranging
to lower frequency items such as “trellis” and “palette”. Individuals are allowed
approximately 20 seconds in which to name each drawing, if the correct word is not
produced in that time, a stimulus cue is given (e.g. “used for writing” for “pencil”) and
an additional 20 seconds allowed for a response. If the name is not produced in that
time, a phonemic cue is given (e.g. “pe” for “pencil”) and another 20 seconds allowed
for the correct response. Correct responses for the spontaneously correct and stimuluscued correct answers are combined in calculating the Boston naming test score.
2.10.12 Composite scores
The neuropsychological battery assesses six cognitive domains (verbal and visual
memory, executive function, language, attention and visuospatial functioning).
Composite scores were calculated for each neuropsychological domain by first
converting raw scores for each measure to overall sample-based Z scores, then
averaging Z scores for the relevant measures to compute a single composite score for
that domain. Neuropsychological tests were assigned to one of the six cognitive
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domains on the basis of a consensus among neuropsychologists, psychologists and
neurologists involved in the AIBL study (Table 2.8 shows neuropsychological tests
included in each composite score; 272). We also constructed a global cognitive score for
each individual by summing the six cognitive domain scores and dividing by six.
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Table 2.8: Neuropsychological tests included in each composite score.
Cognitive Domain

Neuropsychological Test

Outcome Measure

Reference

Verbal memory

Logical memory II

Number of details correctly recalled

Wechsler, 1945 (266)

CVLT-II delayed recall

Number of words correctly recalled

Delis et al. 2000 (267)

CVLT-II recognition discrimination

Discrimination index for recognition of words

Delis et al. 2000 (267)

RCFT 3 minute delay

Number of elements correctly recalled

Meyers & Meyers, 1995 (268)

RCFT 30 minute delay

Number of elements correctly recalled

Meyers & Meyers, 1995 (268)

RCFT recognition

Number of elements correctly recognised

Meyers & Meyers, 1995 (268)

Stroop C/D

Speed of Stroop Colours/Stroop Dots

Strauss, Sherman, & Spreen, 2006 (271)

Controlled Oral Word Association Task

Number of words produced in 1 minute

Delis et al. 2001 (269)

Fruit and furniture switching

Number of words produced in 1 minute

Delis et al. 2001 (269)

Category fluency (Animals/Boys' Names)

Number of words produced in 1 minute

Delis et al. 2001 (269)

Boston naming test

Number of pictures correctly named

Saxton et al. 2000 (273)

Digit span

Total correct trials (forwards and backwards)

Wechsler, 1997 (265)

Stroop dots time

Speed of trial

Strauss, Sherman, & Spreen, 2006 (271)

Digit symbol coding

Number of symbols correctly matched

Wechsler, 1997 (265)

RCFT copy

Number of elements drawn correctly

Meyers & Meyers, 1995 (268)

Clock

Score out of 10

Libon, Swenson, Barnoski & Sands, 1993 (270)

Visual memory

Executive function

Language

Attention

Visuospatial functioning

Abbreviations: CVLT-II, California Verbal Learning Test-II; RCFT, Rey Complex Figure Test; Stroop C/D, Stroop colours/dots.
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2.11. Blood biomarker analysis
2.11.1. Blood collection
Blood was collected using the vacuum method of venipuncture from the antecubital
vein. Twenty one gauge 0.75 Winged Infusion Sets were used, with the attachment of
the multi-adapter to aid in blood collection. Fasting blood samples were collected into
serum-separating (for serum isolation) and tubes containing Ethylenediaminetetraacetic
acid (EDTA; for plasma isolation) some of which contained prostaglandin E1 where
quiescence of platelets was required (+PGE1, 33.3 ng/ml, Sapphire Biosciences,
Waterloo, Australia).
2.11.2. Fractionating plasma from whole blood
The tubes containing EDTA+PGE1 were placed on a rocker for 45 to 60 min following
blood collection. After 20 minutes on a rocker, 200 μL of whole blood was transferred
to a 1.5 mL tube for DNA extraction (see below), and the EDTA+PGE1 tubes were
returned to the rocker. These EDTA+PGE1 tubes were then spun at 200 g at 20°C for
10 minutes, with no brake, in an Allegra™ X-15R centrifuge (Beckman Coulter, Brea,
CA, USA). Following the spin, tubes were removed from the centrifuge, and the platelet
rich plasma supernatants were transferred into fresh tubes. The plasma tubes and
EDTA+PGE1 tubes with packed cell volume were then spun again, this time at 800 g
for 15 minutes at 20°C with the brake on before resultant supernatant was transferred to
a new tube. Plasma was aliquoted into 250 μL and 500 μL volumes in Cryobank vials
(Nalge Nunc International, Rochester, NY, USA). The plasma samples were snap
frozen, prior to being transferred to a liquid nitrogen facility for long-term storage.
2.11.3. DNA extraction and Apolipoprotein E genotyping
DNA was extracted from 200 μL of whole blood using the Blood Mini-Kit (Qiagen,
Hilden, Germany). Briefly, each 200 μL of whole blood was added to proteinase K and
200 μL of buffer. After pulse vortexing for 15 seconds, the samples were incubated at
56°C for 10 minutes. Following quick centrifugation, 200 μL of 96-100% ethanol was
added to the tube. The mixture was then applied to the QIAamp Mini Spin Column and
centrifuged at 6000 g for 1 minute. The tube containing the filtrate was discarded and
the QIAamp Mini Spin Column placed into a clean tube, and 500 μL of buffer was
added to the spin column and centrifuged at 6000 g for 1 minute, the filtrate was then
discarded and the mini spin column placed into a new tube. Following this, 500 μL of
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buffer was added to the spin column and centrifuged at 20,000 g for 3 minutes. The spin
column was then placed into a clean tube with the addition of 200 μL of distilled water.
The tube was incubated at room temperature for 1 minute and then centrifuged at 6000
g for 1 minute. The extracted DNA was Apolipoprotein E (APOE) genotyped via a
method previously described (274). Briefly, genomic DNA was amplified with 200 nM
primer (APOE-F 5’ – GCCTACAAATCGGAACTGGA and APOE-R 5’ –
ACCTGCTCCTTCACCTCGT) in one unit of Platinum Taq polymerase (Invitrogen,
Carlsbad, CA, USA), 1.5 mM magnesium chloride, and 200 μM deoxyribonucleotide
triphosphate with denaturation at 94°C for 7 seconds, followed by 30 cycles of 94°C for
30 seconds, 55°C for 30 seconds and then 72°C for 30 seconds. Sequencing was
completed with BDV3.1 (Applied Biosystems, Foster City, CA, USA) using the APOEF primer on a 3130-xl genetic analyser. From this, the APOE genotype for each
participant was determined. The size of the fragments determined the genotype with the
possible results being: APOE ε2/ε2: 2 fragments (91bp, 83bp); APOE ε3/ε3: 3
fragments (91bp, 48bp, 35bp); APOE ε4/ε4: 3 fragments (72bp, 48bp, 35bp); APOE
ε2/ε4: 5 fragments (91bp, 83bp, 72bp, 48bp, 35bp); APOE ε3/ε4: 4 fragments (91bp,
72bp, 48bp, 35bp) and APOE ε2/ε3: 4 fragments (91bp, 83bp, 48bp, 35bp). APOE
genotyping was undertaken by Dr Simon Laws.
2.11.4. Pathology blood testing
Numerous blood-based analytes were quantified using standard analysis techniques at
PathWest Laboratory Medicine, Nedlands, Western Australia and Melbourne Health,
Victoria. Normal ranges for each of these analytes are listed below. From serum clotted
and EDTA tubes the following analytes were measured: haemoglobin (115 – 160 g/L),
red blood cell count (3.8 – 4.8 x1012/L), platelet count (150 – 400 x109/L), white cell
count (4 – 11 x109/L), neutrophils (2.0 – 7.5 x109/L), lymphocytes (1.2 – 4.0 x109/L),
monocytes (0.2 – 1.0 x109/L), eosinophils (0.00 – 0.50 x109/L), basophils (0.0 – 0.2
x109/L), plasma homocysteine (6.0 – 14.0 μmol/L), plasma glucose (3.0 – 5.4 mmol/L),
plasma total cholesterol (< 5.5 mmol/L), plasma triglycerides (< 1.7 mmol/L), plasma
low density lipoprotein (< 3.0 mmol/L), and plasma high density lipoprotein (> 1.0
mmol/L). Erythrocyte sediment rate (1 – 35 mm/hr) was measured from sodium citrate
tubes.
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2.11.5. Plasma apolipoprotein E assessment
Plasma apolipoprotein E (apoE) was measured using a commercial kit (apoE4/Pan apoE
Enzyme-linked immunosorbent assay (ELISA), MBL co., Ltd., Woburn, USA). This kit
measures the amount of total apoE using affinity purified polyclonal antibodies against
apoE by sandwich ELISA. Briefly, the plasma samples were thawed and then diluted
1:500 using the Assay Diluent solution provided. Standards were prepared to working
concentrations from dilutions of the provided calibrator, which was reconstituted 1:10
with the assay diluents solution. All plasma samples, Controls, and Standards were run
in duplicate. Thawed (room temperature) diluted plasma samples or standards were
loaded into microwell strips, coated with anti-Human Pan-apoE antibody. The plates
were covered and incubated for 60 min at 37°C prior to being washed four times with
wash solution. 100 μL of a peroxidase conjugated anti-apoE polyclonal antibody was
then added prior to incubating for 60 min at 37°C. The plates were again washed before
100 μL of the peroxidase substrate was added and incubated for a further 30 min at
37°C. An acid solution (100 μL) was then added to each well to terminate the enzyme
reaction and stabilize the developed colour. The optical density of each well was
measured at 450 nm using a BMG microplate reader. Concentrations of Pan-apoE were
determined from a standard curve based on reference standards. The sensitivity of the
assay for pan- apoE is 8 ng/ml. The measurement of apoE was undertaken by Dr Veer
Gupta.
2.11.6. Rules Based Medicine biomarker panel analysis
Plasma samples were analysed with a 151-analyte multiplex Human DiscoveryMAP®
v1.0 panel (Rules Based Medicine, RBM; Austin, TX, USA). All samples below the
lower limit of quantification were classed as missing data. From this panel we analysed
markers of inflammation (cortisol, C-Reactive protein (CRP), tumour necrosis factor
alpha (TNFɑ), complement component 3 (C3), cluster of differentiation 40 (CD40),
CD40 ligand, migration inhibitory factor (MIF), macrophage inflammatory protein 1
alpha (MIP1α), macrophage inflammatory protein 1 beta (MIP1β), tumour necrosis
factor receptor II (TNFRII), immunoglobulin M (IgM), interleukin 10, 13, 18, 3, 4, and
8 (IL10, IL13, IL18, IL3, IL4, and IL8) and interleukin 1 receptor antagonist (IL1ra))
and markers of metabolic syndrome (adiponectin, angiotensinogen, glucagon-like
peptide-1, glucagon, insulin, leptin and resistin) for associations with each of the dietary
patterns constructed.
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2.11.7. Lipid profiles
The Lipoprint system (Quantimetrix, Redondo Beach, CA, USA) was used to examine
the plasma cholesterol sub fraction profiles of study participants following the kit
instructions. Briefly, 25 μL of plasma EDTA was combined with 200 μL of the
supplied loading buffer in glass gel tubes and allowed to polymerise for 30 minutes.
Samples were then separated in the electrophoretic chamber for one to one and a half
hours at 3 mA per tube. Finally, gels were scanned and the band intensity of each sub
fraction was obtained using the supplied software. The high density lipoprotein analysis
provided values for ten subclasses of high density lipoprotein which were divided into
three major groups named high density lipoproteins large (subclasses 1 - 3), high
density lipoproteins intermediate (subclasses 4 - 6) and high density lipoproteins small
(subclasses 7 - 10). To obtain the low density lipoprotein sub fraction profiles, 25 μL of
plasma was mixed with 300 μL of the loading buffer and analysed in the same way as
for the high density lipoprotein kit. The low density lipoprotein analysis provided values
for very low density lipoproteins, intermediate density lipoproteins (three subclasses A,
B and C separately), and low density lipoproteins (seven subclasses grouped into two:
subclasses 1 and 2, and subclasses 3 - 7). Lipoprint analysis was undertaken by Mr
Steve Pedrini and Dr Eugene Hone.
2.12. Neuroimaging biomarker analysis
2.12.1. Image acquisition
2.12.1.1. Magnetic resonance imaging
To assess brain structure and volume, participants underwent T1 weighted magnetic
resonance imaging (MRI) using the ADNI 3-dimensional (3D) Magnetization Prepared
Rapid Gradient Echo (MPRAGE) sequence and fluid-attenuated inversion recovery
(FLAIR) sequence on 1.5T or 3T scanners.
2.12.1.2. Pittsburgh compound-B positron emission tomography
To determine brain amyloid beta load, participants underwent a [11C] Pittsburgh
compound-B positron emission tomography (PiB PET) scan at Austin Health Centre for
PET, Melbourne or Western Australia PET and cyclotron service, Sir Charles Gairdner
Hospital and Oceanic Medical Imaging, Perth. [11C] PiB production was performed
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using a one-step [11C] methyl triflate approach. The average radiochemical yield was
30% after a synthesis time of 45 minutes with a purity of > 98% and a specific activity
of 30 ± 7.5 GBq/μmol. Each individual received an intravenous injection of ~370 MBq
[11C] PiB over one minute. PET images were acquired on a Phillips AllegroTM (Phillips
Medical Systems, Eindhoven, The Netherlands) PET camera, 40 - 70 minutes post-PiB
injection. A transmission scan was performed for attenuation correction. PET images
were reconstructed using a 3D RAMLA algorithm using a voxel size of 2.0 x 2.0 x 2.0
mm3 (x y z). Summed images for the 40 - 70 minute time frame were used.
2.12.2. Image processing
2.12.2.1. Magnetic resonance imaging tissue segmentation
For each individual, the T1 weighted images were classified into grey matter, white
matter and cerebrospinal fluid using an implementation of the expectation maximization
segmentation algorithm (275). Briefly, using a mix of Gaussian distributions, this
algorithm models image intensity histograms. The parameters of the Gaussian mixture
are iteratively updated using an expectation maximisation approach. In order to provide
initialization and spatial consistency to the expectation maximisation algorithm, an atlas
and associated probability maps of grey matter, white matter and cerebrospinal fluid
were spatially normalized to each individual scan, first through an affine registration,
and then using a diffeomorphic non-rigid registration (276). The regions of interest
(ROI; hippocampus, anterior cingulate gyrus, posterior cingulated gyrus, temporal lobes
and others) were propagated from the atlas to the T1W to extract the various regional
volumes. To improve the robustness of the approach, the process was repeated nine
times, with different elderly atlases, resulting in nine segmentations and nine ROIs. The
segmentations and the ROIs were voted to generate a consensus grey matter, white
matter and cerebrospinal fluid segmentation as well as a consensus ROI for the
investigated brain regions. The grey matter segmentation was then used to mask out non
grey matter voxels from the ROI. Region of interest volumes were averaged over both
hemispheres. The processing of MRIs was performed by Dr Pierrick Bourgeat of
CSIRO, Brisbane. All volumetric measures of brain regions were corrected for
intracranial volume (ICV) using the following equation:
Adjusted volume = raw volume – b x (ICV – mean ICV); where b is the slope of the
regression of an ROI on ICV.
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2.12.2.2. Pittsburgh compound-B positron emission tomography image
analysis
Acquired [11C] PiB PET images were processed using a semi-automatic ROI method.
The semiautomatic method used a preset template of narrow cortical ROIs that were
applied to the PiB scan via placement on the individuals co-registered MRI by an
operator who was blind to the individuals clinical status. Co-registration of each
individual’s MRI with the PET images was performed with SPM5 (Statistical
Parametric Mapping 5, University College London, UK; 277). The region of interest
template was placed on the co-registered MRI and then transferred to the co-registered
PET images. Follow-up PiB images were co-registered with the baseline PiB images
and the same ROI templates were applied to baseline and follow-up scans. Standardised
uptake values (SUV) for PiB were calculated for all brain regions examined and
standardised uptake value ratios (SUVR) were generated by dividing all regional SUV
by the cerebellar cortex SUV. The cerebrellar cortex was used as a reference region as it
is relatively devoid of senile plaques and shows no PiB binding in controls or AD (48,
278). Region of interest measurements were averaged across both hemispheres.
Neocortical Aβ burden was expressed as the average SUVR of the area-weighted mean
for the following ROIs: frontal (consisting of dorsolateral prefrontal, ventrolateral
prefrontal and orbitofrontal regions), superior parietal, lateral temporal, lateral occipital
and anterior and posterior cingulate. The image analysis of PiB PET scans was
performed by Dr Victor Villemagne and colleagues of Austin Health, Melbourne.
2.13. Statistical analysis
The data contained within this thesis were analysed using various statistical methods
that were deemed appropriate for the hypotheses to be investigated. All statistical
analyses were performed using IBM SPSS Statistics 19 for Windows Vista (SPSS Inc.,
Chicago, IL, USA) or R version 2.14.2 (R Foundation for Statistical Computing,
Vienna, Austria). Unless otherwise stated, a p-value of 0.01 or smaller determined a
significant result for all analyses to balance the risk of type I and type II errors, due to
the large number of statistical tests performed.
2.13.1. Chapter 3 statistical analysis
Descriptive data analyses were undertaken to provide means, standard deviations and
percentages for the entire cohort, and for the cohort following stratification by clinical
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classification. For determination of the absence or presence of a relationship between
clinical classification groups, independent samples t-tests were performed for
continuous data and chisquare (χ2) for categorical data. A p-value of 0.05 or smaller
was deemed significant for these analyses as they are exploratory in nature.
Multinomial logistic regression analyses were run to determine the association between
the continuous baseline diet scores (independent variable) and baseline participant
clinical classification (dependent variable; HC as the reference). The regression model
included age, gender, years of education (≤ 12 years, or > 12 years), APOE ε4 allele
carriage, country of birth (Australia or other), current smoking status, energy intake,
BMI and history of stroke, hypertension, heart attack, diabetes and angina as covariates.
For the remaining analyses, only participants classified as baseline healthy controls
were utilised. Descriptive data analyses were undertaken to provide means, standard
deviations and percentages for the entire healthy control cohort and for the cohort
following stratification by gender and APOE ε4 allele carriage. For determination of the
absence or presence of a relationship between males and females, and APOE ε4 allele
carriers and APOE ε4 allele non-carriers, independent samples t-tests were performed
for continuous data and chisquare (χ2) for categorical data. Bivariate Pearson’s
correlations were undertaken to evaluate the relationship between the four diet scores at
baseline. Multiple linear regression analyses were run to determine the association
between the baseline continuous diet scores and cognitive function variables (in healthy
controls only). The multiple linear regression analyses measured the association
between each diet score (independent variable) and cognitive function (dependent
variable) with age, gender, years of education, APOE ε4 allele carriage, country of birth,
BMI, energy intake, past smoking status, and history of stroke, hypertension, heart
attack, diabetes and angina as independent covariates. In a second model without
cardiovascular (CVD) risk factors, the same variables were used excluding past
smoking status, history of stroke, hypertension, heart attack, diabetes and angina.
Analyses were re-run following gender and APOE genotype stratification.
A series of repeated measures linear mixed model (LMM) analyses (using maximum
likelihood estimation and an unstructured covariance matrix) were conducted to
examine the relationship between baseline diet score and time (baseline, 18 and 36
month follow-up) with respect to cognitive change. In the first model (model 1),
baseline diet score, time, APOE ε4 allele carriage status (presence or absence of ε4
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allele; the most common genetic risk factor for AD), BMI, country of birth (Australia or
other), years of education (≤ 12 years, or > 12 years), past smoking status, energy
intake, history of angina, stroke, hypertension, heart attack, and diabetes were entered as
fixed factors; participant as a random factor; age as a covariate; and cognitive composite
score as the dependent variable. Model 2 included the same covariates as model 1, but
without the CVD risk factors of past smoking status, history of hypertension, angina,
stroke, heart attack and diabetes. Analyses were repeated following sex and APOE
genotype stratification of the cohort. The portion of variance explained was estimated
by comparing the fixed effect variance with and without that particular term in the
LMM.
Finally, a change in clinical classification variable was made by assigning each
participant a 0 if they remained a HC from baseline to the 36 month follow-up and a
score of 1 if they changed to MCI or AD status. This change in classification variable
was then used in multinomial logistic regression models to calculate odds ratios for the
investigation of the association between change from healthy control clinical
classification to MCI or AD status and the four diet scores divided into tertiles; odds
ratios compared the lowest tertile with the highest tertile. For the MeDi score,
individuals with a score of 3 or lower (lowest adherence to MeDi) were assigned to
tertile 1, those with a score of 4 or 5 were assigned to tertile 2, and those with a score of
6 or higher (highest adherence to MeDi) were assigned to tertile 3. For the inflammatory
dietary index, western and prudent diets, the participants’ scores were arranged into
increasing order of adherence and then divided equally into thirds, with the lowest
adherence third to each pattern assigned to tertile 1, the middle third assigned to tertile 2
and the highest adherence third assigned to tertile 3. The same two adjusted models
were used as used in the linear mixed models.
2.13.2. Chapter 4 statistical analysis
Descriptive data analyses were undertaken to provide means, standard deviations and
percentages for the entire cohort; these analyses were repeated after stratification of the
cohort by gender and APOE ε4 allele carriage. For determination of the absence or
presence of a relationship between males and females, and APOE ε4 allele carriers and
APOE ε4 allele non-carriers, independent samples t-tests were performed for continuous
data and chisquare (χ2) for categorical data.
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2.13.2.1. Metabolic syndrome analysis
A metabolic syndrome index was constructed for each individual. We assigned each
participant one point for each of the following five components; 1) obesity (BMI ≥ 25);
2) raised BP (systolic ≥ 140 and/or diastolic ≥ 90 and/or a history of hypertension); 3)
high triglyceride level (> 2 mmol/L); 4) low high density lipoprotein level (≤ 1.0
mmol/L) and; 5) impaired fasting glucose and/or a history of diabetes (glucose level 6.1
≥ x ≤ 6.9 mmol/L). The points were summed to produce an index ranging from 0 - 5,
with a higher score indicating higher risk of metabolic syndrome.
Multiple linear regression analyses were run to determine the association between the
continuous diet scores (independent variable) and this index, as well as the components
of the index separately and additional biomarkers of metabolic syndrome measured as
part of the AIBL study (dependent variable): angiotensinogen, adiponectin, glucagonlike peptide 1, glucagon, insulin, leptin, resistin, apoE. The multiple linear regression
model included age, gender, years of education (≤ 12 years, or > 12 years), APOE ε4
allele carriage, country of birth (Australia vs. Other), BMI and energy intake kCal as
covariates. For the components of the metabolic syndrome index analysed separately,
the models also contained the four other components as covariates.
A metabolic syndrome index was constructed for 36 month follow-up data, using the
same method as for the baseline metabolic syndrome index. The 36 month follow-up
index was subtracted from the baseline index to give a value for ‘change’ in the index
over 36 months. If the index increased participants were assigned a value of 1, if there
was no change in the index participants were assigned a value of 2, and if the index
decreased participants were assigned a score of 3.This ‘change’ in index variable was
then used in multinomial logistic regression models to calculate odds ratios for the
investigation of the association between baseline dietary pattern adherence and change
in metabolic syndrome risk. The four diet scores were divided into tertiles for this
analysis; odds ratios compared the lowest tertile with the highest tertile. For the MeDi
score, individuals with a score of 3 or lower (lowest adherence to MeDi) were assigned
to tertile 1, those with a score of 4 or 5 were assigned to tertile 2, and those with a score
of 6 or higher (highest adherence to MeDi) were assigned to tertile 3. For the
inflammatory dietary index, western and prudent diets, the participants’ scores were
arranged into increasing order of adherence and then divided equally into thirds, with
the lowest adherence third to each pattern assigned to tertile 1, the middle third assigned
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to tertile 2 and the highest adherence third assigned to tertile 3. The same adjusted
model was used as in the linear regression models earlier in this section. After
stratification of the cohort based on gender and APOE ε4 allele carriage all of these
analyses were re-run.
2.13.2.2. Cardiovascular disease analysis
A CVD index was constructed for each individual. We assigned each participant one
point for each of the following nine components; 1) obesity (BMI ≥ 25); 2) raised BP
(systolic ≥ 140 and/or diastolic ≥ 90 and/or a history of hypertension); 3) a history of
angina; 4) a history of stroke; 5) a history of heart attack; 6) a history of smoking; 7) a
history of diabetes; 8) low physical activity (being in the lowest tertile of physical
activity as measured by the IPAQ) and; 9) elevated homocysteine level (> 10 μmol/L).
The points were summed to produce an index ranging from 0 - 9, with a higher score
indicating higher risk of CVD.
Multiple linear regression analyses were run to determine the association between the
continuous diet scores (independent variable) and this index, and additionally the
components of the index separately (dependent variable). The multiple linear regression
model included age, gender, years of education, APOE ε4 allele carriage, country of
birth and energy intake kCal as covariates. For the components of the CVD index
analysed separately, the models also contained the eight other components as covariates.
Additional CVD biomarkers were measured as part of the PathWest analytes at baseline
and 36 month follow-up, including cholesterol, triglycerides, high density lipoproteins,
and low density lipoproteins. These biomarkers were investigated in the same linear
regression analysis as the CVD index, as well as via a longitudinal change in biomarker
level, which was determined for these four biomarkers by subtracting the baseline level
from the 36 month follow-up level; these ‘change scores’ were analysed with the
baseline diet scores to investigate dietary patterns being predictive of biomarker level
change at 36 month follow-up.
Lipid profiles were further analysed at baseline using a Lipoprint system. From this data
the three fractions of high density lipoproteins (large, intermediate and small), very low
density lipoproteins, intermediate density lipoproteins (three subclasses A, B and C
separately), and low density lipoproteins (seven subclasses grouped into two, subclasses
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1 and 2, and subclasses 3 – 7) were investigated in the same linear regression analysis as
the CVD index to assess dietary pattern associations with lipid profiles.
A CVD index was constructed for 36 month follow-up data, using the same method as
for the baseline CVD index. The 36 month follow-up index was subtracted from the
baseline index to give a value for ‘change’ in the index over 36 months. If the index
increased participants were assigned a value of 1, if there was no change in the index
participants were assigned a value of 2, and if the index decreased participants were
assigned a score of 3. This ‘change’ in index variable was then used in multinomial
logistic regression models to calculate odds ratios for the investigation of the
association between baseline dietary adherence and change in CVD risk. The four diet
scores were divided into tertiles for this analysis; odds ratios compared the lowest tertile
with the highest tertile. For the MeDi score, individuals with a score of 3 or lower
(lowest adherence to MeDi) were assigned to tertile 1, those with a score of 4 or 5 were
assigned to tertile 2, and those with a score of 6 or higher (highest adherence to MeDi)
were assigned to tertile 3. For the inflammatory dietary index, western and prudent
diets, the participants’ scores were arranged into increasing order of adherence and then
divided equally into thirds, with the lowest adherence third to each pattern assigned to
tertile 1, the middle third assigned to tertile 2 and the highest adherence third assigned
to tertile 3. The same adjusted model was used as in the linear regression models earlier
in this section. After stratification of the cohort based on gender and APOE ε4 allele
carriage all analyses was re-run.
2.13.2.3. Inflammation analysis
A range of inflammation biomarkers were analysed via Rules Based Medicine as part of
the AIBL study at baseline. We constructed a blood-based inflammation biomarker
index using these biomarkers (cortisol, CRP, TNFα, C3, CD40, CD40 ligand, MIF,
MIP1α, MIP1β, TNF RII, IgM, IL10, IL13, IL18, IL1ra, IL3, IL4, and IL8). There are
no definitive published ‘normal range’ levels for some of these biomarkers, we assigned
a value of one to participants with biomarker levels falling in the top 20% of each
biomarker measured (so if an individual had high levels of these biomarkers we would
expect them to have higher inflammation), participants where levels of each biomarker
fell outside the top 20% were assigned a value of 0. We then added the scores for each
biomarker to construct an inflammation index with a score ranging from 0 to 18. We
then made a blood-based inflammation biomarker index 2 using pathology test results
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measured at baseline (haemoglobin, red blood cell count, erythrocyte sediment rate,
platelet count, white cell count, neutrophils, lymphocytes, monocytes, eosinophils and
basophils). Again we assigned a value of one to participants with analyte levels falling
in the top 20% of each biomarker and a value of 0 to participants where levels fell
outside the top 20%. We then added the scores for each biomarker to construct the
second inflammation index with a score ranging from 0 to 10. Multiple linear regression
analyses assessed both indexes as well as the components of the indexes separately in
relation to the four dietary patterns. The diet score was used as the independent variable,
biomarker or index level was used as the dependent variable with the inclusion of age,
gender, years of education APOE ε4 allele carriage, country of birth, energy intake and
BMI as covariates.
At 36 month follow-up, the pathology test results were again measured, we made a 36
month follow-up blood-based inflammation biomarker index 2, using the same method
as for the baseline blood-based inflammation biomarker index 2. The 36 month followup index was subtracted from the baseline index to give a value for ‘change’ in the
index over 36 months. If the index increased participants were assigned a value of 1, if
there was no change in the index participants were assigned a value of 2, and if the
index decreased participants were assigned a score of 3. This ‘change’ in index variable
was then used in multinomial logistic regression models to calculate odds ratios for the
investigation of the association between baseline dietary adherence and change in
inflammation level. The four diet scores were divided into tertiles for this analysis; odds
ratios compared the lowest tertile with the highest tertile. For the MeDi score,
individuals with a score of 3 or lower (lowest adherence to MeDi) were assigned to
tertile 1, those with a score of 4 or 5 were assigned to tertile 2, and those with a score of
6 or higher (highest adherence to MeDi) were assigned to tertile 3. For the inflammatory
dietary index, western and prudent diets, the participants’ scores were arranged into
increasing order of adherence and then divided equally into thirds, with the lowest
adherence third to each pattern assigned to tertile 1, the middle third assigned to tertile 2
and the highest adherence third assigned to tertile 3. The same adjusted model was used
as in the linear regression models earlier in this section.
To analyse chronic inflammation we assessed the relationship between baseline dietary
patterns (independent variable) and the 36 month follow-up blood-based inflammation
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biomarker index 2 and the components individually (dependent variable) using linear
regression analysis.
All analyses were repeated following stratification of the cohort by gender and APOE
ɛ4 allele carriage.
2.13.2.4. Neuroimaging biomarker analysis
Multiple linear regression analyses were run to determine the association between the
continuous diet scores and neuroimaging biomarkers. An adjusted model measured the
association between each of the four diet scores (independent variable) and brain
biomarker levels (dependent variable) with the inclusion of age, gender, years of
education, APOE ε4 allele carriage, country of birth, energy intake, and BMI as
covariates. Baseline diet scores were analysed against baseline MRI brain region
volumes and PiB PET SUVR (continuous) as a measure of brain amyloid burden. A
‘change’ in biomarker level was also determined for MRI brain region volumes and
continuous PiB PET SUVR by subtracting the baseline level from the 36 month followup level. This ‘change’ score was then analysed with the baseline diet scores to
investigate dietary patterns being predictive of imaging biomarker level change at 36
month follow-up. After stratification of the cohort based on gender, APOE ε4 allele
carriage and PiB PET status (positive or negative) all of these analyses were re-run.
Finally, we analysed PiB PET SUVR as a binary score (0 = PiB PET negative (SUVR <
1.5), 1 = PiB PET positive (SUVR ≥ 1.5)). This binary score (PiB PET negative as the
reference) was used in multinomial logistic regression models to calculate odds ratios
with the same confounding variables controlled for as in the multinomial logistic
regressions earlier in this section. The four diet scores were divided into tertiles for this
analysis (method to calculate tertiles is described in section 2.13.2.3.); odds ratios
compared the lowest tertile with the highest tertile. There were insufficient numbers of
‘converters’ from PiB PET negative to PiB PET positive over the 36 month follow-up
period to provide sufficient statistical power to observe associations between change in
the PiB binary score, therefore this analysis was not undertaken. After stratification of
the cohort based on gender and APOE ε4 allele carriage multinomial logistic regressions
were re-run.
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For all statistically significant associations, the portion of variance explained was
estimated by comparing the fixed effect variance with and without that particular term
in the linear regression.
2.13.3. Chapter 5 statistical analysis
Descriptive data analyses were undertaken to provide means, standard deviations and
percentages for the 49 participants that took part in the validation study; these analyses
were repeated after stratification of the cohort by gender. For determination of the
absence or presence of a relationship between males and females, independent samples
t-tests were performed for continuous data and chisquare (χ2) for categorical data.
For the reliability study, modified CSIROFFQ data was found to be normally
distributed by the Kolmogorov-Smirnov test statistic. Pearson’s correlation coefficients
between the first and second administration of the modified CSIROFFQ were used to
compare the daily food and beverage intakes from the two FFQs and evaluate
reproducibility. The intra-class correlation coefficient (ICC) was calculated as an
indication of test-retest reliability and a measure of the existing within-subject
variability. It is the ratio of variability between participants and total variation, meaning
that the ICC is the fraction of the variability due to causes other than variability within a
participant. Thus, when the ICC is close to 1, this indicates that a single observation
suffices, in that if a subsequent observation were taken, it is likely to be similar to the
original. For items with a low consumption we constructed groups for these
correlations. The groups were made for steamed, baked or grilled fish, oven baked fish,
fried fish, canned fish, milk, cordial, flavoured milk, milkshake or thick shake,
mayonnaise, salad dressing, gravy, cheese, cream, yoghurt, ice-cream, custard, cereals,
popcorn, fats and oils, nuts, seeds, berries, mushrooms, homemade soup, canned soup,
packet soup, souvlaki or gyros, chicken or fish burgers, hamburgers, chicken breast,
thigh or wings, meat goulash, curry, stew or casserole and kidney and liver.
Pearson’s and intra-class correlation coefficients between the first administration of the
modified CSIROFFQ and the four-day weighed food records were used to compare the
daily food and beverage intakes from the FFQ and weighed food records to evaluate
validation of the modified CSIROFFQ.
The validation study revealed there were 12 items added to the modified CSIROFFQ for
which intake as determined by completion of the modified CSIROFFQ was
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significantly correlated with intake documented by completion of the four-day weighed
food record (as determined by Pearson’s correlation coefficients; Section 5.2.3. and
Table 5.3). These 12 items were divided into those for which consumption is proposed
to be beneficial in terms of AD risk and those for which the contrary is suggested.
Participants were assigned a value of 1 for each of the proposed beneficial items if their
consumption was at or above the sex-specific median intake level (total fish, olives,
dark chocolate, total grapes, sesame seeds, sunflower seeds, total seeds, almonds and
total nuts). By contrast, participants were assigned a value of 1 for each of the proposed
detrimental items if their consumption was below the sex-specific median intake level
(white rice). Total chocolate and total rice were not incorporated in the construction of
the ‘AD diet index’, as elements of these food items are expected to be beneficial in
terms of AD risk (dark chocolate and brown rice) whilst other elements are proposed to
be detrimental with respect to AD risk (milk chocolate and white rice). The points were
summed to produce a score ranging from 0 to 10, with a higher score proposed to be
‘beneficial’ in terms of AD risk. Table 2.9 lists the characteristics of the ‘AD diet
index’. Of the 49 individuals who participated in the validation study, and consequently
for whom an ‘AD diet index’ was constructed, no one achieved an ‘AD diet index’
score of 0, 9 or 10. To further divide individuals into proposed ‘higher’ or ‘lower’ AD
risk categories on the basis of ‘AD diet index’ scores, participants with a score of 1 – 4
were assigned a binary value of ‘1’ to represent proposed ‘higher’ AD risk, and
participants with a score of 5 – 8 were assigned a binary value of ‘0’ to represent
proposed ‘lower’ AD risk.
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Table 2.9: Characteristics of the ‘Alzheimer’s disease diet index’
‘Alzheimer’s disease diet index’
High intake of total fish
High intake of olives
High intake of dark chocolate
High intake of total grapes
High intake of sesame seeds
High intake of sunflower seeds
High intake of total seeds
High intake of almonds
High intake of total nuts
Low intake of white rice

The mean neuropsychological test scores for a range of cognitive test MMSE, CVLT-II
delayed recall, recognition and recognition discrimination, RCFT 3 minute delayed
recall and COWAT; see section 2.10.4. for details of test administration and scoring
protocols) were compared between the proposed ‘low’ and ‘high’ AD risk groups
determined on the basis of ‘AD diet index’ adherence. Independent samples t-tests were
initially used to compare means between the two AD risk groups for their
neuropsychological test scores followed by general linear models in order to control for
the most common confounding variables with respect to diet and AD research, i.e. age,
gender, years of education, APOE ε4 allele carriage, country of birth, and BMI. All
analysis were cross-sectional, with the data from the assessment time-point closest to
the date of the validation study utilised in the analysis.
Mean levels of the PathWest blood-based inflammatory biomarkers analysed in section
4.2.4.2. (haemoglobin, red blood cell count, erythrocyte sediment rate, platelet count,
white cell count, neutrophils, lymphocytes, monocytes, eosinophils and basophils) were
compared between the proposed ‘high’ and ‘low’ AD risk groups again determined on
the basis of ‘AD diet index’ adherence using the same methods to those utilised for the
cognition analysis undertaken in the cognition analysis in this section. (i.e. independent
samples t-tests followed by general linear models controlling for common confounders).
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Thirty seven of the 49 participants included in the validation study had undergone a PiB
PET scan. Depending on their PiB PET SUVR they were classified as either PiB PET
negative or PiB PET positive). In multinomial logistic regressions, this binary score
(PiB PET positive 1, PiB PET negative 0) was used to calculate the odds of being PiB
PET positive rather than PiB PET negative if individuals are in the proposed ‘high’ AD
risk group compared to the ‘low’ AD risk group.
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3.1. Introduction
The world’s population is growing older due to improved healthcare and nutrition. As a
result, Alzheimer’s disease (AD) prevalence is rapidly increasing. Cognitive decline is
the progressive loss of cognitive functions, including memory, and may lead to
dementia of which AD is the most common type, accounting for 60 - 80% of cases
(279). The focus of the current research climate is shifting from understanding AD
pathology and diagnosis to primary prevention and intervention strategies. Diet
represents one potential intervention strategy accessible to all.
Individuals consume diets that contain both nutrient and non-nutrient substances rather
than single foods. Consequently, misleading conclusions on the effect of consumption
of a single nutrient, food or dietary component on health outcomes can be drawn. It may
be more useful therefore to examine indices of food and nutrient intake that express
several related aspects of diet concurrently rather than focus on consumption of single
nutrients (280): as a result, dietary pattern analysis has emerged (219).
There are two methods to derive dietary patterns, ‘a priori’ and ‘a posteriori’. ‘A priori’
patterns are hypothesis-driven, they require prior knowledge of diet and diseases and
make use of existing methods to calculate a dietary pattern (158): an example of this is
the Mediterranean diet (MeDi). ‘A posteriori’ patterns are exploratory in nature; they
use statistical methods such as principle components analysis, cluster analysis or
reduced rank regression to derive dietary patterns from previously collected data (243,
281).
Results from previous studies on the association between dietary patterns and cognitive
decline are inconsistent. Several American and European studies have shown a positive
relationship between adherence to the MeDi and slower cognitive decline or reduced
AD risk (1-7). By contrast, studies have concluded that higher consumption of the MeDi
is not protective against cognitive decline (226, 282, 283). Methodological and cohort
variations may account for the contradictory results. Studies examining risk of cognitive
decline using ‘a posteriori’ developed dietary patterns are limited in number, they have
generally found that higher consumption of food from an ‘unhealthy’ dietary pattern
rich in processed foods is associated with increased cognitive decline with the converse
true for a ‘healthy’ or ‘whole food’ dietary pattern (6, 7). To our knowledge, the
association between food consumption from dietary patterns rich in either anti- or pro93
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inflammatory foods with AD risk and cognitive decline has not previously been
investigated. There is a need for further longitudinal investigation of potential
associations between dietary patterns and cognitive decline as well as AD risk in wellcharacterised ageing cohorts: this study aims to address this need.
3.1.1. Methods
Our study utilised a well-characterised, elderly, Australian cohort, taken from the larger
Australian Imaging, Biomarkers and Lifestyle study of ageing (AIBL; 11). All
participants underwent an extensive neuropsychological assessment at baseline, 18 and
36 month follow-up. At each time point, individuals were classified by a clinical panel
(comprising old age psychiatrists, a neurologist, a geriatrician and neuropsychologists)
as cognitively healthy control, mild cognitive impairment (MCI) or AD. Using data
collected via administration of the Cancer Council of Victoria food frequency
questionnaire (CCVFFQ; see Section 2.9.1. for detailed methods) four dietary patterns
were constructed. A MeDi and inflammatory dietary index were constructed using an ‘a
priori’ method and a western and prudent diet pattern by factor analysis (principle
components); an ‘a posteriori’ method. The MeDi is characterised by a high intake of
vegetables, legumes, fruits, cereals, fish and unsaturated fatty acids, low intake of
saturated fatty acids, meat and poultry, low-to-moderate intake of dairy products, and a
regular but moderate intake of alcohol. The inflammatory dietary index includes intake
of foods and nutrients thought to counteract inflammation, including niacin, thiamine,
riboflavin, iron, magnesium, zinc, vitamin A, C and E, folate, beta-carotene, garlic and
onion. A higher consumption of these components results in a lower inflammatory
dietary index. The ‘healthy’ prudent diet pattern includes high consumption of
vegetables, fruit and nuts. Whilst the ‘unhealthy’ western diet includes high
consumption of red and processed meats, chips, refined grains, potatoes, sweets and
condiments. The components of the four dietary patterns are summarised in Table 3.1.

94

Chapter 3 The association of four dietary patterns with clinical classification and cognitive decline

Table 3.1: Components of the four dietary patterns

Mediterranean diet

Inflammatory
dietary index

Prudent diet

Western diet

High intake of vegetables

Niacin

Vegetables

Red meat

High intake of legumes

Thiamine

Fruit

Processed meat

High intake of fruits

Riboflavin

Nuts

Chips

High intake of cereals

Iron

Whole grains

Refined grains

High intake of fish

Magnesium

Tomatoes

Poultry

High intake of

Zinc

Fish

Condiments

unsaturated fatty acids

Vitamin A

Low fat dairy

Potatoes

Low intake of

Vitamin C

Potatoes

Sweets

saturated fatty acids

Vitamin E

Poultry

Breakfast cereals

Low intake of meat

Folate

Garlic

Meat pies

Low intake of poultry

Beta-carotene

Snacks

Margarine

Low to moderate intake of Garlic

High fat dairy

dairy products

Dark yellow

Regular

but

intake of alcohol

Onion
moderate

vegetables
Fruit juice
Snacks
Beer
Hamburger
Pizza
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3.1.2. Chapter aims
This chapter utilises dietary data and neuropsychological assessment data collected as
part of the longitudinal prospective AIBL study to address the following aims:
1) To investigate cross-sectionally the association of four dietary patterns; MeDi,
inflammatory dietary index, western diet and prudent diet, with baseline clinical
classification.
2) To investigate longitudinally the association of these four dietary patterns with
cognition and cognitive change over a three year follow-up period, using a
comprehensive battery of neuropsychological tests.
3) To assess longitudinally whether dietary pattern adherence influences the rate of
transition from healthy control to MCI or AD clinical classification.
Whilst the literature is conflicting, we hypothesise that:
1) Healthy controls have a higher adherence to the MeDi and prudent diet than AD and
MCI participants.
3) Healthy controls have a lower adherence to the western diet pattern and the
inflammatory dietary index than AD and MCI participants.
4) Higher prudent diet and MeDi adherence is associated with less cognitive decline
over 36 months on a range of cognitive assessments compared with lower prudent and
MeDi adherence.
5) Higher western diet adherence and a higher inflammatory dietary index is associated
with increased cognitive decline over 36 months on a range of cognitive assessments
compared with lower western diet adherence and a lower inflammatory dietary index.
6) Higher prudent diet or MeDi adherence at baseline is associated with a decreased
number of participants transitioning from healthy control clinical classification to MCI
or AD after 36 months.
7) Higher western diet adherence and a higher inflammatory dietary index at baseline is
associated with an increased number of participants transitioning from healthy control
clinical classification to MCI or AD after 36 months.
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3.2. Results
3.2.1 Descriptive statistics for the baseline clinical classification analysis
The adherence to dietary patterns and baseline clinical classification analysis included
723 healthy controls (HC), 98 MCI and 149 AD participants who completed the
CCVFFQ at their baseline assessment. The cohort as a whole had an average age of
71.7 ± 7.9 years. Nearly half of the cohort was male (42%), and nearly half had 12 or
less years of education (49%). The average body mass index (BMI) of the cohort at
baseline was 26.2 ± 4.2 kilograms per metres squared (kg/m2).
Inter-classification differences were apparent at baseline. Unsurprisingly, AD
participants were older than both MCI and HC subjects (p < 0.001; ANOVA). The AD
group also had a higher percentage of people carrying an Apolipoprotein (APOE) ε4
allele (p < 0.001; χ2), and a higher percentage of individuals with 12 or less years of
education than the MCI and HC groups (p = 0.007; χ2). The HCs had a higher BMI than
MCI and AD participants (p < 0.001; ANOVA). In regards to cardiovascular risk
factors, the MCI group had a higher percentage of participants with a history of angina
than the AD and HC groups (p = 0.017; χ2), and ADs had a higher percentage of people
with a history of stroke than the HC and MCI groups (p < 0.001; χ2). The descriptive
statistics of the cohort as a whole and following stratification of the cohort by clinical
classification are shown in Table 3.2.
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Table 3.2: Descriptive statistics for the whole cohort and for HC, MCI and AD participants at baseline.
Whole cohort

HC

MCI

AD

(n = 970)

(n = 723)

(n = 98)

(n = 149)

p-values for interclassification
differences

71.7 ± 7.9

69.9 ± 7.0

76.0 ± 7.8

77.5 ± 8.2

0.000

Gender; male; n (%)

407 (42)

303 (42)

41 (42)

63 (42)

0.996

Country of birth; Australian; n (%)

687 (71)

519 (72)

63 (64)

105 (70)

0.308

Presence of APOE ε4 allele; n (%)

331 (34)

186 (26)

52 (53)

93 (62)

0.000

Body mass indexi; kg/m2

26.2 ± 4.2

26.5 ± 4.2

25.6 ± 3.8

24.8 ± 4.3

0.000

Energy intake; kCal

1695 ± 599

1691 ± 594

1710 ± 618

1702 ± 616

0.942

76 (8)

51 (7)

11 (11)

14 (8)

0.263

387 (40)

292 (40)

39 (40)

56 (38)

0.817

Angina; n (%)i i

70 (7)

43 (6)

13 (13)

14 (9)

0.017

Heart attack; n (%)i i

50 (5)

33 (5)

7 (7)

10 (7)

0.360

Stroke; n (%)i i

33 (3)

14 (2)

2 (2)

17 (11)

0.000

Current smoker; n (%)

29 (3)

25 (3)

4 (4)

0 (0)

0.063

Education ≤ 12 y; n (%)

447 (49)

355 (46)

53 (54)

89 (60)

0.007

Age; y

Diabetes; n (%)i i
Hypertension; n (%)i i

Unless otherwise stated, data are presented as mean ± standard deviation of the mean. Bold indicates statistical significance (p < 0.05); Characteristics compared using analysis of variance for continuous variables and χ2 for categorical
variables. iBody mass index is calculated as weight in kilograms divided by height in meters squared. iiHistory of diabetes, hypertension, angina, heart attack or stroke determined by participant self-reported medical history. Abbreviations:
APOE, Apolipoprotein E; AD, Alzheimer’s disease; HC, healthy control; kCal, kilocalorie; Kg, kilogram; m2, meter squared; MCI, mild cognitive impairment; y, years.
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3.2.2 Comparison of diet scores and clinical classification groups
Mean scores were calculated for each of the four dietary patterns both for the cohort as a
whole at baseline and following stratification of the cohort by clinical classification. For
the cohort as a whole, the mean MeDi score at baseline was 4.4 ± 1.6, mean prudent
score was 234.8 ± 121.7, mean western diet score was 133.2 ± 122.3, and mean
inflammatory dietary index was 0.83 ± 1.5. Following stratification by clinical
classification, a significant difference in all four mean dietary pattern scores was
observed between the three clinical classification groups (p < 0.01; ANOVA; Table
3.3).
To further explore the relationship between adherence to each of the four dietary
patterns and clinical classification at baseline, we used multinomial logistic regressions.
The most common confounding variables were controlled for in all analyses, i.e. age,
gender, years of education, APOE ε4 allele carriage, country of birth, BMI, energy
intake, smoking status, and history of hypertension, angina, stroke, diabetes and heart
attack: these variables can affect the outcome of the analysis and failure to include them
in the models can cause misestimates of relationships.
We found that healthy control participants had a higher adherence to the MeDi than
participants with AD or MCI (p < 0.001 and p < 0.05, respectively; Figure 3.1A). There
was no difference in MeDi adherence between MCI and AD participants. Healthy
control participants also had a higher adherence to the prudent diet than participants
with AD or MCI (p < 0.001 and p < 0.05, respectively), and in this case, a difference
was observed between MCI and AD participants with the MCI group demonstrating
higher adherence to the prudent diet than participants with AD (p < 0.05; Figure 3.1B).
In contrast, healthy control and MCI participants had a lower western diet score than
AD participants (p < 0.001 and p < 0.01, respectively; Figure 3.1C) with no difference
in western diet adherence observed between healthy control and MCI participants.
Further, healthy control participants had a higher consumption of anti-inflammatory
foods (indicated by a lower mean inflammatory dietary index) than those with AD (p <
0.001) and MCI (p < 0.01), whilst there was no difference in the inflammatory index
between AD and MCI participants (Figure 3.1D).
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Table 3.3: Mean dietary pattern scores for the whole cohort and for HC, MCI and AD participants at baseline.

MeDi score

Whole cohort
(n = 970)

HC
(n = 723)

MCI
(n = 98)

AD
(n = 149)

p-values
for interclassification
differences

4.4 ± 1.6

4.6 ± 1.6

4.0 ± 1.6

3.8 ± 1.6

0.000

211.8 ± 127.6

176.5 ± 116.1

0.000

132.0 ± 116.8

165.0 ± 110.4

0.002

1.05 ± 1.5

1.23 ± 1.6

0.000

Prudent diet score

234.8 ± 121.7

Western diet score

133.2 ± 122.3

Inflammatory dietary index

0.83 ± 1.5

250.0 ±
118.0
126.8 ±
124.4
0.72 ± 1.4

Data are presented as mean ± standard deviation of the mean. Bold indicates statistical significance (p < 0.01); Characteristics compared using analysis of variance for continuous variables. Abbreviations: AD, Alzheimer’s disease;
HC, healthy control; MCI, mild cognitive impairment; MeDi, Mediterranean diet.
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Figure 3.1: Comparison of mean diet scores for HC, MCI and AD participants at baseline
using multinomial logistic regressions adjusted for necessary covariates. A – MeDi score, B –
prudent diet score, C – western diet score, D – inflammatory dietary index.
Bars represent mean (± standard error). Models adjusted for age, gender, years of education, APOE ε4 allele carriage, country of
birth (Australia vs. Other), body mass index, energy intake kCal, current smoking status, and history of hypertension, angina,
stroke, diabetes and heart attack. * p < 0.05, ** p < 0.01, *** p < 0.001. Abbreviations: APOE, Apolipoprotein E; AD, Alzheimer’s
disease; HC, healthy control; kCal, kilocalorie; MCI, mild cognitive impairment; MeDi, Mediterranean diet.

These results suggest that AD participants in our study had a higher adherence to the
‘unhealthy’ western diet pattern, lower consumption of anti-inflammatory foods, and a
lower adherence to the ‘healthy’ MeDi and prudent dietary patterns at baseline
compared to cognitively ‘healthy’ controls. However, this analysis is cross-sectional
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and therefore we cannot conclude that decreased adherence to a ‘healthy’ dietary pattern
or conversely increased adherence to an ‘unhealthy’ dietary patterns is a risk factor for
AD. It is possible that AD diagnosis may result in a change of dietary habits.
Furthermore, we are using an FFQ that requires estimations of food intake over the
previous year, there is potential therefore for misclassification due to limited accuracy
in estimations, particularly with regard to MCI and AD participants. Consequently,
from this point onwards, to assess the relationship between diet and cognitive decline,
we will only utilise data collected from individuals classified as healthy control at
baseline.
3.2.3 Descriptive statistics for the healthy control cohort
All healthy control participants with a completed CCVFFQ at baseline and cognitive
testing at three time points (baseline, 18 and 36 month follow-up) were included in the
following analyses assessing cognition and cognitive decline: this decreased the number
of healthy control participants included in subsequent analysis from 723 (sections 3.2.1.
and 3.2.2.) to 527.
The average age of the healthy control cohort at baseline was 69.3 ± 6.4 and nearly 40%
were male. Twenty eight per cent had at least one APOE ɛ4 allele, over 45% had 12 or
less years of education and nearly 80% were born in Australia. With respect to the
cardiovascular risk factors; 7.2% had diabetes, 38.1% had a history of hypertension,
5.7% had a history of angina, 4.9% had a history of heart attack, 1.9% had previously
suffered a stroke and 43.3% were past smokers. Mean BMI was 26.3 ± 4.2 and mean
energy intake was 1708 kCal. The average baseline MeDi score was 4.6 ± 1.6, the
average prudent diet score was 307.5 ± 130.0, the average western diet score was 144.3
± 148.9, and the average inflammatory dietary index was 0.67 ± 1.4 (Table 3.4).
Due to reported associations between cognition and gender, the healthy control cohort
was also assessed following stratification by gender. There were several differences
observed between males and females. Females had a higher percentage of people born
in Australia (p = 0.014; χ2), a higher percentage with 12 or less years of education (p =
0.020; χ2) and a lower mean BMI (p = 0.032; ANOVA). As expected, males had a
higher energy intake (p < 0.001; ANOVA). Amongst the male group there was also a
higher percentage of people with a history of angina, a history of heart attack and who
102

Chapter 3 The association of four dietary patterns with clinical classification and cognitive decline

are past smokers (p = 0.020, p = 0.021 and p < 0.001, respectively; χ2). With respect to
the diet scores, the western diet score was significantly higher in males and the
inflammatory dietary index was significantly higher in females (p < 0.001; ANOVA;
Table 3.4).
When the healthy control participants were stratified by APOE ɛ4 allele carriage (the
major genetic risk factor for AD), the only difference between APOE ɛ4 allele carriers
and non-carriers was the prudent diet score which was higher in non-carriers (p = 0.017;
ANOVA; Table 3.4).
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Table 3.4: Descriptive statistics for the healthy control cohort as a whole, and subgroups based on stratification of the cohort by gender and APOE ε4
allele carriage.
Whole cohort
(527)

Males (210)

Females (317)

p-values for gender
differences

APOE ε4 carrier (148)

APOE ε4 non-carrier
(379)

p-values for
APOE ε4 carriage
differences

Age at baseline; y

69.3 ± 6.4

69.7 ± 6.2

69.0 ± 6.6

0.250

68.4 ± 6.1

69.6 ± 6.5

0.054

Gender; men; n (%)

210 (39.8)

61 (41.2)

149 (39.3)

0.689

Country of birth; Australian; n (%)

417 (79.1)

155 (73.8)

262 (82.6)

0.014

120 (81.1)

297 (78.4)

0.490

Presence of APOE ε4 allele; n (%)

148 (28.1)

61 (29.0)

87 (27.4)

0.689

Baseline body mass indexi; kg/m2

26.3 ± 4.2

26.7 ± 3.8

26.0 ± 4.4

0.032

26.0 ± 4.2

26.4 ± 4.1

0.340

1708.1 ± 557.2

1972.5 ± 591.7

1532.9 ± 456.0

0.000

1726.1 ± 577.7

1701.1 ± 549.6

0.644

38 (7.2)

16 (7.6)

22 (6.9)

0.768

13 (8.8)

25 (6.6)

0.383

201 (38.1)

75 (35.7)

126 (39.7)

0.351

51 (34.5)

150 (39.6)

0.277

30 (5.7)

18 (8.6)

12 (3.8)

0.020

10 (6.8)

20 (5.3)

0.510

26 (4.9)

16 (7.6)

10 (3.2)

0.021

9 (6.1)

17 (4.5)

0.447

10 (1.9)

6 (2.9)

4 (1.3)

0.189

3 (2.0)

7 (1.8)

0.892

Past smoker; n (%)

228 (43.3)

112 (53.3)

116 (36.6)

0.000

66 (44.6)

162 (42.7)

0.700

Education ≤ 12 y; n (%)

241 (45.7)

83 (39.5)

158 (49.8)

0.020

77 (52.0)

164 (43.3)

0.070

4.6 ± 1.6

4.6 ± 1.7

4.6 ± 1.6

0.881

4.7 ± 1.5

4.5 ± 1.7

0.164

Baseline prudent diet score

307.5 ± 130.0

306.9 ± 146.1

307.9 ± 118.4

0.931

285.9 ± 116.1

316.0 ± 134.3

0.017

Baseline western diet score

144.3 ± 148.9

218.5 ± 175.2

95.2 ± 102.7

0.000

160.8 ± 152.2

137.9 ± 147.3

0.113

0.67 ± 1.4

0.33 ± 1.4

0.90 ± 1.4

0.000

0.83 ± 1.4

0.61 ± 1.4

0.119

Characteristic

Baseline energy intake; kCal
Diabetes; n (%)ii
Hypertension; n (%)ii
Angina; n (%)ii
Heart Attack; n

(%)ii

Stroke; n (%)ii

Baseline MeDi score

Baseline inflammatory dietary index

Unless otherwise stated, data are presented as mean ± standard deviation of the mean. Bold indicates statistical significance (p < 0.05); Characteristics compared using analysis of variance for continuous variables and χ2 for categorical
variables. iBody mass index is calculated as weight in kilograms divided by height in meters squared. iiHistory of diabetes, hypertension, angina, heart attack or stroke determined by participant self-reported medical history. Abbreviations:
APOE, Apolipoprotein E; kCal, kilocalorie; Kg, kilogram; m2, meter squared; MeDi, Mediterranean diet; y, years.
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3.2.4 Correlation of the four diet scores at baseline
Having constructed MeDi, inflammatory dietary index, prudent and western diet scores
for each healthy control participant at baseline, bivariate Pearson’s correlations were
then used to evaluate how the four dietary patterns related to one another. A positive
correlation indicates that as one score increases, so does the other, whilst a negative
correlation indicates that as one score increases the other decreases. The previous
analysis was exploratory in nature and for this reason we used a p-value of 0.05 or
smaller to determine a significant result. For all subsequent analysis a p-value of 0.01 or
smaller determined a significant result to balance the risk of type I and type II errors,
due to the large number of statistical tests performed.
As expected, there was a positive correlation between prudent diet score and MeDi
score (p < 0.001): both are ‘healthy’ eating patterns. Prudent diet score was also
negatively correlated with western diet score (p < 0.001); suggesting that as a person
eats more foods in the prudent (‘healthy’) dietary pattern, they eat less foods in the
western (‘unhealthy’) dietary pattern. Unexpectedly, MeDi score was not correlated
with western diet score. The inflammatory dietary index was negatively correlated with
MeDi and prudent dietary patterns (p < 0.001), suggesting that as consumption of antiinflammatory foods decreases (increasing inflammatory dietary index), adherence to
‘healthy’ dietary patterns also decreases, however somewhat surprisingly, the
inflammatory dietary index was also negatively correlated with western diet score (p <
0.001; Table 3.5).
After stratifying by gender and APOE ε4 allele carriage, these correlations remained
consistent (data not shown).
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Table 3.5: Correlation matrix of the four diet scores.
MeDi
score
MeDi
score
Prudent
score
Western
score
Inflammatory
dietary index

Prudent
score

Western
score

Inflammatory
dietary index

0.265

0.046

-0.287

-0.339

-0.644

0.265
0.046

-0.339

-0.287

-0.644

-0.181
-0.181

Data is presented as r values from bivariate Pearson’s correlations. Bold indicates statistical significance. Abbreviations: MeDi,
Mediterranean diet.

3.2.5. Cognitive performance of the healthy control cohort
Prior to assessing the relationship between dietary patterns and cognition, we assessed
how cognitive performance changed over the 36 month period of follow-up, and
determined if there were differences in performance between the genders, and APOE ε4
allele carriers and non-carriers. From the comprehensive neuropsychological test battery
administered at baseline, 18 and 36 month follow-up, composite scores were
constructed for six cognitive domains and a global cognitive score was also computed
using these six domains. The six domains assessed were; verbal and visual memory,
attention, language, executive function and visuospatial functioning (detailed methods
of constructing these composites can be found in Section 2.10.12).
All mean cognitive composite domain scores (and therefore the global cognitive score)
were higher at baseline than at 36 month follow-up; a decline in cognitive performance
over 36 months is expected amongst the demographic assessed. There were several
gender-related differences between performances in the cognitive domains assessed.
Females performed better in the verbal memory domain at baseline (p < 0.001;
ANOVA), and in the attention domain at 36 month follow-up (p = 0.005; ANOVA).
Whilst males performed better in the visual memory domain at both time points (p =
0.002 at baseline and p = 0.004 at 36 month follow-up; ANOVA). There were no
differences between males and females in their global cognitive score at baseline or 36
month follow-up. There were no differences between APOE ε4 allele carriers and noncarriers in any of the cognitive domains assessed at baseline or 36 month follow-up. The
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cognitive results over 36 months of the healthy cohort as a whole and following
stratification by gender and APOE ɛ4 allele carriage are shown in Table 3.6.
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Table 3.6: Cognitive performance for the whole healthy control cohort at baseline and 36 month follow-up, and for subgroups following stratification of the cohort by
gender and APOE ε4 allele carriage.
Cognitive Domain

Time
pointi

Verbal memory

1

Visual memory

1

Attention

1

Language

1

Executive function

1

Visuospatial functioning

1

Global cognitive score

1

Verbal memory

3

Visual memory

3

Attention

3

Language

3

Executive function

3

Visuospatial functioning

3

Global cognitive score

3

Total
Sample
0.06
± 0.78
0.03
± 0.81
0.04
± 0.69
0.06
± 0.88
0.02
± 0.60
0.05
± 0.74
0.04
± 0.46
-0.23
± 0.99
-0.16
± 0.87
-0.07
± 0.72
-0.02
± 0.88
-0.16
± 0.60
-0.39
± 0.92
-0.11
± 0.56

n
527
527
527
527
527
527
527
525
523
525
523
524
525
322

Males
-0.15
± 0.78
0.17
± 0.84
-0.01
± 0.67
0.06
± 0.70
-0.05
± 0.56
0.04
± 0.82
0.01
± 0.45
-0.32
± 1.07
0.29
± 0.85
-0.18
± 0.80
-0.00
± 0.77
-0.24
± 0.58
-0.35
± 0.95
-0.13
± 0.57

n
210
210
210
210
210
210
210
210
210
210
210
210
210
210

Females
0.20
± 0.75
-0.06
± 0.79
0.06
± 0.70
0.06
± 0.86
0.07
± 0.61
0.06
± 0.69
0.07
± 0.47
-0.16
± 0.94
0.07
± 0.88
0.00
± 0.66
-0.04
± 0.95
-0.11
± 0.61
-0.41
± 0.90
-0.10
± 0.55

n

p-values for
gender
differences

317

0.000

317

0.002

317

0.246

317

0.915

317

0.024

317

0.820

317

0.152

315

0.069

313

0.004

315

0.005

313

0.648

314

0.019

315

0.414

312

0.445

APOE ε4
allele
carrier
0.05
± 0.78
-0.03
± 0.82
-0.04
± 0.74
-0.03
± 0.86
-0.04
± 0.63
0.05
± 0.74
-0.01
± 0.50
-0.36
± 1.15
0.08
± 0.97
-0.15
± 0.72
-0.18
± 1.07
-0.22
± 0.62
-0.40
± 1.04
-0.18
± 0.62

N
148
148
148
148
148
148
148
148
147
148
147
148
148
146

APOE ε4
allele noncarrier
0.06
± 0.79
0.06
± 0.81
0.07
± 0.67
0.10
± 0.77
0.04
± 0.58
0.05
± 0.74
0.06
± 0.45
-0.17
± 0.92
0.19
± 0.83
-0.04
± 0.72
0.04
± 0.79
-0.14
± 0.59
-0.38
± 0.87
-0.08
± 0.53

n

p-values for
APOE ε4 carriage
differences

379

0.854

379

0.298

379

0.115

379

0.110

379

0.197

379

0.971

379

0.162

377

0.051

376

0.205

377

0.125

376

0.013

376

0.210

377

0.883

376

0.105

Unless otherwise stated, data are presented as mean ± standard deviation of the mean, with a higher score indicating better performance. Bold indicates statistical significance (p < 0.01). Characteristics compared using analysis of variance for
continuous variables. iTime point 1 is baseline, time point 3 is 36 month follow-up. Abbreviations: APOE, Apolipoprotein E.
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3.2.6. Diet score and cognitive function
Multiple linear regression analyses were run to investigate the cross-sectional
association between baseline diet scores and baseline cognitive performance. One
potential mechanism through which diet has been proposed to exert its effect is via the
vascular system (104, 284, 285). To investigate the influence of vascular variables in
our population, consistent with the analysis in section 3.2.2., we analysed an initial
model with the most common confounding variables controlled for, i.e. age, gender,
years of education, APOE ε4 allele carriage, country of birth, BMI, energy intake,
smoking status, and history of hypertension, angina, stroke, diabetes and heart attack,
and additionally analysed a second model with the same confounding variables as the
initial model without the inclusion of the vascular risk factors, i.e. smoking status, and
history of hypertension, angina, stroke, diabetes and heart attack. We saw no
associations in the linear regressions between diet scores and baseline composite scores
in the six cognitive domains assessed or the global cognitive score, in the cohort as a
whole (Table 3.7) or following stratified of the cohort by sex or APOE ε4 allele carriage
(Table 3.8 and 3.9).
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Table 3.7: Relationship between baseline diet scores and baseline cognitive test scores: linear regression analysis. Standardised β values shown.
Model
Composite cognitive
domain
Verbal memory
Visual memory
Executive
function
Language
Attention
Visuospatial
functioning
Global cognitive score

1

2

1

Baseline MeDi score

2

1

Baseline prudent diet score

2

1

Baseline western diet score

2

Baseline inflammatory dietary index

0.015

0.014

-0.000

-0.000

0.000

0.000

0.047

0.048

-0.024

-0.025

-0.000

-0.000

0.000

0.000

-0.043

0.010

0.023

0.023

0.000

0.000

0.000

0.000

0.010

0.010

0.009

0.009

0.001

0.001

-0.000

-0.000

-0.040

-0.041

0.019

0.019

0.000

0.000

-0.000

-0.000

0.077

0.072

-0.018

-0.018

0.000

0.000

-0.000

-0.000

-0.073

-0.074

0.004

0.000

0.000

0.000

-0.000

-0.000

-0.006

0.005

Model 1 - adjusted model includes age, gender, APOE ɛ4 allele carrier status, years of education, country of birth (Australia vs. Other), baseline body mass index, baseline energy intake kCal, past smoking status, and history of
hypertension, angina, stroke, heart attack and diabetes as covariates. Model 2 - adjusted model without CVD risk factors includes the same covariates as the fully adjusted model, without past smoking status, history of
hypertension, angina, stroke, heart attack and diabetes. Abbreviations: APOE, Apolipoprotein E; CVD, cardiovascular disease; kCal, kilocalorie; MeDi, Mediterranean diet.

Table 3.8: Relationship between baseline diet scores and baseline cognitive test scores: linear regression analysis following stratification of the cohort
by gender. Standardised β values shown.
Model
Composite cognitive domain

1
Gender

a

2

1

Baseline MeDi score

2

1

Baseline prudent diet score

2

1

Baseline western diet score

2

Baseline inflammatory dietary index

Verbal memory

M

0.011

0.009

-0.000

-0.000

0.000

0.000

0.076

0.078

Visual memory

M

0.007

-0.001

-0.000

0.000

-0.000

-0.000

-0.076

-0.060

Executive function

M

0.035

0.036

-0.000

-0.000

0.000

0.000

0.077

0.078

Language

M

0.008

0.005

0.000

0.000

0.000

0.000

-0.072

-0.073

Attention

M

0.033

0.029

-0.000

-0.000

-0.000

-0.000

0.113

0.167

Visuospatial functioning

M

-0.035

-0.040

0.001

0.001

-0.001

-0.000

-0.074

-0.075

Global cognitive score

M

0.010

0.006

-0.000

0.000

-0.000

-0.000

0.008

0.020

Verbal memory

F

0.029

0.029

0.000

-0.000

-0.000

-0.000

0.026

0.026

Visual memory

F

-0.045

-0.041

-0.001

-0.001

0.001

0.001

0.015

0.083

Executive function

F

0.008

0.011

0.000

0.000

-0.000

-0.000

-0.009

-0.009

Language

F

0.015

0.017

0.001

0.001

-0.001

-0.001

-0.021

-0.021

Attention

F

0.007

0.011

0.000

0.000

-0.000

-0.000

0.119

0.035

Visuospatial functioning

F

0.003

0.010

0.000

0.000

0.000

0.000

-0.063

-0.063

Global cognitive score

F

0.029

0.029

0.000

-0.000

-0.000

-0.000

0.026

0.026

- M is male, F is female. Model 1 - adjusted model includes age, APOE ɛ4 allele carrier status, years of education, country of birth (Australia vs. Other), baseline body mass index, baseline energy intake kCal, past
smoking status, and history of hypertension, angina, stroke, heart attack and diabetes as covariates. Model 2 - adjusted model without CVD risk factors includes the same covariates as the fully adjusted model, without past
smoking status, history of hypertension, angina, stroke, heart attack and diabetes. Abbreviations: APOE, Apolipoprotein E; CVD, cardiovascular disease; kCal, kilocalorie; MeDi, Mediterranean diet.
aGender

Table 3.9: Relationship between baseline diet scores and baseline cognitive test scores: linear regression analysis following stratification of the cohort
by APOE ε4 allele carriage. Standardised β values shown.
Model
Composite cognitive domain

1
APOE ɛ4 allele carriagea

2

1

Baseline MeDi score

2

1

Baseline prudent diet score

2

1

Baseline western diet score

2

Baseline inflammatory dietary index

Verbal memory

-

0.006

0.007

-0.000

-0.000

0.000

0.000

0.015

0.017

Visual memory

-

-0.039

-0.037

-0.000

-0.000

-0.000

-0.000

-0.031

0.031

Executive function

-

0.005

0.007

0.000

0.000

-0.000

-0.000

0.031

0.032

Language

-

0.001

0.004

0.000

0.001

-0.000

-0.000

-0.024

-0.025

Attention

-

0.005

0.006

0.000

0.000

-0.000

-0.000

0.112

0.077

Visuospatial functioning

-

-0.017

-0.014

0.000

0.000

-0.000

-0.000

-0.068

-0.069

Global cognitive
score

-

0.038

0.033

0.000

0.000

0.000

0.000

0.007

0.014

Verbal memory

+

0.056

0.055

0.001

0.000

-0.001

-0.000

0.192

0.192

Visual memory

+

0.016

0.009

-0.001

-0.001

0.001

0.001

-0.025

0.005

Executive function

+

0.066

0.070

-0.000

-0.000

0.000

0.000

0.031

0.031

Language

+

0.030

0.030

0.001

0.001

-0.000

-0.000

-0.082

-0.082

Attention

+

0.067

0.052

-0.000

-0.000

0.000

0.000

0.036

0.107

Visuospatial functioning

+

-0.009

-0.019

0.000

0.000

0.000

0.000

-0.054

-0.054

Global cognitive
+
0.038
0.033
0.000
0.000
0.000
0.000
0.025
0.047
score
a
APOE ɛ4 allele carriage - is APOE ɛ4 allele non-carrier, + is APOE ɛ4 allele carrier. Model 1 - adjusted model includes age, gender, years of education, country of birth (Australia vs. Other), baseline body mass index, baseline energy
intake kCal, past smoking status, and history of hypertension, angina, stroke, heart attack and diabetes as covariates. Model 2 - adjusted model without CVD risk factors includes the same covariates as the fully adjusted model,
without past smoking status, history of hypertension, angina, stroke, heart attack and diabetes. Abbreviations: APOE, Apolipoprotein E; CVD, cardiovascular disease; kCal, kilocalorie; MeDi, Mediterranean diet.
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Having completed cross-sectional assessment of the relationship between the four diet
scores and cognition, we sought to determine whether there was an association between
diet score at baseline and cognitive performance over 36 months. Linear mixed models
were used to analyse the relationship between MeDi, inflammatory dietary index,
prudent and western diet, the six cognitive domains assessed and the global cognitive
score in the cohort as a whole and following stratification by gender and APOE ɛ4 allele
carriage. Linear mixed models use the baseline, 18 and 36 month follow-up cognitive
domain scores in their analysis. The same two models utilised for the cross-sectional
analysis were used for the longitudinal analysis; the initial model had the most common
confounding variables controlled for, i.e. age, gender, years of education, APOE ε4
allele carriage, country of birth, BMI, energy intake, smoking status, and history of
hypertension, angina, stroke, diabetes and heart attack, and the second model had the
same confounding variables as the initial model without the inclusion of the vascular
risk factors, i.e. smoking status, and history of hypertension, angina, stroke, diabetes
and heart attack. In both models there was a trend towards increased MeDi adherence
and decreased decline in executive function composite score in the cohort as a whole (p
= 0.040; Table 3.10). Subsequent analyses following stratification by APOE ɛ4 allele
genotype indicated this relationship was only significant amongst APOE ɛ4 allele
carriers (p < 0.01; Table 3.12 and Figure 3.2); i.e. a higher MeDi score was associated
with less decline in executive function over three years in APOE ε4 allele carriers. Diet
explained 8.1% of the variance, increasing to 8.6% without CVD risk factors. Even
though 8.6% is a relatively small portion of the fixed effect variance in executive
function composite score, the other statistically significant variables (age, years of
education and history of angina) contributed less, explaining only 5.6%, 5.6% and 6.4%
respectively. This means that of the observed MeDi score association with executive
function amongst the APOE ε4 allele carriers, 8.1% of the relationship was explained by
diet adherence, 5.6% was explained by age, 5.6% by education of the individual, 6.4%
by a history of angina, and the remaining 74.3% by other factors.

In both models there was a negative trend towards western diet adherence and change in
the visuospatial functioning composite score (p = 0.022; Table 3.10), an association
which we subsequently determined was driven by APOE ε4 allele non-carriers (p <
0.01; Table 3.12 and Figure 3.3); i.e. a higher western diet score was associated with
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more decline in visuospatial functioning over three years in APOE ε4 allele noncarriers. Western diet explained 3.6% of the variance, and decreased to 3.4% without
CVD risk factors. By comparison, the other statistically significant variables (age,
baseline BMI and years of education) explained 14.9%, 1.8% and 9.6% respectively of
the fixed effect variance in visuospatial functioning composite score.

No significant relationships between prudent diet adherence, inflammatory dietary index
and cognition were found, however, there was a negative trend towards inflammatory
dietary index and change in the visuospatial functioning composite score in APOE ɛ4
allele carriers (p = 0.021); i.e. lower consumption of anti-inflammatory foods (higher
inflammatory dietary index) was trending towards more decline in visuospatial
functioning over three years in APOE ε4 allele carriers. There were no significant
associations between diet scores and cognition following stratification by gender (Table
3.11). Furthermore, the global cognitive score was not associated with adherence to any
of the four dietary patterns in the cohort as a whole or following stratification by gender
and APOE ε4 allele carriage (Table 3.10 – 3.12).
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Table 3.10: Results of linear mixed model analyses examining the association between baseline diet scores and change in cognitive performance
over 36 months. Standardised β values shown.
Model

Change in composite
cognitive domain

1

2

Baseline MeDi score

1

2

1

Baseline prudent diet score

2

1

Baseline western diet score

2

Baseline inflammatory dietary
index

Verbal memory

0.0157

0.0154

0.0001

0.0001

-0.0002

-0.0002

0.0086

0.0055

Visual memory

-0.0085

-0.0091

-0.0000

-0.0002

-0.0002

-0.0001

-0.0174

-0.0206

Executive function

0.0261

0.0265

0.0000

0.0002

-0.0000

0.0000

0.0041

0.0010

Language

0.0013

0.0015

0.0002

0.0002

-0.0002

-0.0002

-0.0060

-0.0082

Attention

0.0089

0.0097

-0.0000

0.0007

-0.0002

-0.0002

0.0337

0.0291

-0.0267

-0.0269

0.0003

0.0004

-0.0005

-0.0004

-0.0494

-0.0527

0.0010

0.0009

0.0001

0.0002

-0.0002

-0.0002

-0.0055

-0.0084

Visuospatial
functioning
Global cognitive score

Model 1 - adjusted model includes age, gender, APOE ɛ4 allele carrier status, years of education, country of birth (Australia vs. Other), baseline body mass index, baseline energy intake kCal, past smoking status, and
history of hypertension, angina, stroke, heart attack and diabetes as covariates. Model 2 - adjusted model without CVD risk factors includes the same covariates as the fully adjusted model, without past smoking status,
history of hypertension, angina, stroke, heart attack and diabetes. Abbreviations: APOE, Apolipoprotein E; CVD, cardiovascular disease; kCal, kilocalorie; MeDi, Mediterranean diet.

Table 3.11: Results of linear mixed model analyses examining the association between baseline diet scores and change in cognitive performance over 36
months following stratification of the cohort by gender. Standardised β values shown.
Model

1

Gender

Male

2
Male

Change in composite
cognitive domain

1

2

1

2

Female

Female

Male

Male

Baseline MeDi score

1
Female

2

1

2

Female

Male

Male

Baseline prudent diet score

1
Female

2
Female

Baseline western diet score

1

2

Male

Male

1
Female

2
Female

Baseline inflammatory dietary index

Verbal memory

0.0262

0.0242

0.0153

0.0133

0.0003

0.0003

0.0000

-0.0000

-0.0001

-0.0001

-0.0004

-0.0003

-0.0006

-0.0090

0.0154

0.0156

Visual memory

0.0084

0.0041

-0.0173

-0.0148

0.0001

0.0002

-0.0002

-0.0002

-0.0003

-0.0003

0.0000

0.0000

-0.0483

-0.0523

0.0055

0.0028

Executive
function

0.0414

0.0424

0.0138

0.0167

0.0001

0.0001

-0.0001

-0.0000

-0.0000

0.0000

0.0000

-0.0000

0.0097

0.0047

0.0009

-0.0054

Language

0.0041

0.0035

0.0067

0.0054

0.0001

0.0001

0.0002

0.0003

-0.0002

-0.0001

-0.0001

-0.0003

-0.0104

-0.0150

0.0026

-0.0087

Attention

0.0247

0.0228

-0.0013

-0.0001

-0.0003

-0.0002

0.0001

0.0002

-0.0002

-0.0002

-0.0001

-0.0002

0.0534

0.0463

0.0316

0.0209

-0.0517

-0.0061

-0.0025

0.0005

0.0005

0.0003

0.0003

-0.0005

-0.0004

-0.0006

-0.0006

-0.0679

-0.0790

-0.0285

-0.0314

0.0075

0.0013

0.0030

0.0001

0.0002

0.0000

0.0001

-0.0002

-0.0002

-0.0002

-0.0002

-0.0107

-0.0174

0.0023

-0.0024

Visuospatial
functioning
Global cognitive
score

0.0421
0.0104

Model 1 - adjusted model includes age, years of education, APOE ε4 allele carrier status, country of birth (Australia vs. Other), baseline body mass index, baseline energy intake kCal, past smoking status, and history of hypertension, angina,
stroke, heart attack and diabetes as covariates. Model 2 - adjusted model without CVD risk factors includes the same covariates as the fully adjusted model, without past smoking status, history of hypertension, angina, stroke, heart attack
and diabetes. Abbreviations: APOE, Apolipoprotein E; CVD, cardiovascular disease; kCal, kilocalorie; MeDi, Mediterranean diet.

Table 3.12: Results of linear mixed model analyses examining the association between baseline diet scores and change in cognitive performance over 36 months
following stratification of the cohort by APOE ε4 allele carrier status. Standardised β values shown.
Model

1

2

APOE ɛ4 allele carriagea

-

-

Change in composite
cognitive domain

1
+

2

1

2

+

-

-

Baseline MeDi score

1
+

2
+

1

2

1

2

1

2

1

2

-

-

+

+

-

-

+

+

Baseline prudent diet score

Baseline western diet score

Baseline inflammatory dietary index

Verbal memory

0.0149

0.0170

0.0368

0.0297

0.0000

0.0001

0.0003

0.0003

-0.0001

-0.0001

-0.0003

-0.0003

0.0936

0.0919

Visual memory

-0.0164

-0.0142

0.0213

0.0119

-0.0000

-0.0000

-0.0001

-0.0001

-0.0003

-0.0003

0.0005

0.0005

-0.0215

-0.0213

-0.0112

Executive function

0.0077

0.0101

0.0772*
(8.1%ł)

0.0815**
(8.6%ł)

0.0000

0.0001

-0.0001

-0.0001

-0.0001

-0.0001

0.0003

0.0003

0.0207

0.0144

0.0066

Language

-0.0069

-0.0041

0.0272

0.0276

0.0001

0.0001

0.0004

0.0003

-0.0002

-0.0002

0.0000

-0.0000

-0.0038

-0.0040

-0.0041

Attention

0.0014

0.0026

0.0427

0.0289

-0.0000

-0.0000

-0.0000

0.0000

-0.0003

-0.0003

0.0004

0.0003

0.0715

0.0631

0.0292

Visuospatial functioning

-0.0110

-0.0090

-0.0584

-0.0690

0.0004

0.0004

0.0001

0.0001

-0.0006*
(3.6%ł)

-0.0006*
(3.4%ł)

0.0001

0.0001

-0.0100

-0.0085

-0.0570

-0.0023

-0.0002

0.0252

0.0200

0.0001

0.0001

0.0001

0.0001

-0.0003

-0.0003

0.0002

0.0002

0.0195

0.0184

-0.0073

Global cognitive score

-0.0091

0.0157
0.0166
0.0008
0.0119
0.0253
0.0611
0.0132

APOE ɛ4 allele carriage - is APOE ɛ4 allele non-carrier, + is APOE ɛ4 allele carrier. Model 1 - adjusted model includes age, gender, years of education, country of birth (Australia vs. Other), baseline body mass index, baseline energy intake
kCal, past smoking status, and history of hypertension, angina, stroke, heart attack and diabetes as covariates. Model 2 - adjusted model without CVD risk factors includes the same covariates as the fully adjusted model, without past
smoking status, history of hypertension, angina, stroke, heart attack and diabetes. łPortion of variance explained by diet score. Bold indicates statistical significance (* p < 0.01, ** p < 0.001). Abbreviations: APOE, Apolipoprotein E; CVD,
cardiovascular disease; kCal, kilocalorie; MeDi, Mediterranean diet.
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Figure 3.2: Higher baseline MeDi adherence is associated with longitudinally
increased performance in the executive function composite score in APOE ε4 allele
carriers.
Time 0 months; Time 18 months; Time 36 months.
Abbreviations: APOE, Apolipoprotein E; MeDi, Mediterranean diet.
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Figure 3.3: Higher baseline western diet adherence is associated with longitudinally
poorer performance in the visuospatial functioning composite score in APOE ε4 allele
non-carriers.
Time 0 months; Time 18 months; Time 36 months.
Abbreviations: APOE, Apolipoprotein E.
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3.2.7 Dietary pattern adherence and transition from healthy control to mild
cognitive impairment or Alzheimer’s disease clinical classification
In order to assess whether baseline adherence to the four dietary patterns of interest was
associated with change in clinical classification from healthy control to MCI or AD at
36 month follow-up, a change in clinical classification variable was made by assigning
each participant a 0 if they remained a healthy control from baseline to the 36 month
follow-up and a score of 1 if they transitioned to MCI or AD status. This change in
clinical classification variable was then used in multinomial logistic regressions to
calculate odds ratios for the investigation of the association between change from
healthy control clinical classification to MCI or AD status and the four diet scores
divided into tertiles; odds ratios compared the lowest tertile with the highest tertile. For
the MeDi score, individuals with a score of 3 or lower (lowest adherence to MeDi) were
assigned to tertile 1, those with a score of 4 or 5 were assigned to tertile 2, and those
with a score of 6 or higher (highest adherence to MeDi) were assigned to tertile 3. For
the inflammatory dietary index, western and prudent diets, the participants’ scores were
arranged into increasing order of adherence and then divided equally into thirds, with
the lowest adherence third to each pattern assigned to tertile 1, the middle third assigned
to tertile 2 and the highest adherence third assigned to tertile 3. The same two models
utilised previously in this chapter were again used for the transition analysis; the initial
model included the most common confounding variables as covariates, i.e. age, gender,
years of education, APOE ε4 allele carriage, country of birth, BMI, energy intake,
smoking status, and history of hypertension, angina, stroke, diabetes and heart attack,
and the second model incorporated the same confounding variables as the initial model
without the inclusion of the vascular risk factors, i.e. smoking status, and history of
hypertension, angina, stroke, diabetes and heart attack.
None of the four dietary patterns assessed were shown to be associated with the change
in clinical classification variable; eating more ‘unhealthy’ or less anti-inflammatory
foods did not lead to an increase in numbers transitioning from healthy control to MCI
or AD status, and vice versa, i.e. eating more ‘healthy’ foods did not lead to a decrease
in numbers transitioning from healthy control to MCI or AD status after 36 months.
Furthermore, no significant associations were observed when the cohort was stratified
by gender and APOE ε4 allele status (Table 3.13). It is worthy of note however, that
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only 25 participants transitioned from healthy control at baseline to MCI or AD by the
36 month follow-up.
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Table 3.13: Odds Ratios of transitioning to AD or MCI clinical classification compared to remaining a healthy control after 36 months.
Diet Score

Number of transitioners

Model

Odds Ratio

Confidence

p-value

Model

Odds Ratio

Confidence

p-value

Whole cohort

MeDi

25

1

0.889

0.400 – 1.980

0.773

2

0.817

0.374 – 1.790

0.612

Males

MeDi

15

1

0.772

0.281 – 2.120

0.616

2

0.678

0.254 – 1.810

0.439

Females

MeDi

10

1

0.748

0.141 – 3.960

0.733

2

0.797

0.176 – 3.600

0.768

APOE ε4 allele carrier

MeDi

13

1

0.661

0.252 – 1.730

0.398

2

0.702

0.315 – 1.570

0.388

APOE ε4 allele non - carrier

MeDi

12

1

0.857

0.269 – 2.729

0.794

2

0.923

0.308 – 2.769

0.886

Whole cohort

Prudent

25

1

0.835

0.470 – 1.480

0.538

2

0.824

0.463 – 1.470

0.511

Males

Prudent

15

1

0.805

0.390 – 1.660

0.559

2

0.808

0.391 – 1.670

0.565

Females

Prudent

10

1

0.718

0.224 – 2.300

0.577

2

0.767

0.238 – 2.470

0.656

APOE ε4 allele carrier

Prudent

13

1

0.575

0.195 – 1.690

0.316

2

0.719

0.292 – 1.770

0.474

APOE ε4 allele non - carrier

Prudent

12

1

0.790

0.379 – 1.647

0.781

2

0.901

0.423 – 1.919

0.530

Whole cohort

Western

25

1

0.932

0.550 – 1.580

0.795

2

0.939

0.556 – 1.590

0.813

Males

Western

15

1

0.929

0.447 – 1.930

0.844

2

0.960

0.463 – 1.990

0.912

Females

Western

10

1

1.042

0.365 – 2.980

0.939

2

0.975

0.349 – 2.720

0.961

APOE ε4 allele carrier

Western

13

1

0.736

0.262 – 2.060

0.560

2

0.726

0.301 – 1.750

0.475

APOE ε4 allele non – carrier

Western

12

1

1.119

0.562 – 2.228

0.748

2

1.081

0.559 – 2.094

0.816

Whole cohort

Inflammatory dietary index

25

1

1.296

0.841 – 1.996

0.240

2

1.280

0.839 – 1.953

0.252

Males

Inflammatory dietary index

15

1

1.097

0.585 – 2.056

0.773

2

1.473

0.784 – 2.769

0.229

Females

Inflammatory dietary index

10

1

1.426

0.751 – 2.706

0.278

2

1.085

0.999 – 1.001

0.788

APOE ε4 allele carrier

Inflammatory dietary index

13

1

1.555

0.813 – 2.974

0.182

2

1.622

0.870 – 3.024

0.128

APOE ε4 allele non – carrier

Inflammatory dietary index

12

1

0.971

0.525 – 1.797

0.925

2

0.946

0.524 – 1.714

0.860

Group+

Model
adjusted model includes age, gender, years of education, APOE ε4 allele carrier status, country of birth (Australia vs. Other), baseline body mass index, baseline energy intake kCal, past smoking status, and history
of hypertension, angina, stroke, heart attack and diabetes as covariates. Model 2+ - adjusted model without CVD risk factors includes the same covariates as the fully adjusted model, without past smoking status, history of
hypertension, angina, stroke, heart attack and diabetes. +When stratified by gender and APOE ε4 allele status, these characteristics are not included in the models as covariates. Multinomial logistic regression analysis used to
calculate odds ratios. Abbreviations: APOE, Apolipoprotein E; CVD, cardiovascular disease; kCal, kilocalorie; MeDi, Mediterranean diet.
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3.3. Discussion
The objective of this analysis was to investigate the association of four dietary patterns;
MeDi, inflammatory dietary index, western diet and prudent diet, firstly with baseline
clinical classification, then with cognition and cognitive decline over a three year period
amongst individuals classified as healthy controls at baseline, and finally transition from
healthy control to MCI or AD clinical classification after three years.
3.3.1. Adherence to dietary patterns and baseline clinical classification
Our analysis suggests that AD participants in our cohort consume less foods in the
MeDi and prudent diet, less anti-inflammatory foods, and more foods in the western diet
than healthy controls. Healthy controls consume more foods in the MeDi and prudent
diet, and more anti-inflammatory foods than MCI. There was no difference in western
diet consumption between MCI and healthy control participants. MCI and AD
participants consume the same amount of anti-inflammatory foods and MeDi foods, but
MCI subjects consume more foods in the prudent diet and less foods in the western diet
than AD subjects.
These results are cross-sectional, so we cannot assume that they show decreased
adherence to the ‘healthy’ dietary patterns is a risk factor for AD, only that in our cohort
at baseline, the AD participants had a decreased adherence to the ‘healthy’ dietary
patterns, an increased adherence to the ‘unhealthy’ dietary pattern and a decreased
consumption of anti-inflammatory foods. These results could potentially be explained
by a change in diet due to AD diagnosis. To our knowledge, previously published
research has concentrated on longitudinal risk of AD and MCI in the context of dietary
patterns, rather than the association between cross-sectional clinical classification and
diet. To exclude the potential confounder of diagnosis impacting on diet pattern
adherence, for subsequent analysis individuals diagnosed at baseline as MCI or AD
were excluded.
3.3.2. Correlation of the four dietary patterns
When assessing the correlation of the four dietary patterns, we observed that as prudent
diet adherence increases, MeDi adherence increases, and western diet adherence
decreases. The relationship between the MeDi and prudent diet scores is expected as
both are ‘healthy’ eating patterns. The negative correlation between the prudent and
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western dietary patterns is consistent with individuals eating less ‘unhealthy’ western
diet foods if they are eating more ‘healthy’ prudent diet foods. We did not see a
correlation between MeDi and western diet adherence, suggesting that the consumption
of MeDi constituents is likely independent of consumption of western diet constituents,
i.e. individuals can have a high MeDi score and a low, middle or high western diet
score, or a low MeDi score and a low, middle or high western diet score. As antiinflammatory food consumption increases (inflammatory dietary index decreases),
adherence to MeDi and prudent dietary patterns increases, and somewhat counterintuitively, western diet adherence also increases. The MeDi and prudent diets are rich
in antioxidants such as fruit and vegetables which likely contribute to the correlation
with the inflammatory dietary index. The association between increased consumption of
anti-inflammatory foods and increased adherence to the western diet could in part be
due to the high proportion of red and processed meat, and poultry consumed as part of
the western diet: these components also contain some of the main constituents of the
inflammatory dietary index, including niacin, thiamine, riboflavin, iron and zinc.
3.3.3. Adherence to dietary patterns and cognitive decline
When assessing the relationship between dietary patterns, cognition and cognitive
decline amongst individuals classified as healthy control at baseline, we found that 1)
there were no cross-sectional associations between the four dietary patterns and global
cognition or the six composite cognitive domains assessed, 2) longitudinally, there were
no gender-dependent associations between the four dietary patterns and global cognition
or the six composite cognitive domains assessed. Thirdly, it was found that higher
baseline adherence to the ‘healthy’ MeDi was associated with decreased decline in the
executive function composite score 36 months later in APOE ɛ4 allele carriers only, and
4) higher baseline adherence to the ‘unhealthy’ western diet score was associated with
increased cognitive decline in the visuospatial functioning composite score 36 months
later, however in this case only in APOE ε4 allele non-carriers.
We saw no APOE genotype-dependent associations between adherence to any of the
four dietary patterns and global cognitive score over 36 months, suggesting that the
relationship between dietary pattern adherence and cognition is specific to the executive
function and visuospatial functioning domains in our cohort.
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A potential mechanism through which diet may exert its effect is via the vascular system
(104, 284, 285). Scarmeas et al. (3) investigated whether there was attenuation of the
association between MeDi and AD when vascular variables (stroke, diabetes mellitus,
hypertension, heart disease, lipid levels) were simultaneously introduced into their
logistic regression models: they reported that their observed association between MeDi
and AD was not mediated by vascular comorbidities. To investigate the influence of
vascular variables in our population, we analysed two adjusted models for the crosssectional and longitudinal composite cognitive scores analysis; one controlling for
vascular comorbidities and one without inclusion of these covariates. Although the
addition of the CVD risk factors did not make any previously significant associations
non-significant, or vice versa, we did see a change in the significance level of the
executive function association with the MeDi in APOE ε4 allele carriers when the CVD
risk factors were excluded (p < 0.01 to p < 0.001). However, the effect size was
increased in the model without CVD risk factors, suggesting that, in agreement with
Scarmeas et al. CVD risk factors do not appear to contribute significantly to the
observed relationship between MeDi and cognition, and the observed improved
significance may be due to lowering the degrees of freedom.
The deleterious effect of the western diet on visuospatial functioning was smaller in size
than the association seen with the MeDi and executive function, and this association is
likely driven by variation on the Rey Complex Figure Test (RCFT) copy as our clock
test (the other test comprising the visuospatial functioning domain) data was negatively
skewed and kurtosed. Within the RCFT copy there is an executive function domain,
namely planning and use of strategy (268, 286). It could be that instead of a negative
association between the western diet and visuospatial functioning domain, we are
actually observing a negative association with the western diet in another area of
executive function (planning), and therefore the only domain that diet is affecting is
executive function. Of note, the measures comprising the executive function domain in
the present study were heavily loaded with measures requiring cognitive flexibility,
switching, and generativity, but did not include executive tasks relying heavily on
planning. A recommendation for future studies is to measure more comprehensively the
executive function components included in the visuospatial functioning domain to
confirm our reasoning.
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Worsening of executive function is often a debilitating feature of cognitive decline and
AD, and has been shown to be related to decline in activities of daily living and to
predict conversion from MCI to AD (287). Executive functions are a core component of
self-control and self-regulation ability which has been shown to have broad and
significant implications for everyday lives (288). Executive skills help us to connect past
experiences with present actions, plan future behaviour when faced with novel tasks,
judge, organise, change behaviour and strategies, pay attention and remember details for
decision making (289).
We saw no associations with the inflammatory dietary index or the ‘healthy’ prudent
dietary pattern and cognitive decline. The MeDi and prudent diet patterns are similar but
have some significant differences, most notably characterisation of fish intake which
contributes heavily to the MeDi but only represents a small component of the prudent
diet score. Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) are n-3 fatty
acids found in oily fish. These fatty acids are able to affect a number of aspects of
inflammation, and mechanisms underlying their actions include altered cell membrane
phospholipid fatty acid composition, disruption of lipid rafts, inhibition of activation of
the pro-inflammatory transcription factor nuclear factor kappa B so reducing expression
of inflammatory genes, activation of the anti-inflammatory transcription NR1C3 and
binding to the G protein-coupled receptor GPR120. EPA and DHA also increase antiinflammatory

and

inflammation-resolving

resolvins

and

protectins

(290).

Neuroinflammation is a process involved in AD pathogenesis which is thought to be
triggered mostly by Aβ, a hallmark of AD pathology (291). It could be that the
protective effect of MeDi adherence compared to the prudent diet is due to the
consumption of fish oils such as EPA and DHA. Conversely, the negative association
seen with the western diet and aspects of cognition may be due to low consumption of
DHA and EPA for example, rather than high consumption of a detrimental food group.
Several studies have provided reasons for this – for example, EPA and DHA fed to cells
in culture increases production of sAPPα (known to promote neurite outgrowth), which
may also indicate less Aβ will be produced (292). Furthermore, in studies of microglial
cultures, both DHA and EPA were found to stimulate microglial phagocytosis of Aβ1-42,
and decrease levels of pro-inflammatory cytokines (293). However in some earlier
studies, DHA and EPA were found to increase neuronal cell death following exposure
to Aβ1-42 (294), and some clinical studies involving dietary supplementation with DHA
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have not demonstrated clear benefits in people with AD, however this may due to the
fact that the lipids may only be beneficial at pre-clinical stages. It is clear that a better
understanding of DHA (and EPA) metabolism and beneficial effects is required (295).

Previous studies have reported associations between dietary patterns and biomarkers of
inflammation, for example the MeDi has been associated with lower levels of
inflammatory markers (214, 227, 231, 296, 297), in other dietary pattern studies a
‘healthy’ dietary pattern (like our prudent diet) has been shown to lower inflammation
marker levels and an ‘unhealthy’ dietary pattern (like our western diet) has been shown
to increase levels of inflammatory markers (212, 298-302). Although the mechanism
mediating the dietary effects cannot be discerned from the present results, the effect of
MeDi constituents on inflammation is a prime candidate that warrants further
investigation.

Our results suggest that there are differential effects of diet on cognition that are likely
to be contingent on APOE ɛ4 allele carriage; another finding that warrants further
investigation. Compared to the APOE ε2 and ε3 isoforms, APOE ε4 is a less functional
cholesterol transporter (303). Management of cholesterol by fish oils in specific diets,
like the MeDi, has been proposed to prevent and treat the negative effects of the APOE
ε4 genotype (304). Animal studies have shown a positive influence of fish oil
containing diets on behavioural and cognitive performances on APOE ε4 allele target
replacement mice (305). A possible explanation for the MeDi effects observed only in
APOE ε4 allele carriers in our study is that the non-carriers are already functioning
highly in their cholesterol transport due to their ε2/ε3 genotype so MeDi components
are not able to exert any additional significant effect. Ours is not the first study to report
differential effects of lifestyle factors on aspects of cognitive decline and AD-related
pathology that are contingent on APOE ɛ4 allele carriage. Notably, Brown et al. (132)
showed that brain and blood Aβ levels can be modulated by physical activity, in an
APOE genotype-dependent manner. Specifically, the authors reported that high physical
activity is associated with lower plasma Aβ1-42/1-40 in APOE ɛ4 allele non-carriers, while
higher exercising APOE ɛ4 allele carriers had lower levels of brain amyloid. Brown et
al. concluded that physical activity appears to attenuate the high levels of brain amyloid
associated with APOE ɛ4 allele carriers, and the apparent lack of effect on plasma Aβ
levels may reflect poor clearance of Aβ in the periphery in individuals with the APOE
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ɛ4 allele. Taken together, the results of both studies suggest that in future, the
assessment of lifestyle in the context of APOE genotype may help the development of
strategies tailored to the needs of APOE ε4 allele carriers, both with and without AD,
who have the poorest prognosis with current treatment strategies.
The positive relationship between MeDi adherence and better performance on the
executive function composite score described in this paper is consistent with previous
findings in other populations. In several American population studies, Scarmeas et al.
reported higher MeDi adherence was associated with lower AD risk and slower
cognitive decline (2-4). In a French study of 1410 individuals without dementia at
baseline and with a follow-up within five years, it was observed that each additional
MeDi score unit was associated with fewer Mini-Mental State Examination (MMSE)
errors at follow-up (1). A study conducted in Chicago found that higher MeDi scores
were associated with slower rates of cognitive decline in 3790 adults over the age of 65.
Each participant had at least two cognitive assessments at three year intervals, which
consisted of four cognitive tests (5). By contrast, the Personality and Total Health
(PATH) through life study observed that greater MeDi adherence was not protective
against cognitive decline. The apparent lack of protection in this study could be
explained by the heterogeneous nature of the study population. Furthermore, only 66
participants from the original 1528 demonstrated any cognitive decline in the four year
follow-up; a limitation with respect to generating sufficient statistical power to detect
effects of the MeDi (226). Samieri et al. (282) found that long term MeDi adherence
was related to moderately better cognition, but not with cognitive change in a large
cohort of older women from the Nurses’ Health Study (NHS). This study used a limited
telephone interview to assess cognitive status, with only global cognition and verbal
memory assessed. Another study by Samieri et al. (283), this time using the Women’s
Health Study (WHS), found no association with MeDi and cognitive decline. Again this
study used the same telephone interview with only global and verbal memory assessed.
Construction of the MeDi scores used in the NHS and WHS studies was modified from
the ‘traditional’ method to increase relevance to American populations, for example
refined and whole grains were delineated in the modified MeDi. The second ‘a priori’
dietary pattern we assessed, the inflammatory dietary index, has not previously been
analysed in a longitudinal prospective study of ageing cohort. Furthermore, to our
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knowledge, the association of anti- or pro-inflammatory food consumption with
cognitive decline has also not been assessed previously.
There are limited studies relating ‘a posteriori’ dietary patterns such as the western and
prudent patterns investigated here, to cognitive decline in the elderly. This could be due
to identified patterns depending on the study cohort, thereby limiting inter-study
comparison (243). Samieri et al. (6) identified five dietary patterns by cluster analysis,
the ‘healthy diet’ pattern was associated with significantly lower MMSE errors.
Akbaraly et al. (7) found that higher consumption of a ‘whole food’ pattern (similar to
our prudent diet pattern), produced by principal components analysis, was associated
with lower odds of cognitive deficit; whereas higher consumption of a ‘processed food’
pattern (similar to our western diet pattern) was associated with higher odds of cognitive
deficit. However, adjustment for education significantly attenuated most of the
associations seen.
3.3.4. Adherence to dietary patterns and transition from healthy control
classification
Finally, we found that dietary pattern adherence had no effect on the rate of transitioning
from healthy control classification at baseline to MCI or AD status after 36 months in
the cohort as a whole and following stratification of the cohort by gender and APOE ε4
allele status. It should be noted however, that over the 36 month period of follow-up,
only 25 of the 527 participants (4.5%) assessed at baseline transitioned from healthy
control to MCI or AD status by the 36 month follow-up. This relatively small
percentage of ‘transitioners’ may have provided insufficient statistical power to detect
associations between the dietary patterns and change in clinical classification at followup; it is possible that when available, the 54 month follow-up clinical classifications will
provide further insight.
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3.3.5. Summary
In conclusion, our findings are consistent with previous studies which describe a
‘healthy’ (or ‘prudent’) dietary pattern in opposition to a ‘western’ (or ‘processed’)
dietary pattern (6, 7, 219, 244, 245). To our knowledge, this is the first study
extensively comparing the MeDi, inflammatory dietary index, western and prudent diet
patterns to cognition and cognitive decline in an elderly, Australian cohort. Crosssectionally, our analysis suggests that AD participants in our cohort consume fewer
foods in the MeDi and prudent diet, less anti-inflammatory foods, and more foods in the
western diet than healthy controls. Longitudinally, our results suggest a detrimental
nature of a western diet and propose the importance of adhering to a ‘healthy’ dietary
pattern such as the MeDi, with respect to reducing risk for cognitive decline, with
executive function and visuospatial functioning seemingly most susceptible to the
influence of diet. Additionally, dietary pattern adherence had no effect on the rate of
transition from healthy control classification at baseline to MCI or AD status after 36
months, although limited statistical power likely impacts upon these findings. In the
next chapter we will investigate the potential biological mechanisms underlying the
relationships between diet and cognitive decline reported in this chapter.
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4.1. Introduction
In Chapter 3 we reported that higher baseline adherence to the ‘healthy’ Mediterranean
diet (MeDi) was associated with decreased decline in the executive function cognitive
domain composite score over 36 months in Apolipoprotein E (APOE) ɛ4 allele carriers.
By contrast, higher baseline adherence to the ‘unhealthy’ western diet score was
associated with increased decline in the visuospatial functioning cognitive domain
composite score over 36 months in APOE ε4 allele non-carriers. In this chapter, we
therefore sought to explore potential mechanisms that might underlie these observed
effects of diet on cognition by assessing the relationship of the dietary patterns with
blood and neuroimaging biomarker data collected as part of the Australian Imaging,
Biomarkers and Lifestyle study (AIBL) of ageing. A plethora of potential mechanisms
exist, we focussed our investigations on factors that are well-established contributors to
Alzheimer’s disease (AD) risk i.e. metabolic syndrome, cardiovascular disease (CVD),
and inflammation.
Metabolic syndrome is a multifactorial disorder of energy utilization and storage,
diagnosed by a co-occurrence of three out of five of the following medical conditions:
abdominal (central) obesity, elevated blood pressure, elevated fasting plasma glucose,
high serum triglycerides, and low high-density lipoprotein (HDL) levels. Accumulating
evidence suggests that metabolic syndrome is a risk factor for AD (306-309). The
molecular mechanism underlying this relationship is not fully understood, however the
cellular and biochemical alterations observed in metabolic syndrome, such as
impairment of endothelial cell function, abnormality in essential fatty acid metabolism
and alterations in lipid mediators along with abnormal insulin/leptin signalling, are
likely contributors (307).
CVD refers to any disease or condition of the heart and blood vessels. The causes of
CVD are diverse, but atherosclerosis and/or hypertension are the most common
instigators. CVD and metabolic syndrome have many common risk factors, including
elevated blood pressure, obesity, abnormal insulin metabolism and abnormal cholesterol
levels. Data consistently suggests a strong and likely causal association between CVD,
its risk factors, and AD incidence; individuals with subclinical CVD have been shown
to be at greater risk of AD (75, 76, 104, 284, 310-313). Several CVD risk factors are
also risk factors for AD, including hypertension, high low density lipoprotein (LDL)
cholesterol, low HDL cholesterol and diabetes. The mechanisms underlying the CVD
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and AD association are not fully elucidated, however, several candidate mechanisms
have been proposed including; 1) both diseases share similar risk factors, which
independently increase both CVD and AD occurrence; 2) vascular damage in the brain
could create conditions which predispose to neurodegeneration; and 3) CVD risk factors
could affect AD development directly by causing neuronal death, the accumulation of
amyloid beta (Aβ), and the deposition of plaques and neurofibrillary tangles (312).
Abundant evidence suggests MeDi adherence reduces risk of metabolic syndrome and
CVD, with MeDi’s protective effect on obesity and type 2 diabetes proposed as the
primary mechanism (225, 314-319). In the Attica study, MeDi adherence was
associated with a 20% lower risk of having metabolic syndrome (320), and a metaanalysis investigating MeDi and health status concluded adherence to the MeDi
significantly decreases risk of CVD, along with overall mortality and incidence of AD
(225). In regards to ‘healthy’ versus ‘unhealthy’ dietary patterns (similar to the prudent
and western diet patterns constructed in this thesis), ‘healthy’ pattern adherence has
been found to decrease incidence of CVD risk factors and metabolic syndrome, whilst
conversely, ‘unhealthy’ patterns have been shown to increase the relative risk of these
disorders (321-323). For example, a review found dietary patterns high in fruit and
vegetables (similar to our prudent diet pattern) were associated with lower prevalence of
metabolic syndrome, and those high in meat intake (similar to our western diet pattern)
were associated with components of metabolic syndrome (322).
Inflammation is heavily implicated as an important component of AD, with evidence
suggesting that it is both a reaction to the disease process and a contributor to neuronal
damage (324-326). Recent genetic studies provide further evidence that inflammatory
processes are important in the pathogenesis of AD (327-330), for example Jonsson et al.
(327) found a rare missense mutation in the gene encoding triggering receptor expressed
on myeloid cells 2 (TREM2) conferred significantly increased risk of AD; TREM2 has
an anti-inflammatory role in the brain, and the TREM2 variant (an R47H substitution)
may lead to an increased predisposition to AD through impaired containment of
inflammatory processes. The inflammation process involves the production of
inflammatory molecules including cortisol, C-reactive protein (CRP) and interleukins
(IL), many of which have been associated with dietary patterns. For example higher
MeDi adherence has been associated with lower CRP, IL6, IL7, and IL18 levels, and
lower white cell count compared with individuals with low MeDi adherence (214, 227,
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231, 296, 297). Reported results have however, been somewhat inconsistent, for
example, Dai et al. (331) found higher adherence to the MeDi was associated with
reduced levels of IL6 but had no significant effect on CRP, whilst an intervention study
where participants consumed an alcohol free MeDi or a high fat diet for 90 days
reported no detectable effect in CRP levels (332). By contrast, Chrysohoou et al. (214)
found an association between MeDi adherence, CRP, IL6, and white cell count, but
found no association with tumour necrosis factor alpha (TNFα) levels. In regards to
other dietary patterns, a ‘healthy’ dietary pattern (similar to our prudent diet pattern) has
been shown to be inversely related to concentrations of CRP, IL6 and vascular cell
adhesion molecule 1 (299, 300), whilst an ‘unhealthy’ dietary pattern (similar to our
western diet pattern) has been positively associated with serum amyloid A, IL6, and
CRP levels (212, 299).

In addition to assessing the relationship between the four dietary patterns described in
Chapter 3 and the wealth of blood-based analytes measured as part of the AIBL study, this
chapter will also report on the relationship between the four dietary patterns and
neuroimaging biomarkers: specifically Pittsburgh Compound-B positron emission
tomography (PiB PET)-determined cerebral amyloid load (a hallmark of AD), and
magnetic resonance imaging (MRI)-determined brain volume. Whilst higher MeDi
adherence has been associated with reduced odds of having a cerebral infarct (a small
localized area of dead tissue resulting from blood supply failure; 235) as visualised using
MRI, other studies have concentrated on how individual dietary constituents affect brain
volumes and atrophy (97, 333, 334); for example, the meat component of the MeDi score
has been negatively associated with summed grey and white matter volume, but not the
MeDi score as a whole (335). However, studies reporting on dietary pattern adherence and
neuroimaging biomarkers are few in number and, to our knowledge, there are no studies to
date investigating the relationship between diet and brain amyloid load.
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4.1.1. Methods
We assessed the relationship of the four dietary patterns described in Chapter 3 (MeDi,
prudent, western and inflammatory dietary index) with blood-based biomarkers of
metabolic syndrome, CVD and inflammation as well as with neuroimaging biomarkers
of AD. Our aims were investigated in the cohort utilised in the longitudinal cognition
analysis reported in Chapter 3, i.e. a well characterised, elderly, Australian healthy
control cohort, taken from the larger AIBL study (11). Keeping methods consistent
with the longitudinal cognitive data reported in Chapter 3, which has been published in
Molecular Psychiatry, a p-value of 0.01 or smaller determined a significant result for all
analyses to balance the risk of type I and type II errors.
4.1.2. Chapter aims
This chapter utilises dietary data, and blood and brain biomarker data collected as part of
the longitudinal prospective AIBL study to address the following aims:
1. To explore the potential mechanism that might underlie the observed effects of dietary
patterns on cognitive decline reported in Chapter 3 through investigating the relationship
of the dietary patterns with blood-based biomarkers of metabolic syndrome, CVD and
inflammation both cross-sectionally and longitudinally over 36 months.
2. To investigate whether the dietary patterns are associated with brain region volumes,
(measured by MRI), and cerebral amyloid burden (measured by PiB PET), or
longitudinal change in these variables over 36 months.
Whilst the existing literature is limited, we hypothesise that:
1. Higher adherence to the ‘healthy’ MeDi or prudent dietary patterns, lower adherence
to the ‘unhealthy’ western dietary pattern or increased consumption of antiinflammatory foods (lower inflammatory dietary index) is associated with decreases in
levels of CVD and metabolic syndrome blood-based biomarkers.
2. Higher adherence to the ‘healthy’ MeDi or prudent dietary patterns, lower adherence
to the ‘unhealthy’ western dietary pattern or increased consumption of antiinflammatory foods is associated with decreases in levels of blood-based biomarkers of
inflammation.
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3. Higher adherence to the ‘healthy’ MeDi or prudent dietary patterns, lower adherence
to the ‘unhealthy’ western dietary pattern or increased consumption of antiinflammatory foods at baseline is associated cross-sectionally with increased brain
volume and longitudinally with decreased cortical and hippocampal atrophy.
4. Higher adherence to the ‘healthy’ MeDi or prudent dietary patterns, lower adherence
to the ‘unhealthy’ western dietary pattern or increased consumption of antiinflammatory foods at baseline is associated cross-sectionally with lower cerebral
amyloid burden and longitudinally with slower accumulation of cerebral amyloid.
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4.2. Results
4.2.1. Descriptive statistics for the healthy control cohort
This analysis included all healthy control participants with a completed Cancer Council
of Victoria food frequency questionnaire (CCVFFQ) at baseline that were included in
the longitudinal cognition analysis in Chapter 3.
The demographics of this cohort and comparison between genders and APOE ɛ4 allele
carriers and non-carriers were described in section 3.2.3 and Table 3.4. Briefly, the main
differences between males and females were a higher percentage of females born in
Australia, a higher percentage of females with 12 or less years of education, and females
had a lower mean body mass index (BMI). Males had a higher energy intake, and a
higher percentage of people with a history of angina, heart attack and who were past
smokers. With respect to the diet scores, western diet score was significantly higher in
males and inflammatory dietary index was significantly higher in females. The only
difference between APOE ɛ4 allele carriers and non-carriers was a higher prudent diet
score in non-carriers.
A subgroup of the cohort utilised for this analysis underwent brain imaging. Participants
were selected for the neuroimaging study based on their willingness to participate in
neuroimaging (as indicated on the consent form) and their eligibility for neuroimaging
(e.g. individuals with contraindicative metal objects or claustrophobia were excluded
from MRI). The demographics of the neuroimaging sub-cohort are described in section
4.2.5.1. and Table 4.11.
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4.2.2. Diet scores and metabolic syndrome
Metabolic syndrome was the first mechanism investigated as a possible explanation of
the cognition and dietary pattern results observed in Chapter 3. A metabolic syndrome
index was constructed for each individual. Participants were given one point for each of
the following five components; 1) obesity (BMI ≥
(systolic ≥

140 and/or diastolic ≥

25); 2) raised blood pressure

90 and/or a history of hypertension); 3) high

triglyceride level (> 2 mmol/L); 4) low high density lipoprotein level (≤ 1.0 mmol/L)
and; 5) impaired fasting glucose and/or a history of diabetes (glucose level 6.1 ≥ x ≤
6.9 mmol/L). These components were utilised as they are the most common factors
defining metabolic syndrome (336): they are clinical parameters with clinically
determined ranges which were used to construct the index and subsequently define high
and low risk of metabolic syndrome. The points were summed to produce an index
ranging from 0 - 5, with a higher score indicating higher risk of metabolic syndrome.
Multiple linear regression analyses were run to determine the association between the
continuous diet scores (independent variable) and the metabolic syndrome index, as well
as the components of the index individually, and additional biomarkers of metabolic
syndrome measured as part of the AIBL study (dependent variables). The most common
confounding variables were controlled for in all analyses, i.e. age, gender, years of
education, APOE ε4 allele carriage, country of birth, BMI, and energy intake: these
variables can affect the outcome of the analysis and failure to include them in the
models can cause misestimates of relationships. As BMI is an element of the metabolic
syndrome index, it was not included as a covariate in the analysis of the index or when
the components of the index were analysed separately. Following stratification of the
cohort based on gender and APOE ε4 allele carriage, all of these analyses were re-run.
There were no associations between the four baseline dietary scores and the metabolic
syndrome index, or the individual components of the index in the cohort as a whole or
when stratified by gender or APOE ɛ4 allele carriage. In regards to the additional
biomarkers of metabolic syndrome measured as part of the AIBL study, insulin levels
were negatively associated with prudent diet (β = -0.120, p = 0.008) in the cohort as a
whole, with diet explaining 6.2% of the variance in this relationship (Table 4.1). Insulin
was additionally positively associated with the inflammatory dietary index in the cohort
as a whole (β = 0.200, p < 0.001; Table 4.1), as well as in females (β = 0.238, p = 0.002;
Table 4.2) and APOE ɛ4 allele non-carriers (β = 0.185, p = 0.004; Table 4.3); the
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inflammatory dietary index explained 2.8%, 3.5% and 7.8% of the variance in these
relationships, respectively. Thus, a higher prudent diet score and a higher consumption
of anti-inflammatory foods (indicated by a lower inflammatory dietary index) are both
associated with decreased insulin levels.
Glucagon (a hormone secreted by the pancreas which stimulates increases in blood
sugar levels, thus opposing the action of insulin) was negatively associated with western
diet score in males (β = -0.218, p = 0.007; Table 4.2) and APOE ɛ4 allele non-carriers (β
= -0.207, p < 0.001; Table 4.3), with diet explaining 13.3% and 9.4% of the variance in
the relationships respectively. Glucagon-like peptide-1 (which reduces postprandial
glycaemia by modulating gastric emptying and endocrine pancreatic secretion) was also
negatively associated with western diet score though in APOE ɛ4 allele non-carriers
only: and diet explained a 7.2% portion of the variance observed (β = -0.175, p = 0.006;
Table 4.3).
A metabolic syndrome index was also constructed for 36 month follow up data, using
the same method as that utilised during construction of the baseline index. The 36
month follow up index was subtracted from the baseline index for each participant to
give a value for ‘change in the index’ over 36 months. If the index increased over 36
months participants were assigned a value of ‘1’, if there was no change, participants
were assigned a value of ‘2’, and if the index decreased over 36 months, participants
were assigned a value of ‘3’. This ‘change in index’ variable was then used in
multinomial logistic regression models to calculate odds ratios for the investigation of
the association between baseline dietary adherence and change in metabolic syndrome
risk over 36 months (‘no change’ i.e. a score of ‘2’, was the reference). The four diet
scores were divided into tertiles for this analysis; odds ratios compared the lowest tertile
with the highest tertile. For the MeDi score, individuals with a score of 3 or lower
(lowest adherence to MeDi) were assigned to tertile 1, individuals with a score of 4 or 5
were assigned to tertile 2, whilst individuals with a score of 6 or higher (highest
adherence to MeDi) were assigned to tertile 3. For the inflammatory dietary index,
western and prudent diets, the participants’ scores were arranged into increasing order
of adherence and then divided equally into thirds, with the lowest adherence third to
each pattern assigned to tertile 1, the middle third assigned to tertile 2 and the highest
adherence third assigned to tertile 3. The model was adjusted for the same potential
confounders as those incorporated into the linear regression models described earlier in
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this section. Dietary pattern adherence did not affect the likelihood of the metabolic
syndrome index decreasing or increasing over 36 months, in the cohort as a whole or
following stratification of the cohort by gender and APOE ε4 allele carriage (data not
shown).
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Table 4.1: Relationship between baseline diet scores and metabolic syndrome biomarkers: linear regression analysis. Standardised β values shown.
Baseline prudent diet score

Baseline western diet score

Baseline inflammatory
dietary index

0.030

-0.052

0.041

0.120

-0.020

-0.028

0.054

0.076

Raised blood pressureb

0.005

-0.041

0.025

-0.026

High triglyceride levelb

-0.020

-0.083

0.036

0.064

0.075

0.098

-0.113

-0.095

-0.010

0.015

-0.011

0.042

Adiponectincd

0.055

0.005

0.035

-0.058

Angiotensinogence

0.018

0.102

-0.075

-0.077

Glucagon-like peptide-1cf

-0.041

0.044

-0.100

-0.008

Glucagoncg

-0.035

0.085

-0.129

0.002

Insulinch

-0.073

-0.120* (6.2%ł)

-0.024

0.200** (2.8%ł)

Leptinci

-0.061

-0.006

-0.049

0.025

Resistincj

0.022

-0.066

0.028

0.120

ApoE proteink

0.023

0.010

-0.047

0.048

Biomarker
Metabolic syndrome indexa
Obesityab

Low high density lipoprotein levelb
Impaired fasting glucose and/or a history of diabetesb

Baseline MeDi score

Model includes age, gender, years of education, APOE ε4 allele carriage, country of birth (Australia vs. Other), baseline body mass index and baseline energy intake kCal as covariates. For the components of the metabolic
syndrome index analysed separately, the four other components of the index are also included as covariates. Bold indicates statistical significance (*p < 0.01, **p < 0.001). łPortion of variance explained by diet score. aObesity
and metabolic syndrome index do not include body mass index as a covariate. bComponents of the metabolic syndrome index analysed separately. cMeasured as part of Rules Based Medicine biomarker panel analysis. dA
protein hormone that modulates a number of metabolic processes including glucose regulation and fatty acid catabolism. eCauses blood vessels to constrict, and drives blood pressure up. fReduces postprandial glycaemia by
modulating gastric emptying and endocrine pancreatic secretion. gA hormone secreted by the pancreas, which stimulates increases in blood sugar levels; thus opposing the action of insulin. hA hormone which has extensive
effects on metabolism and other body functions such as vascular compliance. iA hormone that helps regulate energy intake and energy expenditure, including appetite and metabolism. jA protein suggested to be linked to
obesity and type 2 diabetes. kMeasured by commercial kit. Abbreviations: APOE, Apolipoprotein E gene; ApoE, Apolipoprotein E protein; kCal, kilocalorie; MeDi, Mediterranean diet.

Table 4.2: Relationship between baseline diet scores and metabolic syndrome biomarkers following stratification of the cohort by gender: linear
regression analysis. Standardised β values shown.
Baseline MeDi score
Gender

Baseline prudent diet score

Baseline western diet score

Male

Female

Male

Female

Male

Female

Biomarker
Metabolic syndrome indexa

0.028

-0.001

-0.089

-0.037

0.018

0.093

0.171

0.106

Obesityab

0.010

-0.029

-0.042

-0.014

0.015

0.090

0.195

-0.026

Raised blood pressureb

-0.033

0.011

-0.131

b

0.029

0.090

-0.021

0.037

-0.071

0.073

-0.084

-0.154

-0.019

0.061

-0.006

0.042

0.084

0.083

0.058

0.161

-0.003

-0.165

0.031

-0.168

0.036

-0.093

0.051

0.045

0.003

-0.036

0.013

-0.047

0.129

0.020

0.112

-0.037

0.065

0.069

0.007

-0.012

-0.158

-0.071

0.093

0.114

0.096

-0.087

-0.049

-0.074

-0.093

Glucagon-like peptide-1

-0.063

-0.018

0.108

-0.024

-0.187

0.044

0.038

-0.097

Glucagoncg

-0.088

0.019

0.163

-0.017

0.049

0.095

-0.152

Insulinch

-0.026

-0.124

-0.086

-0.158

-0.067

0.032

0.157

238* (3.5%ł)

Leptinci

-0.015

-0.083

-0.059

-0.021

-0.052

-0.055

0.114

0.055

-0.032

0.090

-0.181

0.070

0.080

-0.063

0.208

0.019

0.027

0.024

0.016

0.013

-0.031

-0.064

0.049

0.045

High triglyceride level
Low high density lipoprotein
levelb
Impaired fasting glucose and/or
a history of diabetesb
Adiponectincd
Angiotensinogen

ce
cf

Resistin

cj

ApoE proteink

Male

-0.218* (13.3%ł)

Female

Baseline inflammatory dietary index

Model includes age, years of education, APOE ε4 allele carriage, country of birth (Australia vs. Other), baseline body mass index and baseline energy intake kCal as covariates. For the components of the metabolic syndrome
index analysed separately, the four other components of the index are also included as covariates. Bold indicates statistical significance (*p < 0.01). łPortion of variance explained by diet score. aObesity and metabolic syndrome
index do not include body mass index as a covariate. bComponents of the metabolic syndrome index analysed separately. cMeasured as part of Rules Based Medicine biomarker panel analysis. dA protein hormone that
modulates a number of metabolic processes including glucose regulation and fatty acid catabolism. eCauses blood vessels to constrict, and drives blood pressure up. fReduces postprandial glycaemia by modulating gastric
emptying and endocrine pancreatic secretion. gA hormone secreted by the pancreas, which stimulates increases in blood sugar levels; thus opposing the action of insulin. hA hormone which has extensive effects on metabolism
and other body functions such as vascular compliance. iA hormone that helps regulate energy intake and energy expenditure, including appetite and metabolism. jA protein suggested to be linked to obesity and type 2 diabetes.
kMeasured by commercial kit. Abbreviations: APOE, Apolipoprotein E gene; ApoE, Apolipoprotein E protein; kCal, kilocalorie; MeDi, Mediterranean diet.

Table 4.3: Relationship between baseline diet scores and metabolic syndrome biomarkers following stratification of the cohort by APOE ε4 allele
carriage: linear regression analysis. Standardised β values shown.
Baseline prudent diet
score

Baseline MeDi score
APOE ɛ4 allele carrier statusL
Biomarker
Metabolic syndrome indexa
ab

Obesity

-0.017

Baseline western diet score

Baseline inflammatory dietary
index

+

-

+

-

+

-

+

0.037

-0.060

-0.063

0.064

0.005

0.117

0.149

0.011

-0.160

-0.003

-0.118

0.059

0.059

0.048

0.158

Raised blood pressureb

-0.003

-0.003

-0.055

0.008

0.045

-0.038

0.009

-0.102

High triglyceride levelb
Low high density lipoprotein
levelb
Impaired fasting glucose and/or
a history of diabetesb
Adiponectincd

-0.026

0.054

-0.127

0.089

0.078

-0.133

0.108

-0.082

0.031

0.201

0.121

0.037

-0.133

-0.079

-0.067

-0.193

-0.039

0.104

0.007

0.020

0.000

0.022

0.059

-0.001

0.054

0.073

0.003

0.002

0.047

0.029

-0.062

-0.002

-0.006

0.062

0.128

0.006

-0.087

Angiotensinogen

ce
cf

Glucagon-like peptide-1
Glucagon
Insulin

cg

-0.008

ch

Leptinci
Resistincj
ApoE protein
LAPOE

-0.024

k

-0.104
-0.122

0.095
0.128

0.005

-0.102

0.030

-0.085

ł

-0.175* (7.2% )

0.116

-0.093

0.201

-0.029

ł

0.102

-0.082

-0.207** (9.4% )

0.217
ł

0.185* (7.8% )

-0.074

-0.097

-0.132

-0.068

-0.017

-0.063

-0.034

-0.095

-0.010

0.014

-0.028

-0.081

0.018

0.033

0.188

0.054

-0.070

-0.063

-0.068

0.042

-0.041

0.095

0.170

0.032

0.069

0.037

-0.046

-0.097

0.158

0.062

-0.001

ɛ4 allele carriage - is APOE ɛ4 allele non-carrier, + is APOE ɛ4 allele carrier. Model includes age, gender, years of education, country of birth (Australia vs. Other), baseline body mass index and baseline energy intake
kCal as covariates. For the components of the metabolic syndrome index analysed separately, the four other components of the index are also included as covariates. Bold indicates statistical significance (*p < 0.01, **p <
0.001).łPortion of variance explained by diet score. aObesity and metabolic syndrome index do not include body mass index as a covariate. bComponents of the metabolic syndrome index analysed separately. cMeasured
as part of Rules Based Medicine biomarker panel analysis. dA protein hormone that modulates a number of metabolic processes including glucose regulation and fatty acid catabolism. eCauses blood vessels to constrict,
and drives blood pressure up. fReduces postprandial glycaemia by modulating gastric emptying and endocrine pancreatic secretion. gA hormone secreted by the pancreas, which stimulates increases in blood sugar levels;
thus opposing the action of insulin. hA hormone which has extensive effects on metabolism and other body functions such as vascular compliance. iA hormone that helps regulate energy intake and energy expenditure,
including appetite and metabolism. jA protein suggested to be linked to obesity and type 2 diabetes. kMeasured by commercial kit. Abbreviations: APOE, Apolipoprotein E gene; ApoE, Apolipoprotein E protein; kCal,
kilocalorie; MeDi, Mediterranean diet.
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4.2.3. Diet scores and cardiovascular disease
Cardiovascular disease (CVD) was the second mechanism investigated as a possible
explanation of the cognition and dietary pattern results observed in Chapter 3. A CVD
index was constructed for each individual. Participants were given one point for each of the
following nine components; 1) obesity (BMI ≥ 25); 2) raised blood pressure (systolic ≥
140 and/or diastolic ≥ 90 and/or a history of hypertension); 3) a history of angina; 4) a
history of stroke; 5) a history of heart attack; 6) a history of smoking; 7) a history of
diabetes; 8) low physical activity (being in the lowest tertile of physical activity as
measured by the International Physical Activity Questionnaire; IPAQ) and; 9) elevated
homocysteine level (> 10 μmol/L). Analogous to the metabolic syndrome index
construction, these components were utilised in the CVD index as they are the main risk
factors for CVD (337). Obesity, raised blood pressure and homocysteine level are clinical
parameters and therefore we utilised the clinically defined ‘cut-offs’. The other
components, excepting physical activity, are all categorical variables with a ‘yes’ or ‘no’
answer, whilst low physical activity was determined based on the cohort’s reported activity
levels. The points assigned to each individual were summed to produce an index ranging
from 0 - 9, with a higher score indicating higher risk of CVD. There is considerable overlap
between risk factors for metabolic syndrome and CVD, including obesity, elevated blood
pressure, diabetes, increased LDL and decreased HDL: Several of these factors were used
in both the metabolic syndrome and CVD indexes. Additional lipid profile data (including
LDL and HDL subfractions) measured as part of the AIBL study was only included in this
section which investigates the association of dietary patterns and CVD biomarkers.
The relationship between the four dietary patterns and levels of total cholesterol,
triglycerides, HDL, and LDL was determined using the results of clinical tests undertaken
by PathWest laboratories: This analysis was conducted cross-sectionally using baseline
data, and longitudinally by subtracting the baseline level from the 36 month follow up level
for each participant to yield a value for ‘change in analyte levels’ over 36 months. To
supplement the PathWest lipid profile data, a Lipoprint system was used to divide the
baseline lipid profile components further into large, small and intermediate HDL, very low
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density lipoproteins (VLDL), intermediate density lipoprotein (IDL) subfractions (A, B and
C), and LDL subfractions (1 to 2, and 3 to 7).
Multiple linear regression analyses were run to determine the association between the diet
scores (independent variable), the CVD index, individual components of the index, the
PathWest lipid profiles and the Lipoprint-determined lipid subfractions (dependent
variables). As with the metabolic syndrome analysis in section 4.2.2., the most common
confounding variables were controlled for in all analyses, i.e. age, gender, years of
education, APOE ε4 allele carriage, country of birth, BMI, and energy intake. As BMI is an
element of the CVD index, it was not included as a covariate in the analysis of the index or
when the components of the index were analysed separately. Following stratification of the
cohort based on gender and APOE ε4 allele carriage, all analyses were re-run.
The index and its individual components were not associated with the four dietary patterns
in the cohort as a whole (Table 4.4), or following stratification of the cohort by gender or
APOE ɛ4 allele carriage (Tables 4.5 and 4.6).
Several significant results were observed with respect to the PathWest lipid profiles and the
Lipoprint-determined lipid subfractions. Prudent diet score was negatively associated with
triglyceride level in males (β = -0.203, p < 0.006; Table 4.5), and APOE ε4 allele noncarriers (β = -0.148, p < 0.006; Table 4.6), i.e. as prudent diet adherence increased,
triglyceride levels decreased, with diet explaining 3.4% and 1.8% of the variance
respectively. Western diet score was positively associated with IDL-C level in females (β =
0.193, p = 0.003; Table 4.5), i.e. as western diet adherence increased, IDL-C level also
increased, with diet explaining 6.5% of the variance in this relationship. There were no
associations between the lipid profiles and MeDi score or the inflammatory dietary index.
Longitudinally however, there were no associations between change in the lipid profiles
over 36 months and any of the four diet scores in the cohort as a whole or following
stratification of the cohort by gender or APOE ɛ4 allele carriage (Tables 4.4 to 4.6).
A CVD index was also constructed for 36 month follow up data, using the same method as
that utilised during construction of the baseline index. As per the longitudinal metabolic
syndrome index analysis, the 36 month follow up CVD index was subtracted from the
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baseline CVD index for each participant to give a value for ‘change in the index’ over 36
months. If the index increased over 36 months participants were assigned a value of ‘1’, if
there was no change participants were assigned a value of ‘2’, and if the index decreased
over 36 months, participants were assigned a value of ‘3’.
This ‘change in index’ variable was then used in multinomial logistic regression models to
calculate odds ratios for the investigation of the association between baseline dietary
adherence and change in CVD risk over 36 months (‘no change’ i.e. a score of ‘2’, was the
reference). The four diet scores were divided into tertiles for this analysis, as described in
section 4.2.2.; odds ratios compared the lowest tertile with the highest tertile. The model
was adjusted for the same potential confounders as those incorporated into the linear
regression models described earlier in this section.
Prudent diet adherence affected the likelihood of the CVD index remaining stable over 36
months. In females, the odds of the CVD index remaining at the baseline level rather than
increasing at 36 months was 3.66 times higher in the highest tertile of prudent diet
adherence compared to the lowest adherence tertile (Confidence interval (CI): 1.368 –
9.776; p < 0.010). In APOE ɛ4 allele carriers, the odds of the CVD index remaining at the
baseline level rather than increasing at 36 months were also 7.03 times higher in the highest
tertile of prudent diet adherence compared to the lowest adherence tertile (CI: 1.598 –
30.910: p < 0.010). These results are shown in Table 4.7.
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Table 4.4: Relationship between baseline diet scores and CVD biomarkers: linear regression analysis. Standardised β values shown.
Biomarker
Cardiovascular disease indexa

Baseline MeDi score

Baseline prudent diet score

Baseline western diet score

Baseline inflammatory dietary index

0.016

-0.069

0.058

0.074

Obesityia

-0.013

-0.013

0.020

0.079

Low physical activityia
Raised blood pressureia
History of anginaia
History of heart attackia
History of strokeia
History of diabetesia
History of smokingia
Elevated homocysteine levelia

-0.014
0.014
-0.015
0.021
-0.002
0.037
-0.035
0.065

-0.071
-0.023
0.123
-0.042
0.049
0.004
0.010
-0.025

-0.060
0.008
0.063
0.026
-0.049
-0.003
0.057
0.063

0.095
0.003
0.032
-0.018
-0.111
0.023
-0.008
-0.024

Total cholesterolb

-0.019

-0.104

0.097

0.015

Triglyceridesb
High density lipoproteinb
Low density lipoproteinb
High density lipoprotein largec
High density lipoprotein intermediatec
High density lipoprotein smallc
Very low density lipoproteinc

0.004
-0.013
-0.018
0.016
-0.077
0.003
-0.017

-0.114
-0.034
-0.049
0.008
-0.073
-0.100
-0.078

0.051
0.069
0.062
0.028
0.100
0.100
0.022

0.079
0.015
-0.014
-0.002
0.035
0.069
0.075

Intermediate density lipoprotein Ac
Intermediate density lipoprotein Bc
Intermediate density lipoprotein Cc
Low density lipoproteins 1 and 2c
Low density lipoproteins 3 – 7c
Change in total cholesterolb

0.004
-0.003
-0.006
-0.004
0.033
-0.024

0.008
-0.063
-0.104
-0.058
-0.027
0.026

0.043
0.098
0.106
0.046
0.043
-0.021

-0.042
0.040
0.037
-0.001
0.069
-0.013

Change in triglyceridesb

-0.050

-0.060

0.095

0.000

Change in high density lipoproteinb
0.016
0.002
-0.041
-0.013
Change in low density lipoproteinb
-0.023
0.034
-0.023
-0.006
Model includes age, gender, years of education, APOE ε4 allele carriage, country of birth (Australia vs. Other), baseline body mass index and baseline energy intake kCal as covariates. For the components of the CVD index
analysed separately, the eight other components of the index are also included as covariates. iComponents of the CVD index analysed separately. aCVD index and individual components do not include body mass index as a
covariate. bMeasured by PathWest clinical pathology tests. cBaseline lipid subfractions determined using the Lipoprint system. Abbreviations: APOE, Apolipoprotein E; CVD, cardiovascular disease; kCal, kilocalorie; MeDi,
Mediterranean diet.

Table 4.5: Relationship between baseline diet scores and CVD biomarkers following stratification of the cohort by gender: linear regression analysis.
Standardised β values shown.
Baseline MeDi score
Gender

Baseline prudent diet score

Baseline western diet score

Baseline Inflammatory dietary index

Biomarker
Cardiovascular disease indexa
Obesityia
Low physical activityia
Raised blood pressureia
History of anginaia
History of heart attackia
History of strokeia
History of diabetesia
History of smokingia
Elevated homocysteine levelia
Total cholesterolb
Triglyceridesb
High density lipoproteinb
Low density lipoproteinb
High density lipoprotein largec
High density lipoprotein intermediatec
High density lipoprotein smallc

Male

Female

Male

Female

Male

Female

Male

Female

0.008
0.001
-0.042
-0.032
-0.044
0.111
0.023
0.053
-0.081
0.099
-0.003
0.036
0.043
-0.033
0.045
0.001
0.026

0.016
-0.014
-0.009
0.029
0.037
-0.083
-0.089
0.063
0.013
0.004
-0.006
0.005
-0.042
0.010
0.011
0.129
-0.014

-0.111
-0.008
-0.205
-0.117
0.038
-0.048
0.070
0.058
0.096
-0.037
-0.131
-0.203* (3.4%ł)
-0.034
-0.064
0.019
-0.050
-0.098

-0.030
0.017
0.031
0.016
-0.014
-0.096
0.014
0.006
-0.046
-0.057
-0.105
-0.033
-0.033
-0.094
0.025
-0.093
-0.096

0.044
-0.024
-0.020
0.047
0.008
0.038
-0.051
-0.040
0.025
0.123
0.036
0.029
0.148
-0.031
0.085
0.180
0.105

0.065
0.055
-0.088
0.018
0.065
0.051
-0.035
0.033
0.063
-0.007
0.153
0.068
0.019
0.144
-0.009
0.046
0.063

0.132
0.185
0.224
0.067
-0.036
-0.030
-0.110
-0.059
-0.047
-0.060
0.053
0.111
0.002
0.021
-0.066
0.044
0.151

0.037
-0.048
0.014
-0.025
0.051
0.044
-0.053
0.069
0.031
0.060
-0.029
0.042
-0.003
-0.042
0.009
-0.001
0.005

Very low density lipoproteinc

0.004

-0.038

-0.136

-0.029

-0.004

0.019

0.137

0.032

Intermediate density lipoprotein Ac
Intermediate density lipoprotein Bc
Intermediate density lipoprotein Cc
Low density lipoproteins 1 and 2c
Low density lipoproteins 3 – 7c

0.005
-0.051
0.004
-0.030
0.105

0.014
0.034
-0.008
0.022
-0.027

0.046
-0.102
-0.120
-0.050
-0.067

-0.030
-0.055
-0.101
-0.066
-0.003

-0.001
0.073
0.000
0.013
0.093

0.100
0.124
0.193* (6.5%ł)
0.077
-0.014

-0.001
0.119
0.114
-0.091
0.055

-0.083
-0.007
-0.023
0.077
0.098

Change in total cholesterolb

-0.033

-0.015

-0.010

0.092

0.023

0.017

-0.054

-0.091

Change in triglyceridesb
-0.033
-0.083
-0.082
-0.016
0.153
-0.009
0.000
-0.007
Change in high density lipoproteinb
0.054
-0.005
-0.016
0.018
-0.134
0.033
0.076
-0.066
Change in low density lipoproteinb
-0.051
0.006
-0.009
0.107
0.045
-0.117
0.008
-0.039
Model includes age, years of education, APOE ε4 allele carriage, country of birth (Australia vs. Other), baseline body mass index and baseline energy intake kCal as covariates. For the components of the CVD index analysed
separately, the eight other components of the index are also included as covariates. Bold indicates statistical significance (*p < 0.01). iComponents of the CVD index analysed separately. łPortion of variance explained by diet score.
aCVD index and individual components do not include body mass index as a covariate. bMeasured by PathWest clinical pathology tests. cBaseline lipid subfractions determined using the Lipoprint system. Abbreviations: APOE,
Apolipoprotein E; CVD, cardiovascular disease; kCal, kilocalorie; MeDi, Mediterranean diet.

Table 4.6: Relationship between baseline diet scores and CVD biomarkers following stratification of the cohort by APOE ε4 allele carriage:
linear regression analysis. Standardised β values shown.
Baseline MeDi score
APOE ɛ4 allele carrier statusd
Biomarker
Cardiovascular disease indexa
Obesityia
Low physical activityia
Raised blood pressureia
History of anginaia
History of heart attackia
History of strokeia
History of diabetesia
History of smokingia
Elevated homocysteine levelia
Total cholesterolb

Baseline prudent diet score

-

+

0.031
-0.005
0.016
0.010
0.025
-0.036
-0.008
0.012
-0.024
0.087
0.011

-0.031
-0.115
-0.087
0.078
-0.081
0.121
0.075
0.197
-0.099
0.042
-0.068

-

+

Baseline western diet score
-

+

Baseline inflammatory dietary index
-

+

-0.091
-0.020
0.072
0.047
0.063
0.110
0.001
-0.155
0.022
0.102
0.039
0.239
-0.073
-0.054
-0.064
-0.108
0.076
0.205
-0.056
0.072
0.040
-0.088
0.037
-0.053
-0.011
-0.041
-0.017
0.206
0.026
-0.087
-0.063
0.052
0.058
0.039
0.027
-0.287
0.046
0.145
-0.039
-0.109
-0.123
-0.165
-0.037
0.188
0.051
-0.178
0.044
-0.094
0.027
-0.055
0.016
0.193
-0.029
0.047
-0.018
0.007
0.083
-0.102
-0.039
0.074
-0.097
-0.112
0.088
0.138
0.042
-0.024
-0.148*
Triglyceridesb
0.004
0.040
0.013
0.070
-0.031
0.100
0.000
(1.8%ł)
High density lipoproteinb
-0.011
-0.039
-0.014
-0.120
0.075
0.073
0.024
0.035
Low density lipoproteinb
0.015
-0.068
-0.060
-0.071
0.043
0.124
0.004
-0.041
High density lipoprotein largec
0.007
0.044
0.010
-0.013
0.055
-0.039
0.026
-0.063
High density lipoprotein intermediatec
-0.044
-0.153
-0.051
-0.159
0.095
0.157
0.038
0.062
High density lipoprotein smallc
0.013
-0.014
-0.067
-0.188
0.070
0.160
0.008
0.244
Very low density lipoproteinc
0.020
-0.095
-0.075
-0.051
0.017
-0.065
0.113
-0.084
Intermediate density lipoprotein Ac
0.015
-0.002
0.012
0.003
0.050
0.039
-0.022
-0.072
Intermediate density lipoprotein Bc
0.024
-0.039
-0.056
-0.073
0.084
0.146
0.039
0.071
Intermediate density lipoprotein Cc
0.047
-0.126
-0.097
-0.107
0.114
0.069
0.035
0.053
Low density lipoproteins 1 and 2c
0.030
-0.095
-0.057
-0.075
0.048
0.085
-0.015
0.025
Low density lipoproteins 3 – 7c
0.052
-0.019
-0.053
0.067
0.065
-0.023
0.080
0.041
Change in total cholesterolb
0.002
-0.080
0.029
0.021
-0.011
-0.080
0.003
-0.061
Change in triglyceridesb
-0.065
-0.027
-0.081
-0.025
0.131
-0.008
0.019
-0.020
Change in high density lipoproteinb
0.054
-0.045
0.016
-0.019
-0.105
0.125
-0.006
-0.054
Change in low density lipoproteinb
-0.002
-0.069
0.035
0.039
0.001
-0.126
0.009
-0.050
dAPOE ɛ4 allele carriage - is APOE ɛ4 allele non-carrier, + is APOE ɛ4 allele carrier. Model includes age, gender, years of education, country of birth (Australia vs. Other), baseline body mass index and baseline energy
intake kCal as covariates. For the components of the CVD index analysed separately, the eight other components of the index are also included as covariates. Bold indicates statistical significance (*p < 0.01).
iComponents of the CVD index analysed separately. łPortion of variance explained by diet score. aCVD index and individual components do not include body mass index as a covariate. bMeasured by PathWest
clinical pathology tests. cBaseline lipid subfractions determined using the Lipoprint system. Abbreviations: APOE, Apolipoprotein E; CVD, cardiovascular disease; kCal, kilocalorie; MeDi, Mediterranean diet.

Table 4.7 Odds ratios of the CVD index changing over 36 months for the cohort as a whole and following stratification of the cohort by gender and
APOE ɛ4 allele carriage.
Group+
Whole cohort
Males
Females
APOE ε4 allele carrier
APOE ε4 allele non – carrier
Whole cohort
Males
Females
APOE ε4 allele carrier
APOE ε4 allele non – carrier
Whole cohort
Males
Females
APOE ε4 allele carrier
APOE ε4 allele non – carrier
Whole cohort
Males
Females
APOE ε4 allele carrier
APOE ε4 allele non – carrier

MeDi
MeDi

Odds
Ratioa
0.64
0.63

Confidence
Intervala
0.331 – 1.247
0.228 – 1.740

MeDi
MeDi
MeDi
Prudent
Prudent
Prudent
Prudent
Prudent
Western
Western
Western
Western
Western
Inflammatory dietary index
Inflammatory dietary index
Inflammatory dietary index
Inflammatory dietary index
Inflammatory dietary index

0.54
1.08
0.57
1.01
0.70
1.25
1.77
0.85
0.81
2.04
0.44
0.74
0.87
1.37
1.63
0.57
0.29
1.17

0.216 – 1.375
0.279 – 4.180
0.261 – 1.236
0.527 – 1.929
0.266 – 1.840
0.486 – 3.213
0.438 – 7.108
0.399 – 1.795
0.399 – 1.645
0.676 – 6.181
0.154 – 1.273
0.128 – 4.310
0.393 – 1.930
0.637 – 2.947
0.534 – 4.973
0.199 – 1.616
0.058 – 1.499
0.508 – 2.677

Diet Pattern

p-valuea

Odds Ratiob

0.191
0.372

0.70
0.87

Confidence
Intervalb
0.349 – 1.412
0.284 – 2.670

0.198
0.912
0.154
0.981
0.469
0.643
0.424
0.664
0.559
0.205
0.131
0.740
0.734
0.420
0.391
0.288
0.141
0.716

0.62
1.10
0.62
2.05
1.25
3.66
7.03
1.57
0.52
0.80
0.34
0.38
0.55
0.60
1.06
0.35
0.25
0.83

0.244 – 1.591
0.268 – 4.546
0.274 – 1.406
1.050 – 4.000
0.457 – 3.398
1.368 – 9.776
1.598 – 30.910
0.720 – 3.434
0.245 – 1.090
0.227 – 2.822
0.120 – 0.972
0.068 – 2.116
0.231 – 1.296
0.279 – 1.297
0.321 – 2.779
0.117 – 1.055
0.050 – 1.216
0.339 – 2.038

p-valueb
0.321
0.808
0.323
0.891
0.253
0.035
0.667
0.010*
0.010*
0.256
0.083
0.730
0.044
0.269
0.171
0.195
0.926
0.062
0.085
0.687

Model includes age, gender, APOE ε4 allele carriage, years of education, country of birth (Australia vs. Other), baseline body mass index and baseline energy intake kCal as covariates. +When the cohort is stratified by gender and
APOE ε4 allele status, these characteristics are not included in the models as covariates. aOdds ratio, confidence interval and p-value for the odds of a decrease in the CVD index compared to no change in the CVD index over 36
months. bOdds ratio, confidence interval and p-value for the odds of an increase in the CVD index compared to no change in the CVD index over 36 months. Bold indicates statistical significance (* p < 0.01). Multinomial logistic
regression analysis used to calculate odds ratios. Abbreviations: APOE, Apolipoprotein E; CVD, cardiovascular disease; kCal, kilocalorie; MeDi, Mediterranean diet.
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4.2.4. Diet scores and inflammation
4.2.4.1. Blood-based inflammation biomarker index 1
Inflammation was the third mechanism investigated as a possible explanation of the
cognition and dietary pattern results observed in Chapter 3. A range of inflammatory
biomarkers (cortisol, CRP, TNFα, complement component 3, cluster of differentiation 40
(CD40), CD40 ligand, migration inhibitory factor (MIF), macrophage inflammatory protein
(MIP) 1 alpha, MIP 1 beta, TNF receptor II, immunoglobulin M (IgM), interleukin (IL) 3,
IL4, IL8, IL10, IL13, IL18, interleukin 1 receptor antagonist) were analysed by Rules
Based Medicine (RBM) at baseline using the Human DiscoveryMap® v1.0 panel (Austin,
TX, USA). We constructed a blood-based inflammation biomarker index for each
participant using these RBM biomarkers. There are no definitive published ‘normal range’
levels for most of these biomarkers, we consequently assigned a value of ‘1’ to participants
with biomarker levels falling in the top 20% of each biomarker measured (indicating a
more inflammatory profile), participants where levels of each biomarker fell outside the top
20% were assigned a value of ‘0’. We then summed the values for each biomarker to
construct a blood-based inflammation biomarker index with a score ranging from 0 to 18,
with higher scores indicating a higher inflammatory profile. Linear regression analyses
were conducted to assess the relationship of the four dietary patterns (independent variable)
with the index, and additionally with the components of the index individually (dependent
variables; Table 4.8). Consistent with the metabolic syndrome and CVD analyses reported
in sections 4.2.2. and 4.2.3., the most common confounding variables were controlled for in
all analyses, i.e. age, gender, years of education, APOE ε4 allele carriage, country of birth,
BMI, and energy intake.
The inflammatory dietary index was positively associated with the blood-based
inflammation biomarker index in the cohort as a whole, i.e. as individuals consume less
anti-inflammatory dietary components (indicated by a higher inflammatory dietary index),
their blood-based inflammation biomarker index increases; the inflammatory dietary index
explained 4.7% of the variance in the relationship (β = 0.168, p = 0.008; Table 4.8).
Following stratification of the cohort by gender, this positive association was observed in
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females only (β = 0.237, p = 0.007; Figure 4.1) with the inflammatory dietary index
explaining 7.0% of the variance in the relationship. When the cohort was stratified by
APOE ɛ4 allele carriage, a relationship approaching significance was observed in APOE ɛ4
allele non-carriers only (β = 0.166, p = 0.025; data not shown). We observed no
associations between the blood-based inflammation biomarker index and the other three
dietary patterns.
When evaluating the relationship between the four dietary patterns and the components of
the index individually, we observed an unexpected positive association between MeDi
adherence and IgM level (IgM is an antibody produced first in an immune response; β =
0.115, p = 0.009), with diet explaining 3.8% of the variance in this relationship. There were
no associations with any of the dietary patterns and the other 17 biomarkers of
inflammation in the cohort as a whole (Table 4.8). We once again repeated the analysis
following stratification of the cohort by gender and APOE ɛ4 allele carriage; only one
statistically significant relationship was observed, with the inflammatory dietary index
positively associated with IL18 in males; the dietary index explained 7.1% of the variance
in this relationship (β = 0.221, p < 0.010; data not shown).
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Table 4.8: Relationship between baseline diet scores and blood-based inflammation biomarker index 1: linear regression analysis.
Standardised β values shown.
Biomarker
Inflammation index
Cortisolsa
CRPsb
TNFαsc
C3sd
CD40se
CD40 ligandsf
MIFsg
MIP 1αsh
MIP 1βsi
TNF RIIsj

Baseline MeDi score

Baseline prudent diet score

Baseline western diet score

Baseline inflammatory dietary index
0.168* (4.7%ł)

-0.045

-0.039

-0.018

-0.015
-0.018
0.005
-0.069
0.066
-0.062
-0.068
-0.058
-0.001
0.042

-0.019
-0.069
0.001
-0.098
-0.012
-0.053
-0.028
-0.011
0.005
-0.016

0.017
0.052
-0.049
0.044
0.017
0.042
-0.025
-0.056
0.043
0.025

0.038
0.119
0.111
0.092
-0.008
0.073
0.040
0.073
0.083
0.003

IgMsk

0.115* (3.8%ł)

0.067

-0.027

-0.080

IL10sl
IL13sm
IL18sn
IL1raso
IL3sp
IL4sq
IL8sr

-0.021
-0.044
-0.011
-0.074
-0.017
-0.048
0.014

0.020
0.024
-0.049
-0.043
0.016
0.032
0.091

-0.016
-0.042
-0.018
0.023
-0.037
-0.073
-0.109

0.029
0.008
0.095
0.127
0.015
0.009
0.019

Model includes age, gender, years of education, APOE ε4 allele carriage, country of birth (Australia vs. Other), baseline body mass index and baseline energy intake kCal as covariates. Bold indicates statistical
significance (*p < 0.01). łPortion of variance explained by diet score. aA corticosteroid hormone produced by the adrenal gland. bA protein found in the blood in response to inflammation. cA cytokine involved in
systemic inflammation and stimulating the acute phase reaction. dA protein that works with the immune system and plays a role in the development of inflammation. eA costimulatory protein found on antigen
presenting cells, and is required for their activation. fA protein that is primarily expressed on activated T cells. gA lymphokine involved in cell mediated immunity, immunoregulation and inflammation. hA
chemokine with pro-inflammatory activities, also inhibits the proliferation of hematopoietic stem cells. iA factor produced by macrophages that causes local inflammatory responses. jReceptors that bind TNFα.
k
Includes the antibodies that are usually produced first in an immune response which are later replaced by other types of antibodies. lSecreted by antigen-presenting cells, promotes the development of
immunologic tolerance and suppresses the production of inflammatory cytokines. mA cytokine secreted by many cell types, but especially T helper type 2 cells, an important mediator of allergic inflammation and
disease. nA cytokine that works together with IL12 to induce cell-mediated immunity following infection with microbial products. oAn agent which binds to the same receptor on the cell surface as IL1R and
prevents IL1 from sending a signal to that cell. pA cytokine that can improve the body's natural response to disease as part of the immune system. qA cytokine that induces differentiation of naïve helper T cells to
TH2 cells. rA chemokine produced by macrophages and other cell types, an important mediator of the immune reaction in the innate immune system. sComponents of the blood-based inflammation biomarker
index 1 analysed separately. Abbreviations: APOE, Apolipoprotein E; C3, complement component 3; CD40, cluster of differentiation 40; CRP, C-reactive protein; IgM, immunoglobulin M; IL, interleukin; IL1ra,
interleukin 1 receptor antagonist; kCal, kilocalorie; MeDi, Mediterranean diet; MIF, migration inhibitory factor; MIP1α, macrophage inflammatory protein 1 alpha; MIP1β, macrophage inflammatory protein 1
beta; TNFRII, tumour necrosis factor receptor II; TNFα, tumour necrosis factor alpha.
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Figure 4.1: Higher baseline inflammatory dietary index score is associated with higher
blood-based inflammation biomarker index 1 score in females.
Model adjusted for age, years of education, APOE ε4 allele carriage, country of birth (Australia vs. Other), baseline body mass index
and baseline energy intake kCal (residuals plotted). Linear regression analysis. R2adj = 0.249, β = 0.237, p = 0.007, portion of variance
= 7.0%. Abbreviations: APOE, Apolipoprotein E; kCal, kilocalorie.
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4.2.4.2. Blood-based inflammation biomarker index 2
4.2.4.2.1. Blood-based inflammation biomarker index 2 – cross-sectional
analysis
We constructed a second blood-based inflammation biomarker index, based on ten analytes
measured as part of the clinical tests conducted by PathWest laboratories at the baseline
time-point and 36 month follow up (haemoglobin, red blood cell count, erythrocyte
sediment rate, platelet count, white cell count, neutrophils, lymphocytes, monocytes,
eosinophils, basophils). The index was computed using the same method as that employed
to construct the blood-based inflammation biomarker index 1, i.e. we once again assigned a
value of ‘1’ to participants with biomarker levels falling in the top 20% of each biomarker
measured, and a value of ‘0’ to participants whose levels fell outside the top 20%; the
scores for each biomarker were then summed to construct the blood-based inflammation
biomarker index 2 with a value ranging from 0 to 10. Linear regression analyses were again
used to assess the association of this blood-based inflammation biomarker index 2 and its
individual components with the four dietary patterns in the cohort as a whole and following
stratification of the cohort by gender and APOE ɛ4 allele carrier status.
The blood-based inflammation biomarker index 2 was positively correlated with western
diet score in females (β = 0.192, p = 0.002; with diet explaining 3.9% of the variance in this
relationship; Table 4.10 and Figure 4.2), and negatively correlated with prudent diet score
in the whole cohort (β = -0.136, p = 0.004; with diet explaining 2.4% of the variance in this
relationship; Table 4.9) as well as in females only (β = -0.164, p = 0.010; with diet
explaining 2.9% of the variance in this relationship; Table 4.10 and Figure 4.2).
Furthermore, the inflammatory dietary index was positively correlated with the blood-based
inflammation biomarker index 2 in the cohort as a whole (β = 0.181, p < 0.001; with diet
explaining 2.9% of the variance in this relationship; Table 4.9), as well as in APOE ɛ4
allele non-carriers (β = 0.191, p = 0.004; with diet explaining 3.9% of the variance in this
relationship; Table 4.11 and Figure 4.3).
When evaluating the relationship between the four dietary patterns and the components of
the index individually, several associations were observed (Tables 4.9 – 4.11). Briefly, the
MeDi was 1) negatively correlated with platelet count in the cohort as a whole as well as in
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APOE ɛ4 allele carriers; and 2) negatively associated with red blood cell count in females.
Prudent diet was 1) negatively associated with white cell count in the cohort as a whole as
well as in APOE ɛ4 allele non-carriers; 2) negatively associated with eosinophils in APOE
ɛ4 allele carriers; 3) negatively associated with platelet count in females; and 4) positively
associated with haemoglobin level in the cohort as a whole. Western diet was 1) positively
associated with platelet count in the cohort as a whole as well as in females; 2) positively
associated with eosinophils in APOE ɛ4 allele carriers; 3) positively associated with
lymphocytes in females; and 4) negatively associated with haemoglobin and red blood cell
count in the cohort as a whole as well as in both APOE ɛ4 allele non-carriers and in males.
The inflammatory dietary index was 1) positively associated with white cell count in the
cohort as a whole as well as in both males and APOE ɛ4 allele non-carriers; 2) positively
associated with eosinophils in the whole cohort; 3) positively associated with neutrophil
count in males; and 5) positively associated with lymphocyte level in females and APOE ɛ4
allele non-carriers.
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Table 4.9: Relationship between baseline diet scores and blood-based inflammation
biomarker index 2: linear regression analysis. Standardised β values shown.
Baseline MeDi
score

Baseline prudent
diet score

Baseline western
diet score

Baseline
inflammatory
dietary index

Inflammation index 2

-0.003

-0.136* (2.4%ł)

0.090

0.181** (2.9%ł)

Haemoglobini

-0.045

0.108** (0.8%ł)

-0.179** (1.8%ł)

-0.071

Red blood cell counti

-0.035

0.050

-0.173** (1.8%ł)

-0.014

Erythrocyte sediment
ratei

0.039

-0.006

0.024

-0.012

-0.117* (2.1%ł)

-0.116

0.138* (2.0%ł)

0.087

White cell counti

-0.026

-0.135* (2.3%ł)

0.122

0.185** (3.0%ł)

Neutrophilsi

-0.033

-0.110

0.097

0.142

Lymphocytesi

0.008

-0.095

0.100

0.134

Monocytesi

-0.008

-0.065

0.053

0.099

Eosinophilsi

-0.032

-0.075

0.031

0.152* (2.5%ł)

0.038

-0.071

0.058

0.077

Biomarker

Platelet counti

Basophilsi

Model includes age, gender, years of education, APOE ε4 allele carriage, country of birth (Australia vs. Other), baseline body mass index
and baseline energy intake kCal as covariates. Bold indicates statistical significance (*p < 0.01, **p < 0.001). łPortion of variance
explained by diet score. iComponents of the blood-based inflammation biomarker index 2 analysed separately. Abbreviations: APOE,
Apolipoprotein E; kCal, kilocalorie; MeDi, Mediterranean diet.
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Table 4.10: Relationship between baseline diet scores and blood-based inflammation biomarker index 2 following stratification of the cohort by
gender: linear regression analysis. Standardised β values shown.
Baseline MeDi score

Baseline prudent diet score

Baseline western diet score

Baseline
inflammatory dietary index
Male
Female

Biomarker

Male

Inflammation index 2

0.080

-0.043

-0.097

Haemoglobini

0.082

-0.122

0.158

0.099

-0.238* (9.4%ł)

Red blood cell counti

0.068

-0.144*
(2.4%ł)

0.051

0.046

-0.208* (7.0%ł)

Erythrocyte sediment ratei

0.018

0.088

-0.059

0.037

-0.091

-0.129

-0.071

-0.170* (6.5%ł)

0.068

White cell counti

0.058

-0.073

-0.161

-0.114

0.083

Neutrophilsi

0.026

-0.077

-0.175

-0.054

0.104

Lymphocytesi

0.090

-0.017

-0.021

-0.152

0.005

Monocytesi

0.072

-0.047

-0.066

-0.064

0.006

0.107

0.081

0.101

Eosinophilsi

-0.005

-0.030

-0.026

-0.113

-0.052

0.137

0.100

0.163

0.022

0.030

-0.036

-0.123

0.066

0.073

0.108

0.078

Platelet counti

Basophilsi

Female

Male

Female
-0.164* (2.9%ł)

Male
-0.010

0.030

Female
0.192* (3.9%ł)

0.135

0.199

-0.143

-0.112

-0.040

-0.128

-0.022

0.020

0.007

-0.052

-0.021

0.090

0.109

0.145

0.220* (6.5%ł)

0.164

0.072

0.224* (7.7%ł)

0.084

0.193* (6.7%ł)

0.166* (2.8%ł)

0.053

0.204* (2.8%ł)

Model includes age, years of education, APOE ε4 allele carriage, country of birth (Australia vs. Other), baseline body mass index and baseline energy intake kCal as covariates. Bold indicates statistical significance (*p <
0.01). łPortion of variance explained by diet score. iComponents of the blood-based inflammation biomarker index 2 analysed separately. Abbreviations: APOE, Apolipoprotein E; kCal, kilocalorie; MeDi, Mediterranean
diet.

Table 4.11: Relationship between baseline diet scores and blood-based inflammation biomarker index 2 following stratification of the cohort by
APOE ɛ4 allele carriage: linear regression analysis. Standardised β values shown.
Biomarker
APOE ɛ4 allele carrier
statusa

Baseline MeDi score
-

Baseline prudent diet score
+

-

Baseline western diet score

Baseline inflammatory dietary
index

+

-

+

-

+

0.061

0.146

0.191*
(3.9%ł)

0.094

-0.166

-0.062

-0.069

-0.180

-0.017

0.028

Inflammation index 2

-0.014

0.047

-0.113

-0.173

Haemoglobini

-0.008

-0.046

0.116

0.055

Red blood cell counti

-0.034

-0.049

0.071

-0.041

Erythrocyte sediment
ratei

0.057

0.023

-0.021

0.112

0.016

0.019

0.040

-0.265

Platelet counti

-0.069

-0.220*
(7.9%ł)

-0.088

-0.145

0.124

0.141

0.063

0.089

White cell counti

-0.045

0.010

-0.147*
(2.8%ł)

-0.086

0.120

0.107

0.208*
(4.0%ł)

0.057

Neutrophilsi

-0.052

-0.008

-0.144

-0.092

0.084

0.126

0.153

0.065

Lymphocytesi

0.004

0.048

-0.135

0.066

0.143

-0.086

0.182*
(3.4%ł)

-0.078

Monocytesi

-0.001

-0.035

-0.041

-0.131

0.040

0.087

0.072

0.165

Eosinophilsi

-0.053

0.036

-0.025

-0.254*
(6.5%ł)

-0.040

0.312*
(6.7%ł)

0.129

0.210

0.003

0.133

-0.100

-0.011

-0.088

-0.008

0.133

-0.071

Basophilsi

-0.174**
(1.7%ł)
-0.159*
(1.6%ł)

aAPOE ɛ4 allele carriage - is APOE ɛ4 allele non-carrier, + is APOE ɛ4 allele carrier. Model includes age, gender, years of education, country of birth (Australia vs. Other), baseline body mass index and baseline energy
intake kCal as covariates. Bold indicates statistical significance (*p < 0.01, **p < 0.001). łPortion of variance explained by diet score. iComponents of the blood-based inflammation biomarker index 2 analysed separately.
Abbreviations: APOE, Apolipoprotein E; kCal, kilocalorie; MeDi, Mediterranean diet.
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Figure 4.2: Higher baseline western diet score (red triangles) and lower baseline prudent
diet score (blue circles) is associated with higher blood-based inflammation biomarker
index 2 level in females.
Model adjusted for age, years of education, APOE ε4 allele carriage, country of birth (Australia vs. Other), baseline body mass index
and baseline energy intake kCal (residuals plotted). Linear regression analysis: R2adj = 0.093, β = -0.164, p = 0.010, portion of variance =
.9% for the prudent diet association, and R2adj = 0.127, β = 0.192, p = 0.002, portion of variance = 3.9% for the western diet association.
Abbreviations: APOE, Apolipoprotein E; kCal, kilocalorie.
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Figure 4.3: Higher baseline inflammatory dietary index is associated with higher bloodbased inflammation biomarker index 2 level in APOE ɛ4 allele non-carriers.
Model adjusted for age, gender, years of education, country of birth (Australia vs. Other), baseline body mass index and baseline
energy intake kCal (residuals plotted). Linear regression analysis: R2adj = 0.024, β = 0.191, p = 0.004, portion of variance = 3.9%.
Abbreviations: APOE, Apolipoprotein E; kCal, kilocalorie.
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4.2.4.2.2. Blood-based inflammation biomarker index 2 – longitudinal analysis,
change in index over 36 months
In order to assess the relationship of the four diet scores with inflammation longitudinally, a
blood-based inflammation biomarker index 2 was also constructed for 36 month follow up
data, using the same method as that utilised during construction of the baseline blood-based
inflammation biomarker index 2. As per the longitudinal metabolic syndrome and CVD
index analysis, the 36 month follow up inflammation index was subtracted from the
baseline inflammation index score for each participant to give a value for ‘change in the
index’ over 36 months. If the index increased over 36 months participants were assigned a
value of ‘1’, if there was no change participants were assigned a value of ‘2’, and if the
index decreased over 36 months, participants were assigned a value of ‘3’. This ‘change in
index’ variable was then used in multinomial logistic regression models to calculate odds
ratios for the investigation of the association between baseline dietary adherence and
change in inflammation level over 36 months (‘no change’ i.e. a score of ‘2’, was the
reference). The four diet scores were divided into tertiles for this analysis, as described in
section 4.2.2.; odds ratios compared the lowest tertile with the highest tertile. The model
was adjusted for the same potential confounders as those incorporated into the linear
regression models described earlier. Although none of the odds ratios reached the
significance level of p < 0.01, there was a trend towards greater likelihood of the bloodbased inflammation biomarker index 2 increasing over 36 months if inflammatory dietary
index score was in the highest tertile compared to the lowest adherence tertile in APOE ɛ4
allele non-carriers (odds ratio (OR) = 0.41; CI: 0.176 – 0.963; p = 0.041). There was also a
trend towards greater likelihood of the blood-based inflammation biomarker index 2
increasing over 36 months if western diet adherence was in the highest tertile compared to
the lowest adherence tertile in females (OR = 0.39; CI: 0.156 – 0.973; p = 0.044; Table
4.12).
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Table 4.12: Odds ratios of the blood-based inflammation biomarker index2 changing over 36 months for the cohort as a whole and following
stratification of the cohort by gender and APOE ɛ4 allele carriage.
Group+
Whole cohort
Males
Females
APOE ε4 allele carrier
APOE ε4 allele non – carrier
Whole cohort
Males
Females
APOE ε4 allele carrier
APOE ε4 allele non – carrier
Whole cohort
Males
Females
APOE ε4 allele carrier
APOE ε4 allele non – carrier
Whole cohort
Males
Females
APOE ε4 allele carrier
APOE ε4 allele non – carrier

Diet Pattern

Odds
Ratioa

Confidence
Intervala

p-valuea

Odds Ratiob

Confidence
Intervalb

p-valueb

MeDi
MeDi
MeDi
MeDi
MeDi
Prudent
Prudent
Prudent
Prudent
Prudent
Western
Western
Western
Western
Western
Inflammatory dietary index
Inflammatory dietary index
Inflammatory dietary index
Inflammatory dietary index
Inflammatory dietary index

1.03
1.03
1.00
1.4
0.92
1.23
1.29
1.13
2.22
1.06
0.85
1.27
0.70
0.66
0.96
1.19
0.88
1.85
0.80
1.44

0.575 – 1.855
0.419 – 2.550
0.445 – 2.233
0.418 – 4.689
0.465 – 1.819
0.698 – 2.176
0.541 – 3.059
0.512 – 2.506
0.650 – 7.546
0.547 – 2.032
0.460 – 1.580
0.481 – 3.357
0.287 – 1.715
0.158 – 2.727
0.474 – 1.929
0.611 – 2.320
0.318 – 2.455
0.714 – 4.719
0.186 – 3.448
0.666 – 3.134

0.913
0.942
0.995
0.586
0.810
0.471
0.568
0.758
0.203
0.873
0.612
0.629
0.438
0.562
0.902
0.608
0.813
0.207
0.766
0.352

1.55
1.31
1.81
1.46
1.69
1.71
1.53
1.77
2.75
1.42
0.62
1.26
0.39
0.30
0.92
0.53
0.54
0.55
1.16
0.41

0.852 - 2.842
0.489 – 3.523
0.824 – 3.977
0.491 – 4.363
0.800 – 3.559
0.922 – 3.175
0.583 – 4.016
0.760 – 4.126
0.776 – 9.768
0.686 – 2.915
0.323 – 1.206
0.426 – 3.715
0.156 – 0.973
0.075 – 1.242
0.408 – 1.881
0.260 – 1.065
0.176 – 1.625
0.207 – 1.470
0.285 – 4.696
0.176 – 0.963

0.151
0.590
0.139
0.495
0.169
0.089
0.388
0.816
0.117
0.347
0.160
0.679
0.044
0.097
0.794
0.074
0.270
0.234
0.839
0.041

Model includes age, gender, APOE ε4 allele carriage, years of education, country of birth (Australia vs. Other), baseline body mass index and baseline energy intake kCal as covariates. +When the cohort is
stratified by gender and APOE ε4 allele status, these characteristics are not included in the models as covariates. aOdds ratio, confidence interval and p-value for the odds of a decrease in the inflammation index
compared to no change in the inflammation index over 36 months. bOdds ratio, confidence interval and p-value for the odds of an increase in the inflammation index compared to no change in the inflammation
index over 36 months. Multinomial logistic regression analysis used to calculate odds ratios. Abbreviations: APOE, Apolipoprotein E; kCal, kilocalorie; MeDi, Mediterranean diet.
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4.2.4.2.3. Blood-based inflammation biomarker index 2 – cross-sectional
analysis, baseline diet scores associated with 36 month follow-up index
The cross-sectional results reported in section 4.2.4.2.1. suggest a strong relationship
between diet and blood-based biomarkers of inflammation. The longitudinal results
reported in section 4.2.4.2.2. however, report no change in blood-based inflammation
biomarker index 2 over 36 months in association with high or low dietary pattern
adherence. It is conceivable that no change in index over 36 months would be observed in
relation to diet pattern adherence if levels of inflammatory markers remained consistently
high or low. To further investigate this hypothesis, we used linear regression analysis to
assess the relationship between baseline diet scores, the 36 month follow up blood-based
inflammation biomarker index 2 and its individual components.
We did not observe any associations between the 36 month follow up blood-based
inflammation biomarker index 2 and the baseline dietary patterns in the cohort as a whole
or following stratification of the cohort by gender and APOE ɛ4 allele carriage. There were
however, several associations seen in relation to individual components of the 36 month
follow up index and the baseline dietary patterns which were also observed with respect to
the baseline index. Briefly, these consistent results include; 1) inflammatory dietary index
positively associated with white cell count in the cohort as a whole and in APOE ɛ4 allele
non-carriers; 2) prudent diet adherence positively associated with haemoglobin level in the
cohort as a whole; 3) western diet negatively associated with haemoglobin level in the
cohort as a whole; 4) western diet adherence negatively associated with red cell count in the
cohort as a whole; 5) western diet positively associated with platelet level in the cohort as a
whole; 6) western diet adherence positively associated with lymphocyte level in females;
and 7) prudent diet negatively associated with eosinophil level in APOE ɛ4 allele carriers.
We also observed additional associations at 36 months, including; 1) inflammatory dietary
index positively associated with neutrophil count in the cohort as a whole; 2) prudent diet
score association with haemoglobin level in the whole cohort was also seen in males and
APOE ɛ4 allele non-carriers; 3) prudent diet negatively associated with neutrophil count in
males; 4) the association between western diet adherence and lymphocyte level in females
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was also seen in APOE ɛ4 allele non-carriers; and 5) western diet adherence was positively
associated with basophil level in females. Tables 4.13 to 4.15 show the regression results in
the cohort as a whole, and following stratification of the cohort by gender and APOE ɛ4
allele carriage respectively.

Table 4.13: Relationship between baseline diet scores and 36 month follow-up blood-based
inflammation biomarker index 2: linear regression analysis. Standardised β values shown.
Baseline
prudent diet
score

Baseline
western diet
score

Baseline
inflammatory
dietary index

0.015

-0.066

0.060

0.107

Haemoglobini

-0.020

0.114*
(1.1%ł)

-0.141*
(1.3%ł)

-0.097

Red blood cell counti

-0.016

0.085

-0.136*
(1.1%ł)

-0.038

Erythrocyte sediment
ratei

0.023

-0.012

0.018

-0.039

-0.068

-0.079

0.143*
(1.3%ł)

0.000

-0.113

0.093

0.179*
(1.7%ł)

Neutrophilsi

-0.020

-0.075

0.035

0.158*
(1.3%ł)

Lymphocytesi

0.033

-0.100

0.136

0.084

Monocytesi

0.017

-0.042

0.048

0.079

Eosinophilsi

0.009

-0.090

0.044

0.135

-0.020

-0.056

0.078

0.026

Biomarker
Inflammation index 2

Platelet counti
White cell counti

Basophilsi

Baseline MeDi
score

0.018

Model includes age, gender, years of education, APOE ε4 allele carriage, country of birth (Australia vs. Other), baseline body mass index
and baseline energy intake kCal as covariates. Bold indicates statistical significance (*p < 0.01). łPortion of variance explained by diet
score. iComponents of the blood-based inflammation biomarker index 2 analysed separately. Abbreviations: APOE, Apolipoprotein E;
kCal, kilocalorie; MeDi, Mediterranean diet.

168

Table 4.14: Relationship between baseline diet scores and 36 month follow-up blood-based inflammation biomarker index 2 following
stratification of the cohort by gender: linear regression analysis. Standardised β values shown.
Baseline MeDi score

Baseline prudent diet score

Baseline western diet score

Baseline
inflammatory dietary index

Biomarker

Male

Female

Male

Female

Male

Female

Male

Female

Inflammation index 2

0.093

-0.001

-0.044

-0.078

-0.034

0.153

0.136

0.046

Haemoglobini

0.047

-0.089

0.204*
(3.4%ł)

0.077

-0.205

-0.111

-0.205

-0.018

Red blood cell counti

0.073

-0.103

0.134

0.051

-0.161

-0.123

-0.104

0.046

Erythrocyte sediment
ratei

0.021

0.042

-0.024

0.009

-0.033

0.055

-0.028

-0.063

-0.033

-0.081

-0.048

-0.101

0.099

0.165

0.026

0.009

White cell counti

0.132

-0.063

-0.197

-0.057

0.154

0.019

0.198

0.172

Neutrophilsi

0.100

-0.091

-0.226*
(4.2%ł)

0.031

0.167

-0.099

0.195

0.141

Lymphocytesi

0.089

0.032

-0.016

-0.154

0.057

0.182*
(2.5%ł)

0.052

0.109

Monocytesi

0.071

-0.027

-0.004

-0.084

-0.007

0.100

0.045

0.127

Eosinophilsi

0.079

-0.028

-0.065

-0.127

-0.025

0.168

0.142

0.090

Basophilsi

0.030

-0.061

-0.019

-0.141

0.032

0.178*
(2.3%ł)

0.068

0.021

Platelet counti

Model includes age, years of education, APOE ε4 allele carriage, country of birth (Australia vs. Other), baseline body mass index and baseline energy intake kCal as covariates. Bold indicates statistical significance
(*p < 0.01). łPortion of variance explained by diet score. iComponents of the blood-based inflammation biomarker index 2 analysed separately. Abbreviations: APOE, Apolipoprotein E; kCal, kilocalorie; MeDi,
Mediterranean diet.

Table 4.15: Relationship between baseline diet scores and 36 month follow-up blood-based inflammation biomarker index 2 following stratification
of the cohort by APOE ε4 allele carriage: linear regression analysis. Standardised β values shown.
Biomarker
APOE ɛ4 allele carrier
statusa

Baseline MeDi score
-

+

Baseline prudent diet score
-

+

Baseline western diet score
-

Baseline inflammatory dietary
index

+

-

+

Inflammation index 2

0.093

-0.001

-0.044

-0.078

-0.034

0.153

0.136

0.046

Haemoglobini

0.047

-0.089

0.204*
(1.4%ł)

0.077

-0.205

-0.111

-0.205

-0.018

Red blood cell counti

0.073

-0.103

0.134

0.051

-0.161

-0.123

-0.104

0.046

Erythrocyte sediment
ratei

0.021

0.042

-0.024

0.009

-0.033

0.055

-0.028

-0.063

-0.033

-0.081

-0.048

-0.101

0.099

0.165

0.026

0.009

White cell counti

0.132

-0.063

-0.197

-0.057

0.154

0.019

0.198

0.172

Neutrophilsi

0.100

-0.091

-0.226*
(1.7%ł)

0.031

0.167

-0.099

0.195

0.141

Lymphocytesi

0.089

0.032

-0.016

-0.154

0.057

0.182*
(2.4%ł)

0.052

0.109

Monocytesi

0.071

-0.027

-0.004

-0.084

-0.007

0.100

0.045

0.127

Eosinophilsi

0.079

-0.028

-0.065

-0.127

-0.025

0.168

0.142

0.090

Basophilsi

0.030

-0.061

-0.019

-0.141

0.032

0.178*
(1.3%ł)

0.068

0.021

Platelet counti

aAPOE

ɛ4 allele carriage - is APOE ɛ4 allele non-carrier, + is APOE ɛ4 allele carrier. Model includes age, gender, years of education, country of birth (Australia vs. Other), baseline body mass index and baseline energy intake
kCal as covariates. Bold indicates statistical significance (*p < 0.01). łPortion of variance explained by diet score. iComponents of the blood-based inflammation biomarker index 2 analysed separately. Abbreviations:
APOE, Apolipoprotein E; kCal, kilocalorie; MeDi, Mediterranean diet.
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4.2.5. Diet scores and neuroimaging biomarkers
In AD, specific areas of the brain show signs of atrophy when examined using structural
MRI. In general, there is widespread cortical atrophy, yet those areas involved with
processing primary motor and sensory information are spared. Those areas most likely to
show atrophy are parts of the medial and lateral temporal lobes, and the frontal lobes (338343). In PiB PET studies of MCI and AD individuals, higher PiB retention in these people
(indicative of cerebral Aβ load) is associated with greater cognitive decline (43, 51, 344,
345). Additionally, approximately 30% of ‘healthy’ individuals over the age of 75 years
show Aβ deposition at autopsy (346, 347). This supports the belief that neuropathological
changes precede the clinical expression of AD by many years (348), and it is hypothesised
that this group represents preclinical AD (349). Studies show that 20 – 25% of cognitively
‘normal’ elderly participants demonstrate higher cortical PiB retention (48, 49, 350), and
collectively, these studies suggest that early intervention trials for AD should target these
individuals who demonstrate significant cerebral Aβ deposition (49).
The influence of the APOE ɛ4 allele in increasing AD risk is reported by such studies, for
example, in a group of 177 healthy older adults, 33% had high PiB retention; those with
high PiB retention were on average 5 years older and twice as likely to carry an APOE ɛ4
allele (55). It has also been found that carriers of the APOE ε4 allele experience accelerated
brain atrophy compared with non-carriers (351, 352). Considering this evidence
collectively, together with the APOE genotype-dependent effects of diet on cognition in
cognitively healthy individuals (some of whom would be ‘classified’ as preclinical AD)
reported in Chapter 3, we investigated the relationship between dietary pattern adherence
and neuroimaging measures of brain volume (MRI) and cerebral Aβ load (PiB PET): the
influence of APOE genotype on these relationships was also assessed.
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4.2.5.1. Demographics of the neuroimaging cohort
As mentioned in section 4.2.1., a subgroup of the healthy control cohort utilised for the
cognition (Chapter 3) and blood biomarker analysis (Chapter 4) underwent brain imaging:
Table 4.16 lists the demographics of this subgroup. The average age of the neuroimaging
cohort at baseline was 70.6 ± 7.2 and nearly 50% were males. Almost 40% of these
individuals carried at least one APOE ɛ4 allele, over 45% had 12 or less years of education
and 78.9% were born in Australia. Mean BMI was 26.3 ± 4.0 and mean energy intake was
1706.9 ± 568.6 kCal. In relation to the neuroimaging measures, the mean hippocampal,
grey matter, white matter, ventricle and cerebrospinal fluid (CSF) volumes were 3.1 cubic
centimetres (cm3), 668.7cm3, 436.3cm3, 29.6cm3 and 411.2cm3 respectively. The mean PiB
PET standardised uptake value ratio (SUVR) was 1.4 ± 0.4. The average baseline MeDi
score of the subgroup was 4.2 ± 1.5, the average prudent diet score was 299.7 ± 126.5, the
average western diet score was 146.6 ± 143.8, and the average inflammatory dietary index
was 0.6 ± 1.5. There were several differences observed between males and females.
Females had a higher average inflammatory dietary index (p < 0.001; ANOVA). As
expected, males had a higher energy intake (p < 0.001; ANOVA). Males also had a higher
western diet score (p < 0.001; ANOVA). When the healthy control neuroimaging subgroup
was stratified by APOE ɛ4 allele carriage, APOE ɛ4 allele carriers were shown to have a
higher western diet score (p < 0.001; ANOVA) and a higher mean PiB PET SUVR (p <
0.001; ANOVA; Table 4.16). Figure 4.4 shows the distribution of baseline (blue line), 18
month follow up (black line) and 36 month follow up PiB PET SUVR (red line) for each of
the four dietary patterns constructed at baseline. Figure 4.5 shows the distribution of PiB
PET SUVR at baseline (blue box plot), 18 month (black box plot) and 36 month follow up
(red box plot) for each baseline dietary pattern divided into tertiles.
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Table 4.16: Descriptive statistics for the neuroimaging healthy control cohort as a whole, and subgroups following stratification of the cohort by
gender and APOE ε4 allele carriage.
Whole cohort (n
= 123)

Males (n = 60)

Females (n = 63)

p-values for gender
differences

APOE ε4 carrier (n =
49)

APOE ε4 non-carrier
(n = 74)

p-values for
APOE ε4 carriage
differences

Age at baseline; y

70.6 ± 7.2

70.6 ± 7.2

70.7 ± 7.2

0.910

68.9 ± 6.9

71.8 ± 7.2

0.029

Gender, men; n (%)

60 (48.8)

28 (57.1)

32 (43.2)

0.131

Country of birth, Australian; n (%)

97 (78.9)

47 (78.3)

50 (79.4)

0.889

39 (79.6)

58 (78.4)

0.872

Presence of APOE ε4 allele; n (%)

49 (39.8)

28 (46.7)

21 (33.3)

0.131

indexi; kg/m2

26.3 ± 4.0

26.5 ± 4.3

26.2 ± 3.7

0.687

26.2 ± 3.9

26.4 ± 4.1

0.819

1706.9 ± 568.6

1972.3 ± 596.9

1454.0 ± 404.9

0.000

1802.1 ± 591.3

1643.8 ± 548.0

0.131

57 (46.3)

26 (43.3)

31 (49.2)

0.514

29 (59.2)

28 (37.8)

0.020

3.1 ± 0.2

3.1 ± 0.2

3.2 ± 0.2

0.055

3.1 ± 0.2

3.2 ± 0.2

0.186

Baseline MRI grey matter volume; cm3 (n = 111)

668.7 ± 23.1

666.2 ± 29.3

670.9 ± 15.7

0.290

669.5 ± 21.1

668.2 ± 24.4

0.772

Baseline MRI white matter volume; cm3 (n = 111)

436.3 ± 36.5

439.3 ± 38.8

433.6 ± 34.5

0.415

445.6 ± 34.4

430.4 ± 36.8

0.032

29.6 ± 14.2

28.4 ± 16.3

30.6 ± 12.2

0.416

29.3 ± 16.5

29.8 ± 12.7

0.873

411.2 ± 39.7

413.4 ± 41.2

409.4 ± 38.6

0.599

401.5 ± 35.8

417.4 ± 41.1

0.039

Baseline PiB PET SUVR (n = 123)

1.4 ± 0.4

1.4 ± 0.4

1.4 ± 0.4

0.819

1.5 ± 0.5

1.3 ± 0.3

0.000

Baseline MeDi score

4.2 ± 1.5

4.4 ± 1.6

4.0 ± 1.4

0.162

4.4 ± 1.5

4.1 ± 1.5

0.217

Baseline prudent diet score

299.7 ± 126.5

311.1 ± 135.6

288.8 ± 117.3

0.330

282.3 ± 128.9

311.2 ± 124.5

0.215

Baseline western diet score

146.6 ± 143.8

213.4 ± 156.0

82.9 ± 95.4

0.000

197.2 ± 159.2

113.1 ± 122.7

0.001

0.6 ± 1.5

0.2 ± 1.4

1.1 ± 1.4

0.001

0.6 ± 1.4

0.7 ± 1.5

0.975

Baseline body mass

Baseline energy intake; kCal
Education, ≤ 12 y; n (%)
Baseline MRI hippocampal volume;

Baseline MRI ventricle volume;

cm3

cm3

(n = 111)

(n = 111)

Baseline MRI CSF volume; cm3 (n = 111)

Baseline inflammatory dietary index

Unless otherwise described, data are presented as mean ± standard deviation of the mean. Bold indicates statistical significance (p < 0.01); Characteristics compared using analysis of variance for continuous variables and χ2
for categorical variables. iBody mass index is calculated as weight in kilograms divided by height in meters squared. Abbreviations: APOE, Apolipoprotein E; cm3, cubic centimetres; CSF, cerebrospinal fluid; kCal, kilocalorie; Kg,
kilogram; m2, meter squared; MeDi, Mediterranean diet; MRI, magnetic resonance imaging; PiB PET, Pittsburgh compound-B positron emission tomography; SUVR, standardised uptake value ratio; y, years.
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Figure 4.4: Distribution of baseline PiB PET SUVR (blue symbols and line), 18 month
follow up PiB PET SUVR (black symbols and line) and 36 month follow up PiB PET SUVR
(red symbols and line) for each of the four dietary patterns constructed at baseline.
Linear regression analysis; p > 0.05. Abbreviations: PiB PET, Pittsburgh Compound-B positron emission tomography; SUVR, standardised
uptake value ratio.
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Figure 4.5: Distribution of PiB PET SUVR at baseline (0; blue box plot), 18 month follow
up (18; black and white box plot) and 36 month follow up (36; red box plot) for each
baseline dietary pattern divided into tertiles. Tertile 1 = lowest adherence; Tertile 3 =
highest adherence.
Independent samples t-tests; p > 0.05. Abbreviations: PiB PET, Pittsburgh Compound-B positron emission tomography; SUVR,
standardised uptake value ratio.
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4.2.5.2. Dietary patterns, brain volumes and cerebral amyloid load
Multiple linear regression analyses were run to determine the association between the four
continuous diet scores and MRI-determined brain region volumes. After controlling for the
most common confounding variables, i.e. age, gender, years of education, APOE ε4 allele
carriage, country of birth, BMI, and energy intake, there were no significant associations
observed between baseline diet scores and baseline MRI volumes (data not shown). We
were particularly interested in assessing whether baseline diet scores could predict change
in regional brain volumes. Consequently, we calculated a change score for each MRI brain
region, by subtracting the baseline value from the 36 month follow up value for each
individual. These ‘change’ scores were then used in multiple linear regression models to
investigate their association with the baseline diet scores. No associations were found
between these ‘change’ variables and baseline diet scores in the cohort as a whole, or when
stratified by gender or APOE ɛ4 allele carriage (data not shown).
We further investigated these associations following stratification of the cohort by amyloid
status, i.e. PiB PET negative (SUVR < 1.5) or PiB PET positive (SUVR ≥ 1.5), as it can be
argued that the PiB PET positive individuals within the healthy control group represent a
biologically distinct subgroup within whom the processes associated with AD pathogenesis
are more advanced: However, no significant associations were observed following this
stratification (Table 4.17). There were associations trending towards significance, including
western diet approaching a negative association with ventricle volume in PiB PET positive
individuals (β = -0.559, p = 0.047), and MeDi adherence approaching a negative
association with change in hippocampal volume (β = -0.696, p = 0.015), also in PiB PET
positive individuals. It is possible that small sample size limited statistical power when
investigating these relationships. Figure 4.6 shows the mean diet scores at baseline for each
of the four dietary patterns following stratification of the cohort into PiB PET positive and
PiB PET negative groups.
We also assessed the relationship between PiB PET determined cerebral Aβ load (SUVR)
and the baseline dietary patterns whilst again controlling for the most common confounding
variables listed above. There were no significant associations between PiB PET SUVR and
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the diet scores at baseline. To assess the relationship between brain Aβ load and diet score
longitudinally, we computed a change in PiB PET SUVR variable by subtracting the
baseline SUVR from the 36 month follow up SUVR for each individual, however we found
no association between this ‘change in SUVR’ variable and the baseline diet scores.
Furthermore, following stratification of the cohort by gender, APOE ɛ4 allele carriage (data
not shown) and PiB PET status i.e. PiB PET positive or negative (Table 4.17), no
significant associations between cerebral Aβ load and diet scores were observed. There
were some associations trending towards significance, for example, MeDi adherence
approaching a negative association with change in PiB PET SUVR in APOE ɛ4 allele noncarriers (β = -0.273, p = 0.047; data not shown). When stratified by PiB PET status, the
inflammatory dietary index was trending towards a positive association with change in
SUVR in PiB PET negative individuals; i.e. those with lower consumption of antiinflammatory foods at baseline (indicated by a higher inflammatory dietary index) have
greater increase in amyloid load over the next 36 months (β = 0.329, p = 0.035; Table
4.17). The opposite was true for PiB PET positive individuals (β = -0.690, p = 0.035; Table
4.17), and we propose that as they already have high amounts of amyloid in their brain,
dietary factors can no longer have an effect on SUVR. Prudent diet was also trending
towards a negative association with change in PiB PET SUVR amongst PiB PET negative
individuals (β = -0.297, p = 0.024); i.e. as prudent diet adherence increases, there is less
accumulation of cerebral amyloid over 36 months (Table 4.17).
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Figure 4.6: Mean diet scores at baseline for each of the four dietary patterns following
stratification of the cohort into PiB PET positive and PiB PET negative groups.
Data represented as mean ± SEM. Independent samples t-tests; p > 0.05. PiB PET negative – SUVR < 1.5; PiB PET positive – SUVR ≥ 1.5.
Abbreviations: PiB PET, Pittsburgh Compound-B positron emission tomography; SEM, standard error of the mean; SUVR, Standardised
uptake value ratio.
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Table 4.17: Relationship between baseline dietary patterns and baseline MRI volumes, change in MRI volumes over 36 months, baseline PiB
PET SUVR and change in PiB PET SUVR over 36 months, following stratification of the cohort by PiB PET status: linear regression analysis.
Standardised β values shown.
PiB PET positive or negativea
MRI brain region

-

+

-

Baseline MeDi score

+

Baseline prudent diet score

-

+

Baseline western diet score

+
Baseline inflammatory dietary
index

MRI hippocampusb

-0.138

-0.265

-0.021

-0.022

-0.064

0.041

0.045

0.037

MRI grey matterb

-0.086

-0.303

0.106

-0.289

-0.056

0.230

0.145

0.103

MRI white matterb

0.064

0.194

-0.027

0.064

-0.054

-0.052

1.000

0.330

MRI ventricleb

0.140

-0.226

-0.065

0.195

0.130

-0.559

-0.024

-0.056

-0.006

-0.071

-0.035

0.076

0.099

-0.081

-0.104

-0.335

Change in MRI hippocampusb

0.193

-0.696

-0.025

-0.371

-0.214

0.918

-0.187

0.049

Change in MRI grey matterb

0.081

-0.068

0.088

-0.224

-0.278

0.452

-0.161

-0.138

Change in MRI white matterb

-0.233

-0.179

-0.044

0.034

0.052

0.429

-0.074

-0.171

Change in MRI ventricleb

0.167

-0.342

-0.197

-0.201

0.119

0.379

0.168

-0.087

Change in MRI CSFb

0.135

0.365

-0.039

0.196

0.123

-0.705

0.235

0.248

-0.100

0.556

-0.083

-0.285

-0.007

0.244

0.130

0.208

-0.200

0.188

0.046

0.205

-0.043

0.329

-0.690

MRI CSFb

PiB PET SUVR continuous
score
Change in PiB PET SUVR
continuous score
aPiB

-0.297
aPiB

bMRI brain

PET positive or negative, - is PiB PET negative (SUVR < 1.5), + is
PET positive (SUVR ≥ 1.5).
region volumes corrected for intracranial volume. Model includes age, gender, years of education,
APOE ε4 allele carriage, country of birth (Australia vs. Other), baseline body mass index and baseline energy intake kCal as covariates. Abbreviations: APOE, Apolipoprotein E; CSF, cerebrospinal fluid; kCal,
kilocalorie; MeDi, Mediterranean diet; MRI, magnetic resonance imaging; PiB PET, Pittsburgh compound-B positron emission tomography; SUVR, standardised uptake value ratio.
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Finally, we assigned a value of ‘0’ to participants classified as PiB PET negative (SUVR <
1.5) and a value of ‘1’ to participants classified as PiB PET positive (SUVR ≥ 1.5). This
binary score (with PiB PET negative as the reference) was used in multinomial logistic
regression models to calculate odds ratios for the investigation of the association between
baseline dietary pattern adherence and classification as either PiB PET negative or positive.
The four diet scores were again divided into tertiles for this analysis; odds ratios compared
the lowest tertile with the highest tertile. For the MeDi score, individuals with a score of 3
or lower (lowest adherence to MeDi) were assigned to tertile 1, those with a score of 4 or 5
were assigned to tertile 2, and those with a score of 6 or higher (highest adherence to MeDi)
were assigned to tertile 3. For the inflammatory dietary index, western and prudent diets,
the participants’ scores were arranged into increasing order of adherence and then divided
equally into thirds, with the lowest adherence third to each pattern assigned to tertile 1, the
middle third assigned to tertile 2 and the highest adherence third assigned to tertile 3. The
model was adjusted for the same potential confounders as those incorporated into the linear
regression models described earlier in this section. Dietary pattern adherence did not affect
the likelihood of being PiB PET positive when comparing the highest tertile to the lowest
adherence tertile for each of the four dietary patterns, in the cohort as a whole or following
stratification of the cohort by gender and APOE ε4 allele carriage (data not shown).
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4.3. Discussion
In this chapter, we sought to explore potential mechanisms that might underlie the effects
of diet on cognition reported in Chapter 3 by assessing the relationship of the dietary
patterns (MeDi, western diet, prudent diet, and inflammatory dietary index) with blood and
neuroimaging biomarker data collected as part of the AIBL study. A plethora of potential
mechanisms exist, we focussed our investigations on factors that are well-established
contributors to AD risk i.e. metabolic syndrome, CVD, and inflammation. We also assessed
the relationship between the dietary patterns and MRI-determined brain volume and PiB
PET-determined cerebral amyloid load.
4.3.1. Dietary patterns and metabolic syndrome
Metabolic syndrome is a disorder of energy utilization and storage, diagnosed by a cooccurrence of three out of five of the following medical conditions: abdominal (central)
obesity, elevated blood pressure, elevated fasting plasma glucose, high serum triglycerides,
and low HDL levels. To investigate the association of the four dietary patterns with
metabolic syndrome risk, we utilised the parameters listed above to construct a metabolic
syndrome index. We also assessed the relationship of the dietary patterns with the
components of the index individually as well as with additional metabolic syndrome
biomarker data collected as part of the AIBL study.
The main findings reported in this section were;
There were no associations between the four baseline dietary patterns and the metabolic
syndrome index, or the individual components of the index in the cohort as a whole or
following stratification of the cohort by gender or APOE ɛ4 allele carriage.
Longitudinal analysis revealed that the likelihood of the metabolic syndrome index
increasing or decreasing over 36 months was unaffected by dietary pattern adherence, in the
cohort as a whole and following stratification of the cohort by gender and APOE ε4 allele
carriage.
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Investigation of the cross-sectional relationship of the dietary patterns with additional
biomarkers of metabolic syndrome (measured only at baseline) revealed that insulin levels
were negatively associated with prudent diet score in the cohort as a whole. Glucagon was
negatively associated with western diet score in males and APOE ɛ4 allele non-carriers.
Further, glucagon-like peptide-1 was negatively associated with western diet score also in
APOE ɛ4 allele non-carriers.
Glucagon-like peptide-1 is an incretin hormone which regulates postprandial glucose levels
through glucose-dependent insulin secretion: It is expressed in neurons and acts as a
neurotransmitter. Additionally, glucagon-like peptide-1 has been shown to demonstrate
growth factor-like properties, to protect neurons from neurotoxic influences, to reduce the
induction of apoptosis of hippocampal neurons, and improve spatial and associated learning
(353). It is perhaps unsurprising therefore, that adherence to the ‘unhealthy’ western diet
was associated with decreased levels of this beneficial hormone.
Metabolic syndrome and diabetes are inextricably linked. Type 1 diabetes is characterised
by a deficit in the production of insulin, and has been shown to increase cognitive
dysfunction in a review of 33 longitudinal studies (354). Type 2 diabetes is caused by
resistance to the effects of insulin, and is often fuelled by obesity which is believed to be
caused by impaired response to leptin. Insulin and leptin exert their effects through
complex signalling cascades and both pathways share some common components (355).
Leptin and insulin both have roles in the regulation and maintenance of physiological
homeostasis, both hormones have been shown to regulate neuronal and synaptic functions
within the hippocampus, cortex and cerebellum, both hormones protect neurons against
neurodegeneration and cell death (356-359) and also regulate Aβ levels by modulating Aβ
production and Aβ degradation (115, 360-362).
A number of clinical and epidemiological studies have provided evidence of a link
between type 2 diabetes, obesity and AD (114, 117, 120, 363-373). Possible mechanisms
to explain the link between type 2 diabetes and AD include; causing increased risk of
metabolic syndrome (the majority of type 2 diabetes patients are obese and together with
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type 2 diabetes this can lead to the development of hypertension, an additional feature of
metabolic syndrome); causing hyperglycaemia which may have toxic effects on neurons,
and can lead to oxidative stress; and by causing hyperinsulinemia which in itself is a risk
factor for AD (105, 106, 374). A large body of literature implicates hyperinsulinemia and
insulin resistance in AD risk (375), with one study reporting a doubled risk of AD in
people with high insulin levels (110, 284). Amongst individuals with chronically high
peripheral insulin levels, brain insulin levels are also high, and one reason this may
increase AD risk is that degradation of brain Aβ is inhibited due to the competition with
insulin for insulin-degrading enzyme (376).
Dietary modification has the potential to reduce the risk of progression of prediabetic
conditions such as metabolic syndrome to type 2 diabetes (377, 378), primarily through
weight loss (379). Recommendations to reduce weight are a mainstay of diabetes care and
have been formally recommended as the foundation on which all additional diabetes
therapies should rest. High calorie intake and diets high in sugar, added sweeteners and
refined flour are major health concerns in the western world, and along with sedentary
lifestyles have led to the growing incidence of obesity. Ajala et al. (380) reviewed studies
of dietary patterns most suitable for reducing weight, improving glycaemic control and
lipid profiles in people with type 2 diabetes. The authors concluded that low carbohydrate,
low glycaemic index, Mediterranean and high protein diets are effective. High fibre,
vegetarian and vegan diets were not found to be effective. Another meta-analysis by
Liveley et al. (381) also found increasing dietary glycaemic load was associated with
increased risk for type 2 diabetes, although others have advised that a low glycaemic load
diet should not be a recommendation for decreasing type 2 diabetes risk due to imprecision
of published glycaemic index data from which dietary glycaemic load is calculated (382).
Individual studies and a systematic review show that adherence to a MeDi decreases
glycated haemoglobin, fasting blood glucose and the need for antihyperglycemic drug
therapy (230, 383-388). However, we report no relationship between MeDi adherence,
metabolic syndrome index and additional biomarkers of metabolic syndrome. Conversely,
consistent with the literature, we found cross-sectional associations between prudent diet
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adherence and decreased insulin level, and western diet adherence and decreased glucagon
(APOE ɛ4 allele non-carriers and males) and glucagon-like peptide-1 (APOE ɛ4 allele noncarriers).
There is evidence that control of hypertension (a component of our metabolic syndrome
index) is associated with a reduced risk of cognitive impairment and dementia, which is
likely to be due to a reduction in CVD, atherosclerosis and stroke (76, 105, 389, 390).
Some, but not all, studies have suggested that good control of hypertension is associated
with cognitive benefit and decreased AD neuropathology, although this is age-dependent
(109, 391-401). Several clinical trials found no association with hypertension medication
and cognitive performance (105, 402-404). Positive lifestyle modifications may contribute
to management in prehypertensive and treated hypertensive patients (405). The benefits of
diet on hypertension have been emphasised in several studies, in particular a protective
effect of fruit, vegetables, legumes, whole grains, fish, nuts and low-fat dairy products (the
MeDi is composed of many of these foods; 406, 407-418). Vegetarians have also been
shown to have lower blood pressures than non-vegetarians (419). Another study with
evidence of a beneficial effect of dietary intake on blood pressure is the Dietary
Approaches to Stop Hypertension clinical trial (408). In this trial, participants were fed a
control diet low in fruit, vegetables and dairy products, or a diet with a fat content typical
of the average United States of America diet. Participants were then assigned to either; 1)
the control diet; 2) a diet rich in fruit and vegetables; or 3) a combination diet rich in fruit,
vegetables and low fat dairy products with reduced saturated and total fat. The combination
diet lowered both systolic and diastolic blood pressure, and the fruit and vegetables diet
lowered systolic blood pressure in comparison to the control diet. These results show a low
fat diet, rich in fruit and vegetables, with adequate intake of calcium, magnesium and
potassium is required to reduce blood pressure, and individual nutrients are unlikely to be
effective on their own (408). However, in contrast to the studies described here, we found
no association with any of the four dietary patterns and history of hypertension or elevated
blood pressure.

184

Chapter 4 Investigating the mechanisms of action of dietary patterns

Whilst we report associations between dietary pattern adherence and several of the
additional biomarkers of metabolic syndrome measured at baseline, our lack of significant
associations between the four dietary patterns and our metabolic syndrome index as well as
the individual components of the index, suggests that modulation of metabolic syndrome
risk may not be the primary mechanism underlying the effects of diet on cognition
described in chapter 3 of this thesis.
4.3.2. Dietary patterns and cardiovascular disease
CVD refers to any disease or condition of the heart and blood vessels. The causes of CVD
are diverse but atherosclerosis and/or hypertension are the most common. To investigate
the association of the four dietary patterns with CVD risk, we constructed a CVD index
based on the presence of each of the following significant CVD risk factors; obesity, raised
blood pressure, a history of angina, stroke, heart attack, smoking and diabetes, low physical
activity and elevated homocysteine level. We also assessed the relationship of the dietary
patterns with the components of the index individually as well as with additional CVD
biomarker data collected as part of the AIBL study.
The main findings reported in this section were;
The index and its individual components were not associated with the four dietary patterns
in the cohort as a whole or following stratification of the cohort by gender or APOE ɛ4
allele carriage.
Longitudinal analysis revealed that prudent diet adherence affected the likelihood of the
CVD index remaining stable over 36 months. Being in the highest tertile of prudent diet
adherence gave females and APOE ɛ4 allele carriers higher odds of their CVD index
remaining at the baseline level rather than increasing at 36 months compared to the lowest
adherence tertile.
Investigation of the cross-sectional relationship of the dietary patterns with additional
biomarkers of CVD risk revealed that IDL-C was positively associated with western diet
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score in females. Further, higher adherence to prudent diet at baseline was associated with
decreased triglyceride level in males and APOE ε4 allele non-carriers.
There were no associations between dietary pattern adherence and change in the levels of
the additional biomarkers of CVD risk over 36 months in the cohort as a whole or
following stratification of the cohort by gender or APOE ɛ4 allele carriage.
As discussed in Chapter 1, an increase in disorders associated with metabolic syndrome and
CVD can increase an individual’s probability of developing AD (115, 156, 284, 376, 420423), and this consequently represents a potential mechanism by which diet can affect AD
risk and progression. For example, high levels of circulating cholesterol, triglycerides and
LDL and low levels of HDL have been associated with increased AD risk (76, 78, 424428). There is much evidence to suggest that raising HDL levels reduces risk of CVD, AD,
and certain cancers (428, 429). Interestingly, the MeDi has been shown to have beneficial
effects on the cholesterol-HDL cholesterol ratio in a randomised trial of 772 individuals
compared to a low fat diet (418), and specific components of the MeDi, including olive oil
and nuts, have been shown to improve lipid profiles (430, 431). However, we report no
relationship between MeDi adherence, CVD index and additional biomarkers of CVD.
Interestingly it was adherence to the other ‘healthy’ dietary pattern, namely the prudent
diet, which increased the likelihood of the CVD index remaining stable rather than
increasing over 36 months in females and APOE ɛ4 allele carriers. The MeDi and prudent
diet are both heavily loaded with fruit and vegetables, thus we can only hypothesise that it
is their differences (e.g. incorporation of cereals, dairy and alcohol intake into MeDi
construction) that account for the disparate results reported in relation to CVD index.
The results of Chapter 3 reveal beneficial effects of MeDi adherence and detrimental
effects of western diet adherence on cognition over 36 months. Whilst we report
associations between dietary pattern adherence and biomarkers of CVD in this chapter, our
lack of significant associations between the MeDi and western diet patterns and our CVD
index as well as the individual components of the index, again suggests that modulation of
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CVD risk may not be the primary mechanism underlying the effects of diet on cognition
described in chapter 3 of this thesis.
4.3.3. Dietary patterns and inflammation
Inflammation is heavily implicated in AD pathology. To investigate the association of the
four dietary patterns with inflammation we constructed two blood-based indexes of
inflammation. The first index included a range (n = 18) of inflammatory biomarkers
(including interleukins and cytokines) which were analysed at baseline only by Rules Based
Medicine using the Human DiscoveryMap® v1.0 panel (Austin, TX, USA). The second
index was based on ten analytes measured as part of the clinical tests (including
measurement of types of white blood cells etc.) conducted by PathWest laboratories at
baseline and 36 month follow up. We also assessed the relationship of the dietary patterns
with the components of the indexes individually.
The main findings reported in this section were;
The first index was positively associated with the inflammatory dietary index in females;
suggesting that the foods we consume affect levels of blood-based inflammatory
biomarkers. When analysing the components of the index individually, we saw an
association between increased MeDi adherence and increased IgM level, which is
surprising as ‘healthy’ MeDi adherence is proposed to be associated with lower
inflammation levels. Following stratification of the cohort by gender, the inflammatory
dietary index was positively associated with IL18 in males.
The second blood-based inflammation biomarker index was found to be positively
associated with western diet score in females, negatively associated with prudent diet score
in the cohort as a whole as well as in females, and positively associated with the
inflammatory dietary index in the cohort as a whole as well as in APOE ε4 allele noncarriers. These results are consistent with consumption of the ‘healthy’ prudent diet being
associated with reduced levels of inflammation and conversely, adherence to the
‘unhealthy’ western diet and low level consumption of anti-inflammatory foods (indicated
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by a higher inflammatory dietary index) being associated with increased levels of bloodbased biomarkers of inflammation.
The dietary patterns were correlated with many individual components of the second index
of inflammation. Briefly; higher MeDi score was associated with lower levels of
inflammatory biomarkers in the whole cohort (platelet count) and in females (red blood cell
count). Higher prudent diet score was also associated with lower levels of inflammatory
biomarkers (white cell count) in APOE ε4 allele non-carriers, in APOE ε4 allele carriers
(eosinophil levels) and in females (platelet count). Higher western diet score was associated
with increased inflammatory biomarker levels in females (platelet count and lymphocyte
level), and in APOE ε4 allele carriers (eosinophil level). The inflammatory dietary index
was positively associated with increased levels of a number of the inflammatory
biomarkers, namely; white cell count in males and APOE ε4 allele non-carriers, eosinophil
level in the whole cohort, neutrophil level in males and lymphocyte level in females and
APOE ε4 allele non-carriers.
Longitudinal analysis revealed that the likelihood of the second blood-based inflammation
biomarker index increasing or decreasing over 36 months was not significantly affected by
dietary pattern adherence, in the cohort as a whole and following stratification of the cohort
by gender and APOE ε4 allele carriage. Although none of the odds ratios reached the
significance level of p < 0.01, there was a trend towards greater likelihood of the bloodbased inflammation biomarker index 2 increasing over 36 months if inflammatory dietary
index score was in the highest tertile compared to the lowest adherence tertile in APOE ɛ4
allele non-carriers (p = 0.041), and a trend towards greater likelihood of the second bloodbased inflammation biomarker index increasing over 36 months if western diet adherence
was in the highest tertile compared to the lowest adherence tertile in females (p = 0.044).
The cross-sectional results reported in this chapter suggest a strong relationship between
diet and blood-based biomarkers of inflammation. The longitudinal however, report no
change in blood-based inflammation biomarker index 2 over 36 months in association with
high or low dietary pattern adherence. It is conceivable that no change in index over 36
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months would be observed in relation to diet pattern adherence if levels of inflammatory
markers remained consistently high or low. To further investigate this hypothesis, we used
linear regression analysis to assess the relationship between baseline diet scores, the 36
month follow up blood-based inflammation biomarker index 2 and its individual
components.
We did not observe any associations between the 36 month follow up blood-based
inflammation biomarker index 2 and the baseline dietary patterns in the cohort as a whole
or following stratification of the cohort by gender and APOE ɛ4 allele carriage. There were
however, several associations seen in relation to individual components of the 36 month
follow up index and the baseline dietary patterns which were also observed with respect to
the baseline index. Briefly, these consistent results include; 1) inflammatory dietary index
positively associated with white cell count in the cohort as a whole and in APOE ɛ4 allele
non-carriers; 2) prudent diet adherence positively associated with haemoglobin level in the
cohort as a whole; 3) western diet negatively associated with haemoglobin level in the
cohort as a whole; 4) western diet adherence negatively associated with red cell count in the
cohort as a whole; 5) western diet positively associated with platelet level in the cohort as a
whole; 6) western diet adherence positively associated with lymphocyte level in females;
and 7) prudent diet negatively associated with eosinophil level in APOE ɛ4 allele carriers.
We also observed additional associations at 36 months, including; 1) inflammatory dietary
index positively associated with neutrophil count in the cohort as a whole; 2) prudent diet
negatively associated with neutrophil count in males; 3) the association between western
diet adherence and lymphocyte level in females was also seen in APOE ɛ4 allele noncarriers; and 4) western diet adherence was positively associated with basophil level in
females.
The associations between food, nutrients and some diseases (including AD) may be
mediated in part through inflammation. As discussed in Chapter 1, the inflammation
process caused by the aggregation of Aβ in AD involves the production of inflammatory
molecules including cortisol, CRP and interleukins; this inflammation reflects the
development and progression of disease. CRP has been used in many studies as a
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biomarker of inflammation; it is an acute phase protein produced in the liver and its levels
are up-regulated by pro-inflammatory cytokines like interleukin 6 (IL6; 432) and TNFα. In
a study of 1524 men and 1518 women, those in the higher MeDi adherence tertile had on
average a 20% lower CRP level (p = 0.015), a 17% lower IL6 level (p = 0.025), a 15%
lower homocysteine level (p = 0.031) and a 14% lower white cell count (p < 0.001)
compared with those in the lowest tertile. The association with TNFα did not reach
significance (p = 0.076; 214). Gu et al. (227) also found higher adherence to the MeDi was
associated with lower levels of CRP (p < 0.003) in 1219 non-demented elderly participants.
Fung et al. (296) used an alternate MeDi (this alternate MeDi excludes dairy, has a nut
group, has only red and processed meat in the meat section and excludes potatoes) and
concluded that those in the top adherence quintile compared to the bottom quintile had a
24% lower CRP concentration. A protective effect of adherence to the MeDi was found by
Panagiotakos et al. (297); for each unit of increasing adherence to the MeDi, there was a
reduction of 3.1% in the average CRP level and 1.9% in the average IL6 level. An
intervention study with 90 participants following a MeDi and 90 following a prudent diet
found participants that consumed the MeDi compared to the prudent diet had significantly
reduced serum concentrations of CRP, IL6, IL7 and IL18 as well as decreased insulin
resistance (231). However, not all studies have found positive results for these
inflammatory biomarkers, Dai et al. (331) found higher adherence to the MeDi was
associated with reduced levels of IL6 but had no significant effect on CRP. In an
intervention study, 42 healthy male university students had either an alcohol free MeDi or a
high fat diet for 90 days; between days 30 and 60 both diets were supplemented with 240
ml/day red wine. Neither diet nor wine supplementation had a detectable effect on CRP
levels (332), however the cohort was not a large one.
Few studies have examined the contribution of other major dietary patterns to markers of
systemic inflammation. In a cross-sectional study of healthy Iranian women, after adjusting
for potential confounders, a ‘healthy' dietary pattern was inversely related to plasma
concentrations of CRP (p < 0.05) and vascular cell adhesion molecule 1 (p < 0.05). The
western diet score constructed by these researchers was positively related to serum amyloid
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A (p < 0.05) and IL6 (p < 0.001; 300). Fung et al. (212) found significant positive
correlations between their own western dietary pattern and insulin, CRP, leptin and
homocysteine concentrations, and an inverse correlation with plasma folate concentrations.
The prudent dietary pattern constructed by these authors was by contrast positively
associated with plasma folate and inversely correlated with insulin and homocysteine
concentrations. Nettleton et al. (299) derived four dietary patterns using factor analysis:
The fats and processed meats pattern was positively associated with CRP (p for trend <
0.001), IL6 (p for trend < 0.001) and homocysteine (p for trend < 0.002). The beans,
tomatoes and refined grains pattern was positively related to intercellular adhesion
molecule 1 (ICAM1; p for trend < 0.007). The whole grains and fruit pattern was inversely
associated with CRP, IL6, homocysteine (p for trend < 0.001) and ICAM1 (p for trend <
0.034), and the vegetables and fish pattern was inversely associated with IL6 (p for trend <
0.009). Collectively, these results suggest that a ‘healthy’ dietary pattern is related to lower
levels of inflammatory markers.
Consistent with the reported literature, we found our ‘unhealthy’ western dietary pattern to
be positively associated with levels of blood-based biomarkers of inflammation and our
‘healthy’ MeDi and prudent diet patterns to be negatively associated with levels of bloodbased biomarkers of inflammation. We also found our inflammatory dietary index to be
strongly positively correlated with the levels of numerous blood-based biomarkers of
inflammation, i.e. as intake of anti-inflammatory foods decreased (indicated by a higher
inflammatory dietary index), the levels of blood-based biomarkers of inflammation
increased: a relationship that has never before been investigated in a well characterised
ageing cohort. We observed many of these associations in both males and females as well
as in APOE ε4 allele non-carriers and carriers.
As mentioned previously, the results of Chapter 3 reveal beneficial effects of MeDi
adherence and detrimental effects of western diet adherence on cognition over 36 months.
In this chapter we report strong associations between dietary pattern adherence and
biomarkers of inflammation, and suggest that the interplay between diet and elevated
chronic inflammation may contribute to the effects of diet on cognition described in
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chapter 3 of this thesis. This hypothesis certainly warrants further investigation and it will
become increasingly important to understand the ‘pro-inflammatory’ versus ‘antiinflammatory’ contribution of each of the four dietary patterns investigated to further
clarify whether inflammation is the primary candidate mechanism underlying the reported
effects of diet on cognition.
4.3.4. Dietary patterns and neuroimaging
We investigated the relationship between dietary pattern adherence and neuroimaging
biomarkers of AD, specifically; PiB PET-determined cerebral amyloid load and MRIdetermined brain volume. There were no significant associations observed between the four
dietary patterns, cerebral amyloid load, MRI brain region volumes, or change in these
neuroimaging variables, when the cohort was analysed as a whole or following
stratification by gender, APOE ɛ4 allele carriage or binary PiB PET status (i.e. significant
amyloid load or reduced amyloid load). There were also no significant associations
between the four dietary patterns divided into tertiles and PiB PET SUVR as a binary score
(categorised as significant amyloid load or reduced amyloid load) when the cohort was
analysed as a whole or following stratification of the cohort by gender and APOE ɛ4 allele
carriage, although several associations were trending towards significance. It is important
to note however, that only a subgroup of participants underwent neuroimaging thereby
reducing the sample size from 527 to 123. This reduced sample size is likely to have
limited the power to see associations of dietary pattern adherence with brain volumes and
amyloid load, and a larger sample size may have seen the trending associations reach
significance.
In clinical and research settings, MRI can be used to identify areas of the brain that have
undergone changes associated with brain disease. Areas associated with memory including
frontal and temporal lobes, and the hippocampus, all show signs of atrophy in AD patients
(433). A study by Bobinski et al. (434) investigated the validity of using MRI in AD
patients by studying the relationship between post-mortem hippocampal volume,
determined by MRI and histological volumes. The authors found strong correlations
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between MRI and histological measurements of the hippocampus, hippocampus/subiculum
and hippocampus/parahippocampal gyrus (434). It is worthy of note however, that the
participants utilised for analysis in this chapter are all categorised as ‘cognitively healthy’:
A factor that may have also contributed to the unlikelihood of observing a significant
relationship between brain volumes and dietary pattern adherence.
In the first human study to investigate the use of PiB in AD diagnosis, PiB retention (a
measure of amyloid load) was two-fold greater in AD patients, when compared with
cognitively healthy controls (51). In addition, a strong correlation between post-mortem
histological measurement of brain Aβ plaque load and PiB binding has been reported (435).
Higher PiB retention has also been associated with greater cognitive decline in older adults
(349).
There are very few studies investigating the association between dietary patterns and PiB
PET-determined cerebral amyloid load and MRI-determined brain region volumes. Titova
et al. (335) investigated the individual components of the MeDi score in relation to grey
matter, white matter, and the sum of grey and white matter (MeDi score was constructed at
70 years of age and MRI was undertaken at 75 years of age). A low consumption of meat
and meat products was linked to a greater total brain volume (i.e. the sum of grey and white
matter volume; p < 0.03). The MeDi score as a whole explained less variance in brain
volumes than the single meat component, and the authors suggested that the MeDi score
may mask possible associations of single MeDi components with brain health domains
(335). Bowman et al. (436) constructed nutrient biomarker patterns (using plasma
biomarkers of diet) and found a pattern high in plasma vitamins B, C, D and E was
associated with higher total cerebral brain volume whilst a pattern high in trans-fat was
associated with less total cerebral brain volume. Biomarkers linked to pathological
processes which dietary factors affect have also been investigated, for example blood
cholesterol levels have been linked to hippocampal and other brain grey matter volume (97,
333). Higher levels of homocysteine have been linked to greater white matter atrophy in
older adults and individuals with mild cognitive impairment (437; vitamin B can be used to
lower homocysteine levels and may slow the rate of brain atrophy, 438), and elevated
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homocysteine has also been associated with hippocampal atrophy (439, 440). Obesity is
associated with a below-average hippocampal size and high BMI in midlife is associated
with an increased rate of hippocampal atrophy in late life (441-449). Furthermore, higher
peripheral insulin has been associated with decreased brain atrophy (334).
Considered collectively, these results suggest that the relationship between brain volumes
and dietary pattern adherence is worthy of further investigation in our cohort both
longitudinally and with a larger sample size (facilitated by recent participant recruitment).
The paucity of information regarding cerebral amyloid load and diet also makes this
relationship worthy of further investigation; an aim which can again be achieved in our
cohort in the near future courtesy of collection of additional longitudinal data and
supplementary cross-sectional data from new study participants.
4.3.5. Conclusions
The results presented in this chapter describe thorough characterisation of the relationship
between the four dietary patterns (MeDi, prudent diet, western diet and inflammatory
dietary index) and blood-based biomarkers of metabolic syndrome, CVD and inflammation
as well as neuroimaging biomarkers of AD. A study of this nature has to our knowledge,
not previously been undertaken.
Our results suggest that the interplay between diet and elevated chronic inflammation may
contribute to the effects of diet on cognition described in chapter 3 of this thesis. Metabolic
syndrome and CVD appeared to be less likely mechanistic candidates. The results of the
neuroimaging analysis were limited by sample size. Additional work is required to further
characterise these relationships.
We reported positive associations between MeDi and prudent diet adherence and bloodbased biomarkers of inflammation and by contrast, negative associations between western
diet and inflammatory dietary index and these biomarkers of inflammation. Whilst
inflammation is a strong candidate mechanism, it is likely that a complex interplay exists
with overlap of the effects of diet on several mechanisms concurrently. For example, the
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strongest results in chapter 3 of this thesis were related to the beneficial effects of MeDi
adherence on cognition. However, the MeDi did not appear to be highly correlated to any
of the potential mechanisms investigated in this chapter. It may be that the MeDi exerts its
protective effects via independent mechanisms not investigated here, or perhaps more likely
is the possibility that rather than one pronounced mechanism of action, the MeDi acts via
multiple mechanisms of (weaker level) action which synergistically confer protection. Both
are plausible explanations that warrant further investigation. In addition to increasing
sample size and utilising data from further longitudinal assessments, measurement of
nutrient markers in the blood may help to further elucidate the potential mechanisms of
action of diet.
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5.1. Introduction
Food frequency questionnaires (FFQs) are a relatively inexpensive method of
measuring usual food intake over an extended period, particularly among large cohorts.
FFQs are easy to administer and have low subject burden and therefore are the most
practical method for dietary data collection. Measuring diet has long been a challenge
because many factors affect dietary intake recall, including age, gender, weight,
ethnicity, period over which intake is recalled, and number and type of questions asked.
FFQs are more practical for large-scale studies, compared with 24-hour recall methods
and collection of food records which require trained interviewers. In Australia two
FFQs are frequently used, the Cancer Council of Victoria food frequency questionnaire
(CCVFFQ; used in Chapters 3 and 4 of this thesis; 450) and the Commonwealth
Scientific and Industrial Research Organisation food frequency questionnaire
(CSIROFFQ; 451, 452).
Whilst the CCVFFQ utilised in Chapters 3 and 4 of this thesis assesses intake of 74 food
and beverage items, the CSIROFFQ is a quantified FFQ containing over 200 items
including single foods, mixed dishes, beverages and alcohol. We utilised the online
version of the CSIROFFQ in this study, which has serving sizes that can be altered by the
participants and a format capable of modification to allow inclusion of additional
questions. The online CSIROFFQ includes a series of qualitative questions related to
food preparation and cooking techniques, the use of salt, the use of sugar in beverages,
the type of milk used, the type of bread consumed and the type of fats used as spread or
in cooking. To avoid fatigue, the online FFQ was designed to have the foods arranged
into categories and automatically saves data entered, allowing participants to leave the
questionnaire and return later to complete it in multiple sittings. The online form
eliminates incomplete questionnaires, as participants cannot move to the next section
until all questions are fully answered in the previous section. The paper form of the
CSIROFFQ has previously been validated (255-258, 453), but to our knowledge no
validation has been completed for the online version. Participant responses to the online
version are analysed by CSIRO using food composition derived from the Australian Food
and Nutrient Database 2007 (AUSNUT 2007) and the British Food Composition Tables.
AUSNUT 2007 contains analytical data published in Nutrient Tables for use in Australia
2006 (NUTTAB 2006) as well as data from the Food Standards Australia New Zealand
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2006 (FSANZ 2006) analytical program, nutrient data from overseas food composition
tables, food label information, imputed data from similar foods and data calculated using
a recipe approach. The CSIROFFQ takes approximately 45 minutes to complete, requires
access to the internet, and like the CCVFFQ, assesses usual daily intake over the
preceding 12 months.
Accurate assessment of overall dietary intake is crucial to understanding the association
between diet and chronic diseases: incorrect information may lead to false associations
between dietary factors and diseases. There is a need to develop and validate methods of
assessing food and beverage intake to facilitate the development of guidelines for the
prevention of diet-related chronic disease. However, dietary questionnaires need to be
both specific to the population being analysed, and to the disease of interest: currently,
there is no Alzheimer’s disease (AD)-specific FFQ available.
Accuracy in measuring intake of individual dietary constituents is also an important
issue in the analysis and evaluation of results from studies of the association between
diet and disease; because dietary questionnaires do not necessarily estimate true food
intake, their validity needs to be determined. The most common method of validating a
dietary questionnaire is through comparison of responses from the FFQ to actual food
intakes documented for a limited number of days using weighed food records (259). It is
also important to determine whether a FFQ provides reproducible results.
‘Reproducibility’ can also be thought of as ‘reliability’, and this is generally assessed by
administering the FFQ at two time points to the same group of people and assessing the
level of agreement between the two responses (454). We modified the online
CSIROFFQ to include questions relating to intake of food items of interest to AD
research (detailed information on the items included can be found in section 2.9.3.).
Table 5.1 below summarises the questions relating to intake of food items of interest in
AD research added to or altered in the original online CSIROFFQ to produce the
modified CSIROFFQ utilised in this validation study.
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Table 5.1: Food items of interest in Alzheimer’s disease research: questions relating to
intake of these items were added to or altered in the original online CSIROFFQ to
produce the modified CSIROFFQ utilised in the validation study.
Food item
Chocolate type (milk, dark or white)
Increased number of oils added (grape seed, coconut etc.)
Wine type
Green and white tea
Pomegranates and pomegranate juice
Type of grapes (green or red/black)
Type of berries
Kidney, liver and heart
Type of meat used in stew/casserole/curry/goulash
Type of rice (white or brown)
Type of nuts and seeds
Herbs and spices consumed
Supplements consumed
Abbreviations: CSIROFFQ, Commonwealth Scientific and Industrial Research Organisation food frequency questionnaire.

5.1.1. Methods
This study was undertaken by a subset of Perth-based AIBL participants (n = 49). In
summary, the online modified CSIROFFQ was administered at two time-points, on
average seven days apart. Participants completed a four-day weighed food record in
between completion of the first and second administration of the questionnaire;
recording commenced on a Sunday and finished on the following Wednesday. All
participants were classified as cognitively ‘healthy’ controls at the time they completed
the validation study.
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5.1.2. Chapter aims
The aim of this chapter was to determine the suitability of the modified CSIROFFQ for
use in studies of AD through; 1) assessment of ‘reliability’ of the modified CSIROFFQ
by comparing the responses of individuals when the questionnaire was administered on
two occasions, and 2) validation of the modified CSIROFFQ relative to four-day
weighed food records. Following completion of the ‘reliability’ and validation
assessments, we evaluated the relationship between intake of the added food items,
cognitive data, blood-based biomarkers of inflammation and cerebral amyloid load.
We hypothesise that:
1. The modified CSIROFFQ is a reliable assessment tool, as demonstrated by the
correlation of food and beverage intakes from two administrations of the modified
questionnaire.
2. The modified CSIROFFQ is a valid tool for quantifying intake of foods of interest in
AD research, as demonstrated by the correlation of the modified questionnaire
responses to intake from the four-day weighed food records.
3. Participants consuming greater quantities of food items proposed to be beneficial in
terms of AD risk (captured using the modified CSIROFFQ) have lower levels of bloodbased biomarkers of inflammation, lower cerebral amyloid beta load (determined by
Pittsburgh Compound-B positron emission tomography; PiB PET) and higher
neuropsychological test scores compared to individuals consuming smaller quantities of
these food items.
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5.2. Results
5.2.1. Demographics of the validation study cohort
The descriptive statistics of the validation and ‘reliability’ study cohort are shown in
Table 5.2. In summary, 49 individuals participated in the validation and ‘reliability’
study; of these, 32 were female and 17 were male. The participants had an average age
of 72.2 ± 4.4 and an average body mass index (BMI) of 25.9 ± 3.3. Nearly 75% of the
cohort was born in Australia and just over 25% had 12 or less years of education, whilst
over 26% carry the APOE ε4 allele. When comparing the males and females following
stratification of the cohort by gender, we saw that males were significantly older than
females (p = 0.046; ANOVA) and as expected, had a higher BMI (p = 0.028; ANOVA;
Table 5.2).

203

Table 5.2: Descriptive statistics for the validation and ‘reliability’ study healthy control cohort as a whole, and subgroups following stratification of the
cohort by gender.
Total Sample (n = 49)
Age; y

72.2 ± 4.4

Males (n = 17)

Females (n = 32)

p-values for gender
differences

73.9 ± 4.5

71.3 ± 4.2

0.046*

Gender; men, n (%)

17 (34.7)

Country of birth; Australian, n (%)

36 (73.8)

14 (82.4)

22 (68.8)

0.305

25.9 ± 3.3

27.3 ± 4.0

25.2 ± 2.7

0.028*

Presence of APOE ε4 allele; n (%)

13 (26.5)

5 (29.4)

8 (25.0)

0.746

Education ≤ 12 y; n (%)

13 (26.5)

7 (41.2)

6 (18.8)

0.311

Body mass indexi; kg/m2

Unless otherwise stated, data are presented as mean ± standard deviation of the mean. Bold indicates statistical significance (p < 0.05); Characteristics compared using independent samples t-test for continuous variables and
χ2 for categorical variables. iBody mass index is calculated as weight in kilograms divided by height in meters squared. Abbreviations: APOE, Apolipoprotein E; Kg, kilogram; m2, meters squared; y, years.
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5.2.2. Reliability results
It is important to determine if responses to a FFQ are reproducible or ‘reliable’, i.e. if
individuals recall the same intake over the past year on different occasions. To investigate
the ‘reliability’ of the modified CSIROFFQ we assessed the correlation of 207 food and
beverage items or groups of items from two administrations of the modified CSIROFFQ,
which were completed seven days apart, on average. Using Pearson’s correlation
coefficients we determined that seven of these 207 items were correlated at the p < 0.05
level, 24 were correlated at the p < 0.01 level and 154 were highly correlated at the p <
0.001 level. Twenty two items did not show correlation, these uncorrelated items were
comprised of mostly individual fruits and vegetables, and takeaway foods for which low
consumption levels were reported in both administrations of the FFQ. With respect to these
uncorrelated items, the actual difference in the consumption level, determined using the two
completed FFQs, ranged from 0.02 grams for chicken nuggets to 24.03 grams for milk.
Pearson’s correlation coefficients for all items assessed ranged from -0.181 for water or
spring water to 1.000 for rum and soda and frankfurters or saveloys, with a mean of 0.595.
We then used an additional method to assess ‘reliability’ of the two administrations of the
modified CSIROFFQ, namely intra-class correlation coefficients. Using this method, we
found remarkably similar results; observing that 11 of the 207 items were correlated at the
p < 0.05 level, 23 items were correlated at the p < 0.01 level and 148 items were highly
correlated at the p < 0.001 level, leaving a remainder of 25 items for which intake did not
show correlation (20 of these uncorrelated items were identical to uncorrelated items from
Pearson’s correlation coefficients above). The intra-class correlation coefficients for all
items assessed ranged from -0.174 for water or spring water to 1.000 for rum and soda,
with a mean of 0.544. Appendix 4 shows the Pearson’s and intra-class correlation
coefficients for this ‘reliability’ study.
Intake of herbs and spices reported following completion of the FFQ on two occasions was
compared utilising binary scores assigned to ‘yes’ or ‘no’ answers to questions relating to
whether an individual had consumed each of 19 herbs or spices in the last fortnight. Twenty
six of the 49 participants involved in the study gave inconsistent answers in the two
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administrations of the FFQ, i.e. they answered ‘yes’ to one or more of the questions during
the first FFQ administration and ‘no’ during the second administration, or vice versa. In
total there were 127 incorrect answers out of a total of 931 (19 questions x 49 participants)
herb and spice questions asked (13.6%).
Intake of dietary supplements was also assessed using the modified CSIROFFQ. The intake
of a total of 104 supplements was recorded in both administrations of the questionnaire,
whilst intake of 24 supplements was reported only in one administration of the FFQ. Of the
24 supplements reported only once, 18 were consumed with a frequency of once a week or
less, and six were consumed more than once a week. The final question concerning
supplement intake within the modified CSIROFFQ is an open-ended question regarding
intake of “any other supplements” not listed previously within the questionnaire (e.g.
magnesium, iron, and probiotics). Seven supplements included in the response to this openended question were inconsistent between the two administrations of the FFQ, i.e.
participants stated that they consumed a supplement during the first FFQ administration
which was not included in the second administration, or vice versa (this open-ended
question recorded intake of a total of 23 supplements during the two administrations of the
questionnaire). In summary however, the overall results of the ‘reliability’ study suggest
that the vast majority of the modified CSIROFFQ has a ‘good’ and ‘adequate’ degree of
reproducibility with the greatest variance observed within the supplement intake questions.
5.2.3. Validation results
We used a four-day weighed food record to assess the validity of the questions modified or
added to the online CSIROFFQ. Before commencing the validation study, participants
attended an orientation session. During the orientation session, detailed verbal and written
instructions regarding the completion of the four-day weighed food records (Sunday
through to Wednesday) were provided. Digital scales weighing to the nearest gram, and
measuring cups and spoons were also provided to each participant, as was a sample of a
completed food record. Each participant was requested to record the weight of all food and
beverages consumed during the four-day period (either at home or away from home) and to
record brand names, methods of food preparation and ingredients of recipes in a
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specifically designed diary (Appendix 3). Participants were additionally asked to record the
amount of any leftover food at the end of a meal or snack consumed either at home or away
from home, and to also report any dietary supplements consumed. All food records were
reviewed face-to-face with the participant upon completion of the four-day period and
unclear or missing information was clarified. Four-day weighed food records were analysed
using FoodWorks 7 Professional version 7.0 (Xyris Software (Australia) Pty Ltd, Highgate
Hill, QLD) and the AUSNUT 2007 database of Australian Foods, to yield grams per day of
foods and beverages consumed. The grams per day of foods and beverages consumed as
documented by the weighed food records was compared to the intake reported following
completion of the first administration of the modified CSIROFFQ.
Due to the relatively small number of participants undertaking the validation study (n = 49),
there were a small number of people consuming some dietary items (e.g. specific types of
fish, berries, seeds, nuts, fats, and milk chocolate). For this reason, we grouped some items
together for the purpose of validation (e.g. total fish, total seeds, total nuts, total berries,
total grapes, total rice, total chocolate, and total fats), in addition to validating individual
items wherever possible.
Pearson’s correlation coefficients revealed that there was a high correlation (p < 0.001
level) between the recorded intake of seven of the added items according to the modified
CSIROFFQ and the recorded intake of the same foods according to the four-day weighed
food record (total fish, dark chocolate, total chocolate, total grapes, total seeds, total nuts
and almonds), three added items were correlated at the p < 0.01 level (sesame seeds, white
rice, and total rice) and two added items were correlated at the p < 0.05 level (olives and
sunflower seeds). Pearson’s correlation coefficients for all items that were validated ranged
from -0.051 for red wine to 0.946 for cranberries (Table 5.3).
We then utilised intra-class correlation coefficients as a secondary method to assess
validity: the results of the two methods were in general agreement. Using the second
method we observed that six of the added items were highly correlated at the p < 0.001
level (total fish, total grapes, total rice, total seeds, total nuts and almonds), three dietary
items were correlated at the p < 0.01 level (olives, dark chocolate, and total chocolate), and
207

Chapter 5: Validation of the modified Commonwealth Scientific and Industrial Research Organisation food frequency questionnaire

three added items were correlated at the p < 0.05 level (sunflower seeds, white rice, and
canola oil) when comparing intake determined by the modified CSIROFFQ and four-day
weighed food record. The intra-class correlation coefficients for all items validated ranged
from -0.040 for red wine to 0.945 for canola oil (Table 5.3).
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Table 5.3: Pearson’s and intra-class correlation coefficients assessing similarity of intake of dietary items added to the modified CSIROFFQ
compared to intake of these items determined using weighed food records.

Food or beverage
Total canned fish

Pearson's
correlation
coefficient
0.157

p-value

Intra-class correlation
coefficient (F statistic)

p-value

0.117

Number of participants reporting
consumption via the weighed food record
14

Total fish
Seafood

0.784
0.227

***

0.700
0.125

***

44
5

Olives
Dark chocolate
Total chocolate

0.847
0.814
0.449

*
***
***

0.838
0.717
0.406

**
**
**

6
13
21

Red wine
White wine
Sparkling
wine/Champagne
Total wine
Green tea

-0.051
-0.312

-0.040
-0.281

16
11

0.453
0.263
0.273

0.023
0.200
0.041

3
23
13

Black grapes
Green grapes

-0.265
0.320

-0.132
0.076

12
13

Total grapes

0.550

Pumpkin seeds

0.042

***

0.527
0.039

***

23
9

Sesame seeds
Sunflower seeds

0.915
0.831

**
*

0.668
0.799

Total seeds
Strawberries
Blueberries
Cranberries

0.896
-0.209
0.620
0.946

***

0.621
-0.195
0.449
0.753

Total berries

0.234

0.112

19

Walnuts

0.214

0.188

9

Almonds

0.802

Cashew nuts

0.563

0.431

10

Peanuts

0.397

0.342

9

Brazil nuts

-0.593

-0.469

10

Total nuts
White rice
Total rice

0.448
0.694
0.441

Sunflower oil
Olive oil
Extra virgin olive oil
Canola oil

0.225
0.199
0.813
0.945

0.220
0.199
0.650
0.945

Butter
Margarine
Total fats

0.126
-0.185
0.148

0.085
-0.185
0.146

***

***
**
**

0.718

0.429
0.512
0.421

*
***

***

6
6
14
9
7
7

23

***
*
***

33
15
17

*

4
28
5
7

* p < 0.05, ** p < 0.01, *** p < 0.001. Abbreviations: CSIROFFQ, Commonwealth Scientific and Industrial Research Organisation food frequency questionnaire.
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Validation of herb and spice intake revealed that eight people gave at least one incorrect
answer whereby they answered ‘no’ to herb and spice intake questions within the
CSIROFFQ but documented consumption in the weighed food record; this resulted in a
total of ten incorrect answers (1.1% of the possible 931 questions). By contrast, 42
individuals gave at least one incorrect answer whereby they answered ‘yes’ to herb and
spice consumption questions within the CSIROFFQ but documented ‘no consumption’ via
completion of the weighed food record; this yielded a total of 255 incorrect answers (27.4%
of the possible 931 questions). It is important to note however, that the herb and spice
questions in the modified CSIROFFQ ask “which of the following herbs or spices do you
consume at least once a fortnight”, whilst the weighed food record was completed over just
four-days, it is possible therefore that these herbs or spices are consumed at least once a
fortnight but their consumption was not captured by the weighed food record. Additionally,
some specific herbs and spices in mixed dishes and drinks documented by completion of
the weighed food records could not be determined, and hence, could not be included as
‘consumed’, for example spices in chai latte beverages.
Validation of supplement intake revealed that a total of 85 supplements were consumed by
a total of 35 participants during the completion of the four-day weighed food record. Of
these 85 supplements, 81 were included during completion of the modified CSIROFFQ
(individually asked about, not including the final open-ended question in the FFQ; 95%),
leaving four which were consumed during the four-day weighed food record but not stated
as being consumed during completion of the modified CSIROFFQ (5%). By contrast, the
modified CSIROFFQ recorded intake of a total of 119 supplements (captured using specific
individual questions regarding the supplements) consumed by a total of 39 participants. Of
these 119, 81 were included in the corresponding weighed food record (68%) and 38 were
not included in the corresponding weighed food record (32%). Of the 38 that were not
included, 33 were stated as being consumed weekly or less than weekly, therefore it is not
surprising that their intake was not captured during the four-day weighed food record
period. If we exclude these 33 infrequently consumed supplements, we observe 94%
inclusion of supplement intake in both the CSIROFFQ and the weighed food records. For
the remaining supplements which are not individually listed in the modified CSIROFFQ
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but are instead included in the final, open-ended question, 27 supplements were consumed
by 21 participants during the four-day weighed food record period. Of these 27
supplements, 16 (59%) were also included in the response to the final supplement question
within the modified CSIROFFQ (the open-ended question which captures intake of “any
other supplements not individually listed within the preceding questions”). In summary, the
overall results of the validation study suggest that the modified CSIROFFQ can confidently
be used to assess intake of at least 12 of the food and beverage items which were added to
or modified within the online CSIROFFQ. The modified CSIROFFQ can also assess
accurately the intake of herbs and spices, and supplements. However, intake of a number of
items with generally low (or infrequent) consumption levels could not be validated with
this sample size and length of weighed food record, and further work is required.
5.2.4. Relationship between consumption of foods of interest in Alzheimer’s
disease research added to the modified Commonwealth Scientific Industrial and
Research Organisation food frequency questionnaire, cognition, blood-based
biomarkers of inflammation and neuroimaging biomarkers of Alzheimer’s disease
5.2.4.1. Construction of an ‘Alzheimer’s disease diet index’
The validation study described in section 5.2.3 revealed there were 12 items added to the
modified CSIROFFQ for which intake, as determined by completion of the modified
questionnaire, correlated significantly with the intake levels documented by completion of
the four-day weighed food record (assessed using Pearson’s correlation coefficients). These
12 items were divided into those for which consumption is proposed to be beneficial in
terms of AD risk and those for which the contrary is suggested. Participants were assigned
a value of 1 for each of the proposed beneficial items if their consumption was at or above
the sex-specific median intake level (total fish, olives, dark chocolate, total grapes, sesame
seeds, sunflower seeds, total seeds, almonds and total nuts). By contrast, participants were
assigned a value of 1 for each of the proposed detrimental items if their consumption was
below the sex-specific median intake level (white rice). Total chocolate and total rice were
not incorporated in the construction of the ‘AD diet index’, as elements of these food items
are expected to be beneficial in terms of AD risk (dark chocolate and brown rice) whilst
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other elements are proposed to be detrimental with respect to AD risk (milk chocolate and
white rice). The points were summed to produce a score ranging from 0 to 10, with a higher
score proposed to be ‘beneficial’ in terms of AD risk. Table 5.4 lists the characteristics of
the ‘AD diet index’. Of the 49 individuals who participated in the validation study, and
consequently for whom an ‘AD diet index’ was constructed, no one achieved an ‘AD diet
index’ score of 0, 9 or 10. To further divide individuals into proposed ‘higher’ or ‘lower’
AD risk categories on the basis of ‘AD diet index’ scores, participants with a score of 1 – 4
were assigned a binary value of ‘1’ to represent proposed ‘higher’ AD risk, and participants
with a score of 5 – 8 were assigned a binary value of ‘0’ to represent proposed ‘lower’ AD
risk. These binary scores were then assessed cross-sectionally for associations with
cognition, blood-based inflammation biomarkers and neuroimaging data collected as part of
the Australian Imaging, Biomarkers and Lifestyle study (AIBL) of ageing.
Table 5.4: Characteristics of the ‘Alzheimer’s disease diet index’
‘Alzheimer’s disease diet index’
High intake of total fish
High intake of olives
High intake of dark chocolate
High intake of total grapes
High intake of sesame seeds
High intake of sunflower seeds
High intake of total seeds
High intake of almonds
High intake of total nuts
Low intake of white rice
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5.2.4.2. ‘Alzheimer’s disease diet index’ and cognition
A range of cognitive tests including Mini-Mental State Examination (MMSE), California
Verbal Learning Test (CVLT) delayed recall, recognition and recognition discrimination,
Rey Complex Figure Test (RCFT) 3 minute delayed recall, and Controlled Oral Word
Association Task (COWAT) were carried out on the cohort (see section 2.10.4. for details
of test administration and scoring protocols). The mean neuropsychological test scores were
compared between the ‘low’ and ‘high’ AD risk groups, determined on the basis of ‘AD
diet index’ adherence. Independent samples t-tests were initially used to compare mean
neuropsychological test scores between the two AD risk groups, and this analysis was
followed by general linear models in order to control for the most common confounding
variables with respect to diet and cognition; i.e. age, gender, years of education, APOE ε4
allele carriage, country of birth, and BMI. All analyses were cross-sectional, with the data
from the assessment time-point closest to the date of the validation study utilised in the
analysis.
The independent samples t-tests revealed that the participants classified as proposed
‘higher’ risk for AD had significantly worse performance in the CVLT recognition
discrimination test (a measure of verbal learning and memory) than those classified as
‘lower’ AD risk (T = 2.138, p = 0.038; Table 5.5). However, having controlled for the
confounding variables listed above using general linear models, the significant difference
did not remain (data not shown). Figure 5.1 shows unadjusted box plots for the six
neuropsychological tests assessed following stratification of the cohort on the basis of ‘AD
diet index’ into the proposed ‘low’ and ‘high’ AD risk groups.

214

Chapter 5: Validation of the modified Commonwealth Scientific and Industrial Research Organisation food frequency questionnaire

Table 5.5: Difference in mean neuropsychological test scores between the proposed ‘high’ and
‘low’ Alzheimer’s disease risk groups stratified on the basis of ‘AD diet index’; Independent
samples t-tests.
Mean test score Mean test score
– ‘low’ AD risk - ‘high’ AD risk
groupa
groupa

T statistic

p-value

95 % CI

MMSE

29.0 ± 1.1

28.83 ± 1.2

0.502

0.618

-0.501 – 0.834

CVLT delayed recall

12.80 ± 2.3

11.17 ± 3.9

1.779

0.082

-0.214 – 3.418

CVLT recognition

15.52 ± 0.8

14.71 ± 2.1

1.830

0.074

-0.081 – 1.704

CVLT recognition
discrimination

3.41 ± 0.4

3.01 ± 0.8

2.138

0.038*

0.024 – 0.784

RCFT 3 minute
delayed recall

20.42 ± 6.2

17.35 ± 5.1

1.893

0.065

-0.192 – 6.324

COWAT

43.56 ± 9.9

41.33 ± 10.7

0.757

0.453

-3.693 – 8.147

adata presented as mean ± standard deviation. Bold indicates statistical significance (*p < 0.05). Abbreviations: AD, Alzheimer’s disease; CI,
confidence interval; MMSE, Mini-Mental State Examination; CVLT, California Verbal Learning Test; RCFT, Rey Complex Figure Test; COWAT,
Controlled Oral Word Association Task.
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Figure 5.1: Unadjusted box plots for the six neuropsychological tests following
stratification of the cohort on the basis of ‘AD diet index’ into the proposed ‘high’
and ‘low’ AD risk groups.
0 = proposed ‘low’ AD risk, 1 = proposed ‘high’ AD risk. Abbreviations: AD, Alzheimer’s disease; MMSE, Mini-Mental State
Examination; CVLT DR, California Verbal Learning Test delayed recall; CVLT R, California Verbal Learning Test recognition;
CVLT RD, California Verbal Learning Test recognition discrimination; RCFT 3D, Rey Complex Figure Test 3 minute delayed
recall; COWAT, Controlled Oral Word Association Task.
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5.2.4.3. ‘Alzheimer’s disease diet index’ and blood-based biomarkers of
inflammation
It is well established that there are links between inflammation, particularly chronic
inflammation, and AD, and in Chapter 4, relationships between diet and inflammation were
reported. Therefore, it was anticipated that differences may be found when comparing the
mean levels of the blood-based inflammatory biomarkers measured by PathWest
laboratories which were analysed in section 4.2.4.2. (haemoglobin, red blood cell count,
erythrocyte sediment rate, platelet count, white cell count, neutrophils, lymphocytes,
monocytes, eosinophils and basophils) between the proposed ‘high’ and ‘low’ AD risk
groups (again determined on the basis of ‘AD diet index’), using the same methods as those
utilised in the cognition analysis reported in section 5.2.4.2. (i.e. independent samples ttests followed by general linear models controlling for confounding variables). There were
no significant differences in the mean levels of each of the blood-based inflammatory
biomarkers between the proposed ‘high’ and ‘low’ AD risk groups as determined by
independent samples t-tests (data not shown) and general linear models controlling for
confounding variables (Table 5.6).
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Table 5.6: Difference in mean blood-based inflammatory biomarker levels between the
proposed ‘high’ and ‘low’ Alzheimer’s disease risk groups; General linear models.
Mean biomarker
level - ‘low’ AD risk
groupa
Haemoglobin

Mean biomarker
level - ‘high’ AD risk
groupa

F statistic

p-value

143.68 ± 10.5

139.53 ± 9.1

3.723

0.061

Red blood cell count

4.73 ± 0.4

4.58 ± 0.3

2.261

0.140

Erythrocyte sediment
rate

12.83 ± 12.0

8.58 ± 5.8

1.958

0.169

Platelet count

198.36 ± 51.5

221.00 ± 38.6

2.163

0.149

White cell count

5.42 ± 1.1

5.91 ± 1.2

1.708

0.198

Neutrophils

3.21 ± 0.9

3.68 ± 1.1

2.414

0.128

Lymphocytes

1.57 ± 0.4

1.53 ± 0.3

0.431

0.515

Monocytes

0.45 ± 0.1

0.50 ± 0.2

0.446

0.508

Eosinophils

0.16 ± 0.1

0.17 ± 0.1

0.038

0.847

Basophils

0.04 ± 0.1

0.04 ± 0.0

0.435

0.513

Model includes age, gender, years of education, APOE ε4 allele carriage, country of birth (Australia vs. Other), and baseline body
mass index as covariates. adata presented as mean ± standard deviation. Abbreviations: AD, Alzheimer’s disease; APOE,
Apolipoprotein E.
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5.2.4.4. ‘Alzheimer’s disease diet index’ and cerebral amyloid load
Thirty seven of the 49 participants included in the modified CSIROFFQ validation study
had previously undergone a PiB PET scan as part of their routine AIBL study participation.
Depending on an individual’s PiB PET standardised uptake value ratio (SUVR) they were
classified as either PiB PET negative (SUVR < 1.5; representative of lower levels of
amyloid in the brain) or PiB PET positive (SUVR ≥ 1.5; representative of significant
cerebral amyloid load). Multinomial logistic regressions were used to calculate the odds of
being PiB PET positive rather than PiB PET negative if individuals were in the proposed
‘high’ AD risk group compared to the ‘low’ AD risk group determined on the basis of ‘AD
diet index’ score. Interestingly, the odds of being PiB PET positive were 6.589 greater if an
individual was in the proposed ‘high’ risk AD group compared to the ‘low’ risk AD group.
However, this result lacked statistical significance (p = 0.070; Table 5.7), and was merely
approaching significance, likely due to the small sample size.
Table 5.7 Odds ratio of being PiB PET positive rather than PiB PET negative for
individuals in the proposed ‘high’ AD risk group compared to individuals in the proposed
‘low’ AD risk group.
Odds Ratio

Confidence Interval

p-value

6.589

0.860 – 50.508

0.070

Model includes age, gender, APOE ε4 allele carriage, years of education, country of birth (Australia vs. Other), and baseline body mass
index as covariates. PiB PET negative = SUVR < 1.5, PiB PET positive = SUVR ≥ 1.5. Multinomial logistic regression analysis used to
calculate odds ratios. Abbreviations: AD, Alzheimer’s disease; APOE, Apolipoprotein E; PiB PET, Pittsburgh Compound-B positron
emission tomography; SUVR, standardised uptake value ratio.
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5.3. Discussion
The reproducibility and comparative validity of the online modified CSIROFFQ were
assessed in this chapter by comparing data from the modified CSIROFFQ at two
administrations (reproducibility) and by comparing food intake documented using four-day
weighed food records with data generated from the first administration of the modified
CSIROFFQ (validity). Over 85% percent of the 207 food and beverage items or groups of
items assessed for reproducibility were significantly correlated between questionnaire
administrations, as shown by Pearson’s and intra-class correlation coefficients. The items
lacking significant correlation were mainly takeaway foods, and individual fruit and
vegetable items that were consumed at low levels. Thus, the overall reproducibility of the
modified CSIROFFQ appears to be good.
Validity of an FFQ is the degree to which the instrument measures the diet of the subjects it
was designed to study. Our study found that intake of a number of food groups and
individual items that were added to the CSIROFFQ were significantly correlated between
the weighed food record and the modified FFQ results including; total fish, total chocolate,
dark chocolate, total grapes, total seeds, sesame seeds, sunflower seeds, total rice, white
rice, olives, almonds and total nuts, suggesting validity of measurement of intake of these
dietary items. We had a small sample size of 49 participants completing a four-day weighed
food record, and we were attempting to validate foods of interest to AD research, which are
not regularly consumed by the majority of people or are consumed in small amounts. For
this reason, instead of validating all items individually, some items had to be summed to
form food groups. Statistical analysis showed that the intake of the majority of these groups
(determined using the weighed food record) correlated with intake data from the modified
CSIROFFQ.
Of the 12 items added to the modified CSIROFFQ for which intake was significantly
correlated with intake documented by completion of the four-day weighed food record,
items were divided into those with proposed beneficial effect in terms of AD risk and those
with proposed detrimental effect in relation to AD risk. Intake of each of the correlated
items was used to construct an ‘AD diet index’ for every participant, and the index was
220

Chapter 5 Validation of the modified Commonwealth Scientific and Industrial Research Organisation food frequency questionnaire

used to assign individuals to a proposed ‘high’ or ‘low’ AD risk group. The proposed
‘high’ and ‘low’ AD risk groups were then assessed cross-sectionally for associations with
neuropsychological test scores, blood-based biomarkers of inflammation and cerebral
amyloid load data collected as part of the AIBL study.
Independent samples t-tests revealed that the proposed ‘high’ AD risk group performed
worse in the CVLT recognition discrimination test than the proposed ‘low’ AD risk group:
However, these differences were no longer evident when confounding variables were
controlled for. There were no differences in the levels of blood-based biomarkers of
inflammation between the proposed ‘high’ and ‘low’ AD risk groups. Furthermore, there
was no significant difference observed in the odds of being PiB PET positive when
comparing the proposed ‘low’ and ‘high’ AD risk groups; the results were however
trending towards significance (p = 0.070). We hypothesise that with a larger sample size an
association where individuals proposed to be at ‘higher’ risk of AD (consume less
beneficial foods) are more likely to be PiB PET positive (have higher cerebral amyloid
load) may be observed.
These results further suggest that the questions added to or modified within the CSIROFFQ
are valid and demonstrate utility in terms of assigning individuals to proposed ‘lower’ or
‘higher’ AD risk groups on the basis of their ‘AD diet index’ score. It is likely that a larger
sample size and a longer duration of weighed food record (> four days) would strengthen
the relationships observed. Additionally, a future aim is to validate the entire online
modified CSIROFFQ, including nutrient and antioxidant intake.
Whilst the reference dietary method of choice for FFQ validation studies is reported to be
weighed food records (259), ideally, a biochemical measure would provide an independent
and objective assessment of nutrient intake: However, such measures are expensive and
require the use of sophisticated laboratories. An additional future aim is further validation
of the modified CSIROFFQ using a more direct measure of diet such as blood-based
biomarkers.

221

Chapter 5 Validation of the modified Commonwealth Scientific and Industrial Research Organisation food frequency questionnaire

It is also important to note the limitations of the results presented in this chapter. A general
limitation of validation studies, including ours, is that results are not necessarily
transferable to other populations due to regional variations in local foods (455).
Furthermore, agreement between the two methods of dietary data collection utilised in this
chapter may be affected by reporting of items in the FFQ which were not observed in the
four-day weighed food record, or were consumed by few people (e.g. specific types of fish,
seeds and berries). The day of the week may also influence the result of validation studies:
In our study, the greatest proportion of records was collected on weekdays (75%) with the
remaining 25% reflecting a weekend day, this division was deliberate as it is perceived that
‘usual’ dietary intake occurs during the week with greater variation observed at weekends
(259, 454). Finally, an additional limitation of weighed food records is the fact that
participants may have changed their diet on the day’s intake was recorded in an attempt to
make the process easier for themselves, despite requests that participants consume their
normal diet and reassurance from all that this was the case.
Irrespective of the limitations described above, the present study provides initial evidence
of the reliability of the modified CSIROFFQ and of its validity as an alternative measure of
dietary intake. The good level of agreement observed between responses and with respect
to the weighed food records, suggests the modified CSIROFFQ is repeatable and shows a
good level of validity, and thus can provide an acceptable assessment of long-term dietary
intake in Australian older adults. Furthermore, the modified CSIROFFQ appears to make
an important contribution to the tools available for assessing usual dietary intake in
Australian older adults with respect to AD research.
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6.1. Introduction
Alzheimer’s disease (AD) is the most common form of senile dementia and currently affects
over 35 million people worldwide. Intracellular neuritic plaques which are composed mainly
of amyloid beta (Aβ) peptide aggregates, and intracellular neurofibrillary tangles, which
consist of abnormally hyper-phosphorylated tau, are the pathological hallmarks of AD, in the
brain. These are believed to contribute to synaptic dysfunction and neuronal death, although
small oligomers of the Aβ peptide are thought to be the more toxic form of the aggregated
forms of Aβ peptide. Currently, definitive diagnosis of AD relies upon the presence, at
autopsy, of these pathological hallmarks, in specified amounts in discrete regions of the
brain. To date, there is no cure available for AD, and for this reason much attention has been
directed to identifying factors which may delay onset or slow disease progression. We now
know that the neuropathological changes associated with AD precede onset of symptoms by
15 – 20 years, thereby presenting a ‘window of opportunity’ to modify disease course. It is
clear therefore that there is significant benefit to ascertaining which lifestyle factors may
protect against or contribute to the development of AD. Identification of such factors might
permit early intervention to modify disease course, enabling delay or ideally prevention of
onset of AD (11). Diet modification represents one potential intervention strategy accessible
to all which is also economically advantageous over medical interventions with reduced
incidence of adverse side effects.
Individuals consume diets that contain both nutrient and non-nutrient substances rather than
single foods. Consequently, misleading conclusions on the effect of consumption of a single
nutrient, food or dietary component on health outcomes can be drawn. It may be more useful
therefore to examine indices of food and nutrient intake that express several related aspects
of diet concurrently rather than focus on consumption of single nutrients (280):
Consequently, dietary pattern analysis has emerged (219).
The present thesis aimed to further the understanding of the association between diet and
AD. To achieve this aim, four dietary patterns were constructed using data collected via
administration of the Cancer Council of Victoria Food Frequency Questionnaire (CCVFFQ),
namely; Mediterranean diet (MeDi), inflammatory dietary index, prudent diet and western
diet patterns. The relationship of adherence to these dietary patterns, cognition and cognitive
decline was assessed in the large, well-characterised elderly Australian Imaging, Biomarkers
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and Lifestyle Study of Ageing (AIBL) cohort. The potential mechanisms underlying the
observed effects of dietary pattern adherence on cognitive decline were investigated in this
cohort using blood-based and neuroimaging biomarker data collected as part of the AIBL
study. Additionally, by adding questions regarding intake of foods of interest in AD research
to the online Commonwealth Scientific and Industrial Research Organisation food frequency
questionnaire (CSIROFFQ), we aimed to develop and validate an AD-specific food
frequency questionnaire to be utilised for future research into dietary factors and AD risk.
6.2. Summary of main results
The main results from this thesis are as follows:
•

AD participants in our cohort demonstrated reduced adherence to the MeDi and

prudent diets, and greater adherence to the western diet and the inflammatory dietary index
(equating to consumption of less anti-inflammatory foods) compared to healthy controls.
Further, healthy control participants demonstrated greater adherence to the MeDi and
prudent diets, and reduced adherence to the inflammatory dietary index (consumption of
more anti-inflammatory foods) compared to individuals with mild cognitively impairment
(MCI).
•

There were no cross-sectional associations between adherence to the four dietary

patterns and global cognition or any of the six composite cognitive domains assessed.
•

Longitudinally, there were no gender-dependent associations between adherence to

the four dietary patterns and global cognition or any of the six composite cognitive domains
assessed.
•

Higher baseline adherence to the ‘healthy’ MeDi was associated with decreased

decline in the executive function composite cognitive score 36 months later in
Apolipoprotein E (APOE) ɛ4 allele carriers only.
•

Higher baseline adherence to the ‘unhealthy’ western diet was associated with

increased decline in the visuospatial functioning composite cognitive score 36 months later
in APOE ε4 allele non-carriers.
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•

Dietary pattern adherence appeared to have no effect on the rate of transition from

healthy control clinical classification at baseline to mild cognitive impairment (MCI) or AD
status after 36 months in the cohort as a whole and following stratification of the cohort by
gender and APOE ε4 allele carriage (although this analysis was likely limited by low
numbers of individuals transitioning over this period of time).
•

Whilst we report some associations between dietary pattern adherence and blood-

based biomarkers of metabolic syndrome and cardiovascular disease (CVD), our lack of
significant associations between the MeDi and western diet patterns and our metabolic
syndrome and CVD indexes as well as the individual components of the indexes, suggests
that modulation of metabolic syndrome or CVD risk may not be the primary mechanisms
underlying the reported effects of diet on cognition.
•

We found our ‘unhealthy’ western dietary pattern to be positively associated with

levels of blood-based biomarkers of inflammation and our ‘healthy’ MeDi and prudent diet
patterns to be negatively associated with levels of blood-based biomarkers of inflammation.
We also found our inflammatory dietary index to be strongly positively correlated with the
levels of numerous blood-based biomarkers of inflammation, i.e. as intake of antiinflammatory foods decreased (indicated by a higher inflammatory dietary index), the
levels of blood-based biomarkers of inflammation increased. We observed many of these
associations in both males and females as well as in APOE ε4 allele non-carriers and
carriers. Our results suggest that the interplay between diet and elevated chronic
inflammation may contribute to the observed effects of diet on cognition.
•

Our preliminary results suggest that the modified CSIROFFQ is reliable and valid

as a method of capturing dietary intake of foods of particular interest for AD research.
6.3. Dietary patterns and cognitive decline
Chapter 3 provided cross-sectional evidence that AD participants in our cohort consume
fewer foods in the MeDi and prudent diet (high in fruits, vegetables and nuts), less antiinflammatory foods, and more foods in the western diet (high in red and processed meats,
chips, refined grains, potatoes, sweets and condiments) compared to cognitively healthy
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controls. However, the nature of this analysis means that the impact of AD diagnosis on
dietary habits cannot be excluded.

Cognitive decline is the progressive loss of cognitive functions, including memory, and
may lead to dementia of which AD is the most common type, accounting for 60 - 80% of
cases (279). Longitudinal results from Chapter 3 included only those individuals classified
as cognitively healthy at baseline to circumvent the potential confounder of AD diagnosis
described above. The longitudinal results highlighted the detrimental nature of a western
diet and proposed the importance of adhering to a ‘healthy’ dietary pattern such as the
MeDi, with respect to reducing risk for cognitive decline over 36 months, with executive
function and visuospatial functioning seemingly most susceptible to the influence of diet.
Our results suggest that there are differential effects of diet on cognition that are likely to be
contingent on APOE ɛ4 allele carriage; the MeDi effects were observed only in APOE ε4
allele carriers and the western diet association with increased cognitive decline was
observed only in APOE ε4 allele non-carriers.
Results from previous studies on the association between dietary patterns and cognitive
decline are inconsistent. Several American and European studies have shown a positive
relationship between adherence to the MeDi and slower cognitive decline or reduced AD
risk (1-7). By contrast, other studies have concluded that higher consumption of the MeDi
was not protective against cognitive decline (226, 282, 283). Studies examining risk of
cognitive decline using ‘a posteriori’ developed dietary patterns are limited in number:
these studies have generally found that higher consumption of an ‘unhealthy’ dietary
pattern, rich in processed foods (similar to our western diet), is associated with increased
cognitive decline with the converse true for a ‘healthy’ or ‘whole food’ (similar to our
prudent diet) dietary pattern (6, 7). To our knowledge, an investigation into associations
between dietary patterns and risk of AD or cognitive decline, looking specifically at the
anti- or pro-inflammatory nature of dietary components, has not been attempted previously.

Whilst it was evident from our analysis that dietary pattern adherence played an important
role in cognitive decline, we did not observe an association between dietary pattern
adherence and transition from healthy control clinical classification at baseline to MCI or
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AD status after 36 months. It is worthy of note however, that this analysis was likely
limited by low numbers of individuals transitioning over the period of follow up (n = 25;
4.7%), and additional longitudinal data collected from our cohort will further clarify the
relationship between adherence to our dietary patterns and AD risk. To our knowledge, this
is the first study extensively comparing MeDi, inflammatory dietary index, western and
prudent diet pattern adherence to cognitive decline in an elderly, well-characterised cohort.
6.4. Mechanisms of action of dietary patterns
Chapter 4 explored potential mechanisms that might underlie the effects of diet on
cognition reported in Chapter 3 by assessing the relationship of the dietary patterns with
blood and neuroimaging biomarker data collected as part of the AIBL study. Our
investigations focussed on factors that are well-established contributors to AD risk i.e.
metabolic syndrome, CVD, and inflammation. We also assessed the relationship between
the dietary patterns and magnetic resonance imaging (MRI)-determined brain volume and
Pittsburgh Compound-B positron emission tomography (PiB PET)-determined cerebral
amyloid load. A study of this comprehensive nature has, to our knowledge, not previously
been undertaken.
As described earlier, the results of Chapter 3 revealed beneficial effects of MeDi adherence
and detrimental effects of western diet adherence on cognition over 36 months. In Chapter
4, we reported associations between dietary pattern adherence and biomarkers of metabolic
syndrome and CVD. However, our lack of significant associations between the MeDi and
western diet patterns and our metabolic syndrome and CVD indexes as well as the
individual components of the indexes, suggests that modulation of metabolic syndrome or
CVD risk may not be the primary mechanisms underlying the effects of diet on cognition
reported in Chapter 3 of this thesis.
Consistent with published literature, we found our ‘unhealthy’ western dietary pattern to be
positively associated with levels of blood-based biomarkers of inflammation and our
‘healthy’ MeDi and prudent diet patterns to be negatively associated with levels of bloodbased biomarkers of inflammation. We also found our inflammatory dietary index to be
strongly positively correlated with the levels of numerous blood-based biomarkers of
inflammation, i.e. as intake of anti-inflammatory foods decreased (indicated by a higher
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inflammatory dietary index), the levels of blood-based biomarkers of inflammation
increased: A relationship that has never before been investigated in a well characterised
ageing cohort. We observed many of these associations in both males and females as well
as in APOE ε4 allele non-carriers and carriers.
The strong associations between dietary pattern adherence and biomarkers of inflammation
reported in Chapter 4 suggest that the interplay between diet and elevated chronic
inflammation may contribute to the effects of diet on cognition described in Chapter 3 of
this thesis. This hypothesis certainly warrants further investigation and it will become
increasingly important to understand the ‘pro-inflammatory’ versus ‘anti-inflammatory’
contribution of each of the four dietary patterns investigated to further clarify whether
inflammation is the primary candidate mechanism underlying the reported effects of diet on
cognition.
Chronic inflammation processes play an important role in the pathogenesis of AD (456)
and are considered a propagating factor for neurodegeneration, with severity of
neuroinflammation correlating with the degree of tissue loss and cognitive decline.
Cytokines and chemokines are important mediators of inflammation. The identification of
interleukin 1β (IL1β), tumour necrosis factor α (TNFα), interleukin 6 (IL6), monocyte
chemo attractant protein 1 and macrophage inflammatory protein 1β in senile plaques and
associated microglia has further highlighted the importance of inflammation in AD (457,
458). Holmes et al. (459) reported that presence of both acute (manifestation of systemic
inflammatory events over six months) and chronic inflammation (high TNFα level at
baseline) is associated with a ten-fold increased rate of cognitive decline compared with
individuals with low levels of TNFα at baseline and no systemic inflammatory events over
the following six months. The insoluble Aβ and neurofibrillary tangles which are likely to
be the stimuli for inflammation are present from preclinical stages of AD; thus upregulation of complement, cytokines and other inflammatory mediators are likely present
and chronically elevated from the same stage (324). Accumulating literature also supports
the notion of diet influencing levels of inflammation. There is evidence to suggest dietary
fatty acids can modulate markers of inflammation (460-463). Consumption of a diet high
in trans fatty acids has been associated with higher C-reactive protein (CRP) concentrations
and consumption of a diet high in oleic acid has been associated with lower IL6
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concentrations (460). Consumption of a high fat western diet has been shown to result in
increased astrocyte reactivity but no change in cognition, microglial reactivity or cytokine
levels, however a very high fat lard diet resulted in impaired cognition, increased
expression of the cytokines TNFα, IL6, monocyte chemotactic protein 1 and increased
reactive astrocytosis and microgliosis (461). Dietary fish oils suppress production of proinflammatory cytokines in animal and human studies. Fish oil feeding has also been shown
to ameliorate the symptoms of chronic inflammation in animal models and protect against
inflammatory challenges (463). Individuals in a higher MeDi adherence tertile have been
shown to possess on average a 20% lower CRP level, a 17% lower IL6 level, a 15% lower
homocysteine and a 14% lower white cell count compared to those in a lower adherence
tertile. Furthermore, Gu et al. (227) also found higher adherence to the MeDi was
associated with lower levels of CRP. Fung et al. (296) used an alternate MeDi (this
alternate MeDi excludes dairy, has a nut group, has only red and processed meat in the
meat section and excludes potatoes) and concluded that individuals in the top adherence
quintile compared to the bottom quintile had a 24% lower CRP concentration. A protective
effect of adherence to the MeDi has also been reported by Panagiotakos et al. (297); for
each unit of increasing adherence to the MeDi, there was a reduction of 3.1% in the average
CRP level and 1.9% reduction in the average IL6 level. Moreover, an intervention study
with 90 participants following a MeDi and 90 following a prudent diet found that the
participants who consumed the MeDi had significantly reduced serum concentrations of
CRP, IL6, IL7 and IL18 as well as decreased insulin resistance compared to those
consuming the prudent diet (231). However, not all studies have found positive results for
these inflammatory biomarkers: Dai et al. (331) found higher adherence to the MeDi was
associated with reduced levels of IL6 but had no significant effect on CRP.
A ‘healthy' dietary pattern (similar to our prudent diet) has also been inversely related to
plasma concentrations of CRP and vascular cell adhesion molecule 1. The authors
additionally reported that western diet score was positively related to serum amyloid A and
IL6 (p < 0.001; 300). Fung et al. (212) also found significant positive correlations between
western dietary pattern adherence and insulin, CRP, leptin and homocysteine
concentrations, and an inverse correlation with plasma folate concentrations. The authors’
prudent dietary pattern was by contrast positively associated with plasma folate and
inversely correlated with insulin and homocysteine concentrations. Furthermore, Nettleton
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et al. (299) derived four dietary patterns using factor analysis: The fats and processed meats
pattern was positively associated with CRP, IL6 and homocysteine. The beans, tomatoes
and refined grains pattern was positively related to intercellular adhesion molecule 1
(ICAM1). The whole grains and fruit pattern was inversely associated with CRP, IL6,
homocysteine and ICAM1, and the vegetables and fish pattern was inversely associated
with IL6.
As previously mentioned, in Chapter 4 we reported positive associations between MeDi
and prudent diet adherence and blood-based biomarkers of inflammation and by contrast,
negative associations between western diet and inflammatory dietary index and these
biomarkers of inflammation. Whilst inflammation is a strong candidate mechanism to
explain the effects of diet on cognition reported in Chapter 3, it is likely that a complex
interplay exists with overlap of the effects of diet on several mechanisms concurrently. For
example, the strongest results in Chapter 3 of this thesis were related to the beneficial
effects of MeDi adherence on cognition. However, the MeDi did not appear to be highly
correlated to any of the potential mechanisms investigated in Chapter 4. It may be that the
MeDi exerts its protective effects via independent mechanisms not investigated in this
thesis, or perhaps more likely is the possibility that rather than one pronounced mechanism
of action, the MeDi acts via multiple mechanisms of (weaker level) action which
synergistically confer protection: Both are plausible explanations that warrant further
investigation.
Finally, whilst no significant associations were found between dietary pattern adherence,
MRI-determined brain region volumes and PiB PET-determined cerebral amyloid load,
several associations were approaching statistical significance. It is important to note that
only a subgroup of participants underwent neuroimaging thereby reducing the sample size
from 527 to 123. This reduced sample size is likely to have limited the power to observe
associations of dietary pattern adherence with neuroimaging outcome measures.
Consequently, we believe the relationship between diet and neuroimaging biomarkers of
AD to be worthy of further investigation: An aim which can be achieved in our cohort in
the near future courtesy of collection of additional longitudinal data and supplementary
cross-sectional data from new study participants.
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6.5. The effect of the Apolipoprotein E ɛ4 allele
Our results suggest that there are differential effects of diet on cognition that are likely to be
contingent on APOE ɛ4 allele carriage. Compared to the APOE ε2 and ε3 isoforms, APOE
ε4 is a less efficient cholesterol transporter (303). The management of cholesterol levels as
well as high density lipoprotein: low density lipoprotein ratios by fish oils in specific diets,
like the MeDi, has been proposed to prevent and treat the negative effects of the APOE ε4
genotype (304). Studies of APOE ε4 allele target replacement mice have shown a positive
influence of fish oil-containing diets on behavioural and cognitive performances (305). A
possible explanation for the MeDi effects on cognition being observed only in APOE ε4
allele carriers in our study is that the cholesterol transport non-carriers may already be
functioning at a reasonable level due to their ε2/ε3 genotype, so MeDi components are not
able to exert a statistically significant improvement.

Throughout our investigations of the effects of dietary pattern adherence on blood-based
biomarkers of inflammation, we also observed associations that were contingent on APOE
genotype. For example prudent diet was negatively associated with eosinophil level in
APOE ɛ4 allele carriers, and inflammatory dietary index was positively associated with
white cell count in APOE ɛ4 allele non-carriers, cross-sectionally at both the baseline timepoint and 36 month follow up.

It has previously been shown that the apoE protein and the APOE genotype modulate the
immune responses that are evident in most neurological diseases, including AD (464, 465).
For example, mice that lack an APOE gene and subsequently, apoE protein demonstrate a
large increase in pro-inflammatory cytokines, decreased resistance to infection and
increased mortality; results which led the authors to suggest that the presence of apoE
regulates macrophage function and affects overall immune status (464, 466, 467).
Furthermore, microglia derived from APOE ε4/ε4 targeted replacement mice demonstrate a
pro-inflammatory phenotype that includes altered cell morphology, increased nitric oxide
production associated with increased nitric oxide synthase 2 messenger ribonucleic acid,
and higher pro-inflammatory cytokine production (TNFα, IL6, interleukin 12 homodimer)
compared to microglia derived from APOE ε3/ε3 targeted replacement mice. The effect is
gene dependent and increases with the number of APOE ε4 alleles (464).
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Ours is not the first study to report differential effects of lifestyle factors on aspects of
cognitive decline and AD-related pathology that are contingent on APOE ɛ4 allele carriage.
Notably, Brown et al. (132) showed that brain and blood Aβ levels are modulated by
physical activity by APOE genotype-dependent mechanisms. Specifically, the authors
reported that high physical activity is associated with lower plasma Aβ1-42/1-40 in APOE ɛ4
allele non-carriers, while higher exercising APOE ɛ4 allele carriers had lower levels of
brain amyloid. Brown et al. concluded that physical activity appears to attenuate the high
levels of brain amyloid associated with APOE ɛ4 carriers, and the apparent lack of effect on
plasma Aβ levels may reflect poor clearance of Aβ in the periphery in individuals with the
APOE ɛ4 allele. Taken together, the results of Brown et al. and the findings reported in this
thesis suggest that in future the assessment of lifestyle in the context of APOE genotype
may help the development of strategies tailored to the needs of APOE ε4 allele carriers in
the Alzheimer population who have the poorest prognosis with current treatment strategies.
To further assess the relationship between nutrition and AD risk, a validated, AD-specific
food frequency questionnaire is required.
6.6. Validation results
Accurate assessment of overall dietary intake is crucial to understanding the association
between diet and chronic diseases: incorrect information may lead to false associations
between dietary factors and diseases. There is a need to develop and validate methods of
assessing food and beverage intake to facilitate the development of guidelines for the
prevention of diet-related chronic disease. However, dietary questionnaires need to be both
specific to the population being analysed, and to the disease of interest: currently, there is
no AD-specific FFQ available.
From the literature, we identified foods of interest in AD research; included were
pomegranates, nuts and seeds, herbs and spices, supplements, green tea, red wine, chocolate
and oils. Intake of some of these items was already captured by completion of the existing
online CSIROFFQ, however specific details regarding quantity, frequency, and/or subtypes
of items were not collected, whilst information regarding intake of other items was entirely
missing.
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In an attempt to develop a questionnaire specific to AD research, we altered or added
questions to the online CSIROFFQ relating to the foods of interest listed above. Chapter 5
of this thesis assessed the ‘reliability’ (if individuals recall the same intake over the past
year on different occasions) and ‘validity’ (this ensures dietary questionnaires estimate true
food intake) of the online modified CSIROFFQ. Our results showed ‘good reliability’
between dietary intake captured following two administrations of the FFQ, and a ‘good
level of agreement’ between intake of food and beverage items captured by both the
modified CSIROFFQ and a four-day weighed food record (a ‘gold standard’ of collection
of dietary data for the purposes required by this study).
We further investigated the validity of the modified CSIROFFQ by assigning participants
to a proposed ‘high’ or ‘low’ AD risk group depending on consumption of the validated
foods of interest in AD research. We then investigated the difference in mean
neuropsychological tests scores, mean inflammatory biomarker levels and cerebral amyloid
load between these proposed ‘high’ and ‘low’ AD risk groups. Although none of the results
reached statistical significance, several were trending towards an association, in particular
increased likelihood of PiB PET positivity (representative of significant cerebral amyloid
load) among the proposed ‘high’ risk AD group compared to the ‘low’ risk AD group. The
small sample size may account for the lack of statistically significant results observed: The
validation study was conducted on 49 cognitively normal participants and only 37 of these
individuals underwent neuroimaging.
Together, these results suggest that the modified CSIROFFQ is ‘reliable’ and has an
acceptable level of validity, therefore it is a tool which can provide an acceptable
assessment of long-term dietary intake in Australian older adults, particularly in the context
of AD research. However, to further confirm ‘validity’ we require an increased sample size,
preferably with validation of nutrient status also confirmed using blood-based biomarkers.
6.7. Limitations
This thesis reports novel associations between diet and a number of variables associated
with the development of AD. However, these findings should be interpreted within the
context of the limitations of this study. The study utilised a relatively short follow-up
period (36 months) for longitudinal analyses. As dietary intake is a long-term habit
237

Chapter 6 General discussion and future direction

associations between nutrition, cognitive function and blood- and brain-based AD
biomarkers may be more clearly determined in studies of extended follow up. Seasonal
variations in diet should also be considered in such studies.
The AIBL study cohort is highly educated and mostly Caucasian (> 90%); factors which
may impact upon the translatability of our results to the wider community. In an attempt to
counteract the effects of surveying such a homogenous group, the neuropsychological
battery contained a large selection of cognitive tests that are likely to be sensitive to
cognitive differences, even in such a high performing cohort. The ethnic ‘make up’ of the
AIBL cohort however, may limit inferences regarding similar effects in other populations.
The FFQs used in this thesis rely on participants’ estimations of food intake over the
previous 12 month period; this results in a limitation common to studies of diet and disease,
namely misclassification of exposure due to limited accuracy. This point is particularly
salient among AD participants; we are relying on participants’ carers for validation of
answers, or assistance with completion of the FFQ, and therefore assuming the carers are
cognitively intact themselves. Furthermore, misclassification of diet is not equal between
persons with and without cognitive impairment, and this raises the potential for
‘differential’ misclassification bias. One methodological approach which partly
circumvents the issue, and which we have employed in our longitudinal analysis, is
inclusion of only individuals classified as healthy control at baseline (these individuals may
or may not convert to MCI or AD at subsequent follow ups). To further reduce the
likelihood of misclassification of exposure, any reported energy intake that was greater than
3500 kilocalorie (kCal) in women and 4000 kCal in men or lower than 500 kCal in women
and 800 kCal in men was removed from the dataset. An additional limitation is the fact that
the CCVFFQ is known to under-report intake of certain foods, including soft drinks and
snack foods. We recognise that ideally a nutrient biomarker panel that reflects dietary
intake would be employed as an additional approach to circumvent the limitations
associated with using the FFQ; although this approach has its own limitations, i.e. a
biomarker panel cannot be as exhaustive as to include every possible nutrient in food.
Two types of dietary patterns have been used in this thesis, ‘a priori’ and ‘a posteriori’. ‘A
priori’ patterns such as the MeDi and inflammatory dietary index reflect adherence to
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specific dietary patterns or guidelines, and therefore results can only be as good as these
underlying guidelines. The availability of dietary guidelines is required to define dietary
indices, and generally the guidelines are not disease specific, hence adherence may reduce
the risk of some diseases but not others. Dietary indices need to be updated as dietary
recommendations for the population being analysed are modified, a process of continual
revision. Limitations of ‘a posteriori’ methods include the fact that they are exploratory in
nature (281) and are based on complex statistical analyses that require investigator-led
selection of a limited number of components to summarise the food patterns (243).
Moreover, the MeDi score itself has limitations; it weighs equally the underlying individual
food categories, which in turn are composed of different numbers of food constituents.
Further, our study was conducted in an Australian cohort, which is unlikely to adhere
strictly to a diet typical of Mediterranean countries. Therefore, “true MeDi” adherence in
our population may be significantly lower when compared with Mediterranean populations,
and subjects with high MeDi adherence in Australia may be potentially categorized as low
MeDi adherence subjects if compared with Mediterranean populations. However, our
results support the notion that the beneficial effects of the MeDi are transferable to different
populations.
It is also possible that diet is related to socioeconomic status or to other habits or
characteristics related to better health and a lower risk for AD. We attempted to address this
issue by adjusting for country of birth (Australia vs. Other), years of education, and body
mass index, in all our analyses. Another confounder usually considered in nutritional
analysis is caloric intake. We used caloric intake adjusted residuals for MeDi score
calculation and also included caloric intake as a covariate in all analyses (as Willet and
colleagues recommended; 468). Additionally, within the AIBL study we do not collect data
pertaining to family origin, although we acknowledge the influence family origin will likely
have on a participant’s current dietary habits (469).
Despite the limitations discussed above, many additional aspects of our study provide
confidence in our findings. The dietary data reported in Chapters 3 and 4 was collected
using an instrument previously validated in earlier epidemiological studies (450), and we
have taken a very conservative approach by controlling for a wide range of demographic
variables, including age, years of education, and country of birth and using a p-value of
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0.01 to determine statistical significance throughout this thesis. Furthermore, the AIBL
study is renowned for its well-characterised cohort and for the high quality of data collected
as part of the study (e.g. high quality neuropsychological data and high quality rigorously
processed blood samples).
6.8. Future directions
If additional funds and time were available, we would ideally expand on the validation
study results reported in Chapter 5 of this thesis by increasing the sample size, and
collecting blood samples from participants in order to validate the CSIROFFQ with respect
to blood-based biomarkers of nutritional intake.
Additional time would also allow inclusion of data collected from further follow-up
assessment time-points into the cognitive and mechanistic analysis described in Chapters 3
and 4. Thereby providing a larger number of individuals ‘transitioning’ from healthy
control status to MCI or AD and more thorough subsequent investigation of the association
of dietary pattern adherence and diagnostic conversion rate. This additional follow-up data
would also enable longitudinal expansion of our mechanistic investigations.
The field of AD biomarkers is ever-growing, thus, there are some potential biomarkers of
AD that were not included in the current study that would be worthy of inclusion in future
research. Further work would ideally include measurement of blood-based biomarkers of
inflammation such as S100 calcium binding protein B (a potential biomarker of tissue
damage), α1 anti-chymotrypsin (some studies suggest this protease inhibitor enhances the
production of Aβ fibrils), and chemokines including microphage colony-stimulating factor.
Other biomarkers that should be investigated include markers of oxidative stress such as
some products of lipid peroxidation (F2-isoprostanes) and oxidatively modified
deoxyribonucleic acid. These biomarkers may provide further insight in relation to the link
between diet and AD risk. The measurement of tau and Aβ levels in cerebrospinal fluid
(CSF), combined with PiB PET standardised uptake value ratio (SUVR) for the
determination of cerebral Aβ load, have become ‘gold standards’ in the context of AD
biomarker research, with changes in these markers predictive of cognitive decline in
healthy older adults (470). Whilst cerebral Aβ load as determined by PiB PET
neuroimaging was incorporated into this thesis, unfortunately CSF measurements of Aβ
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and tau were unavailable, thus presenting an additional possible avenue for investigation in
the future. Analysis of PiB PET data collected following recent expansion of the
neuroimaging cohort in addition to further longitudinal assessment would also be possible
if more time were available.
Through the establishment of intervention trials, with numerous outcome variables
including changes in levels of the biomarkers discussed above, the effects of diet on the
development of AD neuropathology may become clearer. Tailoring of such intervention
trials using specific trial groups (e.g. different components of the MeDi, supplements,
with/without physical activity etc.), may also enable elucidation of dietary components that
are likely to be most beneficial to cognitive health. Furthermore, such trials would also be
able to investigate the effect of APOE ε4 allele carriage on these associations: For such
investigations, an over-selection of people with this genotype is required. Although it is not
possible to eradicate all confounding factors, such studies will provide more conclusive
results. The collective evidence linking diet to AD risk needs to be recognised, and
implementation of dietary advice favouring a healthy ageing brain in a clinical setting is a
necessary ‘next step’ in this field of research.
6.9. Conclusions
The main findings reported in this thesis indicate that high consumption of a ‘healthy’
dietary pattern incorporating the specific components included in the MeDi, and low
consumption of an ‘unhealthy’ dietary pattern like the western diet pattern has positive
implications for reducing cognitive decline, with executive function and visuospatial
functioning seemingly most susceptible to the effects of diet. Our mechanistic
investigations suggest that interplay between diet and elevated chronic inflammation may
contribute to the effects of diet on cognition described in this thesis. However, whilst
inflammation is a strong candidate mechanism, it is likely that a complex interaction exists
with overlap between the effects of diet on several mechanisms concurrently.
It is increasingly clear that the relationship between diet and brain health is complicated.
The results presented in this thesis contribute to the quest for greater understanding of the
role of nutrition as a protective factor against AD. This thesis also contributes to the
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provision of a validated tool which can be used to further investigate dietary factors specific
to AD.

With the high social and financial cost of AD poised to place considerable burden on
Australian society in the coming decades, and with no cure or effective treatment currently
in sight, it is essential that factors such as diet which may help to prevent or delay cognitive
decline and AD are characterised, and observational studies such as AIBL provide a forum
for this work. Beyond this however, there is a need to extend such knowledge to
interventional research to determine a cause and effect relationship and thereby enhance the
implementation and type of prevention programs involving diet. If successful, such
interventional programmes will impact strongly and positively on both social and economic
aspects of caring for the aged and may contribute to the development of ‘Best Practice’
preventative public health strategies to delay AD onset and reduce incidence in our ageing
population.

Moreover, our assessment of dietary pattern adherence in the context of APOE genotype
also suggests that a ‘one size fits all’ approach to nutrition is unlikely to be effective in
terms of modulating AD risk. Further investigation of the effects of diet on cognition and
AD-related pathology in the context of genotype may assist in the development of dietary
strategies tailored to the needs of those who are at greater genetic risk of developing AD.
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PARTICIPANT INFORMATION AND CONSENT FORM
Version 16: 1st September 2012
STUDY EXTENSION
________________________________________________________________________
Title of Study:The Australian Imaging Biomarkers and Lifestyle (AIBL) Flagship Study of Ageing
Principal Researcher: Professor Ralph N. Martins
Associate Researchers: Dr. Hamid Sohrabi, Professor David Ames, Dr. Kathryn Ellis, Professor
Colin Masters, Dr. Trevor Lockett, Professor Edmond Chiu, Dr. Olga Yastrubetskaya, Dr. Mathew
Samuel, Ms. Kristy Draper, Mr. Kevin Taddei, Mr. Mark Rodrigues, Ms. Belinda Brown, Ms. Tania
Taddei, Ms. Samantha Gardener, Ms. Rebecca Lachovitzki, Dr. Tejal Shah, Ms. Georgia Martins,
Dr. Simon Laws, Dr. Veer Gupta, Dr. Stephanie Rainey-Smith, Dr. Andrea Wilson, Ms Kim Lucy
Do, Ms Sabine Matthaes, Ms Rachel Buckley.

_____________________________________________________
This Participant Information and Consent Form is 16 pages long. Please make sure you have all the
pages.
1.

YOUR CONSENT

You are invited to continue your participation in an extension to this research study of Alzheimer’s
disease.
This Participant Information document contains detailed information about the research project. Its
purpose is to explain to you as openly and clearly as possible all the procedures involved in this
project before you decide whether or not to take part in it.
Please read this Participant Information carefully. Feel free to ask questions about any information
in the document. Should you have questions about the study you may contact:
Professor Ralph Martins (Principal Researcher):
Phone No. 0404-839-305 (all hours)
Dr Hamid Sohrabi (Registered Psychologist):
Phone No. 0404-418-270 (all hours)
Dr Stephanie Rainey-Smith (Study Co-ordinator)
Phone No. 043-898-0552 (all hours)
Office Phone No. for this study: 9347 4200
You may also wish to discuss the project with a relative or friend or your local health worker. Feel
free to do this.
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Once you understand what the project is about and if you agree to take part in it, you will be asked
to sign the Consent Form. By signing the Consent Form, you indicate that you understand the
information and that you give your consent to participate in the research project.
You will be given a copy of the Participant Information and Consent Form to keep as a record.
2.

PURPOSE OF THE STUDY

Approximately 4 years ago you joined this study and underwent clinical assessments at
commencement (baseline) and at an 18 month and 36 month follow-up. The study has generated
much valuable data on the genetic and lifestyle risk factors for Alzheimer’s disease (AD) and
biochemical profiles that may lead to an early diagnostic test for the condition.
From 2010, the study has approval to continue for a further 3 years. This will enable us to follow
study participants over a longer period of time, increasing the quality and amount of valuable
information to further develop risk profiles and diagnostic tests. In the extension, you will be
invited back for 3 additional assessments at 18 month intervals (i.e. at 36, 54 and 72 months from
commencement of the original study). The assessments will be similar to those you underwent at
commencement and at 18 months, in that you will give a blood sample, perform memory tasks and
complete questionnaires about your diet (one paper and pencil food frequency questionnaire (FFQ)
i.e. CCV FFQ, and one computerised FFQ i.e. CSIRO FFQ) and exercise habits.
In addition, as part of the extension (i.e. 36, 54 and 72 month follow-ups), you will be asked to also
provide a sample of your buccal (cheek) cells. The procedure for obtaining cheek cells is simply to
wipe a disposable toothbrush over the cheek from inside your mouth. The collection will take
under 5 minutes to conduct. We will analyse your buccal cells to identify a decrease in frequency
of particular cells beyond the normal aging process that could detect Alzheimer’s patients. This may
reflect changes in the AD and Mild Cognitive Impairment (MCI) brain.
Memory loss is common among the general adult population. It may be nothing of clinical
significance, a symptom of another condition such as depression, or an early sign of dementia such
as the most common form of dementia, Alzheimer’s disease (AD).
There is currently no method of clearly detecting whether a person is likely to develop AD or has
AD, until the disease is well advanced. As treatment is likely to be most effective if given early, it is
critical that researchers establish ways of diagnosing AD at an early stage.
This study aims to examine whether brain images, scores on psychometric tasks,
neuropsychological (measurement of memory loss and thinking ability) tests, and/or blood
biomarkers can help to diagnose AD at an early stage, or predict individuals who are at high risk for
developing AD. This study will also examine lifestyle factors that may be related to AD, which may
lead to the development of new treatments in the future.
This study is being carried out at research centres in Melbourne and Perth, with approximately 1000
participants in total. The following individuals over the age of 60 years will be eligible to
participate in this study:
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People with Alzheimer’s disease (AD)
People with Mild Cognitive Impairment (MCI)
Healthy people, which can include carers of people with AD
This study has been reviewed and granted ethics approval by the Hollywood Private Hospital
Research Ethics Committee and Edith Cowan University Human Research Ethics Committee,
which oversee the ethical conduct of all research undertaken at the Sir James McCusker
Alzheimer’s Disease Research Laboratory.
3.

PROCEDURES

We will perform the following tests and procedures at your 36, 54 and 72 month assessments:
Tests of Cognition (Thinking Ability), Memory Loss, Mood and Behaviour
You will be asked about your mood and behaviour, as this helps the study doctor understand if you
may be at risk of depression. We will also test your memory and related thinking skills. These tests
will take approximately one hour and 10 minutes to complete. The questions cover areas such as
general knowledge, calculation, language, ability to recognise familiar objects and the ability to
recall word lists.
Blood Sample
A nurse or other qualified person will take from you a blood sample using a sterile, disposable
needle. The amount of blood to be taken will be 80 ml, which is equal to about 4 tablespoons.
Researchers will then investigate the cells in your blood, along with the genetic information, known
as DNA, contained in your genes.
We may also wish to use your blood and DNA in the future for related research and tests that are
currently unknown or for other purposes. If this occurs then we have to obtain approval from the
Hollywood Private Hospital and Edith Cowan University Human Research Ethics Committees.
Sometimes blood and/or DNA is sent to other research institutions within Australia and/or overseas.
If this occurs, the researchers involved are required to demonstrate to a local Human Research
Ethics Committee that the study meets the appropriate Australian ethical and privacy standards. If
collaborative research is done with other research institutions, please be assured that your identity
will not be disclosed to individuals working in these other institutions.
Your blood and DNA samples will be stored at the Sir James McCusker Alzheimer’s Disease
Research Laboratory, or at the premises of our research partners, until it is used up or until you
contact us to request it be destroyed. Your samples will be labelled with a unique study code. This
code protects your identity from technicians at the laboratory where the samples are analysed but
allows your study doctor and members of the research team to identify your results. Procedures for
secure and confidential storage of blood and DNA samples are those approved by the Hollywood
Private Hospital and Edith Cowan University Human Research Ethics Committees.
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Buccal (Mouth) Sample
You will need to provide a sample of your buccal (cheek) cells. The procedure for obtaining cheek
cells is simply to wipe a disposable toothbrush over the cheek from inside your mouth. The
collection will take under 5 minutes to conduct.
Consent for access to your Medical Records
In addition to asking your permission to utilise some of your blood for medical research, we also
need to ask your permission for access to identified health information kept about you that is
relevant to medical research. Such medical records may originate from hospitals, General Practice
records, diagnoses by private specialists you have seen in the past, and information that is held on
you by the Department of Health at the Health Information Centre.
Members of the research team may examine your health records. Any information obtained during
the study is coded so that you cannot be identified. By signing the attached Consent Form, you
authorise release of, or access to, this confidential coded information to the relevant study personnel
as noted above. The review of these records may be in respect to this study and any further research
that may be conducted in relation to it. These records will be made available, as described above,
even if you withdraw.
OPTIONAL PROCEDURES
Physical Activity Monitoring – Actigraph Uni-axial Accelerometer
You may be invited to wear a small device called an actigraph to measure your physical activity
levels. The actigraph is a small device (size of matchbox) that is not bulky, and is worn (at waist
level) for the entire day excepting bathing and swimming. You will be asked to wear the actigraph
for a period of 7 days, on three separate occasions. Each occasion will be up to 4 months apart. This
will allow us to measure seasonal variation in your physical activity over a 12-month period. On
each occasion, you will be required to come in 7 days later to return the actigraph, at which time a
‘fasting’ blood sample will be taken from you. The amount of blood to be taken on each occasion
will be 80 ml, which is equal to about 4 tablespoons. We will measure levels of your blood
constituents, such as lipids (cholesterol and triglyceride) and biomarkers related to AD and the
results of these tests will be related to your activity level. If you would like some feedback on your
blood test results and your activity level, please notify one of the researchers who will discuss these
results with you. The Physical Activity Monitoring sub-study is NOT compulsory. You may
continue to participate in the main study even if you decide not to participate in the Physical
Activity Monitoring sub-study.
Body composition and bone density (DXA) scan
You may be invited to undergo a body composition and bone density (DXA) scan. This will take
place on-site at Western Medicine, located within the Hollywood Private Hospital Specialist Centre,
by trained professionals. This information will be used to investigate the association between body
fat and Alzheimer’s disease related proteins. The results of the scan will be discussed with you at
the time of scanning with a qualified person from Western Medicine. You will also be given a copy
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of these results and an information sheet identifying any lifestyle changes that can be made to
improve your bone density. The procedure takes approximately 30-45 minutes and at no cost to
you. As this is an optional part of the study you therefore do not have to participate in this
component of the study.
Please be aware that the DXA scan may reveal you have a low bone mineral density and are at a
high risk of bone fracture (osteoporosis). Should the scan reveal that you have osteoporosis, we
will forward a specialist report to your GP. A copy of this report will be given to you. We will
follow-up with you to ensure you have consulted your GP for further investigation and possible
treatment for the condition. In addition, should you and your GP require assistance in managing
osteoporosis arrangements can be made with a bone density specialist.
Neuroimaging
At each of the clinical assessments you will be invited to receive a magnetic resonance imaging
(MRI) scan of your brain and either one or two positron emission tomography (PET) scans of your
brain. You may also be invited to receive a PET scan of your pancreas. As these are optional parts of
the study you therefore do not have to participate in these components. Please discuss any concerns
that you may have regarding these imaging procedures with the research staff. For the PET and
MRI scans, an additional visit for each scan will be required at each clinical assessment. If you
agree to have your pancreas scanned this will take place on the same day as the PET scan of your
brain.
PET Scans
The PET scans will be conducted at either the WA PET Cyclotron Services Department at Sir
Charles Gairdner Hospital and/or the Oceanic Medical Imaging PET-CT Centre, Hollywood Private
Hospital Medical Centre. You will be asked to fast for 6 hours prior to undergoing the scan. A small
plastic needle will be inserted into a vein in your arm which will be used to inject a small dose of
radioactive tracer (C11-PiB, F18-Flutemetamol, F18-Florbetaben, F18-Florbetapir, or F18-FDG)
which will mix with your blood to travel to your brain and pancreas. You will then rest for 30 to 40
minutes, after which time you will lie in the PET scanner, holding your head and body as still as
possible for about 30-40 minutes while pictures of your brain and pancreas where appropriate, are
taken.
If you are invited to receive one PET scan of your brain, you will be injected with one of three new
F18 radioactive tracers; either F18-Flutemetamol, F18-Florbetaben, or F18-Florbetapir. If you are
invited to receive two PET scans of your brain you will be injected with C11-PiB and F18-FDG on
separate occasions. The radiation dose from the injected tracers is relatively small, and is not
considered to be a threat to your health. To put it into perspective, the radiation dose from the
tracers is less than the dose you would receive from a conventional CT (X-ray) scan of the chest.
Because your radiation exposure is low, you won’t feel any effects and should be able to go home
soon after your scan is complete. Most of the tracer will be flushed from your body within 6 to 8
hours. Other than the radiation exposure, there are no documented side effects associated with
administration of PET tracers. In addition to the radiation risk, the insertion of the intravenous line
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may cause bruising and very infrequently infection. Should a reaction or complication occur, you
will be given appropriate treatment at the hospital.
If you are invited to receive an FDG-PET scan, on the day of your scan, upon arrival at the imaging
centre, you will be asked to confirm that you have fasted and your blood glucose level will then be
checked. Your blood glucose will be measured via a finger prick, in the same way that your
pharmacist or GP may check your glucose levels. Your blood glucose level should be < 140 mg/dL
(7.8 mmol/L). If your blood glucose level is 140 mg/dL or above, the FDG-PET scan may be rescheduled. It is not necessary to check your blood glucose level on the day of any of the other PET
scans, it is however, still essential that you fast for 6 hours prior to your scan.
MRI scans
The MRI scans will be conducted at SKG Radiology. It will require you to lie still in another
scanner for 45 minutes. MRI is a non-invasive technique that enables images of internal parts of the
human body to be generated without the use of ionising radiation such as X-rays. There are no
injections involved in this procedure, nor will anything be removed from your body. However, MRI
involves the use of a strong magnetic field to generate these images and as such, people with
pacemakers, aneurysm clips, artificial heart valves, ear implants or metal/foreign objects in their
eyes or elsewhere in their bodies face serious risk of injury. Thus if you think you may have any
such implants or objects you should not participate in this part of the study. Furthermore, the MRI
may cause anxiety and effects of claustrophobia in some people due to the loud noises generated by
the machine and confined space in which the scan is performed.
Donation of a cerebrospinal fluid (CSF) sample
The brain and spinal cord are bathed in a clear fluid termed “cerebrospinal fluid” (CSF). CSF can be
used to provide an insight into the functioning of the brain. This is in contrast to the blood, as the
brain is protected by specialised blood vessels that prevent the passage of certain molecules into the
brain. CSF is often sampled for diagnostic purposes, for example, the determination of bacterial
meningitis, and is now becoming a substance of great interest in the Alzheimer’s field.
We would like to collect CSF (up to 20 ml, approximately 3 teaspoons of fluid) by a procedure
termed a “lumbar puncture” (otherwise known as a “spinal tap”). The procedure involves the
insertion of a fine needle between the vertebrae (bones that constitute the spine) in the lower back
region and is performed under local anaesthesia and under strictly sterile conditions by an
experienced and highly trained anaesthetist. As this is an optional part of the study you therefore do
not have to participate in this component of the study. Please discuss any concerns that you may
have regarding having a lumbar puncture procedure with the research staff.
As this is an invasive medical procedure, you will be required to attend the Hollywood Private
Hospital Day Surgery Unit for a period of one to two hours, where the lumbar puncture will be
performed and you will be monitored for any side effects (see Risks associated with participation in
the optional sub-studies on pages 9, 10 and 11 of this information and consent form). As a further
measure to ensure you do understand the nature and risks of a lumber puncture, we ask that you
attend the day surgery clinic with a trusted friend or relative. The anaesthetist will speak to the
283

Appendix

person accompanying you to confirm your capacity to fully understand what is involved in
undergoing a lumbar puncture.
You will be asked to lie on your side in a curled-up position on a mattress. The skin will be cleaned
with a disinfectant solution. A local anaesthetic will then be injected into the area to make it numb.
A specialised needle will then be inserted between the vertebrae to collect the CSF. You will be
asked to remain lying down for one hour while your condition is monitored. You will then be free
to leave. The following day, you will receive a follow-up call from the anaesthetist to ensure that
you are not experiencing any side effects.
We may wish to use the CSF that we collect from you in the future for related research and tests
that are currently unknown or for other purposes. If this occurs then we have to obtain approval
from the Hollywood Private Hospital and Edith Cowan University Human Research Ethics
Committees.
Sometimes CSF is sent to other research institutions within Australia and/or overseas. If this
occurs, the researchers involved are required to demonstrate to a local Human Research Ethics
Committee that the study meets the appropriate Australian ethical and privacy standards. If
collaborative research is done with other research institutions, please be assured that your identity
will not be disclosed to individuals working in these other institutions.
Your CSF samples will be stored at the Sir James McCusker Alzheimer’s Disease Research
Laboratory, or at the premises of our research partners, until it is used up or until you contact us to
request it be destroyed. Your samples will be labelled with a unique study code. This code protects
your identity from technicians at the laboratory where the samples are analysed but allows your
study doctor and members of the research team to identify your results. Procedures for secure and
confidential storage of CSF samples are those approved by the Hollywood Private Hospital and
Edith Cowan University Human Research Ethics Committees.
Donation of a urine sample
If you agree to donate a cerebrospinal fluid (CSF) sample, on the day that your CSF is collected,
you will also be asked to provide a urine sample. If you agree to provide a urine sample, you will be
given a collection cup and directed to a bathroom where you will collect 25 ml (approximately 4
teaspoons of fluid) of your own urine in private. Once collection is complete, you will return the
collection cup to a nurse or researcher who will be located nearby. If you do not wish to donate a
CSF sample you may still be asked to donate 25 ml of urine on the day that your blood sample is
collected. As this is an optional part of the study you therefore do not have to participate in this
component of the study.
Cogstate Study
You may be invited to participate in an additional study that will investigate the rate of change in
cognitive function (i.e. thinking, reasoning and memory) in older adults. This study will commence
from the time of your 36–month follow up visit. It will involve 10 sessions of up to 30 minutes each
over the following 18 months.
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You will be assessed with the Cogstate test, which is a computerised series of tasks which use
playing cards. We can arrange for these sessions to take place at your home if you prefer. In
addition, at four time points you will complete four brief neuropsychological measures, which will
be familiar to you.
Subjective Memory Complaint Interview
If you are a healthy or Mild Cognitive Impairment participant, you may be asked to participate in an
interview focusing on (a) your perception of your memory performance in hypothetical scenarios,
and (b) details regarding your recent memories of personal events (for instance how you relive these
memories and your reaction to situational demand on your memory). This study will also involve a
short computerised task. This assessment will last approximately 55 minutes in total and will be
audio recorded with your permission. In order to keep to a minimum the number of visits that you
are asked to make to the research unit, if you agree to participate in this optional study component, a
member of our research team will, with your consent, visit your home and conduct the interview
there.
Study of Care-givers
If you are a participant with Alzheimer’s disease or Mild Cognitive Impairment your next of kin or
care-giver may be given the opportunity to complete a phone survey and paper questionnaires about
care options and utilization of facilities and about the benefits of physical activity and how a
physical activity program would be best implemented.
4.

BENEFITS

You will not receive any direct benefit from participating in this study. If you are a patient with
Alzheimer’s disease or mild cognitive impairment, you may gain more information about your
condition through education during the study. You will receive a report on your current nutritional
intake, which will inform you of any excesses or deficiencies and allow you to adjust your diet if
needed. As a research participant, you will also be contributing to the overall understanding and
knowledge in the area of AD.
5.

RISKS AND DISCOMFORTS

There are a number of potential risks associated with this study.
Risks associated with blood tests
There is a small risk of discomfort, bruising, and in extremely rare cases, infection at the site of the
needle puncture, as a result of taking blood for laboratory testing. Some people feel dizzy or faint
after they give blood. If you must come in for blood tests before a meal i.e. a fasted blood sample,
you will be provided with an opportunity to eat before further testing is done. Food will be
provided by the Study Group.
Risks associated with cognitive tasks
You may experience anxiety or psychological discomfort while completing the memory assessment.
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Risks associated with providing personal information
As with the collection of any personal (private) information, there is a very slight risk of accidental
disclosure of information or breach of computer security. Extensive safeguards are in place to
minimize this potential risk, with hard copies of your information stored in locked cabinets within
the principal researcher’s office and electronic copies stored on file with password restricted access.
If you participate in the Body composition & bone density (DXA) scan sub-study
The DXA scan is a painless, non-invasive procedure and involves the use of X-rays to determine
regional body fat composition and bone mineral density (bone strength). The radiation dose from
one DXA scan is low, approximately 1/50th of a chest X-ray. Your radiation exposure due to the
DXA scan is the same amount you would receive during a 2 hour airplane flight and is less than
normal background radiation you are exposed to on a yearly basis.
If you participate in the Actigraph Accelerometer sub-study
There is a very slight risk of increasing injury severity if the participant were to fall on the activity
monitor but this is no greater than should they fall with anything else in their pocket or wearing a
mobile phone or other tool on their belt.
If you participate in the optional MRI and PET brain imaging component:
Risks associated with MRI scans
The MRI scan does not cause any pain and does not expose you to X-ray radiation. However, MRIs
use a magnetic field that can interact with medical devices or metal in your body. It is important
that you inform the study team if you have any metal or metal devices or electrical parts in your
body. The study doctor will go through a checklist with you. You do not need to tell the study team
if you have fillings in your teeth, as they will have no effect. However, it is important that you tell
your study team if you have tattoos, piercings, or permanent eye makeup. In addition, you will have
to lie still on your back in the MRI scanner, which is a tight space. This may be difficult if you are
claustrophobic. Some MRI machines are noisy and you may find this discomforting.
If you have previously had an MRI and experienced any unusual side effects, symptoms, or
discomforts please tell the study team. If you experience any unusual side effects, symptoms, or
discomforts during the MRI please tell the staff at your MRI appointment and tell the study team
either at your next appointment or via a telephone call.
If you experience any disturbing symptoms at any time during the study or directly following your
participation, you should contact the study doctor immediately.
Risks associated with PET scans
If you take part in the optional PET imaging, you will have a cannula (a small flexible tube with a
needle end) inserted into a vein in your arm. The risks of having a cannula inserted are the same as
those associated with blood tests, which are a small risk of discomfort, bruising, and on extremely
rare occasions infection at the site of needle puncture.
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This research study involves exposure to a small amount of radiation at each 18 month scan. As part
of everyday living, everyone is exposed to naturally occurring background radiation and receives a
dose of about 2 millisieverts (mSv) each year. The effective dose from this research study will vary
between 5.4 mSv and 7 mSv at each review, depending on whether you consent to undergo either
one or two PET scans of your brain. If you consent to undergo one PET scan of your brain, you will
be exposed to up to 7 mSv of radiation through the injection of one of three new F18 radioactive
tracers; either F18-Flutemetamol, F18-Florbetaben, or F18-Florbetapir. If you consent to undergo
two PET scans of your brain, you will be exposed to a total of 5.4 mSv of radiation through the
injection of C11-PiB and F18-FDG on separate occasions. If you are also invited and consent to
receive a PET scan of your pancreas, on the day of your C11-PiB brain scan you will additionally
undergo a brief ‘scouting’ CT scan of your upper abdomen to locate the pancreas. This is
accomplished easily with the combined CT-PET scanner but the ‘scouting’ CT scan entails extra
radiation exposure of 0.5 mSv, thereby increasing the combined radiation dose to 5.9 mSv (C11-PiB
and F18-FDG brain scans 5.4 mSv, + pancreas 0.5 mSv).
To put these radiation doses into perspective, 5.4 mSv is equivalent to two and a half years of
natural background radiation that you would be exposed to through normal daily activities. 5.9 mSv
and 7 mSv are equivalent to approximately three and three and a half years of natural background
radiation respectively. This can be compared to, up to 10 mSv, which is the radiation dose you
would be exposed to during a CT scan of the chest. Furthermore, the Australian Radiation
Protection and Nuclear Safety Agency guidelines stipulate that it is acceptable for research
participants over the age of 60 years to be exposed to up to 8 mSV per year in addition to radiation
received as part of normal clinical management. The acceptable research dose increases to up to 12
mSV per year for research participants who are 70 years or more.
You should however, drink plenty of fluids afterwards to flush the radioactive drugs from your
body. Most of the tracer will be flushed from your body within 6 to 24 hours. Other than the
radiation exposure, there are no documented side effects associated with administration of PET
tracers. It should be noted however, that C11-PiB, F18-Flutemetamol, F18-Florbetaben, and F18Florbetapir are relatively new radiation markers and are currently only used for research purposes.
It is important to note that there are safety precautions for lactating women that must be adhered to.
The F18-FDG tracer does not get into breast milk, but the person who receives the tracer emits a
small amount of radiation for about 4 hours after the F18-FDG injection. Therefore, women should
not have prolonged skin contact with a baby to breastfeed for at least 4 hours after the injection of
the F18-FDG tracer. Breast milk can be safely pumped and fed to a baby by another person anytime
after receiving the F18-FDG tracer.
Risks associated with lumbar puncture
The risks associated with lumbar puncture are greatly minimized when the procedure is performed
by an experienced and highly trained medical professional under sterile conditions. You will also be
monitored for a period of one hour in the Day Surgery unit to observe and treat any side effects,
should they occur. In addition, you will receive a follow-up phone call the day after the procedure
to ensure you are not suffering any side effects. However, there are some risks that you should
carefully consider before agreeing to undergo a lumbar puncture. A lumbar puncture can
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occasionally be uncomfortable or even painful, but the likelihood of this is minimized by the fact it
is being performed by an experienced doctor and by the use of local anaesthetics. The most
common side effect is headache, and, occasionally temporary sensations (such as tingling or
numbness) can occur in the lower limbs. More rarely, bleeding and bruising at the lumbar puncture
site and trauma to the spinal cord can occur, which can result in paralysis. Paralysis is however,
extremely rare as the site of lumbar puncture is below that where nerves leave the spinal cord to
enter the lower limbs. Infection can also occur, however this is reduced by using sterile instruments
and cleaning the area with surgical disinfectants.
Additional possible risks
The possibility exists for a rare reaction to any of the procedures to which the participant will be
exposed.
6.

ALTERNATIVES

You do not have to participate in this study. Choosing not to participate will in no way affect your
current or future medical care at any of the participating health services involved in this study. If
you decide to take part and later change your mind, you are free to withdraw from the project at any
stage. This action will in no way affect your current or future medical care at any of the
participating health services involved in this study.
7.

PRIVACY, CONFIDENTIALITY AND DISCLOSURE OF INFORMATION

Any information obtained in connection with this research study that can identify you will remain
confidential and will not be disclosed to any third party, except as required by law. The results of
this research study may be presented at meetings or in publications. However, your identity will not
be disclosed in those presentations. No patient will be identifiable by name in any
publications/presentations arising from the study.
During the study, research information will be stored within the locked offices of Professor Ralph
Martins at the Sir James McCusker Alzheimer’s Disease Research Unit. The researchers named at
the beginning of this consent form will have access to this information. Electronic data will be
stored on computer with restricted access using password protection, with access limited to
researchers within the study group.
It is desirable that your family GP be advised of your decision to participate in this research study.
By signing the Consent Form, you agree to your family GP being notified of your decision to
participate in this research study, and being kept informed of your progress in the study.
Other research centres may assist us with our research in exchange for our study findings and data.
If this is the case, neither your name nor other information that can identify you personally will be
given to these other research centres. Instead they will only be given data with an ID code, which
only the researchers of this project at the Sir James McCusker Alzheimer’s Disease Research
Laboratory will be able to trace back to you. Therefore, please be assured that all personal
information collected about you as part of this study will remain strictly confidential throughout the
conduct of this study.
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8.

NEW INFORMATION ARISING DURING THE PROJECT

During the research project, new information about the risks and benefits of the project may become
known to the researchers. If this occurs, you will be told about this new information. This new
information may mean that you can no longer participate in this research. If this occurs, the persons
supervising the research will stop your participation. In all cases, you will be offered all available
care to suit your needs and medical condition, if applicable.
9.

RESULTS OF PROJECT

At the completion of the study, the results will be made available through either publication in a
peer-reviewed journal, clinical meetings, and/or study reports. If you would like to be personally
informed of the results, the researchers will provide you or your carer (if applicable) a verbal
summary of the overall results of the study upon request. However, we wish to advise that
information gained at early stages of any research will be preliminary in nature and is unlikely to
have any relevance for you or your relative’s health. You will not be informed of the results of the
investigations other than if unexpected incidental pathology is detected such as a brain tumour or
unknown stroke.
10.

FURTHER INFORMATION OR ANY PROBLEMS

If you require further information or if you have any problems concerning this project you can
contact the Principal researcher, Professor Ralph Martins, Ph: (08)9347 4201 or 0404-839-305;
Associate researcher, Dr. Hamid Sohrabi, Ph: 0404-418-270; the Sir James McCusker Alzheimer’s
Disease Research Unit on (08)9347 4200; or Dr Mathew Samuel, Fremantle Hospital and the
Fremantle Older Adult Mental Health Service (FOAMHS), Ph: (08)9347 4201.
If after agreeing to participate you have further questions or experience an adverse event, you are
encouraged to contact us on the above numbers. Once having agreed to participate, you are free to
withdraw from this study at any time without giving a reason and this will not affect your current or
future medical care.
11.

OTHER ISSUES

If you have any complaints about any aspect of the project, the way it is being conducted, or any
questions about your rights as a research participant, then you may contact:
Dr. Terry Bayliss, Chairperson of the Hollywood Private Hospital Research Ethics Committee on
(08)9346 6345, or Ms Kim Gifkins, Research Ethics Officer at Edith Cowan University on
(08)6304 2170, or Secretary of the Sir Charles Gairdner Hospital Human Research Ethics
Committee on (08)9346 2999, or Chair of the South Metropolitan Adult Health Service (SMAHS)
Human Research Ethics Committee on (08)9431 2929, or Professor Frank Van Bockxmeer,
Chairman of the Royal Perth Hospital Ethics Committee on (08) 9224 2244.
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12.

PARTICIPATION IS VOLUNTARY

Participation in any research project is voluntary. If you do not wish to take part you are not obliged
to. If you decide to take part and later change your mind, you are free to withdraw from the project
at any stage.
Your decision whether to take part or not to take part, or to take part and then withdraw, will not
affect your routine treatment, your relationship with those treating you or your relationship with the
participating health services involved in this study.
Before you make your decision, a member of the research team will be available to answer any
questions you have about the research project. Please feel free to ask for any information you want.
Sign the Consent Form only after you have had a chance to ask your questions and have received
satisfactory answers.
If you decide to withdraw from this project, please notify a member of the research team of your
intent.
13.

ETHICAL GUIDELINES

This project will be carried out according to the National Statement on Ethical Conduct in Research
Involving Humans (2007) produced by the National Health and Medical Research Council of
Australia. This statement has been developed to protect the interests of people who agree to
participate in human research studies.
The ethical aspects of this research project have been approved by the Hollywood Private Hospital,
Edith Cowan University, Sir Charles Gairdner Hospital and South Metropolitan Adult Health
Human Research Ethics Committees and the Ethics Committee of the Royal Perth Hospital.
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The Australian Imaging Biomarkers and Lifestyle (AIBL) Flagship Study of Ageing
Participant Revocation of Consent Form
Version 16: 1st September 2012

I hereby wish to WITHDRAW my consent to participate in the research proposal named above
and understand that such withdrawal WILL NOT jeopardize any treatment or my relationship
with any of the participating Health Services.

Participant’s Name (printed) _________________________________________________

Signature: ____________________________________ Date_______________________
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The Australian Imaging Biomarkers and Lifestyle (AIBL) Flagship Study of Ageing
PARTICIPANT CONSENT FORM Version 16: 1st September 2012
Consent for participation in an extension to the research project
I,
_________________________of______________________________________________________agree
to
continue my participation in an extension to “The Australian Imaging Biomarkers and Lifestyle (AIBL) Flagship
Study of Ageing”. (Doctor or health professional) ……………………………….…. has explained to me and I
understand the consequences involved in my participation in the AIBL Flagship Study of Ageing. I have had an
opportunity to ask questions and am satisfied with the answers given.
I understand my participation in the extension to this study will involve follow-up assessments at 36, 54 and
72 months, and that assessments will be similar to those I underwent at commencement and at 18 months.
I understand that participation in this project will involve:
1.
Completion of questionnaires relating to my diet (one paper/pencil and one computerised) and exercise
levels,
2.
Measurement of mood, behaviour, cognition (thinking ability) and memory loss,
3.
Voluntary Buccal (cheek) cell donation,
4.
Voluntary donation of blood.
In making my donation, I freely agree to participate in this project according to the conditions in the Participant
Information Form. I understand and agree that:
the blood (which in this consent form, includes its constituents, such as DNA, and any cell lines derived from the
blood) and buccal cells will be stored and used in relation to The Australian Imaging Biomarkers and Lifestyle
(AIBL) Flagship Study of Ageing
the AIBL Flagship Study of Ageing will not be liable for any loss of, or damage to my blood, or derived cell
constituents (including DNA) used in accordance with this form,
access to my blood or derived cell constituents (including DNA) for future unspecified research will only be released
where the research proposal has been approved by a Human Research Ethics Committee,
access to my health information relevant to this study and any further research that may be conducted in relation to it,
only where the research proposal has been approved by a Human Research Ethics Committee.
I also understand that:
I will be given a copy of the Participant Information and Consent Form to keep,
the researcher has agreed not to reveal my identity and personal details if information about this project is published
or presented in any public form,
I am free to withdraw from this study at any time without giving a reason and without affecting my current or future
medical care,
I will not benefit financially if this research leads to development of a new treatment or medical test,
I agree to my family GP being notified of my decision to participate in this research study, and being kept informed
of my progress in the study.
Optional parts of the research project; please CIRCLE your response:
I give my consent to participate in the DXA scan sub-study
YES NO
I give my consent to participate in the Actigraph Accelerometer sub-study
YES NO
I give my consent to be contacted about PET and MRI imaging (including
YES NO
imaging of the pancreas)
I may be contacted between visits to provide additional information or receive
study updates
YES NO
I give my consent to be contacted about participation in future studies
YES NO
I give my consent to a lumbar puncture
YES NO
I give my consent to provide a urine sample
YES NO
I give my consent to participate in the Cogstate study
YES NO
I give my consent to participate in the Subjective Memory Complaint Interview YES NO
Participant’s Name (printed) _______________________________________________________________
Signature________________________________________________Date__________________________
Declaration by researcher: I have given a verbal explanation of the research project, its procedures and risks and I
believe that the participant has understood that explanation.
Researcher’s Name (printed) ______________________________________________________________
Signature________________________________________________Date__________________________
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The Australian Imaging Biomarkers and Lifestyle (AIBL) Flagship Study of
Ageing
PARTICIPANT CONSENT FORM Version 16: 1st September 2012

LUMBAR PUNCTURE: confirmation of research
participant’s capacity to give informed consent
This form is to be completed by the anaesthetist after consultation with the person
accompanying the research participant to the lumbar puncture appointment.
I confirm, having assessed……………………………………………………(research
participant’s name)
and having spoken to …………………………………………………………(name of
person accompanying research participant)
of………………………………………………...............................................(address of
accompanying person),
who is the research participant’s………………………………..……………(their
relationship to research participant)
that the research participant demonstrates satisfactory understanding of the nature and
risks of lumbar puncture procedure and a capacity to give informed consent.

Accompanying person’s name (printed):______________________________________

Signature:______________________________ Date:___________________________

Anaesthetist’s name (printed):______________________________________________

Signature:______________________________Date:___________________________
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THE AUSTRALIAN IMAGING BIOMARKERS AND LIFESTYLE (AIBL) FLAGSHIP
STUDY OF AGEING:
FOOD FREQUENCY QUESTIONNAIRE VALIDATION SUB-STUDY: INFORMATION
AND CONSENT FORM
Version 2: 17th September 2013
_____________________________________________________________________
Title of Study: The Australian Imaging Biomarkers and Lifestyle (AIBL) Flagship
Study of Ageing: Food Frequency Questionnaire Validation Sub-study
Principal Researcher: Professor Ralph N. Martins
Associate Researchers: Dr. Stephanie Rainey-Smith, Ms. Samantha Gardener.

_______________________________________________
This Participant Information and Consent Form is 8 pages long. Please
make sure you have all the pages.
1.

YOUR CONSENT

This Food Frequency Questionnaire Validation Sub-Study Information document
contains detailed information about the research study. Its purpose is to explain to you
as openly and clearly as possible all the procedures involved in this study before you
decide whether or not to take part in it.
Please read this Food Frequency Questionnaire Validation Sub-study Information
document carefully. Feel free to ask questions about any information in the document.
Once you understand what the study is about and if you agree to take part in it, you will
be asked to sign the Consent Form. By signing the Consent Form, you indicate that
you understand the information and that you give your consent to participate in the
research study.
You will be given a copy of this document to keep as a record.

2.

PURPOSE OF STUDY

The AIBL study in which you already participate, aims to improve diagnosis of
Alzheimer’s disease and hopes to discover treatments and lifestyle factors that can
prevent or delay the disease. One of the preventative strategies that we are
investigating is diet.
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As part of the AIBL study you may have already completed a paper and pencil diet
questionnaire which asked you to estimate how often and in what quantity you eat and
drink certain foods and beverages. You may also have completed a computerised diet
questionnaire which asked you to estimate how often and in what quantity you eat and
drink a much longer list of foods and beverages.
We have modified the computerised diet questionnaire by adding foods and beverages
that are of particular interest in the field of Alzheimer’s research. These foods and
beverages include items such as green tea, red wine, dark chocolate, pomegranates
as well as any vitamin, mineral or dietary supplements you take.
Before we ask all AIBL study participants to complete the new version of the
computerised diet questionnaire we first need to be sure of its ability to accurately and
consistently estimate dietary intake of all the foods and beverages listed in the new
version: this process is referred to as validation. If the new questionnaire is validated,
the conclusions we make from the data collected using this questionnaire will be more
reliable and will therefore be more valuable to the research community.
The process of validation involves completing a reliability and repeatability assessment,
to ensure that people state the same answer to each question every time. Weighed
food records are the best method for this validation as they are a record of actual
intake of foods and beverages consumed, at the time of consumption.
If you agree to participate in this optional study we will compare the answers you give
in the computerised diet questionnaire to a diary of the food and drink you consume
over a four day period. You will be asked to complete the computerised diet
questionnaire before the beginning and immediately after the end of the four day period
and to keep a written record of everything you eat and drink during the nominated four
days.

This study will be carried out at the McCusker Hollywood Private Hospital
Alzheimer’s Research Centre on the Hollywood Private Hospital campus in
Nedlands, WA. Only individuals without a diagnosed memory problem will be
eligible to participate.
3.

PROCEDURES

Completing the Computerised Diet Questionnaire
You will be asked to complete the computerised diet questionnaire (CSIRO Food
Frequency Questionnaire) before the beginning and immediately after the end of a four
day period and to keep a written record (diary) of everything you eat and drink during
the nominated four days.
The computerised questionnaire takes approximately 45-60 minutes to complete and
can be completed over the internet at home, over the internet in our research centre or
over the telephone. If you choose to answer the questionnaire over the telephone, a
researcher will call you at a mutually convenient time and will ask you the questions
over the telephone; the researcher will enter the answers you give into the
computerised questionnaire whilst they are on the phone to you.
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When completing the computerised questionnaire, the answers are automatically
saved throughout so you can start and stop at times that are convenient, and you can
complete the questionnaire over multiple sessions.
Completing the Written Food and Beverage Diary
You will be asked to keep a written record (diary) of everything you eat and drink for a
period of four consecutive days that fall between the first and second time you
complete the new version of the computerised diet questionnaire. This period of four
consecutive days will start on a Sunday at midnight and finish on a Wednesday at
midnight.
You will be asked to weigh the food you eat (after cooking, just before eating) and to
record the weight on food diary sheets which will be provided to you. A set of scales
will be provided to you, if possible we would like you to, weigh the food in grams using
the scales provided. We will ask you to record both the portion served, and the left
overs including bone skin, core, or that which is just not eaten. If weighing your food is
not possible, we will ask you to approximate the amount of food as accurately as you
can by size using measuring cups and spoons which we will provide to you. We will ask
you to approximate the amount of beverage consumed as accurately as you can using
measuring cups where no detailed measure of volume is available e.g. a 110 ml
serving of red wine consumed in a restaurant.
You will be provided with detailed instructions (both written and oral) of how to
complete your weighed food and beverage diary.
You will receive a phone call on the Monday to confirm there were no issues the
preceding day and to answer any questions. You will also be provided with a mobile
telephone number which can be called anytime to discuss questions or problems that
may arise over the four days.

4.

STUDY SCHEDULE

If you agree to participate in this study you will be asked to attend the research centre
on two occasions (this number increases to four occasions if you decide to complete
the computerised diet questionnaire at the research centre).
Participating in this study involves the following 5 steps:
1.
Completion of a computerised diet questionnaire (this will take between 45 and
60 minutes and needs to be completed over the internet; your answers are
automatically saved so you can complete it over multiple sessions).
2.
Attend a meeting at the research centre to receive instructions (written and oral)
on how to complete a 4 day weighed food diary (diary sheets, a set of scales and
measuring cups and spoons will be provided) (60-90 minutes). There may be other
individuals who are participating in this study present at this meeting; please advise a
researcher if you would prefer to meet with the researcher alone.
3.
Completion of a 4 day weighed food record (Sunday to Wednesday); this
involves weighing and recording all food and drink you consume in these 4 days.
4.
Final meeting to return equipment, discuss any issues and go through your food
diary (30-60 minutes); no other participants will be present.
5.

Completion of the same online diet questionnaire (45-60 minutes).
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5.

BENEFITS

You will not receive any direct benefit from participating in this study. You will receive a
report on your current nutritional intake each time you complete the CSIRO FFQ, which
will inform you of any excesses or deficiencies and allow you to adjust your diet if
needed. As a research participant, you will also be contributing to the overall
understanding and knowledge in the area of Alzheimer’s disease.

6.

RISKS AND DISCOMFORTS

There are no foreseeable risks to you.

7.

ALTERNATIVES

You do not have to participate in this study; participation is voluntary. Choosing not to
participate will in no way affect your current or future medical care at any of the
participating hospitals involved in this research study; including Hollywood Private
Hospital.

8.

PRIVACY, CONFIDENTIALITY AND DISCLOSURE OF INFORMATION

Any information obtained in connection with this research study that can identify you
will remain confidential and will only be used for the purpose of this study. It will only be
disclosed with your permission, except as required by law. The results of this research
study may be presented at research meetings or in peer-reviewed publications;
however, your identity will not be disclosed in those presentations. No participant will
be identifiable by name in any publications/presentations arising from the study. Each
participant in this study is given a unique study identification code to identify all data
related to that participant. This code is the only means of identification which is used in
any analysis, presentation of results, or communication of results with any other
researchers outside of the team for this study.
During the study, research information will be stored within locked offices at the
McCusker Hollywood Private Hospital Alzheimer’s Research Centre. The researchers
named at the beginning of this document are the only people who will have access to
this information. Electronic data will be stored on computer with restricted access using
password protection, with access limited to researchers within the study group.

9.

RESULTS OF PROJECT

At the completion of the study, the results will be made available through either
publication in a peer-reviewed journal, clinical meetings, and/or study reports. If you
would like to be personally informed of the results, the investigators will provide you
with a verbal summary of the overall results of the study upon request.

10.

FURTHER INFORMATION OR ANY PROBLEMS

If you require further information or if you have any problems concerning this project
you can contact the Principal researcher, Professor Ralph Martins, Ph: (08) 9347 4200
or 0404-839-305; Associate researcher, Dr. Stephanie Rainey-Smith, Ph: 043-8980552; or the McCusker Alzheimer’s Research Foundation on (08) 9347 4200.
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11.

OTHER ISSUES

If you have any complaints about any aspect of the project, the way it is being
conducted, or any questions about your rights as a research participant, then you may
contact any of the people below who represent the human ethics research committees
of the research institutions involved in this study: Dr. Terry Bayliss, Chairperson of the
Hollywood Private Hospital Research Ethics Committee (08) 9346 6345, Ms Kim
Gifkins, Research Ethics Officer at Edith Cowan University (08) 6304 2170.

12.

PARTICIPATION IS VOLUNTARY

Participation in any research project is voluntary. If you do not wish to take part you are
not obliged to do so. Furthermore, if you decide to take part and later change your
mind, you are free to withdraw from the project at any stage.
Your decision whether or not to take part, or to take part and then withdraw, will not
affect your routine treatment, your relationship with those treating you or your
relationship with any one of the participating Health Services.
Before you make your decision, a member of the research team will be available to
answer any questions you have about the research project. You can ask for any
information you wish. If you agree to participate in this study, please sign the Consent
Form only after you have had a chance to ask your questions and have received
satisfactory answers.

If you decide to withdraw from this project, we ask that you please notify a
member of the research team before you withdraw.
13.

ETHICAL GUIDELINES

This project will be carried out according to the National Statement on Ethical Conduct
in Research Involving Humans (June 1999) produced by the National Health and
Medical Research Council of Australia. This statement has been developed to protect
the interests of people who agree to participate in human research studies.
The ethical aspects of this research project have been approved by the Hollywood
Private Hospital and Edith Cowan University.
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The Australian Imaging Biomarkers and Lifestyle (AIBL) Flagship Study of
Ageing
FOOD FREQUENCY QUESTIONNAIRE VALIDATION SUB-STUDY CONSENT
FORM
Version 2: 17th September 2013
•
•
•
•
•
•
•
•

I have had an opportunity to ask questions and I am satisfied with the answers I
have received.
I freely agree to participate in this project according to the conditions outlined in
the Food Frequency Questionnaire Validation Sub-study Information document.
I understand that I am free to withdraw from this sub-study at any time without
giving a reason and without affecting my current or future medical care nor my ongoing
involvement in the main AIBL study
I will be given a copy of the Food Frequency Questionnaire Validation Substudy Information and Consent Form to keep.
I will complete the online CSIRO Food Frequency Questionnaire before and
after I complete my weighed food record.
Where possible, I will weigh or measure all food and beverages consumed
during a specified four day period, and will record this information in the food diary.
I understand that the researcher has agreed not to reveal my identity and
personal details if information about this project is published or presented in any public
form.
I will provide information to the best of my knowledge and ability.
Participant’s Name (printed)
______________________________________________________________
Signature_____________________________Date______________________
Declaration by researcher: I have given a verbal explanation of the research project, its
procedures and risks and I believe that the participant has understood that explanation.
Researcher’s Name (printed)
______________________________________________________________
Signature_____________________________Date______________________
Note: All parties signing the Consent Form must date their own signature.

The Australian Imaging Biomarkers and Lifestyle (AIBL) Flagship Study of
Ageing
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FOOD FREQUENCY QUESTIONNAIRE VALIDATION SUB-STUDY
REVOCATION OF CONSENT FORM
Version 2: 17th September 2013

I hereby wish to WITHDRAW my consent to participate in the research study named
above and understand that such withdrawal WILL NOT jeopardize any treatment or my
relationship with any of the participating Health Services.
Participant’s Name (printed)
_______________________________________________

Signature______________________________Date_____________________
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Validation study four day weighed food
diary
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WEIGHED FOOD RECORDS STUDY – 4 DAY FOOD DIARY
Time of day

Food

Description of food

Amount

Weight

EXAMPLE:
12.30pm

Salad
Sandwich

Cos lettuce
Wholemeal bread (Tip Top)
Margarine (Nuttelex)
Hi Low Milk (Brownes)

2 leaves
2 slices
1 teaspoon
1 cup

14g
64g
5g
220ml

Waste

Crust 5g

Name......................................................................Day of Week..............................................................................

Where the food
was eaten
At home

Cooking
method
None

Appendix 4
Pearson’s and intra-class correlation
coefficients for the reliability of the modified
Commonwealth Scientific and Industrial
Research Organisation food frequency
questionnaire
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Food item from
modified CSIROFFQ

Food section

Pearson's
correlation
coefficient

p-value

Intra-class
correlation
coefficient

p-value

Cereals

Cereals

0.665

***

0.665

***

Bread rolls

Cereals

0.142

Wheat germ

Cereals

0.974

***

0.974

***

Linseed, sunflower
seed and almond
mixture

Cereals

0.693

***

0.676

***

Fried rice

Cereals

0.421

**

0.404

**

Risotto

Cereals

0.577

***

0.529

***

Packet pasta and
sauce

Cereals

0.197

Instant noodles

Cereals

0.380

**

0.356

**

Plain pasta

Cereals

0.837

***

0.836

***

Filled pasta

Cereals

0.717

***

0.708

***

Asian noodles

Cereals

0.887

***

0.770

***

Flat breads

Cereals

0.960

***

0.945

***

Crumpets or English
muffins

Cereals

0.957

***

0.956

***

Croissants

Cereals

0.978

***

0.433

***

Fruit loaf or currant
bread

Cereals

0.671

***

0.665

***

Crisp bread, rice cake
or cracker

Cereals

0.585

***

0.550

***

Salted biscuits

Sweets and snacks

0.576

***

0.552

***

Plain sweet biscuits

Sweets and snacks

0.547

***

0.422

***

Fancy sweet biscuits

Sweets and snacks

0.370

**

0.352

**

Muesli bar or health
bar

Sweets and snacks

0.783

***

0.781

***

Cake or sweet muffin

Sweets and snacks

0.788

***

0.763

***

Fruit pie, pastry or
fritters

Sweets and snacks

0.386

**

0.382

**

0.106

0.174
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Cereal-based sweet
desserts

Sweets and snacks

0.667

***

0.450

***

Sweet bun or
doughnut

Sweets and snacks

0.831

***

0.830

***

Potato crisps, twisties
or corn chips

Sweets and snacks

0.303

*

0.248

*

Popcorn

Sweets and snacks

0.444

***

0.366

**

Chocolate covered bar

Sweets and snacks

0.954

***

0.953

***

Lollies or toffees

Sweets and snacks

0.437

**

0.432

***

Pate or liver paste

Sweets and snacks

0.935

***

0.902

***

Milo, Quik, Ovaltine,
cocoa or hot
chocolate

Beverages

0.577

***

0.560

***

Flavoured milk

Beverages

0.967

***

0.293

*

Milkshake or thick
shake

Beverages

0.905

***

0.905

***

Glass of milk

Beverages

0.577

***

0.444

***

Coffee

Beverages

0.447

***

0.446

***

Sugar or honey added
to hot beverages

Beverages

0.942

***

0.942

***

Herbal tea

Beverages

0.599

***

0.421

***

Cheese

Dairy

0.802

***

0.801

***

Cottage cheese

Dairy

0.744

***

0.593

***

Soft cheese

Dairy

0.249

Ricotta cheese

Dairy

0.489

***

0.476

***

Cream

Dairy

0.433

**

0.305

*

Dairy style dessert

Dairy

0.680

***

0.211

Yoghurt

Dairy

0.459

***

0.454

***

Ice cream

Dairy

0.922

***

0.909

***

Ice block or icy pole

Dairy

0.323

*

0.302

*

Custard

Dairy

0.980

***

0.980

***

Fried egg

Dairy

0.686

***

0.686

***

0.201
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Boiled or poached egg

Dairy

0.798

***

0.791

***

Omelette or
scrambled eggs

Dairy

0.577

***

0.570

***

Steak

Meat

0.873

***

0.846

***

Pork chop

Meat

0.743

***

0.710

***

Lamb chop or cutlet

Meat

0.793

***

0.774

***

Roast pork or pork
fillet

Meat

0.524

***

0.524

***

Roast beef or veal

Meat

0.570

***

0.570

***

Roast lamb

Meat

0.497

***

0.454

***

Crumbed veal

Meat

0.858

***

0.847

***

Sausages

Meat

0.822

***

0.772

***

Rissole or meat patty

Meat

0.437

**

0.413

***

Frankfurters or
saveloys

Meat

1.000

***

0.473

***

Bacon

Meat

0.839

***

0.813

***

Ham

Meat

0.665

***

0.641

***

Luncheon meat

Meat

0.822

***

0.234

Continental sausage

Meat

0.782

***

0.769

***

Vegetarian curry, stew
or casserole

Meat

0.638

***

0.635

***

Asian stir-fry

Meat

0.622

***

0.602

***

Vegetarian stir-fry

Meat

0.490

***

0.484

***

Mornay dishes

Meat

0.664

***

0.645

***

Mincemeat dish

Meat

0.428

**

0.432

***

Mincemeat as a sauce

Meat

0.644

***

0.567

***

Pizza

Meat

0.498

***

0.496

***

Meat pie

Meat

0.366

**

0.357

**

Savoury pies / pastries

Meat

0.331

**

0.191

Canned fish

Fish

0.587

***

0.573

***
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Roast / barbeque
chicken

Poultry

0.699

***

0.679

***

Chicken
breast/thighs/wings

Poultry

0.455

***

0.430

***

Chicken cooked in
simmer sauce

Poultry

0.587

***

0.250

*

Crumbed chicken

Poultry

0.520

***

0.510

***

Steamed, grilled or
boiled fish

Fish

0.785

***

0.753

***

Fried fish

Fish

0.521

***

0.494

***

Oven baked fish

Fish

0.524

***

0.517

***

Fish fingers

Fish

0.336

*

0.254

*

Seafood

Fish

0.219

Pizza

Takeaway foods

0.491

Chicken or fish
burgers

Takeaway foods

-0.040

Hamburgers

Takeaway foods

0.524

Souvlaki or gyro

Takeaway foods

-0.026

-0.003

Subs or wraps

Takeaway foods

0.039

0.035

Chicken nuggets

Takeaway foods

-0.021

-0.015

Deep fried chicken

Takeaway foods

0.241

0.101

Deep fried battered
fish

Takeaway foods

0.739

***

0.738

***

Deep fried seafood

Takeaway foods

0.516

***

0.507

***

Potato cakes or
fritters

Takeaway foods

0.420

**

0.404

**

Spring or Chiko roll

Takeaway foods

0.425

**

0.326

**

Fried dim sim

Takeaway foods

0.284

*

0.258

*

Steamed dim sim

Takeaway foods

0.361

*

0.180

Meat or chicken pie

Takeaway foods

0.474

***

0.429

***

Pastie

Takeaway foods

0.906

***

0.821

***

Sausage roll

Takeaway foods

0.671

***

0.671

***

0.195
***

0.399

**

-0.017
***

0.505

***
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Sushi

Takeaway foods

0.793

***

0.723

***

Fries

Takeaway foods

0.658

***

0.620

***

Hot chips

Takeaway foods

0.237

Garlic bread

Takeaway foods

0.512

***

0.467

***

Baked beans

Vegetables

0.618

***

0.609

***

Other beans - dried or
canned

Vegetables

0.873

***

0.819

***

Lentils - dried or
canned

Vegetables

0.759

***

0.577

***

Sweetcorn - canned

Vegetables

0.653

***

0.652

***

Beetroot - canned

Vegetables

0.886

***

0.876

***

Olives

Vegetables

0.795

***

0.780

***

Gherkins or pickled
onions

Vegetables

0.861

***

0.837

***

Other pickled
vegetables

Vegetables

0.942

***

0.784

***

Thick sauces

Miscellaneous

0.614

***

0.578

***

Gravy

Miscellaneous

0.371

**

0.360

**

Mayonnaise

Miscellaneous

0.702

***

0.680

***

Salad dressing

Miscellaneous

0.864

***

0.864

***

Marinades and other
thick sauces

Miscellaneous

0.768

***

0.767

***

Potato - mashed

Vegetables

0.924

***

0.923

***

Potato - boiled

Vegetables

0.052

Potato - roasted

Vegetables

0.594

***

0.594

***

Onion - fried

Vegetables

0.330

**

0.328

**

Onion - raw, baked or
boiled

Vegetables

0.442

***

0.435

***

Tomato

Vegetables

0.402

**

0.402

**

Mushrooms - fresh

Vegetables

0.524

***

0.459

***

Mushrooms - fried

Vegetables

0.105

0.150

0.043

0.082
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Carrots

Vegetables

0.590

***

0.584

***

Turnip or swede

Vegetables

0.451

***

0.320

*

Green beans

Vegetables

0.578

***

0.546

***

Green peas

Vegetables

0.428

**

0.391

**

Zucchini

Vegetables

0.862

***

0.847

***

Cabbage

Vegetables

0.871

***

0.850

***

Brussels sprouts

Vegetables

0.889

***

0.875

***

Silverbeet or spinach

Vegetables

0.416

**

0.415

***

Broccoli

Vegetables

0.488

***

0.488

***

Cauliflower

Vegetables

0.434

**

0.366

**

Pumpkin

Vegetables

0.591

***

0.577

***

Sweetcorn

Vegetables

0.547

***

0.475

***

Lettuce

Vegetables

0.194

Cucumber

Vegetables

0.671

***

0.656

***

Celery

Vegetables

0.465

***

0.458

***

Bean sprouts

Vegetables

0.197

0.140

Capsicum

Vegetables

0.276

0.228

Fried mixed
vegetables (e.g. stir
fry) not accounted for
elsewhere

Vegetables

0.384

**

0.362

**

Oven baked hot chips
prepared at home

Vegetables

0.909

***

0.909

***

Coleslaw

Miscellaneous

0.668

***

0.664

***

Potato salad

Miscellaneous

0.790

***

0.748

***

Orange, mandarin or
grapefruit

Fruit

0.502

***

0.433

***

Apple or pear

Fruit

0.577

***

0.565

***

Banana

Fruit

0.201

Pineapple

Fruit

0.695

***

0.685

***

Avocado

Fruit

0.673

***

0.669

***

0.186

0.148
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Fresh fruit salad

Fruit

0.460

***

0.382

**

Melon

Fruit

0.402

**

0.395

**

Watermelon

Fruit

0.526

***

0.490

***

Peach

Fruit

0.477

***

0.354

**

Plum

Fruit

0.783

***

0.783

***

Nectarine

Fruit

0.208

Apricot

Fruit

0.582

***

0.582

***

Figs

Fruit

0.799

***

0.760

***

Canned fruit

Fruit

0.956

***

0.912

***

Raisins sultanas or
currants

Fruit

0.490

***

0.490

***

Other dried fruit

Fruit

0.549

***

0.421

***

Honey, jam or
marmalade

Miscellaneous

0.791

***

0.788

***

Vegemite or marmite

Miscellaneous

0.779

***

0.747

***

Peanut paste

Miscellaneous

0.513

***

0.433

***

Cordial

Beverages

0.852

***

0.851

***

Diet fizzy drink

Beverages

0.694

***

0.661

***

Regular fizzy drink
including cola drinks
and flavoured mineral
water

Beverages

0.445

***

0.445

***

Fruit drink

Beverages

0.953

***

0.952

***

Pure fruit juice

Beverages

0.772

***

0.746

***

Vegetable juice

Beverages

0.653

***

0.426

***

Water or spring water

Beverages

-0.181

Unflavoured mineral
water

Beverages

0.437

**

0.435

***

Rum and soda

Beverages

1.000

***

1.000

***

Low-alcohol beer

Beverages

0.908

***

0.906

***

Regular beer

Beverages

0.889

***

0.862

***

0.199

-0.174

311

Appendix
Sherry, port or liqueur

Beverages

0.708

***

0.570

***

Alcoholic spirits

Beverages

0.979

***

0.946

***

Homemade soup

Miscellaneous

0.803

***

0.801

***

Canned soup

Miscellaneous

0.706

***

0.705

***

Packet soup

Miscellaneous

0.817

***

0.796

***

Barley

Vegetables

0.913

***

0.913

***

Bok Choy

Vegetables

0.475

***

0.465

***

Couscous

Vegetables

0.626

***

0.497

***

Garlic

Vegetables

0.507

***

0.478

***

Pomegranates

Fruit

0.951

***

0.726

***

Sweet potato

Vegetables

0.405

**

0.404

**

Canned tomatoes

Vegetables

0.230

0.224

Cherries

Fruit

0.278

0.274

*

Kiwifruit

Fruit

0.981

***

0.949

***

Mango

Fruit

0.693

***

0.612

***

Pawpaw

Fruit

0.916

***

0.592

***

Milk

Dairy

0.270

0.269

*

Chocolate

Miscellaneous

0.441

***

0.389

**

Wine and champagne

Beverages

0.873

***

0.873

***

Black tea

Beverages

0.415

**

0.391

**

Green tea

Beverages

0.427

**

0.400

**

White tea

Beverages

0.751

***

0.751

***

Pomegranate juice

Beverages

0.760

***

0.557

***

Red or black grapes

Fruit

0.047

Green grapes

Fruit

0.453

***

0.453

***

Seeds

Miscellaneous

0.800

***

0.794

***

Berries

Fruit

0.293

*

0.167

Liver and kidney

Meat

0.628

***

0.362

0.033

**
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Meat goulash, curry,
stew or casserole

Meat

0.766

***

0.763

***

Rice

Cereals

0.722

***

0.713

***

Nuts

Miscellaneous

0.708

***

0.650

***

Jacket potatoes

Vegetables

0.890

***

0.856

***

Fats and oils

General

0.308

*

0.306

*

* p < 0.05, ** p < 0.01, *** p < 0.001. Abbreviations: CSIROFFQ, Commonwealth Scientific and Industrial Research Organisation food
frequency questionnaire.
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